Group ID|Group Name|Treatment Sequence|Treatment Age|Treatment Type|Treatment Quantity|Treatment Unit|Treatment Application|Treatment Remarks|No of individuals in study|Species|Strain|Sex|Age|Group Endpoints|Individual ID|Group ID|Age at death|Pathology type|Pathology location|Pathology Description|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-1|1|111|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-2|1|111|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-3|1|111|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-4|1|111|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-5|1|111|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-6|1|117|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-7|1|117|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-8|1|117|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-9|1|117|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-10|1|117|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-11|1|117|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-12|1|117|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-13|1|117|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-14|1|117|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-15|1|117|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-16|1|143|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-17|1|143|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-18|1|143|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-19|1|143|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-20|1|172|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-21|1|172|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-22|1|172|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-23|1|172|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-24|1|172|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-25|1|173|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-26|1|173|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-27|1|173|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-28|1|173|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-29|1|173|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-30|1|173|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-31|1|173|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-32|1|173|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-33|1|176|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-34|1|176|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-35|1|180|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-36|1|180|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-37|1|180|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-38|1|180|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-39|1|215|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-40|1|215|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-41|1|222|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-42|1|222|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-43|1|222|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-44|1|224|Neoplasia unclassified|Other local manifestations and miscellaneus|THWB: TBOS TO LIVER.|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-45|1|224|Neoplasia unclassified|Other local manifestations and miscellaneus|THWB: TBOS TO LIVER.|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-46|1|224|Neoplasia unclassified|Other local manifestations and miscellaneus|THWB: TBOS TO LIVER.|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-47|1|224|Neoplasia unclassified|Other local manifestations and miscellaneus|THWB: TBOS TO LIVER.|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-48|1|277|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-49|1|277|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-50|1|278|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-51|1|278|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-52|1|278|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-53|1|278|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-54|1|278|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-55|1|278|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-56|1|278|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-57|1|278|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-58|1|278|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-59|1|278|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-60|1|278|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-61|1|278|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-62|1|278|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-63|1|278|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-64|1|285|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-65|1|285|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-66|1|285|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-67|1|285|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-68|1|317|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-69|1|381|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-70|1|382|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-71|1|382|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-72|1|382|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-73|1|382|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-74|1|382|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-75|1|383|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-76|1|383|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-77|1|383|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-78|1|383|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-79|1|383|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-80|1|388|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-81|1|389|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-82|1|389|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-83|1|390|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-84|1|390|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-85|1|390|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-86|1|390|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-87|1|390|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-88|1|393|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-89|1|393|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-90|1|397|Other deterministic changes|Whole body|MCDU/|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-91|1|417|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-92|1|417|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-93|1|417|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-94|1|417|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-95|1|417|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-96|1|417|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-97|1|417|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-98|1|417|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-99|1|424|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-100|1|424|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-101|1|424|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-102|1|424|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-103|1|424|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-104|1|424|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-105|1|424|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-106|1|424|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-107|1|424|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-108|1|424|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-109|1|424|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-110|1|424|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-111|1|428|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-112|1|441|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-113|1|457|Other deterministic changes|Whole body|MCDU/|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-114|1|457|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-115|1|457|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-116|1|460|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-117|1|460|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-118|1|460|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-119|1|460|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-120|1|492|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-121|1|511|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-122|1|512|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-123|1|520|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-124|1|520|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-125|1|520|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-126|1|520|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-127|1|523|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-128|1|523|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-129|1|525|Inflammation and/or fibrotic diseases|Lower respiratory system,MA: 0000415 - lung|MRMP/  Murine,MPATH: 212 - inflammation|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-130|1|527|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-131|1|527|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-132|1|527|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-133|1|527|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-134|1|530|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-135|1|530|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-136|1|530|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-137|1|530|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-138|1|530|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-139|1|530|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-140|1|530|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-141|1|530|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-142|1|530|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-143|1|530|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-144|1|533|Neoplasia unclassified|Other local manifestations and miscellaneus|TMWC: TCVS EXTENDS INTO MUSCLE.|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-145|1|548|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-146|1|548|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-147|1|548|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-148|1|548|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-149|1|548|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-150|1|548|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-151|1|548|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-152|1|548|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-153|1|548|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-154|1|551|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/  ,MPATH: 242 - hemangiosarcoma|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-155|1|555|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-156|1|555|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-157|1|555|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-158|1|555|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-159|1|555|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-160|1|569|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-161|1|569|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-162|1|569|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-163|1|569|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-164|1|569|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-165|1|569|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-166|1|569|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-167|1|569|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-168|1|569|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-169|1|569|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-170|1|569|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-171|1|569|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-172|1|569|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-173|1|569|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-174|1|569|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-175|1|572|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-176|1|583|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-177|1|583|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-178|1|583|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-179|1|583|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-180|1|584|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/  ,MPATH: 242 - hemangiosarcoma|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-181|1|585|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-182|1|586|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-183|1|593|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-184|1|593|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-185|1|593|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-186|1|599|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/  ,MPATH: 242 - hemangiosarcoma|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-187|1|603|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-188|1|605|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-189|1|610|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-190|1|610|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-191|1|610|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-192|1|610|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-193|1|613|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-194|1|617|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-195|1|618|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-196|1|619|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-197|1|625|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-198|1|625|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-199|1|625|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-200|1|625|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-201|1|627|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-202|1|628|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-203|1|631|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-204|1|631|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-205|1|632|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-206|1|632|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-207|1|632|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-208|1|632|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-209|1|632|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-210|1|633|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-211|1|635|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-212|1|635|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-213|1|646|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-214|1|648|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-215|1|651|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-216|1|652|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases Heart,MPATH: 268 - adenocarcinoma|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-217|1|654|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-218|1|655|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-219|1|655|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-220|1|655|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-221|1|655|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-222|1|656|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-223|1|660|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-224|1|662|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-225|1|663|Other deterministic changes|Whole body|MCDU/|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-226|1|665|Other deterministic changes|Whole body|MCDU/|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-227|1|666|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-228|1|674|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-229|1|676|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-230|1|680|Other deterministic changes|Whole body|MCDU/|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-231|1|682|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-232|1|683|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-233|1|689|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-234|1|689|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-235|1|694|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-236|1|695|Neoplasia malignant|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|THVS/  ,MPATH: 242 - hemangiosarcoma|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-237|1|695|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-238|1|697|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-239|1|700|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-240|1|701|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-241|1|707|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-242|1|709|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-243|1|710|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-244|1|710|Neoplasia unclassified|Other local manifestations and miscellaneus|THWR: TRAC TO LIVER.|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-245|1|715|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-246|1|718|Other deterministic changes|Whole body|MCDU/|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-247|1|720|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-248|1|727|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-249|1|728|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-250|1|729|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-251|1|729|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-252|1|729|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-253|1|729|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-254|1|729|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-255|1|729|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-256|1|729|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-257|1|729|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-258|1|736|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-259|1|736|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-260|1|736|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-261|1|736|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-262|1|736|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-263|1|737|Neoplasia unclassified|Other local manifestations and miscellaneus|THWR: TRAC TO LIVER.|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-264|1|742|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-265|1|743|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  Head/neck missing Eye(s) missing,MPATH: 513 - Lymphoid neoplasms|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-266|1|745|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-267|1|747|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-268|1|751|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-269|1|752|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-270|1|754|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-271|1|757|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-272|1|757|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-273|1|759|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|TSFS/ skin of hind limb. Metastases  Muscle tsfs of skin of hind limb in skeletal muscle.,MPATH: 219 - adnexal and skin appendage tumor|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-274|1|762|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-275|1|764|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-276|1|764|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-277|1|765|Neoplasia unclassified|Other local manifestations and miscellaneus|TMWC: TCVS EXTENDS INTO MUSCLE.|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-278|1|766|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-279|1|771|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-280|1|773|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-281|1|773|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-282|1|777|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-283|1|778|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-284|1|780|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-285|1|786|Neoplasia malignant|Bloodvessels among cardiovascular system|TXVS/ prostate. Metastases  txvs invading adnexal musc & skin.|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-286|1|792|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-287|1|792|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-288|1|792|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-289|1|792|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-290|1|792|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-291|1|792|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-292|1|793|Other deterministic changes|Whole body|MCDU/  Head/neck missing|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-293|1|793|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-294|1|794|Other deterministic changes|Whole body|MCDU/|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-295|1|795|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-296|1|796|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-297|1|798|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-298|1|798|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases Liver,MPATH: 268 - adenocarcinoma|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-299|1|799|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-300|1|799|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-301|1|799|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-302|1|799|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-303|1|799|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-304|1|799|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-305|1|800|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-306|1|800|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-307|1|802|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-308|1|806|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-309|1|806|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-310|1|808|Neoplasia unclassified|Other local manifestations and miscellaneus|TLWR: TRAC TO MEDIASTINAL NODE.|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-311|1|809|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-312|1|809|Neoplasia unclassified|Other local manifestations and miscellaneus|TLWR: TRAC TO MEDIASTINAL NODE.|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-313|1|809|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-314|1|809|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-315|1|810|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  Head/neck missing,MPATH: 513 - Lymphoid neoplasms|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-316|1|812|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-317|1|813|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-318|1|815|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-319|1|815|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-320|1|817|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-321|1|819|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-322|1|820|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-323|1|820|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-324|1|821|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-325|1|821|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-326|1|822|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-327|1|823|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-328|1|824|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-329|1|828|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-330|1|831|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-331|1|833|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-332|1|833|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-333|1|834|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLSL/  undifferentiated leukemia lymphoret.tissue,MPATH: 335 - hematopoietic/lymphoid malignancies/disorder|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-334|1|834|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-335|1|835|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-336|1|836|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-337|1|836|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-338|1|836|Neoplasia malignant|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|THVS/  ,MPATH: 242 - hemangiosarcoma|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-339|1|839|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-340|1|841|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-341|1|844|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-342|1|845|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-343|1|848|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-344|1|849|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-345|1|850|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-346|1|852|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-347|1|852|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-348|1|852|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-349|1|855|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-350|1|855|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-351|1|856|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-352|1|856|Neoplasia unclassified|Other local manifestations and miscellaneus|TLWR: TRAC TO MEDIASTINAL NODE.|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-353|1|857|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-354|1|859|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-355|1|859|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-356|1|861|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-357|1|861|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-358|1|862|Neoplasia unclassified|Other local manifestations and miscellaneus|TLWR: TRAC TO MEDIASTINAL NODE.|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-359|1|863|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-360|1|863|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-361|1|863|Neoplasia malignant|Liver among hepato-pancreatic system diseases|THAC/|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-362|1|864|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-363|1|865|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-364|1|865|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-365|1|866|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-366|1|867|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-367|1|869|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-368|1|869|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-369|1|870|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-370|1|871|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-371|1|873|Other deterministic changes|Whole body|MCDU/  Head/neck missing|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-372|1|874|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-373|1|878|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-374|1|879|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-375|1|879|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-376|1|882|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-377|1|882|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-378|1|883|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-379|1|884|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-380|1|886|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-381|1|886|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-382|1|886|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-383|1|887|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-384|1|887|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-385|1|888|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-386|1|890|Neoplasia malignant|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|THVS/  ,MPATH: 242 - hemangiosarcoma|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-387|1|890|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-388|1|890|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-389|1|893|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-390|1|893|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-391|1|894|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-392|1|895|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-393|1|896|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-394|1|898|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-395|1|899|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-396|1|900|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-397|1|900|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-398|1|900|Neoplasia unclassified|Other local manifestations and miscellaneus|TMWC: TCFS INFILTR. SKELETAL MUSCLE OF THORAX.|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-399|1|901|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-400|1|901|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-401|1|902|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-402|1|903|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-403|1|903|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-404|1|905|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-405|1|906|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-406|1|906|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-407|1|907|Other deterministic changes|Whole body|MCDU/  Eye(s) missing|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-408|1|908|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-409|1|908|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-410|1|909|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-411|1|909|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-412|1|910|Other deterministic changes|Whole body|MCDU/|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-413|1|910|Neoplasia unclassified|Other local manifestations and miscellaneus|TMWR: TRAC TO RIB CAGE MUSCLE.|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-414|1|911|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-415|1|912|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-416|1|912|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-417|1|915|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-418|1|917|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-419|1|918|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-420|1|918|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-421|1|920|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/  ,MPATH: 242 - hemangiosarcoma|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-422|1|921|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-423|1|924|Neoplasia unclassified|Other local manifestations and miscellaneus|TMWX: TXVS INVADING ADNEXAL MUSC & SKIN.|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-424|1|924|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-425|1|925|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-426|1|926|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-427|1|926|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-428|1|928|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-429|1|928|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-430|1|931|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-431|1|931|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-432|1|931|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-433|1|933|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-434|1|935|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-435|1|935|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-436|1|936|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-437|1|936|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-438|1|936|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-439|1|937|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-440|1|937|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-441|1|940|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-442|1|940|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  Head/neck missing,MPATH: 513 - Lymphoid neoplasms|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-443|1|941|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/   Metastases  Muscle trac to rib cage muscle.,MPATH: 513 - Lymphoid neoplasms|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-444|1|941|Neoplasia systemic|Haematolymphatic system|TLPS/   Metastases Heart|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-445|1|942|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-446|1|942|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-447|1|943|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-448|1|943|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-449|1|943|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-450|1|943|Neoplasia unclassified|Other local manifestations and miscellaneus|TMWC: TCFS INFILTR. SKELETAL MUSCLE OF THORAX.|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-451|1|946|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-452|1|948|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-453|1|949|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-454|1|950|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-455|1|950|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-456|1|952|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-457|1|953|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-458|1|954|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-459|1|955|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-460|1|957|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-461|1|958|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-462|1|958|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-463|1|959|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLSS/  undifferentiated lymphoma,MPATH: 513 - Lymphoid neoplasms|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-464|1|959|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-465|1|959|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-466|1|960|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-467|1|962|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-468|1|963|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-469|1|964|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-470|1|967|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-471|1|969|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-472|1|969|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-473|1|970|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-474|1|970|Inflammation and/or fibrotic diseases|Lower digestive tract,MA: 0000328 - intestine|MIIA/ sm. intestine.Enteritis acute,MPATH: 212 - inflammation|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-475|1|972|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  Head/neck missing,MPATH: 513 - Lymphoid neoplasms|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-476|1|973|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-477|1|973|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-478|1|974|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-479|1|974|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-480|1|974|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-481|1|975|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-482|1|975|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-483|1|976|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-484|1|977|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-485|1|977|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-486|1|979|Other deterministic changes|Whole body|MCDU/|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-487|1|980|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-488|1|980|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-489|1|981|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-490|1|981|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-491|1|982|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-492|1|983|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-493|1|983|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-494|1|983|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-495|1|986|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-496|1|986|Neoplasia malignant|Liver among hepato-pancreatic system diseases|THAC/  Head/neck missing|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-497|1|987|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-498|1|991|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-499|1|993|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-500|1|993|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-501|1|994|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-502|1|995|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-503|1|996|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-504|1|997|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-505|1|998|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-506|1|998|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-507|1|1000|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-508|1|1001|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-509|1|1001|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-510|1|1001|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-511|1|1001|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-512|1|1002|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-513|1|1003|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-514|1|1004|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-515|1|1004|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-516|1|1006|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-517|1|1006|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-518|1|1007|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-519|1|1008|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-520|1|1010|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-521|1|1010|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-522|1|1010|Other deterministic changes|Whole body|MCDU/|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-523|1|1011|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-524|1|1011|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-525|1|1012|Neoplasia malignant|Bloodvessels among cardiovascular system|TCVS/ subcut. thigh region. Metastases  Muscle tcvs invas. of skeletal muscle of thigh.|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-526|1|1012|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-527|1|1012|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-528|1|1015|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-529|1|1016|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-530|1|1017|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-531|1|1018|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-532|1|1019|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-533|1|1020|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-534|1|1022|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-535|1|1023|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-536|1|1023|Other deterministic changes|Whole body|MCDU/  Head/neck missing Eye(s) missing|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-537|1|1024|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-538|1|1024|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-539|1|1025|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-540|1|1025|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-541|1|1026|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-542|1|1026|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-543|1|1027|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-544|1|1027|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-545|1|1027|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  Head/neck missing Eye(s) missing,MPATH: 513 - Lymphoid neoplasms|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-546|1|1030|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-547|1|1030|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/  ,MPATH: 242 - hemangiosarcoma|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-548|1|1032|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-549|1|1032|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-550|1|1033|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-551|1|1033|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-552|1|1035|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-553|1|1036|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-554|1|1036|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-555|1|1037|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-556|1|1038|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-557|1|1038|Inflammation and/or fibrotic diseases|Lower respiratory system,MA: 0000415 - lung|MPNU/  Acute and subacute,MPATH: 212 - inflammation|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-558|1|1040|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-559|1|1041|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-560|1|1042|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-561|1|1042|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-562|1|1044|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-563|1|1045|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-564|1|1045|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-565|1|1047|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-566|1|1049|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases  Muscle tcfs invas of skel musc.,MPATH: 268 - adenocarcinoma|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-567|1|1051|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-568|1|1051|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-569|1|1052|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  Head/neck missing,MPATH: 513 - Lymphoid neoplasms|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-570|1|1054|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-571|1|1057|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-572|1|1058|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-573|1|1058|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-574|1|1059|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-575|1|1059|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-576|1|1060|Neoplasia malignant|Liver among hepato-pancreatic system diseases|THAC/|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-577|1|1062|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  Eye(s) missing,MPATH: 513 - Lymphoid neoplasms|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-578|1|1062|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-579|1|1063|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-580|1|1063|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-581|1|1064|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-582|1|1065|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-583|1|1066|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-584|1|1066|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-585|1|1067|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-586|1|1067|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-587|1|1068|Neoplasia malignant|Bloodvessels among cardiovascular system|TLVS/ in ln w/ tumor growth through capsule & into surr fatty tiss & lung metastasis. Lymphoret.tissue|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-588|1|1069|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-589|1|1069|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-590|1|1069|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-591|1|1071|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-592|1|1071|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-593|1|1071|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-594|1|1072|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-595|1|1073|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-596|1|1073|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-597|1|1074|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases  Lymphoret.System trac to pt ln. Metastases Liver Metastases  trac to pleura of thorax & trachea.,MPATH: 268 - adenocarcinoma|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-598|1|1075|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-599|1|1075|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-600|1|1075|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-601|1|1076|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  Head/neck missing,MPATH: 513 - Lymphoid neoplasms|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-602|1|1076|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-603|1|1076|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  Head/neck missing Eye(s) missing,MPATH: 513 - Lymphoid neoplasms|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-604|1|1077|Other deterministic changes|Whole body|MCDU/  Eye(s) missing Head/neck missing|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-605|1|1078|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-606|1|1078|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-607|1|1081|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-608|1|1081|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-609|1|1081|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-610|1|1082|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-611|1|1083|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-612|1|1086|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-613|1|1086|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-614|1|1086|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLSS/  undifferentiated lymphoma,MPATH: 513 - Lymphoid neoplasms|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-615|1|1087|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-616|1|1087|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-617|1|1087|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-618|1|1088|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-619|1|1088|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-620|1|1088|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  Head/neck missing Eye(s) missing,MPATH: 513 - Lymphoid neoplasms|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-621|1|1089|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-622|1|1089|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-623|1|1089|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-624|1|1089|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-625|1|1090|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-626|1|1091|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-627|1|1094|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-628|1|1094|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-629|1|1095|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-630|1|1095|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-631|1|1096|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-632|1|1099|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-633|1|1100|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-634|1|1100|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-635|1|1101|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-636|1|1104|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-637|1|1104|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-638|1|1106|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-639|1|1112|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/  ,MPATH: 242 - hemangiosarcoma|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-640|1|1113|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-641|1|1113|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-642|1|1113|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-643|1|1113|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-644|1|1113|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-645|1|1114|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-646|1|1116|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-647|1|1116|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-648|1|1117|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-649|1|1117|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-650|1|1120|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-651|1|1121|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-652|1|1121|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-653|1|1121|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-654|1|1122|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-655|1|1122|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-656|1|1122|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-657|1|1122|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-658|1|1125|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-659|1|1125|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-660|1|1125|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-661|1|1126|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-662|1|1127|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-663|1|1128|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-664|1|1130|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-665|1|1130|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-666|1|1131|Neoplasia malignant|Bloodvessels among cardiovascular system|TLVS/ mn ln. Lymphoret.tissue|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-667|1|1132|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-668|1|1132|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-669|1|1132|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-670|1|1132|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-671|1|1135|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-672|1|1135|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-673|1|1138|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-674|1|1138|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-675|1|1139|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-676|1|1140|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-677|1|1144|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-678|1|1144|Neoplasia unclassified|Other local manifestations and miscellaneus|TMWR: TRAC TO RIB CAGE MUSCLE.|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-679|1|1144|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-680|1|1145|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  Eye(s) missing,MPATH: 513 - Lymphoid neoplasms|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-681|1|1145|Inflammation and/or fibrotic diseases|Lower respiratory system,MA: 0000415 - lung|MRMP/  Murine,MPATH: 212 - inflammation|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-682|1|1146|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-683|1|1147|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-684|1|1148|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-685|1|1148|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-686|1|1148|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-687|1|1148|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-688|1|1149|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-689|1|1149|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-690|1|1151|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-691|1|1152|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-692|1|1154|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-693|1|1156|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-694|1|1156|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-695|1|1162|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-696|1|1162|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-697|1|1162|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-698|1|1162|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-699|1|1167|Other deterministic changes|Whole body|MCDU/|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-700|1|1167|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-701|1|1170|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-702|1|1170|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-703|1|1170|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-704|1|1171|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-705|1|1171|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-706|1|1172|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-707|1|1172|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  Eye(s) missing Head/neck missing,MPATH: 513 - Lymphoid neoplasms|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-708|1|1173|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-709|1|1175|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-710|1|1176|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-711|1|1178|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  Eye(s) missing Head/neck missing,MPATH: 513 - Lymphoid neoplasms|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-712|1|1178|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-713|1|1179|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-714|1|1180|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-715|1|1182|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-716|1|1182|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-717|1|1182|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-718|1|1184|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-719|1|1186|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-720|1|1187|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-721|1|1187|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-722|1|1188|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-723|1|1191|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-724|1|1192|Hyperplastic changes|Cardiovascular system|MPAN/  Polyarteritis nodosa|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-725|1|1194|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-726|1|1200|Neoplasia malignant|Bone among musculo-skeletal system diseases|TBOS/ along vertebral col. in thorax & on rib ends. Metastases Lung Metastases Liver|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-727|1|1200|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/   Metastases  tsfs of skin of hind limb infilt. bulbourethral gland & scrotal sac.,MPATH: 513 - Lymphoid neoplasms|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-728|1|1203|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-729|1|1205|Inflammation and/or fibrotic diseases|Lower respiratory system,MA: 0000415 - lung|MRMP/  Murine,MPATH: 212 - inflammation|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-730|1|1207|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-731|1|1212|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|TCFS/ associated with lung. Metastases  Muscle tcfs infiltr. skeletal muscle of thorax. Metastases Lung,MPATH: 408 - soft tissue fibrosarcoma|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-732|1|1212|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-733|1|1214|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  Eye(s) missing Head/neck missing,MPATH: 513 - Lymphoid neoplasms|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-734|1|1214|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-735|1|1215|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-736|1|1216|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-737|1|1216|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-738|1|1218|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-739|1|1221|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-740|1|1222|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-741|1|1223|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-742|1|1226|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-743|1|1227|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-744|1|1227|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-745|1|1230|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-746|1|1230|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/   Metastases  Lymphoret.System trac to mediastinal node.,MPATH: 513 - Lymphoid neoplasms|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-747|1|1231|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-748|1|1231|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-749|1|1233|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-750|1|1233|Inflammation and/or fibrotic diseases|Integumentary system|MSDA/  acute|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-751|1|1235|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-752|1|1235|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-753|1|1237|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-754|1|1239|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-755|1|1240|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-756|1|1240|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-757|1|1242|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-758|1|1242|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-759|1|1245|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-760|1|1247|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-761|1|1248|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-762|1|1248|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-763|1|1249|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-764|1|1249|Neoplasia malignant|Liver among hepato-pancreatic system diseases|THAC/|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-765|1|1249|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-766|1|1251|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-767|1|1254|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-768|1|1254|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-769|1|1255|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-770|1|1256|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-771|1|1258|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-772|1|1258|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-773|1|1260|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-774|1|1262|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-775|1|1263|Other deterministic changes|Whole body|MCDU/|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-776|1|1265|Other deterministic changes|Whole body|MCDU/|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-777|1|1268|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-778|1|1269|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-779|1|1272|Other deterministic changes|Whole body|MCDU/|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-780|1|1274|Other deterministic changes|Whole body|MCDU/|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-781|1|1276|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-782|1|1284|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-783|1|1289|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-784|1|1290|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-785|1|1293|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-786|1|1296|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-787|1|1299|Neoplasia malignant|Bloodvessels among cardiovascular system|TCVS/ subcut. right axillary reg. Metastases  Muscle tcvs extends into muscle.|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-788|1|1310|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-789|1|1312|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-790|1|1313|Neoplasia malignant|Liver among hepato-pancreatic system diseases|THAC/|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-791|1|1315|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-792|1|1317|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-793|1|1321|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-794|1|1324|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-795|1|1325|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-796|1|1332|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-797|1|1333|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-798|1|1338|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-799|1|1340|Neoplasia benign|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVO/  ,MPATH: 240 - hemangioma|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-800|1|1347|Other deterministic changes|Whole body|MCDU/|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-801|1|1348|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-802|1|1350|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-803|1|1365|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-804|1|1366|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-805|1|1367|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-806|1|1368|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-807|1|1384|Other deterministic changes|Whole body|MCDU/|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-808|1|1387|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-809|1|1389|n/a|n/a|n/a|
1003-29-1|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|810 (810 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|592 records survival 882 ± 8 lifespan study|1003-29-1-810|1|1471|Other deterministic changes|Whole body|MCDU/|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-1|2|110|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-2|2|110|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-3|2|110|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-4|2|110|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-5|2|110|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-6|2|110|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-7|2|110|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-8|2|110|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-9|2|110|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-10|2|110|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-11|2|117|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-12|2|117|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-13|2|117|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-14|2|117|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-15|2|117|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-16|2|232|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-17|2|266|Inflammation and/or fibrotic diseases|Lower respiratory system,MA: 0000415 - lung|MRMP/  Murine,MPATH: 212 - inflammation|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-18|2|320|Hyperplastic changes|Cardiovascular system|MPAN/  Polyarteritis nodosa|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-19|2|426|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-20|2|473|Hyperplastic changes|Cardiovascular system|MPAN/  Polyarteritis nodosa|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-21|2|484|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-22|2|492|Other deterministic changes|Whole body|MCDU/   Metastases  Muscle tcvs adjac. to spine invasion of vert. muscle.|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-23|2|529|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-24|2|582|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-25|2|587|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-26|2|589|Neoplasia malignant|Bone among musculo-skeletal system diseases|TBOS/ femur.Head/neck missing|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-27|2|607|Neoplasia malignant|Bloodvessels among cardiovascular system|TCVS/ subcut. vent. inguinal reg.|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-28|2|610|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-29|2|618|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-30|2|618|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-31|2|618|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-32|2|620|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-33|2|624|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-34|2|632|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-35|2|633|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-36|2|633|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-37|2|643|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-38|2|644|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-39|2|646|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-40|2|651|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/  ,MPATH: 242 - hemangiosarcoma|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-41|2|651|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-42|2|652|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-43|2|654|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-44|2|655|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-45|2|655|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-46|2|656|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-47|2|659|Neoplasia malignant|Bloodvessels among cardiovascular system|TCVS/ in fatty tissue in abd. cavity.|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-48|2|664|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-49|2|666|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-50|2|675|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-51|2|677|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-52|2|678|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-53|2|683|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-54|2|683|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-55|2|684|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-56|2|689|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases  Lymphoret.System trac to cervical & parathymic nodes. Metastases  trac to mediastinum & visceral & parietal pleura.,MPATH: 268 - adenocarcinoma|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-57|2|691|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-58|2|692|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-59|2|693|Inflammation and/or fibrotic diseases|Lower digestive tract,MA: 0000328 - intestine|MIIA/ colon.Enteritis acute,MPATH: 212 - inflammation|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-60|2|699|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-61|2|699|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-62|2|707|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-63|2|712|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-64|2|715|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-65|2|715|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-66|2|715|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-67|2|716|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|TPAC/  Carcinoma,MPATH: 218 - neoplasm|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-68|2|717|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-69|2|718|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-70|2|719|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-71|2|720|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-72|2|721|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-73|2|723|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-74|2|726|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-75|2|728|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-76|2|730|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-77|2|734|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-78|2|737|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-79|2|738|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-80|2|738|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-81|2|742|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-82|2|743|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-83|2|745|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-84|2|745|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-85|2|748|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-86|2|749|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-87|2|751|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-88|2|753|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-89|2|758|Other deterministic changes|Whole body|MCDU/|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-90|2|761|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-91|2|767|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-92|2|768|Inflammation and/or fibrotic diseases|Other local manifestations and miscellaneus|MMTA/  Metritis|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-93|2|770|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-94|2|770|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-95|2|771|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-96|2|771|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-97|2|778|Other deterministic changes|Whole body|MCDU/|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-98|2|779|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-99|2|781|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-100|2|784|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-101|2|790|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-102|2|793|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-103|2|797|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-104|2|805|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-105|2|806|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-106|2|807|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-107|2|808|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-108|2|811|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-109|2|812|Other deterministic changes|Whole body|MCDU/|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-110|2|813|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-111|2|813|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-112|2|816|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-113|2|816|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-114|2|818|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-115|2|818|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-116|2|820|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-117|2|820|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/   Metastases  tpac invasion of cerebrum.,MPATH: 513 - Lymphoid neoplasms|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-118|2|821|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-119|2|822|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-120|2|823|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-121|2|823|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-122|2|826|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-123|2|826|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-124|2|826|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-125|2|827|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-126|2|829|Other deterministic changes|Whole body|MCDU/|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-127|2|834|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-128|2|836|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-129|2|839|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-130|2|840|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-131|2|841|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  Head/neck missing Eye(s) missing,MPATH: 513 - Lymphoid neoplasms|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-132|2|841|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-133|2|842|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-134|2|842|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-135|2|846|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-136|2|847|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-137|2|848|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-138|2|848|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-139|2|849|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-140|2|849|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-141|2|849|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-142|2|850|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-143|2|852|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-144|2|853|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-145|2|854|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-146|2|855|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-147|2|857|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-148|2|857|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  Head/neck missing,MPATH: 513 - Lymphoid neoplasms|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-149|2|858|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-150|2|859|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-151|2|859|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-152|2|860|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-153|2|862|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases  Muscle trac invas of thoracic wall musc. Metastases  Lymphoret.System trac invas of parathymus.,MPATH: 268 - adenocarcinoma|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-154|2|862|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-155|2|863|Other deterministic changes|Whole body|MCDU/|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-156|2|863|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-157|2|863|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-158|2|865|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-159|2|866|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-160|2|868|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-161|2|868|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-162|2|869|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-163|2|869|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-164|2|870|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-165|2|872|Neoplasia malignant|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|THVS/  ,MPATH: 242 - hemangiosarcoma|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-166|2|875|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-167|2|875|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-168|2|877|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-169|2|878|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-170|2|878|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-171|2|878|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-172|2|878|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-173|2|879|Other deterministic changes|Whole body|MCDU/|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-174|2|880|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-175|2|880|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-176|2|880|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-177|2|881|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-178|2|884|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-179|2|884|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-180|2|885|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-181|2|886|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-182|2|887|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-183|2|887|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-184|2|887|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLSL/  undifferentiated leukemia lymphoret.tissue,MPATH: 335 - hematopoietic/lymphoid malignancies/disorder|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-185|2|888|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-186|2|890|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-187|2|891|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-188|2|892|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-189|2|892|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLSS/  undifferentiated lymphomaHead/neck missing,MPATH: 513 - Lymphoid neoplasms|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-190|2|892|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-191|2|893|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-192|2|894|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-193|2|895|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-194|2|897|Other deterministic changes|Whole body|MCDU/|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-195|2|899|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-196|2|900|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-197|2|901|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases  trac to pleura & mediastinal tiss.,MPATH: 268 - adenocarcinoma|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-198|2|903|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-199|2|903|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-200|2|904|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-201|2|904|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-202|2|905|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-203|2|906|Neoplasia systemic|Haematolymphatic system|TLPS/|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-204|2|906|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-205|2|907|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-206|2|907|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-207|2|907|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-208|2|910|Inflammation and/or fibrotic diseases|Lower digestive tract,MA: 0000328 - intestine|MIIA/ esophagus.Enteritis acute,MPATH: 212 - inflammation|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-209|2|910|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-210|2|911|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-211|2|912|Neoplasia malignant|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOVS/  ,MPATH: 242 - hemangiosarcoma|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-212|2|913|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-213|2|914|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-214|2|915|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-215|2|915|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-216|2|916|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-217|2|917|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-218|2|917|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-219|2|918|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-220|2|918|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-221|2|919|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-222|2|920|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-223|2|922|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-224|2|924|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-225|2|924|Other deterministic changes|Whole body|MCDU/|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-226|2|925|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/   Metastases  tuac invas through uterine wall to visc perit and panc.,MPATH: 513 - Lymphoid neoplasms|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-227|2|925|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  Head/neck missing Eye(s) missing,MPATH: 268 - adenocarcinoma|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-228|2|926|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-229|2|926|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-230|2|927|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-231|2|928|Neoplasia malignant|Other local manifestations and miscellaneus|TMLS/ flat subcut mass outside rib cage. Metastases  tmls from rib cage to pleura. Metastases Lung tmls from rib cage to lung.|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-232|2|928|Hyperplastic changes|Other local manifestations and miscellaneus,MA: 0000003 - organ system|MOCY/  Ovary or testis,MPATH: 62 - cyst|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-233|2|929|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-234|2|930|Other deterministic changes|Whole body|MCDU/|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-235|2|931|Hyperplastic changes|Other local manifestations and miscellaneus,MA: 0000003 - organ system|MOCY/  Ovary or testisHead/neck missing,MPATH: 62 - cyst|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-236|2|931|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-237|2|931|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-238|2|934|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-239|2|934|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-240|2|936|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-241|2|936|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-242|2|937|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-243|2|937|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-244|2|939|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-245|2|940|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-246|2|941|Neoplasia systemic|Haematolymphatic system|TLML/|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-247|2|944|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-248|2|944|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-249|2|945|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-250|2|946|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOVO/  ,MPATH: 242 - hemangiosarcoma|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-251|2|946|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-252|2|948|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-253|2|948|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-254|2|948|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-255|2|950|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-256|2|951|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/ with metastasis to heart,MPATH: 242 - hemangiosarcoma|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-257|2|951|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-258|2|953|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-259|2|953|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-260|2|953|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-261|2|956|Neoplasia systemic|Haematolymphatic system|TLPS/|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-262|2|956|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-263|2|956|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-264|2|958|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-265|2|959|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-266|2|960|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-267|2|961|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  Eye(s) missing,MPATH: 268 - adenocarcinoma|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-268|2|963|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  Head/neck missing Eye(s) missing,MPATH: 513 - Lymphoid neoplasms|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-269|2|966|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-270|2|967|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-271|2|968|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-272|2|971|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-273|2|971|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-274|2|971|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-275|2|973|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-276|2|973|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  Head/neck missing Thorax missing,MPATH: 513 - Lymphoid neoplasms|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-277|2|974|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-278|2|975|Neoplasia malignant|Bone among musculo-skeletal system diseases|TBOS/ lumbar vertebra.|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-279|2|977|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-280|2|977|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-281|2|977|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-282|2|978|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-283|2|981|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-284|2|981|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-285|2|982|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-286|2|982|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-287|2|982|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/   Metastases  trac to visc pleura & hemorr.,MPATH: 513 - Lymphoid neoplasms|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-288|2|984|Other deterministic changes|Whole body|MCDU/  Head/neck missing|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-289|2|984|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-290|2|984|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|TMAA/  ,MPATH: 218 - neoplasm|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-291|2|985|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-292|2|986|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-293|2|987|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-294|2|988|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOVO/  ,MPATH: 242 - hemangiosarcoma|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-295|2|988|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-296|2|988|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-297|2|989|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-298|2|989|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-299|2|989|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-300|2|989|Inflammation and/or fibrotic diseases|Other local manifestations and miscellaneus|MPNA/  Pancreatitis|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-301|2|991|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-302|2|991|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-303|2|991|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-304|2|993|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-305|2|993|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-306|2|995|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/   Metastases Liver,MPATH: 513 - Lymphoid neoplasms|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-307|2|995|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-308|2|996|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-309|2|997|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-310|2|998|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-311|2|998|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-312|2|999|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/  ,MPATH: 242 - hemangiosarcoma|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-313|2|1001|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-314|2|1001|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-315|2|1002|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-316|2|1002|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-317|2|1003|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  Eye(s) missing Head/neck missing Thorax missing,MPATH: 513 - Lymphoid neoplasms|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-318|2|1003|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-319|2|1003|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-320|2|1004|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-321|2|1004|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-322|2|1004|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-323|2|1006|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-324|2|1007|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-325|2|1007|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|TCFS/ lt upper hind leg (thigh). Metastases Lung Metastases  Muscle tcfs of lt thigh infiltration of skel musc.,MPATH: 408 - soft tissue fibrosarcoma|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-326|2|1007|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-327|2|1009|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-328|2|1011|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-329|2|1011|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-330|2|1012|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-331|2|1013|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-332|2|1013|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-333|2|1014|Metabolic abnormalities|Other local manifestations and miscellaneus|MATA/|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-334|2|1016|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-335|2|1016|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-336|2|1016|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-337|2|1017|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-338|2|1019|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-339|2|1021|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-340|2|1021|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-341|2|1022|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-342|2|1022|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-343|2|1023|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-344|2|1024|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-345|2|1024|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-346|2|1024|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-347|2|1026|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-348|2|1026|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-349|2|1026|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-350|2|1028|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-351|2|1029|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-352|2|1030|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-353|2|1030|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-354|2|1030|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-355|2|1030|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-356|2|1031|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-357|2|1031|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-358|2|1031|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-359|2|1032|Neoplasia malignant|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|THVS/  ,MPATH: 242 - hemangiosarcoma|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-360|2|1032|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-361|2|1032|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-362|2|1033|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-363|2|1033|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-364|2|1033|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-365|2|1033|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-366|2|1034|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-367|2|1034|Hyperplastic changes|Other local manifestations and miscellaneus,MA: 0000003 - organ system|MOCY/  Ovary or testis,MPATH: 62 - cyst|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-368|2|1038|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/   Metastases Lung,MPATH: 513 - Lymphoid neoplasms|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-369|2|1038|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-370|2|1039|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-371|2|1040|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-372|2|1040|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-373|2|1040|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-374|2|1042|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-375|2|1043|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-376|2|1043|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-377|2|1045|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-378|2|1045|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-379|2|1045|Neoplasia malignant|Other local manifestations and miscellaneus|TMLS/ vaginal muscle wall & infiltr. connect. tiss.|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-380|2|1047|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-381|2|1047|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-382|2|1047|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-383|2|1048|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-384|2|1049|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-385|2|1051|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-386|2|1051|Neoplasia unclassified|Ovary among reproductive system diseases|TOGC/|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-387|2|1052|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-388|2|1054|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-389|2|1055|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-390|2|1057|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-391|2|1057|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-392|2|1057|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-393|2|1058|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-394|2|1061|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-395|2|1062|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-396|2|1063|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-397|2|1064|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-398|2|1065|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|TCFS/ spinal region & surround kidn. Metastases  Muscle tcfs in spinal region & surround kidn infiltrates skel musc.,MPATH: 408 - soft tissue fibrosarcoma|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-399|2|1067|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-400|2|1068|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-401|2|1068|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/   Metastases  tmls of vaginal wall to visc. peritoneum of colon & ureter.,MPATH: 513 - Lymphoid neoplasms|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-402|2|1068|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-403|2|1068|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-404|2|1069|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/   Metastases Heart Metastases Liver,MPATH: 242 - hemangiosarcoma|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-405|2|1069|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-406|2|1071|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-407|2|1074|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-408|2|1075|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/  ,MPATH: 242 - hemangiosarcoma|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-409|2|1076|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-410|2|1078|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-411|2|1078|Neoplasia malignant|Bloodvessels among cardiovascular system|TCVS/ rt thigh. Metastases  Muscle tcvs of rt thigh invas of skel musc & bone.|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-412|2|1080|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-413|2|1081|Neoplasia malignant|Bloodvessels among cardiovascular system|TMVS/ spinal musc. Muscle|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-414|2|1082|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-415|2|1082|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-416|2|1082|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|TCFS/ subcut. left axilla. Metastases  tcfs invas. into pleural cavity.,MPATH: 408 - soft tissue fibrosarcoma|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-417|2|1084|Neoplasia unclassified|Ovary among reproductive system diseases|TOGC/|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-418|2|1086|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-419|2|1086|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-420|2|1088|Neoplasia unclassified|Uterus among reproductive system diseases,MA: 0000389 - uterus|TUAC/   Metastases  Lymphoret.System tuac to mesenteric node. Metastases Lung,MPATH: 218 - neoplasm|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-421|2|1088|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-422|2|1088|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|TCFS/ back of neck & lt axillary region. Metastases  Muscle tcfs to musc of upper arm. Metastases  tcfs to salivary gl. Metastases  Skin tcfs to skin of upper arm.,MPATH: 408 - soft tissue fibrosarcoma|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-423|2|1090|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-424|2|1091|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-425|2|1091|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-426|2|1091|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-427|2|1095|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-428|2|1096|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-429|2|1096|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-430|2|1100|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-431|2|1100|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-432|2|1101|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  Eye(s) missing,MPATH: 513 - Lymphoid neoplasms|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-433|2|1101|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-434|2|1104|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLSS/  undifferentiated lymphoma,MPATH: 513 - Lymphoid neoplasms|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-435|2|1105|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-436|2|1106|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/   Metastases Heart,MPATH: 513 - Lymphoid neoplasms|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-437|2|1106|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-438|2|1106|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-439|2|1107|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-440|2|1107|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-441|2|1109|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-442|2|1109|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-443|2|1109|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-444|2|1110|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-445|2|1111|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-446|2|1114|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-447|2|1115|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-448|2|1116|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-449|2|1117|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-450|2|1117|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-451|2|1118|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-452|2|1118|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-453|2|1118|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-454|2|1119|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-455|2|1119|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-456|2|1120|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  Eye(s) missing,MPATH: 513 - Lymphoid neoplasms|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-457|2|1120|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-458|2|1121|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-459|2|1121|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-460|2|1121|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-461|2|1124|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-462|2|1126|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-463|2|1127|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-464|2|1127|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-465|2|1128|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-466|2|1129|Hyperplastic changes|Other local manifestations and miscellaneus,MA: 0000003 - organ system|MOCY/  Ovary or testis,MPATH: 62 - cyst|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-467|2|1130|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-468|2|1130|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-469|2|1130|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-470|2|1131|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-471|2|1132|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-472|2|1132|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-473|2|1132|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-474|2|1133|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-475|2|1136|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-476|2|1136|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-477|2|1137|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  Head/neck missing Eye(s) missing,MPATH: 513 - Lymphoid neoplasms|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-478|2|1140|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-479|2|1140|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-480|2|1140|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-481|2|1141|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  Eye(s) missing Head/neck missing,MPATH: 513 - Lymphoid neoplasms|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-482|2|1142|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-483|2|1144|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-484|2|1146|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-485|2|1146|Other deterministic changes|Whole body|MCDU/|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-486|2|1146|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-487|2|1147|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-488|2|1149|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-489|2|1149|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-490|2|1149|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-491|2|1151|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-492|2|1152|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-493|2|1153|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-494|2|1154|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-495|2|1157|Neoplasia malignant|Liver among hepato-pancreatic system diseases|THAC/|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-496|2|1158|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-497|2|1161|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-498|2|1163|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-499|2|1163|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-500|2|1163|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-501|2|1166|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-502|2|1166|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-503|2|1167|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-504|2|1167|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-505|2|1168|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-506|2|1169|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-507|2|1170|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-508|2|1170|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-509|2|1170|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-510|2|1171|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-511|2|1171|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-512|2|1173|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-513|2|1175|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-514|2|1176|Other deterministic changes|Whole body|MCDU/|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-515|2|1177|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-516|2|1178|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-517|2|1181|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-518|2|1183|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-519|2|1185|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-520|2|1185|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-521|2|1186|Other deterministic changes|Whole body|MCDU/|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-522|2|1186|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-523|2|1187|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-524|2|1188|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  Eye(s) missing Head/neck missing Thorax missing,MPATH: 513 - Lymphoid neoplasms|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-525|2|1189|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-526|2|1191|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-527|2|1191|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|TCFS/ subcutaneous dorsal & left lateral. Metastases  tcfs infiltration adipose tissue  & visc. perit. of spleen, pancr. & kidney.,MPATH: 408 - soft tissue fibrosarcoma|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-528|2|1192|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-529|2|1192|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-530|2|1192|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-531|2|1193|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-532|2|1193|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-533|2|1193|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-534|2|1195|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-535|2|1196|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-536|2|1200|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-537|2|1201|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-538|2|1201|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-539|2|1211|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  Head/neck missing Eye(s) missing,MPATH: 513 - Lymphoid neoplasms|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-540|2|1211|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-541|2|1213|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-542|2|1215|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-543|2|1217|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-544|2|1221|Neoplasia malignant|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|THVS/  ,MPATH: 242 - hemangiosarcoma|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-545|2|1222|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-546|2|1223|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-547|2|1226|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-548|2|1228|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-549|2|1228|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-550|2|1231|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-551|2|1236|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-552|2|1239|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-553|2|1239|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-554|2|1241|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-555|2|1244|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-556|2|1245|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-557|2|1246|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-558|2|1246|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-559|2|1258|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/   Metastases  Muscle tcfs infilt. of skeletal muscle.,MPATH: 513 - Lymphoid neoplasms|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-560|2|1260|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOVO/  ,MPATH: 242 - hemangiosarcoma|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-561|2|1260|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-562|2|1261|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-563|2|1263|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-564|2|1264|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-565|2|1264|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|TCFS/ subcut. left latero-ventral region. Metastases Liver Metastases  tcfs metast. to pleura & peritoneum. Metastases Lung,MPATH: 408 - soft tissue fibrosarcoma|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-566|2|1266|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-567|2|1267|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-568|2|1269|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-569|2|1270|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-570|2|1273|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-571|2|1275|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-572|2|1280|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-573|2|1282|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-574|2|1286|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-575|2|1289|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-576|2|1294|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-577|2|1295|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|TCFS/ subcut. right thoracic region. Metastases Lung tmaa to lung. Metastases Lung Metastases  tcfs spread to visc. pleura & pericard. & epicard.,MPATH: 408 - soft tissue fibrosarcoma|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-578|2|1296|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-579|2|1303|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-580|2|1303|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-581|2|1310|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-582|2|1313|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-583|2|1324|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-584|2|1327|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-585|2|1332|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-586|2|1332|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-587|2|1337|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-588|2|1339|Other deterministic changes|Whole body|MCDU/|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-589|2|1346|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-590|2|1349|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-591|2|1351|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-592|2|1366|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-593|2|1366|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-594|2|1373|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-595|2|1388|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-596|2|1390|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-597|2|1428|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-598|2|1433|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-599|2|1440|n/a|n/a|n/a|
1003-29-2|n/a,OX|1|100|shamexposed|0|grays|External exposure|code 0X (0A OB OC OX combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|584 records survival 873 ± 8 lifespan study|1003-29-2-600|2|1471|Other deterministic changes|Whole body|MCDU/|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-1|3|115|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-2|3|115|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-3|3|115|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-4|3|115|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-5|3|115|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-6|3|226|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-7|3|428|Neoplasia unclassified|Other local manifestations and miscellaneus|TKWR: TRAC TO KIDNEY.|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-8|3|484|Neoplasia malignant|Bloodvessels among cardiovascular system|TCVS/ back-cervical in adipose tissue.|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-9|3|493|Neoplasia malignant|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|THVS/  ,MPATH: 242 - hemangiosarcoma|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-10|3|505|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-11|3|512|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-12|3|512|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-13|3|516|Neoplasia malignant|Nervous system and special sense organs,MA: 0000016 - nervous system|TNNS/ along lumbar spine. Metastases Lung Metastases  Muscle rib cage from tnns.,MPATH: 437 - neurofibrosarcoma|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-14|3|518|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-15|3|525|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-16|3|535|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-17|3|560|Neoplasia unclassified|Other local manifestations and miscellaneus|TXWR: TRAC TO ADNEXUS OF RIBS.|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-18|3|563|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/   Metastases  Muscle tsec infiltr. of skel. muscle.,MPATH: 513 - Lymphoid neoplasms|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-19|3|565|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-20|3|567|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-21|3|572|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-22|3|573|Neoplasia malignant|Liver among hepato-pancreatic system diseases|THAC/|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-23|3|593|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-24|3|603|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-25|3|611|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-26|3|615|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-27|3|615|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-28|3|620|Other deterministic changes|Whole body|MCDU/|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-29|3|624|Neoplasia malignant|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|THVS/  ,MPATH: 242 - hemangiosarcoma|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-30|3|626|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-31|3|626|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-32|3|629|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-33|3|639|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-34|3|643|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-35|3|652|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-36|3|652|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-37|3|654|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-38|3|663|Inflammation and/or fibrotic diseases|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|MHCN/  Coagulative focal hepatitis,MPATH: 212 - inflammation|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-39|3|669|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-40|3|674|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-41|3|674|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-42|3|677|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-43|3|680|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-44|3|690|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-45|3|692|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-46|3|693|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-47|3|694|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-48|3|698|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-49|3|698|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-50|3|699|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-51|3|703|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-52|3|705|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases Kidney Metastases  trac to visceral & parietal pleura. Metastases  Muscle trac to intercostal muscles. Metastases Heart,MPATH: 268 - adenocarcinoma|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-53|3|708|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-54|3|715|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/  ,MPATH: 242 - hemangiosarcoma|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-55|3|716|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-56|3|720|Neoplasia malignant|Bloodvessels among cardiovascular system|TIVS/ jejunum.|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-57|3|721|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-58|3|724|Neoplasia malignant|Nervous system and special sense organs,MA: 0000016 - nervous system|TNMS/  ,MPATH: 551 - sarcoma|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-59|3|725|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-60|3|727|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-61|3|730|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-62|3|731|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-63|3|732|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-64|3|733|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-65|3|733|Neoplasia malignant|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|THVS/  ,MPATH: 242 - hemangiosarcoma|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-66|3|733|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-67|3|734|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-68|3|738|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-69|3|742|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-70|3|743|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-71|3|744|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-72|3|744|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-73|3|747|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-74|3|750|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-75|3|751|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  Eye(s) missing Head/neck missing,MPATH: 513 - Lymphoid neoplasms|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-76|3|751|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-77|3|754|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-78|3|757|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-79|3|757|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-80|3|759|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-81|3|763|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-82|3|763|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases Kidney,MPATH: 268 - adenocarcinoma|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-83|3|764|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-84|3|764|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-85|3|765|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-86|3|765|Other deterministic changes|Whole body|MCDU/|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-87|3|766|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-88|3|771|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-89|3|772|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-90|3|773|Neoplasia malignant|Bloodvessels among cardiovascular system|TCVS/ fat of subcutis of head. Metastases  Muscle tcvs invades musc of head. Metastases  Skin tcvs invades skin of head.|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-91|3|773|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-92|3|775|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-93|3|777|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-94|3|778|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-95|3|779|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-96|3|779|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-97|3|780|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-98|3|782|Neoplasia unclassified|Other local manifestations and miscellaneus|TMWB: TBOS OF SACRAL SPINE INVAS OF SKEL MUSC.|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-99|3|783|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-100|3|784|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-101|3|784|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-102|3|785|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-103|3|786|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-104|3|786|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-105|3|793|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-106|3|793|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-107|3|793|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-108|3|794|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-109|3|795|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-110|3|796|Neoplasia unclassified|Central nervous system among nervous system|TNOS/|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-111|3|797|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-112|3|798|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-113|3|800|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-114|3|802|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-115|3|802|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-116|3|803|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-117|3|804|Neoplasia unclassified|Other local manifestations and miscellaneus|TXWR: TRAC TO ADNEXUS OF RIBS.|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-118|3|806|Other deterministic changes|Whole body|MCDU/|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-119|3|806|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-120|3|807|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-121|3|807|Neoplasia unclassified|Other local manifestations and miscellaneus|TKWR: TRAC TO KIDNEY.|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-122|3|811|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-123|3|811|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-124|3|812|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/  ,MPATH: 242 - hemangiosarcoma|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-125|3|813|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-126|3|814|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-127|3|815|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/   Metastases Lung,MPATH: 513 - Lymphoid neoplasms|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-128|3|817|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-129|3|819|Neoplasia unclassified|Other local manifestations and miscellaneus|TMWN: RIB CAGE FROM TNNS.|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-130|3|820|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-131|3|820|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-132|3|822|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-133|3|823|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-134|3|826|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-135|3|826|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-136|3|827|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-137|3|828|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-138|3|829|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-139|3|831|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-140|3|832|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-141|3|833|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-142|3|834|Neoplasia unclassified|Other local manifestations and miscellaneus|TMWG: TGAC TO MUSCLE OF ORBIT.|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-143|3|835|Other deterministic changes|Whole body|MCDU/|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-144|3|836|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-145|3|836|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-146|3|837|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-147|3|837|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-148|3|840|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-149|3|841|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-150|3|841|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-151|3|841|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-152|3|843|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-153|3|844|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases  Muscle trac to rib cage musc. Metastases  Lymphoret.System trac to ptln. Metastases Heart Metastases Kidney Metastases  hard gl & panc invas by trac.,MPATH: 268 - adenocarcinoma|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-154|3|845|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-155|3|848|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-156|3|849|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-157|3|854|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-158|3|858|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-159|3|858|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-160|3|860|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-161|3|860|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-162|3|861|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  Eye(s) missing Head/neck missing,MPATH: 513 - Lymphoid neoplasms|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-163|3|861|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-164|3|862|Neoplasia malignant|Bloodvessels among cardiovascular system|TMVS/ sacral spinal region. Muscle Metastases  tmvs invasion of spinal nerves.|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-165|3|864|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-166|3|864|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-167|3|864|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases  Muscle trac invades intercostal muscle. Metastases  Lymphoret.System trac invade pt. & br. ln. Metastases  Muscle tcvs invades skeletal muscle of thigh.,MPATH: 268 - adenocarcinoma|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-168|3|866|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-169|3|867|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-170|3|867|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-171|3|868|Neoplasia unclassified|Other local manifestations and miscellaneus|TLWR: TRAC TO PARATHYMUS.|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-172|3|869|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-173|3|869|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-174|3|869|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-175|3|869|Neoplasia unclassified|Other local manifestations and miscellaneus|TXWR: TRAC TO PLEURA & PARAESOPHAGEAL TISS.|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-176|3|871|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-177|3|871|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-178|3|871|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases  trac to adnexus of ribs.,MPATH: 268 - adenocarcinoma|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-179|3|873|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-180|3|874|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-181|3|875|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-182|3|880|Neoplasia malignant|Liver among hepato-pancreatic system diseases|THAC/|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-183|3|880|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-184|3|881|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-185|3|882|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-186|3|884|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-187|3|884|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-188|3|885|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-189|3|885|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-190|3|885|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-191|3|886|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-192|3|887|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases  trac to pleura & paraesophageal tiss.,MPATH: 268 - adenocarcinoma|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-193|3|888|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-194|3|889|Neoplasia unclassified|Other local manifestations and miscellaneus|TMWB: TBVS OF LUMBAR SPINE INVADES SKEL MUSC.|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-195|3|889|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-196|3|890|Other deterministic changes|Whole body|MCDU/|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-197|3|890|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-198|3|892|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-199|3|893|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-200|3|894|Neoplasia malignant|Bloodvessels among cardiovascular system|TBVS/ lumbar spine. Metastases  Muscle tbvs of lumbar spine invades skel musc.|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-201|3|895|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-202|3|896|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-203|3|896|Neoplasia unclassified|Other local manifestations and miscellaneus|TXWR: TRAC TO PLEURA & PARAESOPHAGEAL TISS.|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-204|3|897|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-205|3|899|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-206|3|899|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLSS/  undifferentiated lymphoma,MPATH: 513 - Lymphoid neoplasms|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-207|3|900|Neoplasia unclassified|Other local manifestations and miscellaneus|TKWR: TRAC TO KIDNEY.|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-208|3|900|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-209|3|901|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-210|3|901|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-211|3|901|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-212|3|903|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-213|3|903|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-214|3|904|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-215|3|904|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/   Metastases  trac invade visc. pleura & parietal,MPATH: 513 - Lymphoid neoplasms|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-216|3|905|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-217|3|908|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-218|3|908|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-219|3|908|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-220|3|910|Neoplasia malignant|Bloodvessels among cardiovascular system|TCVS/ abdominal soft tissues.|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-221|3|910|Neoplasia unclassified|Other local manifestations and miscellaneus|TMWB: TBVS OF LUMBAR SPINE INVADES SKEL MUSC.|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-222|3|911|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-223|3|914|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-224|3|917|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases Heart Metastases  Lymphoret.System trac to parathymus.,MPATH: 268 - adenocarcinoma|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-225|3|918|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-226|3|918|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-227|3|918|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-228|3|920|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-229|3|920|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-230|3|924|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-231|3|924|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-232|3|925|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-233|3|926|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases  trac to visceral pleura. Metastases Liver Metastases Kidney Metastases  Lymphoret.System trac to parathymic.,MPATH: 268 - adenocarcinoma|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-234|3|926|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-235|3|927|Neoplasia malignant|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|THVS/ also perit adj to ureter & kidney.,MPATH: 242 - hemangiosarcoma|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-236|3|928|Neoplasia benign|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVO/   Metastases Heart,MPATH: 240 - hemangioma|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-237|3|930|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-238|3|931|Neoplasia malignant|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|THVS/  ,MPATH: 242 - hemangiosarcoma|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-239|3|933|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-240|3|934|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-241|3|935|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-242|3|936|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-243|3|936|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-244|3|937|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-245|3|942|Neoplasia unclassified|Other local manifestations and miscellaneus|TKWR: TRAC TO KIDNEY.|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-246|3|942|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-247|3|943|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases Lung,MPATH: 268 - adenocarcinoma|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-248|3|944|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-249|3|945|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-250|3|946|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-251|3|949|Neoplasia unclassified|Other local manifestations and miscellaneus|TMWC: TCVS INVADES MUSC OF HEAD.|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-252|3|949|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-253|3|950|Neoplasia unclassified|Other local manifestations and miscellaneus|TLWR: TRAC INVADE PT. & BR. LN.|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-254|3|951|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-255|3|951|Neoplasia unclassified|Other local manifestations and miscellaneus|TLWR: TRAC TO THORACIC NODE.|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-256|3|952|Neoplasia systemic|Haematolymphatic system|TLML/|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-257|3|952|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-258|3|953|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-259|3|955|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-260|3|956|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-261|3|956|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-262|3|956|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-263|3|957|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-264|3|958|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-265|3|959|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-266|3|960|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-267|3|962|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-268|3|962|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/   Metastases  Lymphoret.System trac to thoracic node.,MPATH: 513 - Lymphoid neoplasms|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-269|3|962|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-270|3|962|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-271|3|963|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-272|3|964|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-273|3|966|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-274|3|967|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-275|3|968|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-276|3|968|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-277|3|968|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-278|3|970|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-279|3|973|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-280|3|973|Inflammation and/or fibrotic diseases|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|MHCN/  Coagulative focal hepatitis,MPATH: 212 - inflammation|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-281|3|973|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-282|3|974|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-283|3|974|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-284|3|974|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-285|3|976|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases  trac to pleura pariet. & visc.Head/neck missing Eye(s) missing,MPATH: 268 - adenocarcinoma|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-286|3|977|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-287|3|977|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-288|3|977|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|TKAC/  ,MPATH: 549 - carcinoma|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-289|3|978|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-290|3|979|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-291|3|979|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-292|3|982|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-293|3|983|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-294|3|983|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-295|3|983|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-296|3|984|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-297|3|985|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-298|3|985|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-299|3|985|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-300|3|986|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-301|3|986|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-302|3|989|Neoplasia malignant|Bloodvessels among cardiovascular system|TMVS/ subcut dorsal rt pelvic region. Muscle|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-303|3|989|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-304|3|990|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-305|3|990|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-306|3|990|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-307|3|991|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-308|3|992|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  Head/neck missing Eye(s) missing,MPATH: 513 - Lymphoid neoplasms|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-309|3|993|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|TXEC/ inguinal & lower abdominal regions.Eye(s) missing Head/neck missing,MPATH: 446 - squamous cell carcinoma|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-310|3|994|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-311|3|995|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-312|3|995|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-313|3|995|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-314|3|996|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-315|3|996|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-316|3|997|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-317|3|998|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-318|3|999|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-319|3|1000|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-320|3|1000|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-321|3|1000|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-322|3|1001|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-323|3|1001|Neoplasia unclassified|Other local manifestations and miscellaneus|TMWN: RIB CAGE FROM TNNS.|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-324|3|1001|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-325|3|1002|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-326|3|1002|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/  ,MPATH: 242 - hemangiosarcoma|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-327|3|1002|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLSL/  undifferentiated leukemia lymphoret.tissue,MPATH: 335 - hematopoietic/lymphoid malignancies/disorder|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-328|3|1002|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-329|3|1002|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-330|3|1003|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-331|3|1005|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-332|3|1006|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-333|3|1006|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/  ,MPATH: 242 - hemangiosarcoma|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-334|3|1007|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-335|3|1008|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-336|3|1009|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-337|3|1009|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases Kidney,MPATH: 268 - adenocarcinoma|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-338|3|1010|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  Head/neck missing Eye(s) missing,MPATH: 513 - Lymphoid neoplasms|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-339|3|1011|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases  trac to pleura.,MPATH: 268 - adenocarcinoma|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-340|3|1011|Neoplasia malignant|Liver among hepato-pancreatic system diseases|THAC/|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-341|3|1012|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-342|3|1016|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-343|3|1016|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-344|3|1017|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-345|3|1017|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-346|3|1017|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-347|3|1018|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  Head/neck missing,MPATH: 268 - adenocarcinoma|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-348|3|1018|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/   Metastases  tbvs of lumbar spine invades sp canal, sp cd & nerves of spine.,MPATH: 513 - Lymphoid neoplasms|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-349|3|1019|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-350|3|1020|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-351|3|1020|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-352|3|1021|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-353|3|1022|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-354|3|1022|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-355|3|1023|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-356|3|1024|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-357|3|1024|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-358|3|1025|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-359|3|1026|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-360|3|1028|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-361|3|1028|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-362|3|1029|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-363|3|1031|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-364|3|1031|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-365|3|1032|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-366|3|1033|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/  ,MPATH: 242 - hemangiosarcoma|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-367|3|1034|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  Eye(s) missing Head/neck missing,MPATH: 513 - Lymphoid neoplasms|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-368|3|1036|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-369|3|1036|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-370|3|1039|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-371|3|1039|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/  ,MPATH: 242 - hemangiosarcoma|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-372|3|1040|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-373|3|1041|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-374|3|1043|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-375|3|1043|Other deterministic changes|Whole body|MCDU/  Head/neck missing|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-376|3|1044|Neoplasia unclassified|Other local manifestations and miscellaneus|TMWG: TGAC TO MUSCLE OF ORBIT.|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-377|3|1044|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-378|3|1044|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  Head/neck missing Eye(s) missing,MPATH: 513 - Lymphoid neoplasms|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-379|3|1044|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-380|3|1044|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-381|3|1046|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-382|3|1046|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  Head/neck missing Eye(s) missing,MPATH: 513 - Lymphoid neoplasms|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-383|3|1049|Neoplasia unclassified|Other local manifestations and miscellaneus|TMWN: RIB CAGE FROM TNNS.|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-384|3|1050|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-385|3|1051|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-386|3|1051|Neoplasia unclassified|Other local manifestations and miscellaneus|TXWR: TRAC TO ADNEXUS OF RIBS.|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-387|3|1052|Other deterministic changes|Whole body|MCDU/|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-388|3|1053|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-389|3|1053|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-390|3|1054|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-391|3|1055|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-392|3|1055|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-393|3|1055|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-394|3|1056|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-395|3|1057|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/   Metastases  trac metastasis to panc & perit of spleen.,MPATH: 513 - Lymphoid neoplasms|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-396|3|1057|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-397|3|1057|Neoplasia unclassified|Other local manifestations and miscellaneus|TLWR: TRAC TO PARATHYMUS.|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-398|3|1058|Neoplasia unclassified|Other local manifestations and miscellaneus|TRWH: THAC TO LUNG.|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-399|3|1058|Neoplasia malignant|Bone among musculo-skeletal system diseases|TBOS/ left thigh.|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-400|3|1059|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-401|3|1061|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-402|3|1062|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-403|3|1062|Neoplasia malignant|Bloodvessels among cardiovascular system|TCVS/ abd. cavity-dorsal. Metastases  Muscle tcvs of abd. cavity invas. of muscle & on visc. perit.|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-404|3|1063|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-405|3|1064|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-406|3|1066|Neoplasia unclassified|Other local manifestations and miscellaneus|TKWR: TRAC TO KIDNEY.|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-407|3|1067|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-408|3|1068|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-409|3|1069|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-410|3|1069|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/   Metastases  Muscle trac to costal muscles.,MPATH: 513 - Lymphoid neoplasms|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-411|3|1071|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-412|3|1072|Inflammation and/or fibrotic diseases|Lower respiratory system,MA: 0000415 - lung|MRMP/  Murine,MPATH: 212 - inflammation|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-413|3|1072|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-414|3|1073|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-415|3|1074|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-416|3|1075|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-417|3|1075|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-418|3|1077|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-419|3|1079|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-420|3|1079|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-421|3|1080|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-422|3|1080|Neoplasia malignant|Bloodvessels among cardiovascular system|TYVS/  Heart|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-423|3|1080|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-424|3|1081|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-425|3|1081|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-426|3|1081|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-427|3|1081|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-428|3|1084|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-429|3|1085|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-430|3|1085|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-431|3|1086|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-432|3|1086|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-433|3|1088|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-434|3|1088|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-435|3|1088|Other deterministic changes|Whole body|MCDU/|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-436|3|1089|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-437|3|1090|Neoplasia systemic|Haematolymphatic system|TLML/|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-438|3|1090|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-439|3|1092|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-440|3|1092|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-441|3|1094|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-442|3|1094|Neoplasia malignant|Other local manifestations and miscellaneus|TMLS/ dorsal rt thigh & base of tail w/ invas of skin.|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-443|3|1094|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-444|3|1095|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-445|3|1096|Other deterministic changes|Whole body|MCDU/|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-446|3|1097|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-447|3|1098|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-448|3|1098|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-449|3|1098|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-450|3|1099|Neoplasia unclassified|Other local manifestations and miscellaneus|TMWN: RIB CAGE FROM TNNS.|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-451|3|1100|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-452|3|1101|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-453|3|1101|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-454|3|1102|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-455|3|1103|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-456|3|1104|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-457|3|1104|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-458|3|1104|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-459|3|1104|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-460|3|1105|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  Eye(s) missing Head/neck missing,MPATH: 513 - Lymphoid neoplasms|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-461|3|1107|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-462|3|1108|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-463|3|1108|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-464|3|1109|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-465|3|1111|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-466|3|1113|Other deterministic changes|Whole body|MCDU/|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-467|3|1113|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-468|3|1114|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-469|3|1116|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-470|3|1116|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-471|3|1118|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/  ,MPATH: 242 - hemangiosarcoma|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-472|3|1118|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  Head/neck missing Eye(s) missing,MPATH: 513 - Lymphoid neoplasms|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-473|3|1119|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-474|3|1119|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-475|3|1120|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-476|3|1121|Neoplasia unclassified|Other local manifestations and miscellaneus|TKWR: TRAC TO KIDNEY.|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-477|3|1123|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-478|3|1123|Neoplasia systemic|Haematolymphatic system|TLML/|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-479|3|1123|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-480|3|1123|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-481|3|1124|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-482|3|1124|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-483|3|1124|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-484|3|1125|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-485|3|1125|Other deterministic changes|Whole body|MCDU/|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-486|3|1125|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-487|3|1126|Neoplasia malignant|Other local manifestations and miscellaneus|TMLS/ musc of thorax.|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-488|3|1128|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-489|3|1128|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-490|3|1128|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-491|3|1129|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-492|3|1134|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-493|3|1135|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-494|3|1136|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-495|3|1136|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/  ,MPATH: 242 - hemangiosarcoma|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-496|3|1137|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-497|3|1138|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-498|3|1138|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-499|3|1138|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-500|3|1138|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-501|3|1141|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-502|3|1142|Neoplasia unclassified|Other local manifestations and miscellaneus|TKWR: TRAC TO KIDNEY.|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-503|3|1144|Neoplasia malignant|Endocrine system|TGAC/   Metastases  Muscle tgac to muscle of orbit. Metastases Lung|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-504|3|1145|Other deterministic changes|Whole body|MCDU/|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-505|3|1145|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-506|3|1147|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-507|3|1148|Neoplasia unclassified|Other local manifestations and miscellaneus|TMWS: TSEC INFILTR. OF SKEL. MUSCLE.|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-508|3|1149|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-509|3|1150|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-510|3|1151|Neoplasia malignant|Bone among musculo-skeletal system diseases|TBOS/ sacral spine. Metastases  Muscle tbos of sacral spine invas of skel musc. Metastases Lung Metastases  tbos of sacral spine invas of spinal nerves.|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-511|3|1155|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-512|3|1156|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-513|3|1157|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-514|3|1158|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-515|3|1159|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-516|3|1160|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-517|3|1161|Neoplasia unclassified|Other local manifestations and miscellaneus|TKWR: TRAC TO KIDNEY.|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-518|3|1161|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-519|3|1161|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-520|3|1163|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-521|3|1170|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-522|3|1170|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-523|3|1170|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-524|3|1171|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-525|3|1171|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-526|3|1171|Neoplasia malignant|Liver among hepato-pancreatic system diseases|THAC/|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-527|3|1172|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-528|3|1172|Other deterministic changes|Whole body|MCDU/|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-529|3|1172|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-530|3|1173|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-531|3|1178|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/   Metastases  Muscle trac invading skel musc of thorax.,MPATH: 513 - Lymphoid neoplasms|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-532|3|1179|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-533|3|1181|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-534|3|1181|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-535|3|1181|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-536|3|1184|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-537|3|1184|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-538|3|1184|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-539|3|1184|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-540|3|1185|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-541|3|1187|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-542|3|1188|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-543|3|1189|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-544|3|1191|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-545|3|1191|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-546|3|1195|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|TXAC/ salivary gland. Metastases  Lung txac (salivary gland) metast. to lungs.,MPATH: 268 - adenocarcinoma|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-547|3|1195|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-548|3|1198|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-549|3|1198|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-550|3|1200|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-551|3|1202|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-552|3|1202|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  Head/neck missing,MPATH: 513 - Lymphoid neoplasms|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-553|3|1203|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-554|3|1204|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-555|3|1204|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-556|3|1208|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-557|3|1214|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-558|3|1214|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-559|3|1216|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-560|3|1217|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-561|3|1218|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-562|3|1220|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-563|3|1221|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-564|3|1224|Neoplasia unclassified|Other local manifestations and miscellaneus|TXWR: TRAC TO PLEURA.|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-565|3|1227|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/   Metastases  Muscle trac to skel. musc. over vertebrae.,MPATH: 513 - Lymphoid neoplasms|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-566|3|1236|Neoplasia unclassified|Other local manifestations and miscellaneus|TMWG: TGAC TO MUSCLE OF ORBIT.|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-567|3|1239|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-568|3|1240|Other deterministic changes|Whole body|MCDU/|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-569|3|1245|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-570|3|1251|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-571|3|1251|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-572|3|1251|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-573|3|1263|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-574|3|1265|Neoplasia unclassified|Other local manifestations and miscellaneus|TMWC: TCVS INVADES MUSC OF HEAD.|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-575|3|1265|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-576|3|1267|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-577|3|1270|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-578|3|1273|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-579|3|1274|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-580|3|1280|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-581|3|1281|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-582|3|1282|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-583|3|1288|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-584|3|1290|Neoplasia malignant|Liver among hepato-pancreatic system diseases|THAC/|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-585|3|1298|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-586|3|1301|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-587|3|1306|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-588|3|1308|Neoplasia unclassified|Other local manifestations and miscellaneus|TKWR: TRAC TO KIDNEY.|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-589|3|1310|Other deterministic changes|Whole body|MCDU/|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-590|3|1311|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-591|3|1312|Inflammation and/or fibrotic diseases|Integumentary system|MSDA/  acute|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-592|3|1327|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-593|3|1336|n/a|n/a|n/a|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-594|3|1341|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  Head/neck missing Eye(s) missing,MPATH: 268 - adenocarcinoma|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-595|3|1353|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-596|3|1381|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-597|3|1385|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-598|3|1387|Other deterministic changes|Whole body|MCDU/|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-599|3|1404|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-3|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|594 records survival 861 ± 7 lifespan study|1003-29-3-600|3|1421|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-1|4|215|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-2|4|281|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-3|4|285|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-4|4|394|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-5|4|466|Other deterministic changes|Whole body|MCDU/|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-6|4|512|Other deterministic changes|Whole body|MCDU/|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-7|4|519|Other deterministic changes|Whole body|MCDU/|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-8|4|520|Other deterministic changes|Whole body|MCDU/|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-9|4|530|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-10|4|532|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-11|4|535|Hyperplastic changes|Other local manifestations and miscellaneus,MA: 0000003 - organ system|MOCY/  Ovary or testis,MPATH: 62 - cyst|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-12|4|536|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-13|4|546|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-14|4|550|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-15|4|551|Other deterministic changes|Whole body|MCDU/|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-16|4|555|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-17|4|561|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-18|4|561|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/   Metastases  Muscle tcvs to muscle of femur & abd. wall & femur.,MPATH: 242 - hemangiosarcoma|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-19|4|579|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-20|4|590|Hyperplastic changes|Other local manifestations and miscellaneus,MA: 0000003 - organ system|MOCY/  Ovary or testis,MPATH: 62 - cyst|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-21|4|590|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-22|4|596|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-23|4|597|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-24|4|603|Other deterministic changes|Whole body|MCDU/|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-25|4|607|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-26|4|607|Neoplasia unclassified|Other local manifestations and miscellaneus|TMWC: TCVS TO MUSCLE OF FEMUR & ABD. WALL & FEMUR.|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-27|4|611|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-28|4|612|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-29|4|613|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-30|4|618|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-31|4|628|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-32|4|636|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-33|4|649|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-34|4|654|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-35|4|666|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-36|4|668|Neoplasia malignant|Bloodvessels among cardiovascular system|TCVS/ in adipose tissue of left hind leg.|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-37|4|671|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-38|4|673|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-39|4|679|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-40|4|681|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-41|4|684|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-42|4|686|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-43|4|686|Neoplasia malignant|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOVS/  Thorax missing Head/neck missing Eye(s) missing,MPATH: 242 - hemangiosarcoma|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-44|4|687|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-45|4|687|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-46|4|688|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-47|4|689|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-48|4|695|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-49|4|699|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-50|4|702|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-51|4|703|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-52|4|704|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-53|4|706|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-54|4|706|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-55|4|706|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-56|4|708|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-57|4|709|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-58|4|711|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-59|4|712|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-60|4|715|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-61|4|715|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-62|4|718|Hyperplastic changes|Other local manifestations and miscellaneus,MA: 0000003 - organ system|MOCY/  Ovary or testis,MPATH: 62 - cyst|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-63|4|722|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-64|4|722|Hyperplastic changes|Other local manifestations and miscellaneus,MA: 0000003 - organ system|MOCY/  Ovary or testis,MPATH: 62 - cyst|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-65|4|725|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-66|4|727|Neoplasia unclassified|Other local manifestations and miscellaneus|TMWC: TCFS INVAS. OF THIGH MUSCLE.|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-67|4|728|Neoplasia systemic|Haematolymphatic system|TLML/|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-68|4|730|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  Eye(s) missing Head/neck missing,MPATH: 513 - Lymphoid neoplasms|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-69|4|730|Neoplasia malignant|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|THVS/  ,MPATH: 242 - hemangiosarcoma|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-70|4|731|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-71|4|735|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-72|4|736|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-73|4|736|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-74|4|736|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-75|4|737|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-76|4|739|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-77|4|740|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-78|4|743|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-79|4|744|Inflammation and/or fibrotic diseases|Cardiovascular system,MA: 0000164 - myocardium|MMCC/ MMCC/ MMCC/ MMCC/  chronic,MPATH: 212 - inflammation|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-80|4|745|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-81|4|745|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-82|4|746|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-83|4|747|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-84|4|748|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-85|4|751|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-86|4|752|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-87|4|755|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-88|4|756|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-89|4|760|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-90|4|760|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-91|4|761|Neoplasia unclassified|Other local manifestations and miscellaneus|TMWC: TCFS OF ABD. CAVITY INVADES ABD. MUSCLE.|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-92|4|761|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-93|4|764|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-94|4|764|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-95|4|766|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-96|4|766|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-97|4|768|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-98|4|768|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-99|4|771|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-100|4|772|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-101|4|774|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-102|4|774|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-103|4|777|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-104|4|778|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-105|4|780|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-106|4|780|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-107|4|782|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-108|4|783|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-109|4|786|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-110|4|786|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-111|4|788|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-112|4|791|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-113|4|793|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-114|4|795|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-115|4|797|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-116|4|798|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-117|4|799|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-118|4|800|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-119|4|800|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-120|4|801|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-121|4|802|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-122|4|803|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-123|4|807|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-124|4|809|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-125|4|810|Hyperplastic changes|Other local manifestations and miscellaneus,MA: 0000003 - organ system|MOCY/  Ovary or testis,MPATH: 62 - cyst|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-126|4|811|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-127|4|811|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-128|4|812|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-129|4|812|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-130|4|814|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-131|4|818|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-132|4|820|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-133|4|820|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  Head/neck missing,MPATH: 513 - Lymphoid neoplasms|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-134|4|821|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-135|4|822|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-136|4|823|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-137|4|824|Other deterministic changes|Whole body|MCDU/|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-138|4|824|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-139|4|825|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-140|4|826|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-141|4|826|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-142|4|826|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-143|4|826|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-144|4|827|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-145|4|827|Neoplasia unclassified|Other local manifestations and miscellaneus|TMWC: TCFS OF ABD. CAV. INVASION OF MUSCLE OF ABD. WALL.|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-146|4|828|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-147|4|828|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-148|4|828|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-149|4|832|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-150|4|833|Neoplasia unclassified|Other local manifestations and miscellaneus|TOWX: TXVS OF PERIT. INFILTRATING OVARY.|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-151|4|834|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-152|4|837|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  Eye(s) missing,MPATH: 513 - Lymphoid neoplasms|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-153|4|840|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-154|4|842|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/   Metastases Lung,MPATH: 513 - Lymphoid neoplasms|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-155|4|844|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-156|4|847|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-157|4|848|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-158|4|849|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-159|4|849|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-160|4|849|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-161|4|849|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-162|4|849|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-163|4|850|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-164|4|852|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases  Muscle trac metas. to costal muscle & dermis.,MPATH: 268 - adenocarcinoma|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-165|4|855|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-166|4|856|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-167|4|857|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-168|4|857|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-169|4|858|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-170|4|858|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  Eye(s) missing Head/neck missing,MPATH: 513 - Lymphoid neoplasms|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-171|4|858|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-172|4|859|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-173|4|860|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-174|4|860|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-175|4|861|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-176|4|862|Other deterministic changes|Whole body|MCDU/  Head/neck missing|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-177|4|862|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-178|4|863|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|TCFS/ in abdominal cavity. Metastases  tcfs of abd. cavity invades visc. perit. of spl. & kidney, intest wall & uterine outer wall. Metastases  Muscle tcfs of abd. cavity invades abd. muscle.,MPATH: 408 - soft tissue fibrosarcoma|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-179|4|863|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-180|4|864|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-181|4|864|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-182|4|864|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-183|4|864|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-184|4|865|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-185|4|866|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-186|4|866|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-187|4|866|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-188|4|866|Other deterministic changes|Whole body|MCDU/  Eye(s) missing Thorax missing Head/neck missing|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-189|4|869|Other deterministic changes|Whole body|MCDU/  Eye(s) missing|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-190|4|869|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-191|4|870|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  Eye(s) missing Head/neck missing,MPATH: 513 - Lymphoid neoplasms|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-192|4|871|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-193|4|871|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-194|4|873|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-195|4|874|Hyperplastic changes|Other local manifestations and miscellaneus,MA: 0000003 - organ system|MOCY/  Ovary or testis,MPATH: 62 - cyst|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-196|4|874|Neoplasia unclassified|Other local manifestations and miscellaneus|TRWX: TDTC (UBLAD) TO LUNG.|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-197|4|875|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-198|4|877|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-199|4|877|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-200|4|878|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-201|4|878|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-202|4|879|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-203|4|879|Neoplasia malignant|Liver among hepato-pancreatic system diseases|THAC/|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-204|4|880|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-205|4|881|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXL/  Mixed histiocyt.leukemia,MPATH: 513 - Lymphoid neoplasms|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-206|4|881|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-207|4|882|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-208|4|883|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-209|4|886|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-210|4|886|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-211|4|886|Degenerative changes|Kidney among urinary system diseases,MA: 0000368 - kidney|MCRD/  ,MPATH: 1 - cell and tissue damage|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-212|4|888|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-213|4|888|Neoplasia unclassified|Other local manifestations and miscellaneus|TMWC: TCFS INVAS. OF SKEL. MUSCLE.|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-214|4|889|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-215|4|889|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-216|4|890|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-217|4|891|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-218|4|892|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-219|4|892|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-220|4|893|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-221|4|893|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-222|4|893|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-223|4|893|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-224|4|893|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-225|4|894|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-226|4|895|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-227|4|896|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-228|4|897|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-229|4|897|Neoplasia unclassified|Other local manifestations and miscellaneus|TMWR: TRAC METAS. TO COSTAL MUSCLE & DERMIS.|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-230|4|900|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-231|4|900|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  Eye(s) missing Head/neck missing,MPATH: 513 - Lymphoid neoplasms|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-232|4|902|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-233|4|903|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-234|4|903|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-235|4|904|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-236|4|904|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-237|4|904|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-238|4|908|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-239|4|909|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-240|4|909|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-241|4|912|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-242|4|912|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-243|4|913|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-244|4|913|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-245|4|914|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-246|4|915|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-247|4|917|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-248|4|918|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-249|4|918|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-250|4|919|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-251|4|919|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-252|4|920|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-253|4|920|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-254|4|921|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-255|4|921|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-256|4|921|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-257|4|923|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-258|4|925|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-259|4|925|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-260|4|925|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-261|4|926|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-262|4|927|Neoplasia malignant|Bloodvessels among cardiovascular system|TCVS/ subcut groin region.|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-263|4|927|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-264|4|928|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-265|4|928|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-266|4|928|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-267|4|930|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-268|4|932|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-269|4|932|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-270|4|934|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-271|4|935|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/   Metastases  Muscle tcfs of abd. cav. invasion of muscle of abd. wall.,MPATH: 513 - Lymphoid neoplasms|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-272|4|938|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/  ,MPATH: 242 - hemangiosarcoma|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-273|4|939|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-274|4|939|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-275|4|940|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-276|4|941|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  Eye(s) missing Head/neck missing,MPATH: 268 - adenocarcinoma|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-277|4|941|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-278|4|941|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/  Head/neck missing,MPATH: 242 - hemangiosarcoma|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-279|4|941|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-280|4|941|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-281|4|941|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-282|4|942|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-283|4|943|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-284|4|943|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/  ,MPATH: 242 - hemangiosarcoma|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-285|4|944|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-286|4|945|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-287|4|945|Neoplasia malignant|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOVS/   Metastases  Lymphoret.System trac to mediastinal nodes.,MPATH: 242 - hemangiosarcoma|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-288|4|946|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-289|4|946|Neoplasia unclassified|Other local manifestations and miscellaneus|TMWC: TCFS OF ABD. CAV. INVASION OF MUSCLE OF ABD. WALL.|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-290|4|947|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-291|4|947|Neoplasia benign|Other local manifestations and miscellaneus|TMSO/ ileal-caecal junction.|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-292|4|949|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-293|4|949|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-294|4|950|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-295|4|952|Neoplasia unclassified|Other local manifestations and miscellaneus|TMWC: TCFS INVADES MUSCLE.|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-296|4|953|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-297|4|954|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-298|4|955|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-299|4|957|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-300|4|957|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-301|4|957|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-302|4|958|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-303|4|958|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-304|4|960|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-305|4|961|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-306|4|962|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-307|4|964|Other deterministic changes|Whole body|MCDU/|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-308|4|965|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-309|4|965|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-310|4|966|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-311|4|967|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-312|4|969|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-313|4|969|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-314|4|970|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-315|4|970|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-316|4|971|Neoplasia malignant|Urinary system,MA: 0002636 - lower urinary tract|TDTC/  Transitional cell Metastases  Lung tdtc (ublad) to lung.,MPATH: 549 - carcinoma|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-317|4|972|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-318|4|973|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-319|4|975|Neoplasia malignant|Bloodvessels among cardiovascular system|TXVS/ peritoneum surrounding uterus & infiltrating gut. Metastases Ovary|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-320|4|976|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-321|4|978|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-322|4|980|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-323|4|981|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-324|4|981|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-325|4|981|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-326|4|982|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-327|4|982|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  Head/neck missing,MPATH: 513 - Lymphoid neoplasms|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-328|4|982|Hyperplastic changes|Other local manifestations and miscellaneus,MA: 0000003 - organ system|MOCY/  Ovary or testis,MPATH: 62 - cyst|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-329|4|982|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-330|4|984|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-331|4|984|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-332|4|985|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-333|4|985|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-334|4|987|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-335|4|989|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-336|4|990|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-337|4|991|Hyperplastic changes|Other local manifestations and miscellaneus,MA: 0000003 - organ system|MOCY/  Ovary or testis,MPATH: 62 - cyst|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-338|4|991|Neoplasia unclassified|Ovary among reproductive system diseases|TOGC/   Metastases Lung|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-339|4|992|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-340|4|993|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-341|4|993|Neoplasia malignant|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|THVS/  ,MPATH: 242 - hemangiosarcoma|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-342|4|994|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-343|4|994|Inflammation and/or fibrotic diseases|Cardiovascular system,MA: 0000164 - myocardium|MMCA/ MMCA/ MMCA/ MMCA/  acute,MPATH: 212 - inflammation|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-344|4|995|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-345|4|995|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-346|4|996|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-347|4|996|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-348|4|996|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-349|4|998|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-350|4|1000|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-351|4|1000|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  Head/neck missing Eye(s) missing,MPATH: 513 - Lymphoid neoplasms|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-352|4|1000|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-353|4|1002|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-354|4|1002|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-355|4|1003|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-356|4|1006|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-357|4|1006|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-358|4|1009|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-359|4|1009|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-360|4|1012|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-361|4|1013|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-362|4|1013|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-363|4|1013|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-364|4|1016|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-365|4|1016|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-366|4|1017|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-367|4|1019|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-368|4|1019|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-369|4|1019|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-370|4|1020|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-371|4|1020|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-372|4|1022|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-373|4|1023|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-374|4|1023|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-375|4|1024|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  Eye(s) missing Head/neck missing,MPATH: 513 - Lymphoid neoplasms|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-376|4|1025|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-377|4|1026|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-378|4|1028|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-379|4|1028|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-380|4|1028|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-381|4|1029|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-382|4|1029|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-383|4|1031|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-384|4|1031|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-385|4|1032|Neoplasia unclassified|Other local manifestations and miscellaneus|TMWC: TCFS INVAS OF MUSC.|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-386|4|1032|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-387|4|1033|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  Eye(s) missing Head/neck missing,MPATH: 513 - Lymphoid neoplasms|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-388|4|1035|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-389|4|1038|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-390|4|1039|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/  ,MPATH: 242 - hemangiosarcoma|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-391|4|1039|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-392|4|1041|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-393|4|1041|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-394|4|1043|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-395|4|1043|Neoplasia unclassified|Other local manifestations and miscellaneus|TXWK: TKAC TO VISC. PERIT.|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-396|4|1044|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-397|4|1044|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-398|4|1044|Neoplasia systemic|Haematolymphatic system|TLML/|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-399|4|1047|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-400|4|1047|Other deterministic changes|Whole body|MCDU/|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-401|4|1047|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-402|4|1047|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|TCFS/ thigh. Metastases  Muscle tcfs invas. of thigh muscle. Metastases  tcfs invas. of visc. perit., pariet. perit. Metastases  Skin tcfs invas. of skin of thigh.,MPATH: 408 - soft tissue fibrosarcoma|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-403|4|1048|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-404|4|1050|Neoplasia unclassified|Other local manifestations and miscellaneus|TXWK: TKAC TO VISC. PERIT.|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-405|4|1050|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-406|4|1050|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-407|4|1051|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-408|4|1051|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-409|4|1052|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-410|4|1055|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/  ,MPATH: 242 - hemangiosarcoma|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-411|4|1055|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-412|4|1055|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-413|4|1058|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-414|4|1058|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-415|4|1058|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  Head/neck missing Eye(s) missing,MPATH: 513 - Lymphoid neoplasms|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-416|4|1059|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-417|4|1060|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-418|4|1060|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-419|4|1062|Hyperplastic changes|Cardiovascular system|MPAN/  Polyarteritis nodosa|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-420|4|1062|Other deterministic changes|Whole body|MCDU/  Head/neck missing|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-421|4|1062|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  Eye(s) missing Head/neck missing,MPATH: 513 - Lymphoid neoplasms|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-422|4|1063|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-423|4|1064|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-424|4|1065|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-425|4|1065|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-426|4|1066|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-427|4|1067|Neoplasia unclassified|Other local manifestations and miscellaneus|TMWC: TCVS TO MUSCLE OF FEMUR & ABD. WALL & FEMUR.|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-428|4|1067|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-429|4|1068|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-430|4|1069|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-431|4|1069|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-432|4|1071|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-433|4|1073|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/   Metastases  Muscle tcfs invas of musc.,MPATH: 513 - Lymphoid neoplasms|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-434|4|1073|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/  ,MPATH: 242 - hemangiosarcoma|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-435|4|1073|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-436|4|1076|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-437|4|1076|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-438|4|1076|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-439|4|1076|Neoplasia unclassified|Other local manifestations and miscellaneus|TMWR: TRAC METAS. TO COSTAL MUSCLE & DERMIS.|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-440|4|1076|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-441|4|1078|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-442|4|1079|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-443|4|1079|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-444|4|1079|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/  ,MPATH: 242 - hemangiosarcoma|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-445|4|1080|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-446|4|1080|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-447|4|1081|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-448|4|1082|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-449|4|1082|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  Head/neck missing Eye(s) missing,MPATH: 513 - Lymphoid neoplasms|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-450|4|1083|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-451|4|1083|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-452|4|1084|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-453|4|1084|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-454|4|1084|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-455|4|1084|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-456|4|1085|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-457|4|1086|Neoplasia unclassified|Lower digestive tract,MA: 0000328 - intestine|TIAC/ pylo.,MPATH: 218 - neoplasm|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-458|4|1086|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-459|4|1086|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-460|4|1086|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-461|4|1087|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-462|4|1087|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-463|4|1087|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-464|4|1089|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-465|4|1093|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-466|4|1094|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  Head/neck missing Eye(s) missing,MPATH: 513 - Lymphoid neoplasms|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-467|4|1094|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-468|4|1095|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-469|4|1096|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-470|4|1099|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-471|4|1101|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-472|4|1104|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-473|4|1105|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-474|4|1107|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-475|4|1109|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-476|4|1111|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-477|4|1112|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-478|4|1113|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-479|4|1115|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-480|4|1116|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-481|4|1116|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOVO/  ,MPATH: 242 - hemangiosarcoma|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-482|4|1117|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-483|4|1117|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-484|4|1122|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-485|4|1123|Neoplasia systemic|Haematolymphatic system|TLPS/|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-486|4|1123|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-487|4|1124|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-488|4|1126|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-489|4|1126|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-490|4|1127|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-491|4|1128|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-492|4|1128|Other deterministic changes|Whole body|MCDU/|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-493|4|1129|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-494|4|1131|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-495|4|1133|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-496|4|1134|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-497|4|1134|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-498|4|1137|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-499|4|1137|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-500|4|1137|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-501|4|1137|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/  ,MPATH: 242 - hemangiosarcoma|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-502|4|1138|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-503|4|1138|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-504|4|1139|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-505|4|1140|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  Head/neck missing Eye(s) missing,MPATH: 513 - Lymphoid neoplasms|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-506|4|1142|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-507|4|1142|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-508|4|1143|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-509|4|1146|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-510|4|1148|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-511|4|1149|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  Eye(s) missing Head/neck missing,MPATH: 513 - Lymphoid neoplasms|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-512|4|1150|Neoplasia unclassified|Other local manifestations and miscellaneus|TMWC: TCFS INVAS OF MUSC.|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-513|4|1150|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-514|4|1150|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-515|4|1151|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-516|4|1153|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/  Eye(s) missing Head/neck missing,MPATH: 242 - hemangiosarcoma|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-517|4|1155|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-518|4|1157|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-519|4|1157|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-520|4|1157|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-521|4|1157|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-522|4|1157|Neoplasia malignant|Bloodvessels among cardiovascular system|TCVS/ abdominal fat.|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-523|4|1157|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  Eye(s) missing Head/neck missing,MPATH: 513 - Lymphoid neoplasms|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-524|4|1158|Other deterministic changes|Whole body|MCDU/|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-525|4|1158|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-526|4|1158|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-527|4|1162|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-528|4|1163|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-529|4|1165|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-530|4|1170|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-531|4|1171|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-532|4|1171|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-533|4|1174|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-534|4|1179|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-535|4|1179|Neoplasia malignant|Bloodvessels among cardiovascular system|TYVS/  Heart|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-536|4|1184|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-537|4|1184|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-538|4|1186|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-539|4|1192|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-540|4|1194|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-541|4|1199|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-542|4|1207|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|TKAC/   Metastases  tkac to visc. perit.,MPATH: 549 - carcinoma|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-543|4|1207|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-544|4|1208|Other deterministic changes|Whole body|MCDU/|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-545|4|1211|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-546|4|1213|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-547|4|1213|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-548|4|1215|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  Thorax missing Eye(s) missing Head/neck missing,MPATH: 513 - Lymphoid neoplasms|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-549|4|1218|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-550|4|1218|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-551|4|1219|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-552|4|1222|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-553|4|1223|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-554|4|1224|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-555|4|1227|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-556|4|1228|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-557|4|1228|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-558|4|1232|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-559|4|1237|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-560|4|1242|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-561|4|1243|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-562|4|1244|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-563|4|1245|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-564|4|1246|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|TCFS/ subcut. dorsal over right hind leg. Metastases  Muscle tcfs invas. of skel. muscle. Metastases  Skin tcfs invas. of skin.,MPATH: 408 - soft tissue fibrosarcoma|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-565|4|1248|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-566|4|1250|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|TCFS/ subcut. dorsal in thoracic region & along spine. Metastases  tcfs invades peritoneum & vertebra. Metastases  Muscle tcfs invades muscle.,MPATH: 408 - soft tissue fibrosarcoma|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-567|4|1254|Inflammation and/or fibrotic diseases|Kidney among urinary system diseases,MA: 0000368 - kidney|MINA/  acute,MPATH: 212 - inflammation|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-568|4|1255|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-569|4|1261|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-570|4|1261|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-571|4|1263|Neoplasia benign|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOTA/  ,MPATH: 270 - adenoma|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-572|4|1264|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-573|4|1268|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-574|4|1272|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-575|4|1274|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-576|4|1274|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-577|4|1275|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-578|4|1280|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-579|4|1281|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-580|4|1282|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-581|4|1291|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-582|4|1294|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-583|4|1302|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-584|4|1306|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|TCFS/ colon wall.,MPATH: 408 - soft tissue fibrosarcoma|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-585|4|1307|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-586|4|1322|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-587|4|1331|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-588|4|1332|Other deterministic changes|Whole body|MCDU/|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-589|4|1335|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-590|4|1335|Neoplasia benign|Bloodvessels among cardiovascular system|TCVO/ heart-left ventricle.|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-591|4|1341|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-592|4|1341|Other deterministic changes|Whole body|MCDU/|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-593|4|1356|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-594|4|1368|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-595|4|1381|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-596|4|1388|Other deterministic changes|Whole body|MCDU/|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-597|4|1430|n/a|n/a|n/a|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-598|4|1440|Hyperplastic changes|Cardiovascular system|MPAN/  Polyarteritis nodosa|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-599|4|1451|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-4|n/a,1X|1|100|gamma-rays Co-60|1|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|598 records survival 846 ± 8 lifespan study|1003-29-4-600|4|1489|n/a|n/a|n/a|
1003-29-5|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|220 (220 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 840 ± 14 lifespan study|1003-29-5-1|5|171|n/a|n/a|n/a|
1003-29-5|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|220 (220 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 840 ± 14 lifespan study|1003-29-5-2|5|171|n/a|n/a|n/a|
1003-29-5|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|220 (220 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 840 ± 14 lifespan study|1003-29-5-3|5|171|n/a|n/a|n/a|
1003-29-5|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|220 (220 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 840 ± 14 lifespan study|1003-29-5-4|5|177|n/a|n/a|n/a|
1003-29-5|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|220 (220 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 840 ± 14 lifespan study|1003-29-5-5|5|178|n/a|n/a|n/a|
1003-29-5|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|220 (220 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 840 ± 14 lifespan study|1003-29-5-6|5|178|n/a|n/a|n/a|
1003-29-5|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|220 (220 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 840 ± 14 lifespan study|1003-29-5-7|5|283|n/a|n/a|n/a|
1003-29-5|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|220 (220 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 840 ± 14 lifespan study|1003-29-5-8|5|283|n/a|n/a|n/a|
1003-29-5|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|220 (220 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 840 ± 14 lifespan study|1003-29-5-9|5|283|n/a|n/a|n/a|
1003-29-5|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|220 (220 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 840 ± 14 lifespan study|1003-29-5-10|5|283|n/a|n/a|n/a|
1003-29-5|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|220 (220 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 840 ± 14 lifespan study|1003-29-5-11|5|283|n/a|n/a|n/a|
1003-29-5|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|220 (220 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 840 ± 14 lifespan study|1003-29-5-12|5|283|n/a|n/a|n/a|
1003-29-5|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|220 (220 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 840 ± 14 lifespan study|1003-29-5-13|5|283|n/a|n/a|n/a|
1003-29-5|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|220 (220 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 840 ± 14 lifespan study|1003-29-5-14|5|283|n/a|n/a|n/a|
1003-29-5|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|220 (220 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 840 ± 14 lifespan study|1003-29-5-15|5|381|n/a|n/a|n/a|
1003-29-5|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|220 (220 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 840 ± 14 lifespan study|1003-29-5-16|5|381|n/a|n/a|n/a|
1003-29-5|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|220 (220 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 840 ± 14 lifespan study|1003-29-5-17|5|381|n/a|n/a|n/a|
1003-29-5|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|220 (220 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 840 ± 14 lifespan study|1003-29-5-18|5|381|n/a|n/a|n/a|
1003-29-5|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|220 (220 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 840 ± 14 lifespan study|1003-29-5-19|5|381|n/a|n/a|n/a|
1003-29-5|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|220 (220 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 840 ± 14 lifespan study|1003-29-5-20|5|388|n/a|n/a|n/a|
1003-29-5|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|220 (220 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 840 ± 14 lifespan study|1003-29-5-21|5|388|n/a|n/a|n/a|
1003-29-5|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|220 (220 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 840 ± 14 lifespan study|1003-29-5-22|5|388|n/a|n/a|n/a|
1003-29-5|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|220 (220 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 840 ± 14 lifespan study|1003-29-5-23|5|388|n/a|n/a|n/a|
1003-29-5|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|220 (220 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 840 ± 14 lifespan study|1003-29-5-24|5|388|n/a|n/a|n/a|
1003-29-5|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|220 (220 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 840 ± 14 lifespan study|1003-29-5-25|5|393|n/a|n/a|n/a|
1003-29-5|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|220 (220 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 840 ± 14 lifespan study|1003-29-5-26|5|393|n/a|n/a|n/a|
1003-29-5|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|220 (220 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 840 ± 14 lifespan study|1003-29-5-27|5|429|Other deterministic changes|Whole body|MCDU/|
1003-29-5|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|220 (220 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 840 ± 14 lifespan study|1003-29-5-28|5|464|n/a|n/a|n/a|
1003-29-5|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|220 (220 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 840 ± 14 lifespan study|1003-29-5-29|5|484|n/a|n/a|n/a|
1003-29-5|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|220 (220 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 840 ± 14 lifespan study|1003-29-5-30|5|484|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-5|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|220 (220 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 840 ± 14 lifespan study|1003-29-5-31|5|484|n/a|n/a|n/a|
1003-29-5|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|220 (220 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 840 ± 14 lifespan study|1003-29-5-32|5|484|n/a|n/a|n/a|
1003-29-5|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|220 (220 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 840 ± 14 lifespan study|1003-29-5-33|5|521|n/a|n/a|n/a|
1003-29-5|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|220 (220 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 840 ± 14 lifespan study|1003-29-5-34|5|521|n/a|n/a|n/a|
1003-29-5|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|220 (220 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 840 ± 14 lifespan study|1003-29-5-35|5|527|n/a|n/a|n/a|
1003-29-5|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|220 (220 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 840 ± 14 lifespan study|1003-29-5-36|5|527|n/a|n/a|n/a|
1003-29-5|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|220 (220 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 840 ± 14 lifespan study|1003-29-5-37|5|527|n/a|n/a|n/a|
1003-29-5|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|220 (220 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 840 ± 14 lifespan study|1003-29-5-38|5|527|n/a|n/a|n/a|
1003-29-5|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|220 (220 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 840 ± 14 lifespan study|1003-29-5-39|5|528|n/a|n/a|n/a|
1003-29-5|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|220 (220 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 840 ± 14 lifespan study|1003-29-5-40|5|528|n/a|n/a|n/a|
1003-29-5|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|220 (220 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 840 ± 14 lifespan study|1003-29-5-41|5|528|n/a|n/a|n/a|
1003-29-5|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|220 (220 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 840 ± 14 lifespan study|1003-29-5-42|5|528|n/a|n/a|n/a|
1003-29-5|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|220 (220 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 840 ± 14 lifespan study|1003-29-5-43|5|529|n/a|n/a|n/a|
1003-29-5|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|220 (220 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 840 ± 14 lifespan study|1003-29-5-44|5|529|n/a|n/a|n/a|
1003-29-5|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|220 (220 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 840 ± 14 lifespan study|1003-29-5-45|5|574|Neoplasia systemic|Haematolymphatic system|TLML/|
1003-29-5|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|220 (220 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 840 ± 14 lifespan study|1003-29-5-46|5|609|n/a|n/a|n/a|
1003-29-5|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|220 (220 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 840 ± 14 lifespan study|1003-29-5-47|5|616|n/a|n/a|n/a|
1003-29-5|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|220 (220 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 840 ± 14 lifespan study|1003-29-5-48|5|617|n/a|n/a|n/a|
1003-29-5|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|220 (220 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 840 ± 14 lifespan study|1003-29-5-49|5|626|n/a|n/a|n/a|
1003-29-5|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|220 (220 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 840 ± 14 lifespan study|1003-29-5-50|5|630|n/a|n/a|n/a|
1003-29-5|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|220 (220 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 840 ± 14 lifespan study|1003-29-5-51|5|630|Other deterministic changes|Whole body|MCDU/|
1003-29-5|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|220 (220 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 840 ± 14 lifespan study|1003-29-5-52|5|633|n/a|n/a|n/a|
1003-29-5|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|220 (220 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 840 ± 14 lifespan study|1003-29-5-53|5|675|n/a|n/a|n/a|
1003-29-5|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|220 (220 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 840 ± 14 lifespan study|1003-29-5-54|5|679|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-5|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|220 (220 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 840 ± 14 lifespan study|1003-29-5-55|5|692|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/  ,MPATH: 242 - hemangiosarcoma|
1003-29-5|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|220 (220 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 840 ± 14 lifespan study|1003-29-5-56|5|695|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-5|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|220 (220 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 840 ± 14 lifespan study|1003-29-5-57|5|700|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-5|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|220 (220 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 840 ± 14 lifespan study|1003-29-5-58|5|705|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-5|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|220 (220 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 840 ± 14 lifespan study|1003-29-5-59|5|706|Other deterministic changes|Whole body|MCDU/|
1003-29-5|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|220 (220 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 840 ± 14 lifespan study|1003-29-5-60|5|709|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/  ,MPATH: 242 - hemangiosarcoma|
1003-29-5|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|220 (220 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 840 ± 14 lifespan study|1003-29-5-61|5|713|Other deterministic changes|Whole body|MCDU/|
1003-29-5|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|220 (220 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 840 ± 14 lifespan study|1003-29-5-62|5|714|Neoplasia malignant|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|THVS/  ,MPATH: 242 - hemangiosarcoma|
1003-29-5|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|220 (220 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 840 ± 14 lifespan study|1003-29-5-63|5|723|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-5|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|220 (220 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 840 ± 14 lifespan study|1003-29-5-64|5|748|n/a|n/a|n/a|
1003-29-5|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|220 (220 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 840 ± 14 lifespan study|1003-29-5-65|5|750|Neoplasia malignant|Bone among musculo-skeletal system diseases|TBOS/ caudal vertebrae. Metastases Lung Metastases  Muscle tbos in spinal skeletal muscle.|
1003-29-5|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|220 (220 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 840 ± 14 lifespan study|1003-29-5-66|5|764|n/a|n/a|n/a|
1003-29-5|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|220 (220 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 840 ± 14 lifespan study|1003-29-5-67|5|768|Other deterministic changes|Whole body|MCDU/|
1003-29-5|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|220 (220 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 840 ± 14 lifespan study|1003-29-5-68|5|775|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-5|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|220 (220 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 840 ± 14 lifespan study|1003-29-5-69|5|775|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-5|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|220 (220 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 840 ± 14 lifespan study|1003-29-5-70|5|782|n/a|n/a|n/a|
1003-29-5|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|220 (220 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 840 ± 14 lifespan study|1003-29-5-71|5|786|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-29-5|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|220 (220 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 840 ± 14 lifespan study|1003-29-5-72|5|787|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/  ,MPATH: 242 - hemangiosarcoma|
1003-29-5|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|220 (220 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 840 ± 14 lifespan study|1003-29-5-73|5|788|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/  ,MPATH: 242 - hemangiosarcoma|
1003-29-5|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|220 (220 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 840 ± 14 lifespan study|1003-29-5-74|5|788|Other deterministic changes|Whole body|MCDU/  Head/neck missing|
1003-29-5|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|220 (220 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 840 ± 14 lifespan study|1003-29-5-75|5|790|n/a|n/a|n/a|
1003-29-5|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|220 (220 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 840 ± 14 lifespan study|1003-29-5-76|5|792|Neoplasia unclassified|Other local manifestations and miscellaneus|TRWK: TKAC TO LUNG.|
1003-29-5|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|220 (220 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 840 ± 14 lifespan study|1003-29-5-77|5|792|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-5|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|220 (220 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 840 ± 14 lifespan study|1003-29-5-78|5|795|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-5|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|220 (220 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 840 ± 14 lifespan study|1003-29-5-79|5|805|n/a|n/a|n/a|
1003-29-5|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|220 (220 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 840 ± 14 lifespan study|1003-29-5-80|5|808|Degenerative changes|Kidney among urinary system diseases,MA: 0000368 - kidney|MCRD/  ,MPATH: 1 - cell and tissue damage|
1003-29-5|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|220 (220 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 840 ± 14 lifespan study|1003-29-5-81|5|816|Neoplasia malignant|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|THVS/  ,MPATH: 242 - hemangiosarcoma|
1003-29-5|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|220 (220 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 840 ± 14 lifespan study|1003-29-5-82|5|819|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-29-5|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|220 (220 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 840 ± 14 lifespan study|1003-29-5-83|5|820|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-5|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|220 (220 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 840 ± 14 lifespan study|1003-29-5-84|5|821|n/a|n/a|n/a|
1003-29-5|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|220 (220 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 840 ± 14 lifespan study|1003-29-5-85|5|821|Neoplasia malignant|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|THVS/  ,MPATH: 242 - hemangiosarcoma|
1003-29-5|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|220 (220 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 840 ± 14 lifespan study|1003-29-5-86|5|827|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-5|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|220 (220 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 840 ± 14 lifespan study|1003-29-5-87|5|828|n/a|n/a|n/a|
1003-29-5|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|220 (220 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 840 ± 14 lifespan study|1003-29-5-88|5|829|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-5|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|220 (220 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 840 ± 14 lifespan study|1003-29-5-89|5|833|n/a|n/a|n/a|
1003-29-5|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|220 (220 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 840 ± 14 lifespan study|1003-29-5-90|5|836|n/a|n/a|n/a|
1003-29-5|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|220 (220 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 840 ± 14 lifespan study|1003-29-5-91|5|847|n/a|n/a|n/a|
1003-29-5|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|220 (220 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 840 ± 14 lifespan study|1003-29-5-92|5|849|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-5|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|220 (220 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 840 ± 14 lifespan study|1003-29-5-93|5|855|n/a|n/a|n/a|
1003-29-5|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|220 (220 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 840 ± 14 lifespan study|1003-29-5-94|5|861|n/a|n/a|n/a|
1003-29-5|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|220 (220 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 840 ± 14 lifespan study|1003-29-5-95|5|861|n/a|n/a|n/a|
1003-29-5|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|220 (220 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 840 ± 14 lifespan study|1003-29-5-96|5|862|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-5|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|220 (220 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 840 ± 14 lifespan study|1003-29-5-97|5|867|n/a|n/a|n/a|
1003-29-5|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|220 (220 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 840 ± 14 lifespan study|1003-29-5-98|5|869|n/a|n/a|n/a|
1003-29-5|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|220 (220 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 840 ± 14 lifespan study|1003-29-5-99|5|871|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases  Muscle trac to musc & skin of thorax. Metastases Kidney Metastases Heart Metastases  trac to pleura.,MPATH: 268 - adenocarcinoma|
1003-29-5|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|220 (220 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 840 ± 14 lifespan study|1003-29-5-100|5|875|n/a|n/a|n/a|
1003-29-5|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|220 (220 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 840 ± 14 lifespan study|1003-29-5-101|5|877|Neoplasia benign|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVO/  ,MPATH: 240 - hemangioma|
1003-29-5|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|220 (220 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 840 ± 14 lifespan study|1003-29-5-102|5|880|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-5|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|220 (220 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 840 ± 14 lifespan study|1003-29-5-103|5|883|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-5|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|220 (220 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 840 ± 14 lifespan study|1003-29-5-104|5|883|Neoplasia unclassified|Other local manifestations and miscellaneus|TMWB: TBOS IN SPINAL SKELETAL MUSCLE.|
1003-29-5|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|220 (220 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 840 ± 14 lifespan study|1003-29-5-105|5|884|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  Head/neck missing,MPATH: 513 - Lymphoid neoplasms|
1003-29-5|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|220 (220 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 840 ± 14 lifespan study|1003-29-5-106|5|889|n/a|n/a|n/a|
1003-29-5|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|220 (220 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 840 ± 14 lifespan study|1003-29-5-107|5|891|n/a|n/a|n/a|
1003-29-5|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|220 (220 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 840 ± 14 lifespan study|1003-29-5-108|5|903|n/a|n/a|n/a|
1003-29-5|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|220 (220 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 840 ± 14 lifespan study|1003-29-5-109|5|905|n/a|n/a|n/a|
1003-29-5|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|220 (220 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 840 ± 14 lifespan study|1003-29-5-110|5|906|Neoplasia malignant|Liver among hepato-pancreatic system diseases|THAC/   Metastases Lung Metastases Heart|
1003-29-5|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|220 (220 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 840 ± 14 lifespan study|1003-29-5-111|5|907|Other deterministic changes|Whole body|MCDU/|
1003-29-5|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|220 (220 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 840 ± 14 lifespan study|1003-29-5-112|5|919|n/a|n/a|n/a|
1003-29-5|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|220 (220 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 840 ± 14 lifespan study|1003-29-5-113|5|921|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-5|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|220 (220 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 840 ± 14 lifespan study|1003-29-5-114|5|923|n/a|n/a|n/a|
1003-29-5|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|220 (220 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 840 ± 14 lifespan study|1003-29-5-115|5|926|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-5|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|220 (220 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 840 ± 14 lifespan study|1003-29-5-116|5|928|n/a|n/a|n/a|
1003-29-5|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|220 (220 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 840 ± 14 lifespan study|1003-29-5-117|5|928|Other deterministic changes|Whole body|MCDU/|
1003-29-5|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|220 (220 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 840 ± 14 lifespan study|1003-29-5-118|5|931|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  Head/neck missing Eye(s) missing,MPATH: 513 - Lymphoid neoplasms|
1003-29-5|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|220 (220 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 840 ± 14 lifespan study|1003-29-5-119|5|931|Other deterministic changes|Whole body|MCDU/|
1003-29-5|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|220 (220 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 840 ± 14 lifespan study|1003-29-5-120|5|933|Neoplasia malignant|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|THVS/  ,MPATH: 242 - hemangiosarcoma|
1003-29-5|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|220 (220 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 840 ± 14 lifespan study|1003-29-5-121|5|936|Neoplasia unclassified|Other local manifestations and miscellaneus|TLWR: TRAC TO PT LN.|
1003-29-5|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|220 (220 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 840 ± 14 lifespan study|1003-29-5-122|5|940|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-5|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|220 (220 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 840 ± 14 lifespan study|1003-29-5-123|5|941|Neoplasia systemic|Haematolymphatic system|TLML/|
1003-29-5|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|220 (220 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 840 ± 14 lifespan study|1003-29-5-124|5|942|Neoplasia unclassified|Other local manifestations and miscellaneus|TLWR: TRAC TO PT LN.|
1003-29-5|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|220 (220 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 840 ± 14 lifespan study|1003-29-5-125|5|953|n/a|n/a|n/a|
1003-29-5|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|220 (220 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 840 ± 14 lifespan study|1003-29-5-126|5|953|Neoplasia systemic|Haematolymphatic system|TLPS/|
1003-29-5|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|220 (220 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 840 ± 14 lifespan study|1003-29-5-127|5|954|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases  Lymphoret.System trac to pt ln. Metastases  trac to pleura.,MPATH: 268 - adenocarcinoma|
1003-29-5|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|220 (220 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 840 ± 14 lifespan study|1003-29-5-128|5|959|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-5|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|220 (220 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 840 ± 14 lifespan study|1003-29-5-129|5|961|Neoplasia unclassified|Other local manifestations and miscellaneus|THWR: TRAC TO LIVER.|
1003-29-5|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|220 (220 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 840 ± 14 lifespan study|1003-29-5-130|5|963|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/  ,MPATH: 242 - hemangiosarcoma|
1003-29-5|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|220 (220 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 840 ± 14 lifespan study|1003-29-5-131|5|966|n/a|n/a|n/a|
1003-29-5|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|220 (220 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 840 ± 14 lifespan study|1003-29-5-132|5|968|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-5|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|220 (220 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 840 ± 14 lifespan study|1003-29-5-133|5|971|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-5|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|220 (220 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 840 ± 14 lifespan study|1003-29-5-134|5|971|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-29-5|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|220 (220 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 840 ± 14 lifespan study|1003-29-5-135|5|975|n/a|n/a|n/a|
1003-29-5|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|220 (220 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 840 ± 14 lifespan study|1003-29-5-136|5|985|n/a|n/a|n/a|
1003-29-5|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|220 (220 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 840 ± 14 lifespan study|1003-29-5-137|5|986|n/a|n/a|n/a|
1003-29-5|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|220 (220 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 840 ± 14 lifespan study|1003-29-5-138|5|987|n/a|n/a|n/a|
1003-29-5|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|220 (220 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 840 ± 14 lifespan study|1003-29-5-139|5|989|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/ w/ leukemia.,MPATH: 513 - Lymphoid neoplasms|
1003-29-5|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|220 (220 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 840 ± 14 lifespan study|1003-29-5-140|5|991|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  Head/neck missing,MPATH: 513 - Lymphoid neoplasms|
1003-29-5|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|220 (220 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 840 ± 14 lifespan study|1003-29-5-141|5|993|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-5|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|220 (220 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 840 ± 14 lifespan study|1003-29-5-142|5|993|Other deterministic changes|Whole body|MCDU/|
1003-29-5|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|220 (220 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 840 ± 14 lifespan study|1003-29-5-143|5|997|n/a|n/a|n/a|
1003-29-5|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|220 (220 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 840 ± 14 lifespan study|1003-29-5-144|5|1000|Neoplasia malignant|Bloodvessels among cardiovascular system|TCVS/ diaphragm.Head/neck missing Eye(s) missing|
1003-29-5|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|220 (220 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 840 ± 14 lifespan study|1003-29-5-145|5|1003|n/a|n/a|n/a|
1003-29-5|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|220 (220 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 840 ± 14 lifespan study|1003-29-5-146|5|1004|Neoplasia systemic|Haematolymphatic system|TLPS/|
1003-29-5|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|220 (220 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 840 ± 14 lifespan study|1003-29-5-147|5|1004|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-5|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|220 (220 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 840 ± 14 lifespan study|1003-29-5-148|5|1005|Neoplasia unclassified|Other local manifestations and miscellaneus|TMWB: TBOS IN SPINAL SKELETAL MUSCLE.|
1003-29-5|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|220 (220 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 840 ± 14 lifespan study|1003-29-5-149|5|1006|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/   Metastases Liver,MPATH: 513 - Lymphoid neoplasms|
1003-29-5|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|220 (220 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 840 ± 14 lifespan study|1003-29-5-150|5|1007|n/a|n/a|n/a|
1003-29-5|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|220 (220 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 840 ± 14 lifespan study|1003-29-5-151|5|1008|n/a|n/a|n/a|
1003-29-5|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|220 (220 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 840 ± 14 lifespan study|1003-29-5-152|5|1009|Neoplasia unclassified|Other local manifestations and miscellaneus|THWR: TRAC TO LIVER.|
1003-29-5|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|220 (220 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 840 ± 14 lifespan study|1003-29-5-153|5|1009|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  Eye(s) missing Head/neck missing,MPATH: 513 - Lymphoid neoplasms|
1003-29-5|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|220 (220 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 840 ± 14 lifespan study|1003-29-5-154|5|1010|Hyperplastic changes|Cardiovascular system|MPAN/  Polyarteritis nodosa|
1003-29-5|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|220 (220 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 840 ± 14 lifespan study|1003-29-5-155|5|1011|Neoplasia unclassified|Other local manifestations and miscellaneus|TMWB: TBOS IN SPINAL SKELETAL MUSCLE.|
1003-29-5|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|220 (220 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 840 ± 14 lifespan study|1003-29-5-156|5|1012|Other deterministic changes|Whole body|MCDU/|
1003-29-5|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|220 (220 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 840 ± 14 lifespan study|1003-29-5-157|5|1016|n/a|n/a|n/a|
1003-29-5|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|220 (220 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 840 ± 14 lifespan study|1003-29-5-158|5|1016|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLSS/  undifferentiated lymphomaHead/neck missing Eye(s) missing,MPATH: 513 - Lymphoid neoplasms|
1003-29-5|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|220 (220 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 840 ± 14 lifespan study|1003-29-5-159|5|1023|n/a|n/a|n/a|
1003-29-5|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|220 (220 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 840 ± 14 lifespan study|1003-29-5-160|5|1023|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-5|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|220 (220 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 840 ± 14 lifespan study|1003-29-5-161|5|1026|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/  ,MPATH: 242 - hemangiosarcoma|
1003-29-5|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|220 (220 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 840 ± 14 lifespan study|1003-29-5-162|5|1027|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-29-5|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|220 (220 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 840 ± 14 lifespan study|1003-29-5-163|5|1029|n/a|n/a|n/a|
1003-29-5|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|220 (220 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 840 ± 14 lifespan study|1003-29-5-164|5|1032|n/a|n/a|n/a|
1003-29-5|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|220 (220 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 840 ± 14 lifespan study|1003-29-5-165|5|1036|n/a|n/a|n/a|
1003-29-5|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|220 (220 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 840 ± 14 lifespan study|1003-29-5-166|5|1039|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-5|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|220 (220 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 840 ± 14 lifespan study|1003-29-5-167|5|1043|n/a|n/a|n/a|
1003-29-5|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|220 (220 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 840 ± 14 lifespan study|1003-29-5-168|5|1044|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  Head/neck missing Eye(s) missing,MPATH: 513 - Lymphoid neoplasms|
1003-29-5|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|220 (220 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 840 ± 14 lifespan study|1003-29-5-169|5|1047|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-29-5|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|220 (220 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 840 ± 14 lifespan study|1003-29-5-170|5|1047|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-5|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|220 (220 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 840 ± 14 lifespan study|1003-29-5-171|5|1059|n/a|n/a|n/a|
1003-29-5|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|220 (220 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 840 ± 14 lifespan study|1003-29-5-172|5|1060|n/a|n/a|n/a|
1003-29-5|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|220 (220 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 840 ± 14 lifespan study|1003-29-5-173|5|1065|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-5|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|220 (220 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 840 ± 14 lifespan study|1003-29-5-174|5|1066|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-5|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|220 (220 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 840 ± 14 lifespan study|1003-29-5-175|5|1069|n/a|n/a|n/a|
1003-29-5|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|220 (220 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 840 ± 14 lifespan study|1003-29-5-176|5|1073|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-5|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|220 (220 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 840 ± 14 lifespan study|1003-29-5-177|5|1073|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-5|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|220 (220 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 840 ± 14 lifespan study|1003-29-5-178|5|1079|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-5|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|220 (220 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 840 ± 14 lifespan study|1003-29-5-179|5|1087|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-5|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|220 (220 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 840 ± 14 lifespan study|1003-29-5-180|5|1089|Neoplasia malignant|Bloodvessels among cardiovascular system|TMVS/ right femur. MuscleEye(s) missing Head/neck missing|
1003-29-5|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|220 (220 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 840 ± 14 lifespan study|1003-29-5-181|5|1095|Neoplasia unclassified|Other local manifestations and miscellaneus|TRWK: TKAC TO LUNG.|
1003-29-5|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|220 (220 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 840 ± 14 lifespan study|1003-29-5-182|5|1097|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-5|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|220 (220 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 840 ± 14 lifespan study|1003-29-5-183|5|1099|Other deterministic changes|Whole body|MCDU/|
1003-29-5|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|220 (220 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 840 ± 14 lifespan study|1003-29-5-184|5|1101|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-5|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|220 (220 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 840 ± 14 lifespan study|1003-29-5-185|5|1102|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-5|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|220 (220 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 840 ± 14 lifespan study|1003-29-5-186|5|1107|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-5|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|220 (220 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 840 ± 14 lifespan study|1003-29-5-187|5|1132|n/a|n/a|n/a|
1003-29-5|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|220 (220 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 840 ± 14 lifespan study|1003-29-5-188|5|1133|Neoplasia malignant|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|THVS/  ,MPATH: 242 - hemangiosarcoma|
1003-29-5|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|220 (220 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 840 ± 14 lifespan study|1003-29-5-189|5|1137|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-5|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|220 (220 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 840 ± 14 lifespan study|1003-29-5-190|5|1138|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/  ,MPATH: 242 - hemangiosarcoma|
1003-29-5|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|220 (220 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 840 ± 14 lifespan study|1003-29-5-191|5|1142|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-5|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|220 (220 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 840 ± 14 lifespan study|1003-29-5-192|5|1143|Changes due to an abnormal circulation|Bloodvessels among cardiovascular system|MTHR/  auricular|
1003-29-5|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|220 (220 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 840 ± 14 lifespan study|1003-29-5-193|5|1144|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|TKAC/   Metastases Lung,MPATH: 549 - carcinoma|
1003-29-5|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|220 (220 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 840 ± 14 lifespan study|1003-29-5-194|5|1146|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-5|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|220 (220 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 840 ± 14 lifespan study|1003-29-5-195|5|1150|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  Eye(s) missing,MPATH: 513 - Lymphoid neoplasms|
1003-29-5|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|220 (220 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 840 ± 14 lifespan study|1003-29-5-196|5|1151|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-5|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|220 (220 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 840 ± 14 lifespan study|1003-29-5-197|5|1153|Neoplasia malignant|Bloodvessels among cardiovascular system|TCVS/ subcut. located over testes.|
1003-29-5|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|220 (220 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 840 ± 14 lifespan study|1003-29-5-198|5|1156|n/a|n/a|n/a|
1003-29-5|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|220 (220 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 840 ± 14 lifespan study|1003-29-5-199|5|1159|n/a|n/a|n/a|
1003-29-5|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|220 (220 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 840 ± 14 lifespan study|1003-29-5-200|5|1163|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-5|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|220 (220 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 840 ± 14 lifespan study|1003-29-5-201|5|1185|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-5|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|220 (220 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 840 ± 14 lifespan study|1003-29-5-202|5|1189|Inflammation and/or fibrotic diseases|Lower digestive tract,MA: 0000328 - intestine|MIIC/ esophagus.Enteritis chronic,MPATH: 212 - inflammation|
1003-29-5|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|220 (220 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 840 ± 14 lifespan study|1003-29-5-203|5|1197|Neoplasia malignant|Bloodvessels among cardiovascular system|TCVS/ pelvic region. Metastases  Muscle tcvs invas. of skeletal muscle.|
1003-29-5|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|220 (220 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 840 ± 14 lifespan study|1003-29-5-204|5|1198|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-5|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|220 (220 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 840 ± 14 lifespan study|1003-29-5-205|5|1199|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-5|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|220 (220 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 840 ± 14 lifespan study|1003-29-5-206|5|1202|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-5|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|220 (220 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 840 ± 14 lifespan study|1003-29-5-207|5|1203|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-29-5|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|220 (220 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 840 ± 14 lifespan study|1003-29-5-208|5|1211|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-5|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|220 (220 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 840 ± 14 lifespan study|1003-29-5-209|5|1221|n/a|n/a|n/a|
1003-29-5|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|220 (220 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 840 ± 14 lifespan study|1003-29-5-210|5|1226|Other deterministic changes|Whole body|MCDU/|
1003-29-5|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|220 (220 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 840 ± 14 lifespan study|1003-29-5-211|5|1226|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-29-5|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|220 (220 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 840 ± 14 lifespan study|1003-29-5-212|5|1238|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-5|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|220 (220 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 840 ± 14 lifespan study|1003-29-5-213|5|1245|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-5|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|220 (220 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 840 ± 14 lifespan study|1003-29-5-214|5|1247|n/a|n/a|n/a|
1003-29-5|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|220 (220 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 840 ± 14 lifespan study|1003-29-5-215|5|1265|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-5|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|220 (220 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 840 ± 14 lifespan study|1003-29-5-216|5|1272|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-29-5|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|220 (220 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 840 ± 14 lifespan study|1003-29-5-217|5|1275|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-5|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|220 (220 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 840 ± 14 lifespan study|1003-29-5-218|5|1281|Changes due to an abnormal circulation|Bloodvessels among cardiovascular system|MTHR/  auricular|
1003-29-5|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|220 (220 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 840 ± 14 lifespan study|1003-29-5-219|5|1325|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-5|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|220 (220 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 840 ± 14 lifespan study|1003-29-5-220|5|1341|Other deterministic changes|Whole body|MCDU/|
1003-29-6|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|180 (180 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|174 records survival 819 ± 15 lifespan study|1003-29-6-1|6|261|n/a|n/a|n/a|
1003-29-6|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|180 (180 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|174 records survival 819 ± 15 lifespan study|1003-29-6-2|6|261|n/a|n/a|n/a|
1003-29-6|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|180 (180 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|174 records survival 819 ± 15 lifespan study|1003-29-6-3|6|261|n/a|n/a|n/a|
1003-29-6|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|180 (180 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|174 records survival 819 ± 15 lifespan study|1003-29-6-4|6|261|n/a|n/a|n/a|
1003-29-6|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|180 (180 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|174 records survival 819 ± 15 lifespan study|1003-29-6-5|6|261|n/a|n/a|n/a|
1003-29-6|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|180 (180 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|174 records survival 819 ± 15 lifespan study|1003-29-6-6|6|275|n/a|n/a|n/a|
1003-29-6|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|180 (180 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|174 records survival 819 ± 15 lifespan study|1003-29-6-7|6|414|n/a|n/a|n/a|
1003-29-6|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|180 (180 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|174 records survival 819 ± 15 lifespan study|1003-29-6-8|6|441|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-6|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|180 (180 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|174 records survival 819 ± 15 lifespan study|1003-29-6-9|6|463|Hyperplastic changes|Cardiovascular system|MPAN/  Polyarteritis nodosa|
1003-29-6|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|180 (180 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|174 records survival 819 ± 15 lifespan study|1003-29-6-10|6|522|Other deterministic changes|Whole body|MCDU/  Head/neck missing Eye(s) missing|
1003-29-6|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|180 (180 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|174 records survival 819 ± 15 lifespan study|1003-29-6-11|6|526|Hyperplastic changes|Other local manifestations and miscellaneus,MA: 0000003 - organ system|MOCY/  Ovary or testis,MPATH: 62 - cyst|
1003-29-6|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|180 (180 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|174 records survival 819 ± 15 lifespan study|1003-29-6-12|6|529|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-6|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|180 (180 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|174 records survival 819 ± 15 lifespan study|1003-29-6-13|6|532|Other deterministic changes|Whole body|MCDU/   Metastases Lung|
1003-29-6|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|180 (180 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|174 records survival 819 ± 15 lifespan study|1003-29-6-14|6|544|n/a|n/a|n/a|
1003-29-6|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|180 (180 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|174 records survival 819 ± 15 lifespan study|1003-29-6-15|6|551|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-6|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|180 (180 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|174 records survival 819 ± 15 lifespan study|1003-29-6-16|6|611|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-6|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|180 (180 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|174 records survival 819 ± 15 lifespan study|1003-29-6-17|6|611|n/a|n/a|n/a|
1003-29-6|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|180 (180 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|174 records survival 819 ± 15 lifespan study|1003-29-6-18|6|633|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-6|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|180 (180 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|174 records survival 819 ± 15 lifespan study|1003-29-6-19|6|641|n/a|n/a|n/a|
1003-29-6|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|180 (180 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|174 records survival 819 ± 15 lifespan study|1003-29-6-20|6|653|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-6|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|180 (180 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|174 records survival 819 ± 15 lifespan study|1003-29-6-21|6|673|Hyperplastic changes|Cardiovascular system|MPAN/  Polyarteritis nodosa|
1003-29-6|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|180 (180 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|174 records survival 819 ± 15 lifespan study|1003-29-6-22|6|677|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-6|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|180 (180 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|174 records survival 819 ± 15 lifespan study|1003-29-6-23|6|681|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-6|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|180 (180 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|174 records survival 819 ± 15 lifespan study|1003-29-6-24|6|681|Neoplasia malignant|Bone among musculo-skeletal system diseases|TBOS/ skull Metastases  Muscle tbos of skull to skeletal muscle of head.|
1003-29-6|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|180 (180 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|174 records survival 819 ± 15 lifespan study|1003-29-6-25|6|684|Neoplasia malignant|Bloodvessels among cardiovascular system|TCVS/ adbominal fat in lower abd.|
1003-29-6|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|180 (180 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|174 records survival 819 ± 15 lifespan study|1003-29-6-26|6|694|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-6|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|180 (180 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|174 records survival 819 ± 15 lifespan study|1003-29-6-27|6|695|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-6|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|180 (180 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|174 records survival 819 ± 15 lifespan study|1003-29-6-28|6|700|n/a|n/a|n/a|
1003-29-6|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|180 (180 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|174 records survival 819 ± 15 lifespan study|1003-29-6-29|6|707|n/a|n/a|n/a|
1003-29-6|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|180 (180 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|174 records survival 819 ± 15 lifespan study|1003-29-6-30|6|716|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-6|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|180 (180 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|174 records survival 819 ± 15 lifespan study|1003-29-6-31|6|716|n/a|n/a|n/a|
1003-29-6|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|180 (180 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|174 records survival 819 ± 15 lifespan study|1003-29-6-32|6|718|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-6|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|180 (180 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|174 records survival 819 ± 15 lifespan study|1003-29-6-33|6|725|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-6|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|180 (180 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|174 records survival 819 ± 15 lifespan study|1003-29-6-34|6|740|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-6|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|180 (180 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|174 records survival 819 ± 15 lifespan study|1003-29-6-35|6|744|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-6|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|180 (180 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|174 records survival 819 ± 15 lifespan study|1003-29-6-36|6|748|n/a|n/a|n/a|
1003-29-6|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|180 (180 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|174 records survival 819 ± 15 lifespan study|1003-29-6-37|6|764|n/a|n/a|n/a|
1003-29-6|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|180 (180 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|174 records survival 819 ± 15 lifespan study|1003-29-6-38|6|769|Other deterministic changes|Whole body|MCDU/|
1003-29-6|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|180 (180 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|174 records survival 819 ± 15 lifespan study|1003-29-6-39|6|774|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/   Metastases  visceral & parietal pleura & pericardium. bone primary not found.,MPATH: 513 - Lymphoid neoplasms|
1003-29-6|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|180 (180 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|174 records survival 819 ± 15 lifespan study|1003-29-6-40|6|778|n/a|n/a|n/a|
1003-29-6|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|180 (180 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|174 records survival 819 ± 15 lifespan study|1003-29-6-41|6|783|n/a|n/a|n/a|
1003-29-6|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|180 (180 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|174 records survival 819 ± 15 lifespan study|1003-29-6-42|6|792|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-6|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|180 (180 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|174 records survival 819 ± 15 lifespan study|1003-29-6-43|6|793|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/  ,MPATH: 242 - hemangiosarcoma|
1003-29-6|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|180 (180 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|174 records survival 819 ± 15 lifespan study|1003-29-6-44|6|803|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-6|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|180 (180 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|174 records survival 819 ± 15 lifespan study|1003-29-6-45|6|806|n/a|n/a|n/a|
1003-29-6|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|180 (180 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|174 records survival 819 ± 15 lifespan study|1003-29-6-46|6|807|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-6|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|180 (180 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|174 records survival 819 ± 15 lifespan study|1003-29-6-47|6|810|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-6|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|180 (180 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|174 records survival 819 ± 15 lifespan study|1003-29-6-48|6|813|Other deterministic changes|Whole body|MCDU/|
1003-29-6|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|180 (180 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|174 records survival 819 ± 15 lifespan study|1003-29-6-49|6|817|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-6|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|180 (180 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|174 records survival 819 ± 15 lifespan study|1003-29-6-50|6|820|n/a|n/a|n/a|
1003-29-6|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|180 (180 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|174 records survival 819 ± 15 lifespan study|1003-29-6-51|6|820|Other deterministic changes|Whole body|MCDU/|
1003-29-6|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|180 (180 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|174 records survival 819 ± 15 lifespan study|1003-29-6-52|6|824|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/  Head/neck missing Eye(s) missing Thorax missing,MPATH: 242 - hemangiosarcoma|
1003-29-6|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|180 (180 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|174 records survival 819 ± 15 lifespan study|1003-29-6-53|6|832|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-6|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|180 (180 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|174 records survival 819 ± 15 lifespan study|1003-29-6-54|6|834|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  Eye(s) missing,MPATH: 513 - Lymphoid neoplasms|
1003-29-6|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|180 (180 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|174 records survival 819 ± 15 lifespan study|1003-29-6-55|6|835|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|TMAB/  Predominantly ductal,MPATH: 218 - neoplasm|
1003-29-6|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|180 (180 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|174 records survival 819 ± 15 lifespan study|1003-29-6-56|6|836|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-6|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|180 (180 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|174 records survival 819 ± 15 lifespan study|1003-29-6-57|6|838|Other deterministic changes|Whole body|MCDU/|
1003-29-6|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|180 (180 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|174 records survival 819 ± 15 lifespan study|1003-29-6-58|6|839|Inflammation and/or fibrotic diseases|Lower respiratory system,MA: 0000415 - lung|MRMP/  Murine,MPATH: 212 - inflammation|
1003-29-6|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|180 (180 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|174 records survival 819 ± 15 lifespan study|1003-29-6-59|6|840|n/a|n/a|n/a|
1003-29-6|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|180 (180 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|174 records survival 819 ± 15 lifespan study|1003-29-6-60|6|841|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  Eye(s) missing Head/neck missing,MPATH: 513 - Lymphoid neoplasms|
1003-29-6|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|180 (180 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|174 records survival 819 ± 15 lifespan study|1003-29-6-61|6|844|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-6|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|180 (180 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|174 records survival 819 ± 15 lifespan study|1003-29-6-62|6|845|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  Head/neck missing,MPATH: 513 - Lymphoid neoplasms|
1003-29-6|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|180 (180 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|174 records survival 819 ± 15 lifespan study|1003-29-6-63|6|845|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-6|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|180 (180 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|174 records survival 819 ± 15 lifespan study|1003-29-6-64|6|848|n/a|n/a|n/a|
1003-29-6|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|180 (180 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|174 records survival 819 ± 15 lifespan study|1003-29-6-65|6|855|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-6|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|180 (180 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|174 records survival 819 ± 15 lifespan study|1003-29-6-66|6|856|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-6|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|180 (180 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|174 records survival 819 ± 15 lifespan study|1003-29-6-67|6|857|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-6|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|180 (180 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|174 records survival 819 ± 15 lifespan study|1003-29-6-68|6|859|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/   Metastases Lung,MPATH: 513 - Lymphoid neoplasms|
1003-29-6|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|180 (180 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|174 records survival 819 ± 15 lifespan study|1003-29-6-69|6|866|n/a|n/a|n/a|
1003-29-6|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|180 (180 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|174 records survival 819 ± 15 lifespan study|1003-29-6-70|6|869|n/a|n/a|n/a|
1003-29-6|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|180 (180 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|174 records survival 819 ± 15 lifespan study|1003-29-6-71|6|890|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-6|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|180 (180 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|174 records survival 819 ± 15 lifespan study|1003-29-6-72|6|903|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-6|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|180 (180 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|174 records survival 819 ± 15 lifespan study|1003-29-6-73|6|905|Neoplasia systemic|Haematolymphatic system|TLML/|
1003-29-6|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|180 (180 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|174 records survival 819 ± 15 lifespan study|1003-29-6-74|6|908|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-6|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|180 (180 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|174 records survival 819 ± 15 lifespan study|1003-29-6-75|6|909|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/  Head/neck missing Eye(s) missing,MPATH: 242 - hemangiosarcoma|
1003-29-6|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|180 (180 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|174 records survival 819 ± 15 lifespan study|1003-29-6-76|6|911|n/a|n/a|n/a|
1003-29-6|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|180 (180 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|174 records survival 819 ± 15 lifespan study|1003-29-6-77|6|912|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-6|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|180 (180 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|174 records survival 819 ± 15 lifespan study|1003-29-6-78|6|913|Neoplasia systemic|Haematolymphatic system|TLML/ without leukemia.|
1003-29-6|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|180 (180 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|174 records survival 819 ± 15 lifespan study|1003-29-6-79|6|915|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-6|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|180 (180 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|174 records survival 819 ± 15 lifespan study|1003-29-6-80|6|917|n/a|n/a|n/a|
1003-29-6|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|180 (180 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|174 records survival 819 ± 15 lifespan study|1003-29-6-81|6|917|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-6|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|180 (180 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|174 records survival 819 ± 15 lifespan study|1003-29-6-82|6|918|n/a|n/a|n/a|
1003-29-6|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|180 (180 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|174 records survival 819 ± 15 lifespan study|1003-29-6-83|6|922|n/a|n/a|n/a|
1003-29-6|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|180 (180 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|174 records survival 819 ± 15 lifespan study|1003-29-6-84|6|924|Neoplasia malignant|Bloodvessels among cardiovascular system|TMVS/ thigh Muscle|
1003-29-6|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|180 (180 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|174 records survival 819 ± 15 lifespan study|1003-29-6-85|6|924|Neoplasia malignant|Bloodvessels among cardiovascular system|TCVS/ soft connective tissue adjac. to kidney.|
1003-29-6|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|180 (180 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|174 records survival 819 ± 15 lifespan study|1003-29-6-86|6|925|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-29-6|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|180 (180 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|174 records survival 819 ± 15 lifespan study|1003-29-6-87|6|926|n/a|n/a|n/a|
1003-29-6|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|180 (180 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|174 records survival 819 ± 15 lifespan study|1003-29-6-88|6|933|Neoplasia systemic|Haematolymphatic system|TLML/|
1003-29-6|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|180 (180 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|174 records survival 819 ± 15 lifespan study|1003-29-6-89|6|934|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-6|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|180 (180 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|174 records survival 819 ± 15 lifespan study|1003-29-6-90|6|935|n/a|n/a|n/a|
1003-29-6|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|180 (180 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|174 records survival 819 ± 15 lifespan study|1003-29-6-91|6|936|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-6|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|180 (180 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|174 records survival 819 ± 15 lifespan study|1003-29-6-92|6|937|n/a|n/a|n/a|
1003-29-6|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|180 (180 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|174 records survival 819 ± 15 lifespan study|1003-29-6-93|6|939|Neoplasia systemic|Haematolymphatic system|TLML/|
1003-29-6|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|180 (180 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|174 records survival 819 ± 15 lifespan study|1003-29-6-94|6|939|n/a|n/a|n/a|
1003-29-6|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|180 (180 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|174 records survival 819 ± 15 lifespan study|1003-29-6-95|6|939|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-6|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|180 (180 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|174 records survival 819 ± 15 lifespan study|1003-29-6-96|6|946|n/a|n/a|n/a|
1003-29-6|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|180 (180 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|174 records survival 819 ± 15 lifespan study|1003-29-6-97|6|958|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-6|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|180 (180 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|174 records survival 819 ± 15 lifespan study|1003-29-6-98|6|959|n/a|n/a|n/a|
1003-29-6|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|180 (180 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|174 records survival 819 ± 15 lifespan study|1003-29-6-99|6|963|n/a|n/a|n/a|
1003-29-6|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|180 (180 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|174 records survival 819 ± 15 lifespan study|1003-29-6-100|6|963|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-6|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|180 (180 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|174 records survival 819 ± 15 lifespan study|1003-29-6-101|6|968|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|TUVS/  ,MPATH: 242 - hemangiosarcoma|
1003-29-6|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|180 (180 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|174 records survival 819 ± 15 lifespan study|1003-29-6-102|6|974|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-6|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|180 (180 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|174 records survival 819 ± 15 lifespan study|1003-29-6-103|6|974|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-6|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|180 (180 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|174 records survival 819 ± 15 lifespan study|1003-29-6-104|6|974|n/a|n/a|n/a|
1003-29-6|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|180 (180 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|174 records survival 819 ± 15 lifespan study|1003-29-6-105|6|976|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-29-6|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|180 (180 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|174 records survival 819 ± 15 lifespan study|1003-29-6-106|6|978|n/a|n/a|n/a|
1003-29-6|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|180 (180 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|174 records survival 819 ± 15 lifespan study|1003-29-6-107|6|980|n/a|n/a|n/a|
1003-29-6|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|180 (180 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|174 records survival 819 ± 15 lifespan study|1003-29-6-108|6|983|Hyperplastic changes|Cardiovascular system|MPAN/  Polyarteritis nodosa|
1003-29-6|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|180 (180 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|174 records survival 819 ± 15 lifespan study|1003-29-6-109|6|984|Hyperplastic changes|Cardiovascular system|MPAN/  Polyarteritis nodosa|
1003-29-6|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|180 (180 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|174 records survival 819 ± 15 lifespan study|1003-29-6-110|6|986|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-6|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|180 (180 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|174 records survival 819 ± 15 lifespan study|1003-29-6-111|6|988|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-6|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|180 (180 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|174 records survival 819 ± 15 lifespan study|1003-29-6-112|6|995|n/a|n/a|n/a|
1003-29-6|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|180 (180 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|174 records survival 819 ± 15 lifespan study|1003-29-6-113|6|996|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|TKAC/  ,MPATH: 549 - carcinoma|
1003-29-6|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|180 (180 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|174 records survival 819 ± 15 lifespan study|1003-29-6-114|6|1001|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-6|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|180 (180 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|174 records survival 819 ± 15 lifespan study|1003-29-6-115|6|1003|n/a|n/a|n/a|
1003-29-6|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|180 (180 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|174 records survival 819 ± 15 lifespan study|1003-29-6-116|6|1006|Other deterministic changes|Whole body|MCDU/|
1003-29-6|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|180 (180 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|174 records survival 819 ± 15 lifespan study|1003-29-6-117|6|1006|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-6|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|180 (180 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|174 records survival 819 ± 15 lifespan study|1003-29-6-118|6|1007|n/a|n/a|n/a|
1003-29-6|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|180 (180 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|174 records survival 819 ± 15 lifespan study|1003-29-6-119|6|1008|Inflammation and/or fibrotic diseases|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|MHIA/  acute,MPATH: 212 - inflammation|
1003-29-6|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|180 (180 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|174 records survival 819 ± 15 lifespan study|1003-29-6-120|6|1011|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-6|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|180 (180 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|174 records survival 819 ± 15 lifespan study|1003-29-6-121|6|1012|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-6|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|180 (180 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|174 records survival 819 ± 15 lifespan study|1003-29-6-122|6|1016|n/a|n/a|n/a|
1003-29-6|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|180 (180 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|174 records survival 819 ± 15 lifespan study|1003-29-6-123|6|1016|n/a|n/a|n/a|
1003-29-6|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|180 (180 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|174 records survival 819 ± 15 lifespan study|1003-29-6-124|6|1018|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  Head/neck missing,MPATH: 513 - Lymphoid neoplasms|
1003-29-6|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|180 (180 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|174 records survival 819 ± 15 lifespan study|1003-29-6-125|6|1018|n/a|n/a|n/a|
1003-29-6|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|180 (180 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|174 records survival 819 ± 15 lifespan study|1003-29-6-126|6|1022|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-6|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|180 (180 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|174 records survival 819 ± 15 lifespan study|1003-29-6-127|6|1023|n/a|n/a|n/a|
1003-29-6|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|180 (180 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|174 records survival 819 ± 15 lifespan study|1003-29-6-128|6|1029|n/a|n/a|n/a|
1003-29-6|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|180 (180 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|174 records survival 819 ± 15 lifespan study|1003-29-6-129|6|1031|n/a|n/a|n/a|
1003-29-6|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|180 (180 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|174 records survival 819 ± 15 lifespan study|1003-29-6-130|6|1045|Neoplasia systemic|Haematolymphatic system|TLPS/|
1003-29-6|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|180 (180 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|174 records survival 819 ± 15 lifespan study|1003-29-6-131|6|1046|n/a|n/a|n/a|
1003-29-6|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|180 (180 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|174 records survival 819 ± 15 lifespan study|1003-29-6-132|6|1047|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-6|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|180 (180 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|174 records survival 819 ± 15 lifespan study|1003-29-6-133|6|1048|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-6|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|180 (180 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|174 records survival 819 ± 15 lifespan study|1003-29-6-134|6|1051|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ histiocytic granulomas with malakoplakia bodies.,MPATH: 513 - Lymphoid neoplasms|
1003-29-6|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|180 (180 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|174 records survival 819 ± 15 lifespan study|1003-29-6-135|6|1053|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|TUVS/  Eye(s) missing Head/neck missing,MPATH: 242 - hemangiosarcoma|
1003-29-6|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|180 (180 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|174 records survival 819 ± 15 lifespan study|1003-29-6-136|6|1064|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  Head/neck missing,MPATH: 513 - Lymphoid neoplasms|
1003-29-6|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|180 (180 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|174 records survival 819 ± 15 lifespan study|1003-29-6-137|6|1065|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-6|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|180 (180 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|174 records survival 819 ± 15 lifespan study|1003-29-6-138|6|1067|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-6|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|180 (180 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|174 records survival 819 ± 15 lifespan study|1003-29-6-139|6|1068|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  Head/neck missing Eye(s) missing,MPATH: 513 - Lymphoid neoplasms|
1003-29-6|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|180 (180 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|174 records survival 819 ± 15 lifespan study|1003-29-6-140|6|1069|Other deterministic changes|Whole body|MCDU/|
1003-29-6|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|180 (180 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|174 records survival 819 ± 15 lifespan study|1003-29-6-141|6|1073|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-6|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|180 (180 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|174 records survival 819 ± 15 lifespan study|1003-29-6-142|6|1076|n/a|n/a|n/a|
1003-29-6|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|180 (180 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|174 records survival 819 ± 15 lifespan study|1003-29-6-143|6|1087|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-6|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|180 (180 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|174 records survival 819 ± 15 lifespan study|1003-29-6-144|6|1092|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-6|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|180 (180 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|174 records survival 819 ± 15 lifespan study|1003-29-6-145|6|1098|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  Head/neck missing Eye(s) missing,MPATH: 513 - Lymphoid neoplasms|
1003-29-6|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|180 (180 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|174 records survival 819 ± 15 lifespan study|1003-29-6-146|6|1101|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-6|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|180 (180 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|174 records survival 819 ± 15 lifespan study|1003-29-6-147|6|1103|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-6|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|180 (180 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|174 records survival 819 ± 15 lifespan study|1003-29-6-148|6|1108|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-29-6|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|180 (180 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|174 records survival 819 ± 15 lifespan study|1003-29-6-149|6|1108|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-6|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|180 (180 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|174 records survival 819 ± 15 lifespan study|1003-29-6-150|6|1115|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-6|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|180 (180 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|174 records survival 819 ± 15 lifespan study|1003-29-6-151|6|1118|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-6|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|180 (180 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|174 records survival 819 ± 15 lifespan study|1003-29-6-152|6|1122|n/a|n/a|n/a|
1003-29-6|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|180 (180 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|174 records survival 819 ± 15 lifespan study|1003-29-6-153|6|1124|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-6|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|180 (180 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|174 records survival 819 ± 15 lifespan study|1003-29-6-154|6|1130|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|TCFS/ subcut. dorsal-across shoulders.,MPATH: 408 - soft tissue fibrosarcoma|
1003-29-6|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|180 (180 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|174 records survival 819 ± 15 lifespan study|1003-29-6-155|6|1139|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|TCFS/ ventral subcut. lower abd. region. Metastases  Skin tcfs invades muscle. Metastases  Muscle tcfs invades skin.,MPATH: 408 - soft tissue fibrosarcoma|
1003-29-6|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|180 (180 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|174 records survival 819 ± 15 lifespan study|1003-29-6-156|6|1139|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-6|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|180 (180 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|174 records survival 819 ± 15 lifespan study|1003-29-6-157|6|1140|Neoplasia malignant|Liver among hepato-pancreatic system diseases|THAC/|
1003-29-6|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|180 (180 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|174 records survival 819 ± 15 lifespan study|1003-29-6-158|6|1143|Neoplasia malignant|Bloodvessels among cardiovascular system|TCVS/ mesentery adj. to kidney. Metastases  Lymphoret.System tcvs invades mn ln. Metastases  Muscle tcvs invades muscle adj. to kid.Eye(s) missing|
1003-29-6|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|180 (180 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|174 records survival 819 ± 15 lifespan study|1003-29-6-159|6|1149|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-6|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|180 (180 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|174 records survival 819 ± 15 lifespan study|1003-29-6-160|6|1151|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  Head/neck missing Eye(s) missing,MPATH: 513 - Lymphoid neoplasms|
1003-29-6|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|180 (180 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|174 records survival 819 ± 15 lifespan study|1003-29-6-161|6|1160|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-6|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|180 (180 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|174 records survival 819 ± 15 lifespan study|1003-29-6-162|6|1161|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-6|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|180 (180 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|174 records survival 819 ± 15 lifespan study|1003-29-6-163|6|1161|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-6|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|180 (180 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|174 records survival 819 ± 15 lifespan study|1003-29-6-164|6|1163|n/a|n/a|n/a|
1003-29-6|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|180 (180 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|174 records survival 819 ± 15 lifespan study|1003-29-6-165|6|1164|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-6|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|180 (180 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|174 records survival 819 ± 15 lifespan study|1003-29-6-166|6|1170|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-6|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|180 (180 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|174 records survival 819 ± 15 lifespan study|1003-29-6-167|6|1178|n/a|n/a|n/a|
1003-29-6|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|180 (180 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|174 records survival 819 ± 15 lifespan study|1003-29-6-168|6|1190|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-6|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|180 (180 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|174 records survival 819 ± 15 lifespan study|1003-29-6-169|6|1192|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-29-6|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|180 (180 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|174 records survival 819 ± 15 lifespan study|1003-29-6-170|6|1194|Other deterministic changes|Whole body|MCDU/|
1003-29-6|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|180 (180 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|174 records survival 819 ± 15 lifespan study|1003-29-6-171|6|1204|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-6|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|180 (180 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|174 records survival 819 ± 15 lifespan study|1003-29-6-172|6|1205|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOVO/  ,MPATH: 242 - hemangiosarcoma|
1003-29-6|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|180 (180 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|174 records survival 819 ± 15 lifespan study|1003-29-6-173|6|1210|n/a|n/a|n/a|
1003-29-6|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|180 (180 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|174 records survival 819 ± 15 lifespan study|1003-29-6-174|6|1258|Neoplasia systemic|Haematolymphatic system|TLPS/|
1003-29-6|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|180 (180 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|174 records survival 819 ± 15 lifespan study|1003-29-6-175|6|1268|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases  Lymphoret.System trac to pt ln. Metastases  trac to visc. perit. of lung.,MPATH: 268 - adenocarcinoma|
1003-29-6|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|180 (180 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|174 records survival 819 ± 15 lifespan study|1003-29-6-176|6|1269|Other deterministic changes|Whole body|MCDU/|
1003-29-6|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|180 (180 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|174 records survival 819 ± 15 lifespan study|1003-29-6-177|6|1288|n/a|n/a|n/a|
1003-29-6|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|180 (180 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|174 records survival 819 ± 15 lifespan study|1003-29-6-178|6|1294|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-6|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|180 (180 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|174 records survival 819 ± 15 lifespan study|1003-29-6-179|6|1349|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-6|n/a,2X|1|100|gamma-rays Co-60|2|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|180 (180 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|174 records survival 819 ± 15 lifespan study|1003-29-6-180|6|1352|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-1|7|116|n/a|n/a|n/a|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-2|7|116|n/a|n/a|n/a|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-3|7|116|n/a|n/a|n/a|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-4|7|116|n/a|n/a|n/a|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-5|7|116|n/a|n/a|n/a|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-6|7|138|n/a|n/a|n/a|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-7|7|138|n/a|n/a|n/a|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-8|7|138|n/a|n/a|n/a|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-9|7|173|n/a|n/a|n/a|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-10|7|173|n/a|n/a|n/a|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-11|7|173|n/a|n/a|n/a|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-12|7|173|n/a|n/a|n/a|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-13|7|173|n/a|n/a|n/a|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-14|7|173|n/a|n/a|n/a|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-15|7|173|n/a|n/a|n/a|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-16|7|173|n/a|n/a|n/a|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-17|7|173|n/a|n/a|n/a|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-18|7|173|n/a|n/a|n/a|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-19|7|180|n/a|n/a|n/a|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-20|7|180|n/a|n/a|n/a|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-21|7|180|n/a|n/a|n/a|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-22|7|180|n/a|n/a|n/a|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-23|7|180|n/a|n/a|n/a|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-24|7|180|n/a|n/a|n/a|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-25|7|180|n/a|n/a|n/a|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-26|7|180|n/a|n/a|n/a|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-27|7|180|n/a|n/a|n/a|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-28|7|180|n/a|n/a|n/a|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-29|7|216|n/a|n/a|n/a|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-30|7|216|n/a|n/a|n/a|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-31|7|222|n/a|n/a|n/a|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-32|7|222|n/a|n/a|n/a|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-33|7|223|n/a|n/a|n/a|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-34|7|223|n/a|n/a|n/a|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-35|7|223|n/a|n/a|n/a|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-36|7|278|n/a|n/a|n/a|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-37|7|278|n/a|n/a|n/a|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-38|7|278|n/a|n/a|n/a|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-39|7|278|n/a|n/a|n/a|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-40|7|278|n/a|n/a|n/a|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-41|7|278|n/a|n/a|n/a|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-42|7|278|n/a|n/a|n/a|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-43|7|278|n/a|n/a|n/a|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-44|7|278|n/a|n/a|n/a|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-45|7|278|n/a|n/a|n/a|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-46|7|278|n/a|n/a|n/a|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-47|7|278|n/a|n/a|n/a|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-48|7|278|n/a|n/a|n/a|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-49|7|285|n/a|n/a|n/a|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-50|7|285|n/a|n/a|n/a|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-51|7|285|n/a|n/a|n/a|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-52|7|285|n/a|n/a|n/a|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-53|7|285|n/a|n/a|n/a|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-54|7|285|n/a|n/a|n/a|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-55|7|285|n/a|n/a|n/a|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-56|7|285|n/a|n/a|n/a|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-57|7|285|n/a|n/a|n/a|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-58|7|304|n/a|n/a|n/a|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-59|7|367|Hyperplastic changes|Cardiovascular system|MPAN/  Polyarteritis nodosa|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-60|7|373|Neoplasia malignant|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|THVS/  ,MPATH: 242 - hemangiosarcoma|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-61|7|381|n/a|n/a|n/a|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-62|7|381|n/a|n/a|n/a|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-63|7|381|n/a|n/a|n/a|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-64|7|383|n/a|n/a|n/a|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-65|7|383|n/a|n/a|n/a|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-66|7|383|n/a|n/a|n/a|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-67|7|383|n/a|n/a|n/a|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-68|7|383|n/a|n/a|n/a|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-69|7|383|n/a|n/a|n/a|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-70|7|383|n/a|n/a|n/a|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-71|7|383|n/a|n/a|n/a|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-72|7|383|n/a|n/a|n/a|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-73|7|383|n/a|n/a|n/a|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-74|7|383|n/a|n/a|n/a|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-75|7|383|n/a|n/a|n/a|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-76|7|388|n/a|n/a|n/a|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-77|7|390|n/a|n/a|n/a|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-78|7|390|n/a|n/a|n/a|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-79|7|390|n/a|n/a|n/a|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-80|7|390|n/a|n/a|n/a|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-81|7|393|Neoplasia systemic|Haematolymphatic system|TLML/|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-82|7|417|n/a|n/a|n/a|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-83|7|417|n/a|n/a|n/a|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-84|7|417|n/a|n/a|n/a|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-85|7|417|n/a|n/a|n/a|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-86|7|417|n/a|n/a|n/a|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-87|7|417|n/a|n/a|n/a|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-88|7|417|n/a|n/a|n/a|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-89|7|417|n/a|n/a|n/a|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-90|7|424|n/a|n/a|n/a|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-91|7|424|n/a|n/a|n/a|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-92|7|424|n/a|n/a|n/a|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-93|7|424|n/a|n/a|n/a|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-94|7|424|n/a|n/a|n/a|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-95|7|424|n/a|n/a|n/a|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-96|7|424|n/a|n/a|n/a|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-97|7|424|n/a|n/a|n/a|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-98|7|424|n/a|n/a|n/a|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-99|7|424|n/a|n/a|n/a|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-100|7|424|n/a|n/a|n/a|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-101|7|424|n/a|n/a|n/a|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-102|7|424|n/a|n/a|n/a|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-103|7|424|n/a|n/a|n/a|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-104|7|424|n/a|n/a|n/a|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-105|7|453|n/a|n/a|n/a|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-106|7|453|n/a|n/a|n/a|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-107|7|453|n/a|n/a|n/a|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-108|7|453|n/a|n/a|n/a|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-109|7|460|n/a|n/a|n/a|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-110|7|460|n/a|n/a|n/a|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-111|7|515|n/a|n/a|n/a|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-112|7|515|n/a|n/a|n/a|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-113|7|515|n/a|n/a|n/a|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-114|7|515|n/a|n/a|n/a|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-115|7|515|n/a|n/a|n/a|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-116|7|523|n/a|n/a|n/a|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-117|7|523|n/a|n/a|n/a|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-118|7|523|n/a|n/a|n/a|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-119|7|523|n/a|n/a|n/a|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-120|7|523|n/a|n/a|n/a|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-121|7|523|n/a|n/a|n/a|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-122|7|523|n/a|n/a|n/a|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-123|7|523|n/a|n/a|n/a|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-124|7|523|n/a|n/a|n/a|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-125|7|523|n/a|n/a|n/a|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-126|7|523|n/a|n/a|n/a|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-127|7|523|n/a|n/a|n/a|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-128|7|523|n/a|n/a|n/a|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-129|7|523|n/a|n/a|n/a|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-130|7|523|n/a|n/a|n/a|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-131|7|523|n/a|n/a|n/a|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-132|7|527|n/a|n/a|n/a|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-133|7|530|n/a|n/a|n/a|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-134|7|530|n/a|n/a|n/a|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-135|7|530|n/a|n/a|n/a|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-136|7|530|n/a|n/a|n/a|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-137|7|548|n/a|n/a|n/a|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-138|7|548|n/a|n/a|n/a|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-139|7|548|n/a|n/a|n/a|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-140|7|548|n/a|n/a|n/a|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-141|7|548|n/a|n/a|n/a|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-142|7|548|n/a|n/a|n/a|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-143|7|548|n/a|n/a|n/a|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-144|7|548|n/a|n/a|n/a|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-145|7|548|n/a|n/a|n/a|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-146|7|548|n/a|n/a|n/a|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-147|7|548|n/a|n/a|n/a|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-148|7|548|n/a|n/a|n/a|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-149|7|548|n/a|n/a|n/a|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-150|7|548|n/a|n/a|n/a|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-151|7|548|n/a|n/a|n/a|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-152|7|557|Neoplasia malignant|Bloodvessels among cardiovascular system|TCVS/ right inguinal region.|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-153|7|562|n/a|n/a|n/a|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-154|7|562|n/a|n/a|n/a|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-155|7|562|n/a|n/a|n/a|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-156|7|562|n/a|n/a|n/a|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-157|7|562|n/a|n/a|n/a|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-158|7|569|n/a|n/a|n/a|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-159|7|569|n/a|n/a|n/a|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-160|7|569|n/a|n/a|n/a|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-161|7|569|n/a|n/a|n/a|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-162|7|569|n/a|n/a|n/a|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-163|7|569|n/a|n/a|n/a|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-164|7|569|n/a|n/a|n/a|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-165|7|569|n/a|n/a|n/a|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-166|7|569|n/a|n/a|n/a|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-167|7|569|n/a|n/a|n/a|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-168|7|590|n/a|n/a|n/a|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-169|7|590|n/a|n/a|n/a|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-170|7|590|n/a|n/a|n/a|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-171|7|590|n/a|n/a|n/a|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-172|7|590|n/a|n/a|n/a|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-173|7|591|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-174|7|610|n/a|n/a|n/a|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-175|7|610|n/a|n/a|n/a|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-176|7|610|n/a|n/a|n/a|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-177|7|610|n/a|n/a|n/a|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-178|7|612|Neoplasia unclassified|Other local manifestations and miscellaneus|TRWC: TCFS INVAS. OF LUNG.|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-179|7|625|n/a|n/a|n/a|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-180|7|626|n/a|n/a|n/a|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-181|7|626|n/a|n/a|n/a|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-182|7|626|n/a|n/a|n/a|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-183|7|626|n/a|n/a|n/a|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-184|7|626|n/a|n/a|n/a|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-185|7|626|n/a|n/a|n/a|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-186|7|628|n/a|n/a|n/a|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-187|7|628|n/a|n/a|n/a|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-188|7|632|n/a|n/a|n/a|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-189|7|632|n/a|n/a|n/a|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-190|7|632|n/a|n/a|n/a|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-191|7|633|n/a|n/a|n/a|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-192|7|635|n/a|n/a|n/a|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-193|7|635|n/a|n/a|n/a|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-194|7|641|n/a|n/a|n/a|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-195|7|641|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-196|7|647|n/a|n/a|n/a|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-197|7|662|n/a|n/a|n/a|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-198|7|662|n/a|n/a|n/a|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-199|7|692|n/a|n/a|n/a|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-200|7|695|Neoplasia malignant|Bloodvessels among cardiovascular system|TCVS/ femur. Metastases  Muscle tcvs skeletal muscle & smooth muscle of leg and periton. wall. Metastases  Muscle tcvs invades skel. muscle, bm, & bone of femur.|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-201|7|703|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/  ,MPATH: 242 - hemangiosarcoma|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-202|7|704|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-203|7|708|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-204|7|711|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-205|7|729|n/a|n/a|n/a|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-206|7|729|n/a|n/a|n/a|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-207|7|729|n/a|n/a|n/a|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-208|7|729|n/a|n/a|n/a|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-209|7|729|n/a|n/a|n/a|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-210|7|729|n/a|n/a|n/a|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-211|7|736|n/a|n/a|n/a|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-212|7|736|n/a|n/a|n/a|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-213|7|736|n/a|n/a|n/a|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-214|7|736|n/a|n/a|n/a|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-215|7|737|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-216|7|747|n/a|n/a|n/a|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-217|7|747|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-218|7|751|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases  Lymphoret.System trac in ax. l.n. Metastases  trac in area of adrenal growing on visc. perit. of kidney.,MPATH: 268 - adenocarcinoma|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-219|7|761|n/a|n/a|n/a|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-220|7|764|Neoplasia malignant|Bloodvessels among cardiovascular system|TCVS/ in abdominal cavity. Metastases Liver Metastases  tcvs invades pancreatic renal & adrenal visc. peritoneum.|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-221|7|764|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-222|7|766|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-223|7|772|Neoplasia malignant|Bloodvessels among cardiovascular system|TCVS/ connective tissue around kidney. Metastases Lung Metastases  Muscle tcvs invas of spinal musc & vert.|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-224|7|785|n/a|n/a|n/a|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-225|7|785|n/a|n/a|n/a|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-226|7|785|n/a|n/a|n/a|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-227|7|792|n/a|n/a|n/a|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-228|7|792|n/a|n/a|n/a|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-229|7|792|n/a|n/a|n/a|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-230|7|799|n/a|n/a|n/a|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-231|7|799|n/a|n/a|n/a|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-232|7|799|n/a|n/a|n/a|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-233|7|799|n/a|n/a|n/a|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-234|7|799|n/a|n/a|n/a|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-235|7|799|n/a|n/a|n/a|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-236|7|806|n/a|n/a|n/a|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-237|7|818|n/a|n/a|n/a|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-238|7|827|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-239|7|835|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-240|7|840|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|TCFS/ subcut from axilla & along ribs. Metastases Lung,MPATH: 408 - soft tissue fibrosarcoma|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-241|7|844|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-242|7|850|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-243|7|859|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-244|7|862|n/a|n/a|n/a|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-245|7|871|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-246|7|874|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  Head/neck missing,MPATH: 268 - adenocarcinoma|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-247|7|876|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-248|7|881|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-249|7|895|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-250|7|898|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-251|7|904|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  Head/neck missing Eye(s) missing,MPATH: 513 - Lymphoid neoplasms|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-252|7|917|Neoplasia unclassified|Other local manifestations and miscellaneus|TLWX: TXAC(SALIVARY GLAND) METAST. TO CN LN.|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-253|7|919|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-254|7|933|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-255|7|934|Neoplasia unclassified|Other local manifestations and miscellaneus|THWC: TCVS TO LIVER.|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-256|7|939|n/a|n/a|n/a|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-257|7|954|Neoplasia malignant|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|THVS/ infiltrates peritoneum & pancreas.,MPATH: 242 - hemangiosarcoma|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-258|7|955|n/a|n/a|n/a|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-259|7|964|Neoplasia unclassified|Other local manifestations and miscellaneus|TRWC: TCFS INVAS. OF LUNG.|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-260|7|969|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-261|7|975|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-262|7|984|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-263|7|991|n/a|n/a|n/a|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-264|7|995|Neoplasia unclassified|Other local manifestations and miscellaneus|TRWC: TCFS INVAS. OF LUNG.|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-265|7|996|Neoplasia malignant|Other local manifestations and miscellaneus|TMLS/ ublad.|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-266|7|999|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  Eye(s) missing Head/neck missing,MPATH: 268 - adenocarcinoma|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-267|7|1005|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-268|7|1017|n/a|n/a|n/a|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-269|7|1044|n/a|n/a|n/a|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-270|7|1046|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  Head/neck missing Eye(s) missing,MPATH: 513 - Lymphoid neoplasms|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-271|7|1050|n/a|n/a|n/a|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-272|7|1055|n/a|n/a|n/a|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-273|7|1055|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-274|7|1067|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-275|7|1073|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-276|7|1073|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  Head/neck missing Eye(s) missing,MPATH: 513 - Lymphoid neoplasms|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-277|7|1086|Other deterministic changes|Whole body|MCDU/|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-278|7|1099|Neoplasia unclassified|Other local manifestations and miscellaneus|TLWR: TRAC IN AX. L.N.|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-279|7|1108|Neoplasia unclassified|Other local manifestations and miscellaneus|THWC: TCVS TO LIVER.|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-280|7|1115|Other deterministic changes|Whole body|MCDU/  Thorax missing Head/neck missing Eye(s) missing|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-281|7|1121|n/a|n/a|n/a|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-282|7|1135|n/a|n/a|n/a|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-283|7|1136|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-284|7|1142|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-285|7|1164|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-286|7|1164|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-287|7|1165|n/a|n/a|n/a|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-288|7|1173|n/a|n/a|n/a|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-289|7|1177|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-290|7|1178|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-291|7|1186|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-292|7|1202|n/a|n/a|n/a|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-293|7|1233|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|TXAC/ salivary gland with squamous differentiation. Metastases  Lymphoret.System txac(salivary gland) metast. to cn ln.,MPATH: 268 - adenocarcinoma|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-294|7|1234|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-7|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|295 (295 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|83 records survival 832 ± 20 lifespan study|1003-29-7-295|7|1396|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-29-8|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|79 records survival 782 ± 20 lifespan study|1003-29-8-1|8|360|n/a|n/a|n/a|
1003-29-8|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|79 records survival 782 ± 20 lifespan study|1003-29-8-2|8|396|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-8|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|79 records survival 782 ± 20 lifespan study|1003-29-8-3|8|506|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-8|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|79 records survival 782 ± 20 lifespan study|1003-29-8-4|8|577|Neoplasia malignant|Bloodvessels among cardiovascular system|TCVS/ thorax.|
1003-29-8|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|79 records survival 782 ± 20 lifespan study|1003-29-8-5|8|617|n/a|n/a|n/a|
1003-29-8|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|79 records survival 782 ± 20 lifespan study|1003-29-8-6|8|649|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-29-8|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|79 records survival 782 ± 20 lifespan study|1003-29-8-7|8|668|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-8|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|79 records survival 782 ± 20 lifespan study|1003-29-8-8|8|678|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|TMFS/ thigh.muscle,MPATH: 408 - soft tissue fibrosarcoma|
1003-29-8|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|79 records survival 782 ± 20 lifespan study|1003-29-8-9|8|690|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-8|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|79 records survival 782 ± 20 lifespan study|1003-29-8-10|8|701|n/a|n/a|n/a|
1003-29-8|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|79 records survival 782 ± 20 lifespan study|1003-29-8-11|8|702|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-8|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|79 records survival 782 ± 20 lifespan study|1003-29-8-12|8|729|Hyperplastic changes|Other local manifestations and miscellaneus,MA: 0000003 - organ system|MOCY/  Ovary or testis,MPATH: 62 - cyst|
1003-29-8|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|79 records survival 782 ± 20 lifespan study|1003-29-8-13|8|734|Neoplasia malignant|Bloodvessels among cardiovascular system|TCVS/ hind quarters. Metastases  Muscle tcvs in bone, bone marrow, & skeletal muscle of femur & spine.|
1003-29-8|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|79 records survival 782 ± 20 lifespan study|1003-29-8-14|8|758|Neoplasia malignant|Bloodvessels among cardiovascular system|TIVS/ stomach wall. Metastases  tivs throughout peritonium of spleen, liver, panc. and adrenal.|
1003-29-8|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|79 records survival 782 ± 20 lifespan study|1003-29-8-15|8|764|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-8|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|79 records survival 782 ± 20 lifespan study|1003-29-8-16|8|764|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-8|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|79 records survival 782 ± 20 lifespan study|1003-29-8-17|8|768|Changes due to an abnormal circulation|Bloodvessels among cardiovascular system|MTHR/  auricular|
1003-29-8|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|79 records survival 782 ± 20 lifespan study|1003-29-8-18|8|768|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-8|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|79 records survival 782 ± 20 lifespan study|1003-29-8-19|8|771|Other deterministic changes|Whole body|MCDU/|
1003-29-8|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|79 records survival 782 ± 20 lifespan study|1003-29-8-20|8|773|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-8|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|79 records survival 782 ± 20 lifespan study|1003-29-8-21|8|775|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-8|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|79 records survival 782 ± 20 lifespan study|1003-29-8-22|8|781|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/  ,MPATH: 242 - hemangiosarcoma|
1003-29-8|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|79 records survival 782 ± 20 lifespan study|1003-29-8-23|8|799|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-29-8|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|79 records survival 782 ± 20 lifespan study|1003-29-8-24|8|815|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-8|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|79 records survival 782 ± 20 lifespan study|1003-29-8-25|8|815|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-8|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|79 records survival 782 ± 20 lifespan study|1003-29-8-26|8|822|n/a|n/a|n/a|
1003-29-8|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|79 records survival 782 ± 20 lifespan study|1003-29-8-27|8|823|Neoplasia malignant|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOVS/  ,MPATH: 242 - hemangiosarcoma|
1003-29-8|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|79 records survival 782 ± 20 lifespan study|1003-29-8-28|8|828|n/a|n/a|n/a|
1003-29-8|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|79 records survival 782 ± 20 lifespan study|1003-29-8-29|8|829|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-8|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|79 records survival 782 ± 20 lifespan study|1003-29-8-30|8|839|Neoplasia malignant|Bloodvessels among cardiovascular system|TCVS/ perit conn tiss adnexa of uterus.|
1003-29-8|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|79 records survival 782 ± 20 lifespan study|1003-29-8-31|8|856|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/ spread to surrounding soft tiss.,MPATH: 242 - hemangiosarcoma|
1003-29-8|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|79 records survival 782 ± 20 lifespan study|1003-29-8-32|8|856|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/   Metastases  tcvs in urethra.,MPATH: 513 - Lymphoid neoplasms|
1003-29-8|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|79 records survival 782 ± 20 lifespan study|1003-29-8-33|8|856|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/  ,MPATH: 242 - hemangiosarcoma|
1003-29-8|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|79 records survival 782 ± 20 lifespan study|1003-29-8-34|8|860|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-8|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|79 records survival 782 ± 20 lifespan study|1003-29-8-35|8|867|n/a|n/a|n/a|
1003-29-8|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|79 records survival 782 ± 20 lifespan study|1003-29-8-36|8|867|n/a|n/a|n/a|
1003-29-8|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|79 records survival 782 ± 20 lifespan study|1003-29-8-37|8|869|n/a|n/a|n/a|
1003-29-8|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|79 records survival 782 ± 20 lifespan study|1003-29-8-38|8|876|n/a|n/a|n/a|
1003-29-8|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|79 records survival 782 ± 20 lifespan study|1003-29-8-39|8|889|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-8|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|79 records survival 782 ± 20 lifespan study|1003-29-8-40|8|889|n/a|n/a|n/a|
1003-29-8|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|79 records survival 782 ± 20 lifespan study|1003-29-8-41|8|894|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-8|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|79 records survival 782 ± 20 lifespan study|1003-29-8-42|8|900|n/a|n/a|n/a|
1003-29-8|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|79 records survival 782 ± 20 lifespan study|1003-29-8-43|8|906|n/a|n/a|n/a|
1003-29-8|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|79 records survival 782 ± 20 lifespan study|1003-29-8-44|8|913|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-8|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|79 records survival 782 ± 20 lifespan study|1003-29-8-45|8|917|n/a|n/a|n/a|
1003-29-8|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|79 records survival 782 ± 20 lifespan study|1003-29-8-46|8|925|Neoplasia malignant|Other local manifestations and miscellaneus|TMLS/ mediastinum & heart.|
1003-29-8|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|79 records survival 782 ± 20 lifespan study|1003-29-8-47|8|934|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-8|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|79 records survival 782 ± 20 lifespan study|1003-29-8-48|8|936|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-8|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|79 records survival 782 ± 20 lifespan study|1003-29-8-49|8|978|Other deterministic changes|Whole body|MCDU/  Head/neck missing Eye(s) missing|
1003-29-8|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|79 records survival 782 ± 20 lifespan study|1003-29-8-50|8|979|Neoplasia malignant|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|THVS/  ,MPATH: 242 - hemangiosarcoma|
1003-29-8|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|79 records survival 782 ± 20 lifespan study|1003-29-8-51|8|984|Neoplasia unclassified|Ovary among reproductive system diseases|TOGC/  Eye(s) missing Head/neck missing|
1003-29-8|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|79 records survival 782 ± 20 lifespan study|1003-29-8-52|8|987|n/a|n/a|n/a|
1003-29-8|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|79 records survival 782 ± 20 lifespan study|1003-29-8-53|8|998|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-8|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|79 records survival 782 ± 20 lifespan study|1003-29-8-54|8|1002|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-8|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|79 records survival 782 ± 20 lifespan study|1003-29-8-55|8|1002|Neoplasia malignant|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|THVS/  ,MPATH: 242 - hemangiosarcoma|
1003-29-8|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|79 records survival 782 ± 20 lifespan study|1003-29-8-56|8|1009|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  Eye(s) missing Head/neck missing Thorax missing,MPATH: 513 - Lymphoid neoplasms|
1003-29-8|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|79 records survival 782 ± 20 lifespan study|1003-29-8-57|8|1009|n/a|n/a|n/a|
1003-29-8|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|79 records survival 782 ± 20 lifespan study|1003-29-8-58|8|1010|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  Head/neck missing Eye(s) missing,MPATH: 513 - Lymphoid neoplasms|
1003-29-8|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|79 records survival 782 ± 20 lifespan study|1003-29-8-59|8|1012|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-8|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|79 records survival 782 ± 20 lifespan study|1003-29-8-60|8|1018|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-8|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|79 records survival 782 ± 20 lifespan study|1003-29-8-61|8|1019|n/a|n/a|n/a|
1003-29-8|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|79 records survival 782 ± 20 lifespan study|1003-29-8-62|8|1021|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-29-8|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|79 records survival 782 ± 20 lifespan study|1003-29-8-63|8|1022|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-8|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|79 records survival 782 ± 20 lifespan study|1003-29-8-64|8|1022|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  Eye(s) missing Head/neck missing Thorax missing,MPATH: 513 - Lymphoid neoplasms|
1003-29-8|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|79 records survival 782 ± 20 lifespan study|1003-29-8-65|8|1028|n/a|n/a|n/a|
1003-29-8|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|79 records survival 782 ± 20 lifespan study|1003-29-8-66|8|1031|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-29-8|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|79 records survival 782 ± 20 lifespan study|1003-29-8-67|8|1034|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|TMAB/  Predominantly ductal,MPATH: 218 - neoplasm|
1003-29-8|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|79 records survival 782 ± 20 lifespan study|1003-29-8-68|8|1048|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-29-8|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|79 records survival 782 ± 20 lifespan study|1003-29-8-69|8|1057|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  Head/neck missing Thorax missing Eye(s) missing,MPATH: 513 - Lymphoid neoplasms|
1003-29-8|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|79 records survival 782 ± 20 lifespan study|1003-29-8-70|8|1065|n/a|n/a|n/a|
1003-29-8|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|79 records survival 782 ± 20 lifespan study|1003-29-8-71|8|1065|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-8|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|79 records survival 782 ± 20 lifespan study|1003-29-8-72|8|1070|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-8|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|79 records survival 782 ± 20 lifespan study|1003-29-8-73|8|1104|n/a|n/a|n/a|
1003-29-8|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|79 records survival 782 ± 20 lifespan study|1003-29-8-74|8|1113|n/a|n/a|n/a|
1003-29-8|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|79 records survival 782 ± 20 lifespan study|1003-29-8-75|8|1125|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-8|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|79 records survival 782 ± 20 lifespan study|1003-29-8-76|8|1125|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  Eye(s) missing,MPATH: 513 - Lymphoid neoplasms|
1003-29-8|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|79 records survival 782 ± 20 lifespan study|1003-29-8-77|8|1131|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-8|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|79 records survival 782 ± 20 lifespan study|1003-29-8-78|8|1148|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-8|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|79 records survival 782 ± 20 lifespan study|1003-29-8-79|8|1320|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-8|n/a,3X|1|100|gamma-rays Co-60|3|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|79 records survival 782 ± 20 lifespan study|1003-29-8-80|8|1335|n/a|n/a|n/a|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-1|9|173|n/a|n/a|n/a|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-2|9|173|n/a|n/a|n/a|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-3|9|173|n/a|n/a|n/a|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-4|9|173|n/a|n/a|n/a|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-5|9|173|n/a|n/a|n/a|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-6|9|173|n/a|n/a|n/a|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-7|9|180|n/a|n/a|n/a|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-8|9|180|n/a|n/a|n/a|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-9|9|180|n/a|n/a|n/a|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-10|9|180|n/a|n/a|n/a|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-11|9|180|n/a|n/a|n/a|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-12|9|180|n/a|n/a|n/a|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-13|9|180|n/a|n/a|n/a|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-14|9|180|n/a|n/a|n/a|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-15|9|180|n/a|n/a|n/a|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-16|9|180|n/a|n/a|n/a|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-17|9|180|n/a|n/a|n/a|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-18|9|180|n/a|n/a|n/a|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-19|9|183|n/a|n/a|n/a|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-20|9|183|n/a|n/a|n/a|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-21|9|184|n/a|n/a|n/a|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-22|9|216|n/a|n/a|n/a|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-23|9|216|n/a|n/a|n/a|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-24|9|222|n/a|n/a|n/a|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-25|9|222|n/a|n/a|n/a|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-26|9|222|n/a|n/a|n/a|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-27|9|223|n/a|n/a|n/a|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-28|9|223|n/a|n/a|n/a|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-29|9|223|n/a|n/a|n/a|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-30|9|277|n/a|n/a|n/a|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-31|9|277|n/a|n/a|n/a|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-32|9|277|n/a|n/a|n/a|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-33|9|278|n/a|n/a|n/a|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-34|9|278|n/a|n/a|n/a|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-35|9|278|n/a|n/a|n/a|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-36|9|278|n/a|n/a|n/a|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-37|9|278|n/a|n/a|n/a|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-38|9|278|n/a|n/a|n/a|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-39|9|278|n/a|n/a|n/a|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-40|9|278|n/a|n/a|n/a|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-41|9|285|n/a|n/a|n/a|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-42|9|285|n/a|n/a|n/a|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-43|9|285|n/a|n/a|n/a|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-44|9|285|n/a|n/a|n/a|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-45|9|285|n/a|n/a|n/a|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-46|9|285|n/a|n/a|n/a|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-47|9|285|n/a|n/a|n/a|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-48|9|285|n/a|n/a|n/a|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-49|9|285|n/a|n/a|n/a|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-50|9|285|n/a|n/a|n/a|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-51|9|285|n/a|n/a|n/a|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-52|9|285|n/a|n/a|n/a|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-53|9|285|n/a|n/a|n/a|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-54|9|285|n/a|n/a|n/a|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-55|9|381|n/a|n/a|n/a|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-56|9|381|n/a|n/a|n/a|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-57|9|383|n/a|n/a|n/a|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-58|9|388|n/a|n/a|n/a|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-59|9|388|n/a|n/a|n/a|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-60|9|388|n/a|n/a|n/a|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-61|9|388|n/a|n/a|n/a|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-62|9|390|n/a|n/a|n/a|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-63|9|390|n/a|n/a|n/a|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-64|9|390|n/a|n/a|n/a|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-65|9|390|n/a|n/a|n/a|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-66|9|390|n/a|n/a|n/a|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-67|9|390|n/a|n/a|n/a|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-68|9|390|n/a|n/a|n/a|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-69|9|390|n/a|n/a|n/a|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-70|9|390|n/a|n/a|n/a|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-71|9|390|n/a|n/a|n/a|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-72|9|390|n/a|n/a|n/a|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-73|9|390|n/a|n/a|n/a|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-74|9|390|n/a|n/a|n/a|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-75|9|417|n/a|n/a|n/a|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-76|9|417|n/a|n/a|n/a|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-77|9|417|n/a|n/a|n/a|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-78|9|417|n/a|n/a|n/a|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-79|9|417|n/a|n/a|n/a|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-80|9|417|n/a|n/a|n/a|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-81|9|417|n/a|n/a|n/a|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-82|9|424|n/a|n/a|n/a|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-83|9|424|n/a|n/a|n/a|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-84|9|424|n/a|n/a|n/a|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-85|9|424|n/a|n/a|n/a|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-86|9|424|n/a|n/a|n/a|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-87|9|424|n/a|n/a|n/a|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-88|9|424|n/a|n/a|n/a|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-89|9|424|n/a|n/a|n/a|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-90|9|424|n/a|n/a|n/a|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-91|9|424|n/a|n/a|n/a|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-92|9|424|n/a|n/a|n/a|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-93|9|424|n/a|n/a|n/a|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-94|9|424|n/a|n/a|n/a|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-95|9|424|n/a|n/a|n/a|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-96|9|450|n/a|n/a|n/a|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-97|9|457|n/a|n/a|n/a|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-98|9|460|n/a|n/a|n/a|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-99|9|460|n/a|n/a|n/a|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-100|9|460|n/a|n/a|n/a|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-101|9|460|n/a|n/a|n/a|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-102|9|515|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-103|9|530|n/a|n/a|n/a|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-104|9|530|n/a|n/a|n/a|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-105|9|530|n/a|n/a|n/a|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-106|9|530|n/a|n/a|n/a|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-107|9|530|n/a|n/a|n/a|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-108|9|530|n/a|n/a|n/a|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-109|9|530|n/a|n/a|n/a|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-110|9|530|n/a|n/a|n/a|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-111|9|530|n/a|n/a|n/a|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-112|9|530|n/a|n/a|n/a|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-113|9|530|n/a|n/a|n/a|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-114|9|530|n/a|n/a|n/a|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-115|9|530|n/a|n/a|n/a|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-116|9|530|n/a|n/a|n/a|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-117|9|530|n/a|n/a|n/a|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-118|9|530|n/a|n/a|n/a|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-119|9|530|n/a|n/a|n/a|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-120|9|530|n/a|n/a|n/a|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-121|9|530|n/a|n/a|n/a|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-122|9|543|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-123|9|544|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-124|9|548|n/a|n/a|n/a|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-125|9|548|n/a|n/a|n/a|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-126|9|548|n/a|n/a|n/a|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-127|9|548|n/a|n/a|n/a|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-128|9|548|n/a|n/a|n/a|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-129|9|548|n/a|n/a|n/a|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-130|9|548|n/a|n/a|n/a|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-131|9|548|n/a|n/a|n/a|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-132|9|548|n/a|n/a|n/a|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-133|9|548|n/a|n/a|n/a|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-134|9|555|n/a|n/a|n/a|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-135|9|555|n/a|n/a|n/a|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-136|9|555|n/a|n/a|n/a|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-137|9|555|n/a|n/a|n/a|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-138|9|555|n/a|n/a|n/a|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-139|9|562|n/a|n/a|n/a|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-140|9|562|n/a|n/a|n/a|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-141|9|562|n/a|n/a|n/a|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-142|9|562|n/a|n/a|n/a|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-143|9|562|n/a|n/a|n/a|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-144|9|562|n/a|n/a|n/a|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-145|9|562|n/a|n/a|n/a|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-146|9|562|n/a|n/a|n/a|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-147|9|562|n/a|n/a|n/a|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-148|9|562|n/a|n/a|n/a|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-149|9|569|n/a|n/a|n/a|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-150|9|569|n/a|n/a|n/a|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-151|9|569|n/a|n/a|n/a|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-152|9|569|n/a|n/a|n/a|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-153|9|569|n/a|n/a|n/a|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-154|9|575|n/a|n/a|n/a|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-155|9|583|n/a|n/a|n/a|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-156|9|583|n/a|n/a|n/a|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-157|9|583|n/a|n/a|n/a|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-158|9|583|n/a|n/a|n/a|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-159|9|583|n/a|n/a|n/a|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-160|9|592|Other deterministic changes|Whole body|MCDU/|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-161|9|617|n/a|n/a|n/a|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-162|9|617|n/a|n/a|n/a|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-163|9|617|n/a|n/a|n/a|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-164|9|617|n/a|n/a|n/a|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-165|9|625|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-166|9|626|n/a|n/a|n/a|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-167|9|626|n/a|n/a|n/a|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-168|9|626|n/a|n/a|n/a|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-169|9|631|n/a|n/a|n/a|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-170|9|631|n/a|n/a|n/a|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-171|9|631|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases  trac in visceral & parietal pleura.Eye(s) missing Head/neck missing,MPATH: 268 - adenocarcinoma|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-172|9|631|n/a|n/a|n/a|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-173|9|631|n/a|n/a|n/a|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-174|9|632|n/a|n/a|n/a|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-175|9|632|n/a|n/a|n/a|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-176|9|632|n/a|n/a|n/a|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-177|9|632|n/a|n/a|n/a|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-178|9|633|n/a|n/a|n/a|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-179|9|633|n/a|n/a|n/a|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-180|9|633|n/a|n/a|n/a|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-181|9|633|n/a|n/a|n/a|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-182|9|634|n/a|n/a|n/a|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-183|9|634|n/a|n/a|n/a|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-184|9|641|n/a|n/a|n/a|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-185|9|648|n/a|n/a|n/a|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-186|9|655|n/a|n/a|n/a|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-187|9|655|n/a|n/a|n/a|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-188|9|662|n/a|n/a|n/a|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-189|9|662|n/a|n/a|n/a|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-190|9|662|n/a|n/a|n/a|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-191|9|662|n/a|n/a|n/a|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-192|9|675|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/  Head/neck missing Eye(s) missing,MPATH: 242 - hemangiosarcoma|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-193|9|682|Other deterministic changes|Whole body|MCDU/|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-194|9|683|n/a|n/a|n/a|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-195|9|686|Other deterministic changes|Whole body|MCDU/|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-196|9|687|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-197|9|703|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-198|9|706|Other deterministic changes|Whole body|MCDU/|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-199|9|707|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-200|9|713|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases  Muscle trac to intercostal muscles. Metastases Heart Metastases  trac to parietal pleura of rib cage.,MPATH: 268 - adenocarcinoma|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-201|9|724|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-202|9|727|n/a|n/a|n/a|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-203|9|729|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-204|9|729|n/a|n/a|n/a|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-205|9|729|n/a|n/a|n/a|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-206|9|729|n/a|n/a|n/a|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-207|9|729|n/a|n/a|n/a|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-208|9|736|n/a|n/a|n/a|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-209|9|736|n/a|n/a|n/a|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-210|9|736|n/a|n/a|n/a|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-211|9|736|n/a|n/a|n/a|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-212|9|736|n/a|n/a|n/a|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-213|9|736|n/a|n/a|n/a|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-214|9|737|Neoplasia malignant|Bloodvessels among cardiovascular system|TMVS/ spinal vert. muscle. Muscle Metastases  tmvs to visc. peritoneum surrounding kidney & adrenal.|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-215|9|744|Neoplasia unclassified|Other local manifestations and miscellaneus|TMWR: TRAC IN INTERCOSTAL MUSCLES.|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-216|9|744|Other deterministic changes|Whole body|MCDU/|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-217|9|746|n/a|n/a|n/a|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-218|9|750|n/a|n/a|n/a|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-219|9|761|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-220|9|764|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-221|9|783|Other deterministic changes|Whole body|MCDU/|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-222|9|785|n/a|n/a|n/a|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-223|9|785|n/a|n/a|n/a|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-224|9|786|n/a|n/a|n/a|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-225|9|789|Neoplasia unclassified|Other local manifestations and miscellaneus|TMWR: TRAC IN INTERCOSTAL MUSCLES.|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-226|9|789|n/a|n/a|n/a|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-227|9|793|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-228|9|799|n/a|n/a|n/a|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-229|9|799|n/a|n/a|n/a|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-230|9|799|n/a|n/a|n/a|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-231|9|799|n/a|n/a|n/a|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-232|9|799|n/a|n/a|n/a|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-233|9|806|n/a|n/a|n/a|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-234|9|806|n/a|n/a|n/a|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-235|9|806|n/a|n/a|n/a|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-236|9|806|Neoplasia unclassified|Other local manifestations and miscellaneus|TRWG: TGAC TO LUNG.|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-237|9|836|n/a|n/a|n/a|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-238|9|846|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  Eye(s) missing Head/neck missing,MPATH: 268 - adenocarcinoma|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-239|9|853|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-240|9|856|n/a|n/a|n/a|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-241|9|865|Other deterministic changes|Whole body|MCDU/|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-242|9|871|Other deterministic changes|Whole body|MCDU/|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-243|9|878|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-244|9|900|n/a|n/a|n/a|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-245|9|903|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-246|9|909|Neoplasia unclassified|Other local manifestations and miscellaneus|TRWK: TKAC TO LUNG.|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-247|9|915|n/a|n/a|n/a|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-248|9|919|Other deterministic changes|Whole body|MCDU/|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-249|9|920|Neoplasia unclassified|Other local manifestations and miscellaneus|TRWK: TKAC TO LUNG.|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-250|9|935|Neoplasia malignant|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|THVS/  ,MPATH: 242 - hemangiosarcoma|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-251|9|941|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-252|9|944|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-253|9|969|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/   Metastases  Lymphoret.System trac to pt. l.n. Metastases Lung,MPATH: 513 - Lymphoid neoplasms|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-254|9|971|n/a|n/a|n/a|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-255|9|984|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-256|9|987|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-257|9|987|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-258|9|988|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  Eye(s) missing,MPATH: 513 - Lymphoid neoplasms|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-259|9|989|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-260|9|989|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-261|9|991|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-262|9|1002|Neoplasia unclassified|Other local manifestations and miscellaneus|TLWR: TRAC TO PT. L.N.|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-263|9|1011|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-264|9|1026|n/a|n/a|n/a|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-265|9|1026|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-266|9|1026|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-267|9|1031|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-268|9|1036|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/   Metastases  Muscle trac in intercostal muscles.,MPATH: 513 - Lymphoid neoplasms|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-269|9|1039|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-270|9|1040|n/a|n/a|n/a|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-271|9|1047|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-272|9|1049|n/a|n/a|n/a|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-273|9|1068|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-274|9|1068|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-275|9|1073|n/a|n/a|n/a|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-276|9|1080|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|TKAC/   Metastases Lung,MPATH: 549 - carcinoma|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-277|9|1080|Other deterministic changes|Whole body|MCDU/|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-278|9|1088|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-279|9|1091|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-280|9|1099|Neoplasia malignant|Endocrine system|TGAC/   Metastases Lung|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-281|9|1106|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-282|9|1115|Inflammation and/or fibrotic diseases|Lower respiratory system,MA: 0000415 - lung|Murine,MPATH: 212 - inflammation|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-283|9|1124|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-284|9|1128|n/a|n/a|n/a|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-285|9|1142|n/a|n/a|n/a|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-286|9|1144|Other deterministic changes|Whole body|MCDU/|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-287|9|1223|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-288|9|1233|Other deterministic changes|Whole body|MCDU/|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-289|9|1260|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-9|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|86 records survival 813 ± 19 lifespan study|1003-29-9-290|9|1390|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-10|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|75 records survival 784 ± 18 lifespan study|1003-29-10-1|10|610|n/a|n/a|n/a|
1003-29-10|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|75 records survival 784 ± 18 lifespan study|1003-29-10-2|10|629|n/a|n/a|n/a|
1003-29-10|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|75 records survival 784 ± 18 lifespan study|1003-29-10-3|10|634|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-10|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|75 records survival 784 ± 18 lifespan study|1003-29-10-4|10|649|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-10|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|75 records survival 784 ± 18 lifespan study|1003-29-10-5|10|656|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/   Metastases  Muscle tsec of rt. side of head and neck to muscle of head. Metastases  Lymphoret.System tsec of rt. side of head and neck to c.n.,MPATH: 513 - Lymphoid neoplasms|
1003-29-10|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|75 records survival 784 ± 18 lifespan study|1003-29-10-6|10|661|Other deterministic changes|Whole body|MCDU/|
1003-29-10|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|75 records survival 784 ± 18 lifespan study|1003-29-10-7|10|663|Other deterministic changes|Whole body|MCDU/|
1003-29-10|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|75 records survival 784 ± 18 lifespan study|1003-29-10-8|10|689|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-10|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|75 records survival 784 ± 18 lifespan study|1003-29-10-9|10|701|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-10|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|75 records survival 784 ± 18 lifespan study|1003-29-10-10|10|720|n/a|n/a|n/a|
1003-29-10|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|75 records survival 784 ± 18 lifespan study|1003-29-10-11|10|721|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-10|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|75 records survival 784 ± 18 lifespan study|1003-29-10-12|10|722|n/a|n/a|n/a|
1003-29-10|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|75 records survival 784 ± 18 lifespan study|1003-29-10-13|10|722|n/a|n/a|n/a|
1003-29-10|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|75 records survival 784 ± 18 lifespan study|1003-29-10-14|10|722|n/a|n/a|n/a|
1003-29-10|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|75 records survival 784 ± 18 lifespan study|1003-29-10-15|10|722|n/a|n/a|n/a|
1003-29-10|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|75 records survival 784 ± 18 lifespan study|1003-29-10-16|10|722|n/a|n/a|n/a|
1003-29-10|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|75 records survival 784 ± 18 lifespan study|1003-29-10-17|10|739|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-10|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|75 records survival 784 ± 18 lifespan study|1003-29-10-18|10|743|n/a|n/a|n/a|
1003-29-10|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|75 records survival 784 ± 18 lifespan study|1003-29-10-19|10|746|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  Head/neck missing,MPATH: 513 - Lymphoid neoplasms|
1003-29-10|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|75 records survival 784 ± 18 lifespan study|1003-29-10-20|10|770|n/a|n/a|n/a|
1003-29-10|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|75 records survival 784 ± 18 lifespan study|1003-29-10-21|10|772|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-10|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|75 records survival 784 ± 18 lifespan study|1003-29-10-22|10|774|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-10|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|75 records survival 784 ± 18 lifespan study|1003-29-10-23|10|775|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-10|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|75 records survival 784 ± 18 lifespan study|1003-29-10-24|10|778|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-10|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|75 records survival 784 ± 18 lifespan study|1003-29-10-25|10|782|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|TCFS/ inside peritoneal wall. Metastases  tcfs infiltrates visc. perit. of intestine, uterus, ovaries, kids, adrenals, fat of mesenteries & pancreas.,MPATH: 408 - soft tissue fibrosarcoma|
1003-29-10|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|75 records survival 784 ± 18 lifespan study|1003-29-10-26|10|792|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-10|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|75 records survival 784 ± 18 lifespan study|1003-29-10-27|10|792|n/a|n/a|n/a|
1003-29-10|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|75 records survival 784 ± 18 lifespan study|1003-29-10-28|10|796|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/  ,MPATH: 242 - hemangiosarcoma|
1003-29-10|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|75 records survival 784 ± 18 lifespan study|1003-29-10-29|10|796|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases  Lymphoret.System trac to thoracic ln.,MPATH: 268 - adenocarcinoma|
1003-29-10|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|75 records survival 784 ± 18 lifespan study|1003-29-10-30|10|803|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-10|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|75 records survival 784 ± 18 lifespan study|1003-29-10-31|10|806|Other deterministic changes|Whole body|MCDU/|
1003-29-10|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|75 records survival 784 ± 18 lifespan study|1003-29-10-32|10|806|n/a|n/a|n/a|
1003-29-10|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|75 records survival 784 ± 18 lifespan study|1003-29-10-33|10|809|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-10|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|75 records survival 784 ± 18 lifespan study|1003-29-10-34|10|812|n/a|n/a|n/a|
1003-29-10|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|75 records survival 784 ± 18 lifespan study|1003-29-10-35|10|822|Other deterministic changes|Whole body|MCDU/|
1003-29-10|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|75 records survival 784 ± 18 lifespan study|1003-29-10-36|10|825|n/a|n/a|n/a|
1003-29-10|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|75 records survival 784 ± 18 lifespan study|1003-29-10-37|10|841|n/a|n/a|n/a|
1003-29-10|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|75 records survival 784 ± 18 lifespan study|1003-29-10-38|10|851|n/a|n/a|n/a|
1003-29-10|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|75 records survival 784 ± 18 lifespan study|1003-29-10-39|10|856|Neoplasia malignant|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|THVS/  ,MPATH: 242 - hemangiosarcoma|
1003-29-10|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|75 records survival 784 ± 18 lifespan study|1003-29-10-40|10|865|Hyperplastic changes|Other local manifestations and miscellaneus,MA: 0000003 - organ system|MOCY/  Ovary or testis,MPATH: 62 - cyst|
1003-29-10|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|75 records survival 784 ± 18 lifespan study|1003-29-10-41|10|868|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-10|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|75 records survival 784 ± 18 lifespan study|1003-29-10-42|10|877|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-10|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|75 records survival 784 ± 18 lifespan study|1003-29-10-43|10|884|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-10|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|75 records survival 784 ± 18 lifespan study|1003-29-10-44|10|907|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLSS/  undifferentiated lymphoma,MPATH: 513 - Lymphoid neoplasms|
1003-29-10|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|75 records survival 784 ± 18 lifespan study|1003-29-10-45|10|911|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-10|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|75 records survival 784 ± 18 lifespan study|1003-29-10-46|10|912|n/a|n/a|n/a|
1003-29-10|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|75 records survival 784 ± 18 lifespan study|1003-29-10-47|10|925|n/a|n/a|n/a|
1003-29-10|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|75 records survival 784 ± 18 lifespan study|1003-29-10-48|10|936|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-10|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|75 records survival 784 ± 18 lifespan study|1003-29-10-49|10|937|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  Eye(s) missing Head/neck missing,MPATH: 513 - Lymphoid neoplasms|
1003-29-10|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|75 records survival 784 ± 18 lifespan study|1003-29-10-50|10|938|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-10|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|75 records survival 784 ± 18 lifespan study|1003-29-10-51|10|941|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-10|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|75 records survival 784 ± 18 lifespan study|1003-29-10-52|10|942|Neoplasia systemic|Haematolymphatic system|TLML/  Head/neck missing|
1003-29-10|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|75 records survival 784 ± 18 lifespan study|1003-29-10-53|10|955|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-10|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|75 records survival 784 ± 18 lifespan study|1003-29-10-54|10|957|n/a|n/a|n/a|
1003-29-10|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|75 records survival 784 ± 18 lifespan study|1003-29-10-55|10|959|n/a|n/a|n/a|
1003-29-10|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|75 records survival 784 ± 18 lifespan study|1003-29-10-56|10|967|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-10|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|75 records survival 784 ± 18 lifespan study|1003-29-10-57|10|971|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  Head/neck missing Eye(s) missing,MPATH: 513 - Lymphoid neoplasms|
1003-29-10|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|75 records survival 784 ± 18 lifespan study|1003-29-10-58|10|985|Neoplasia malignant|Other local manifestations and miscellaneus|TMLS/ musc of l upper arm & shoulder w/ infiltration of skin. Metastases Lung tmls of musc. metast to lung.|
1003-29-10|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|75 records survival 784 ± 18 lifespan study|1003-29-10-59|10|993|n/a|n/a|n/a|
1003-29-10|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|75 records survival 784 ± 18 lifespan study|1003-29-10-60|10|1008|n/a|n/a|n/a|
1003-29-10|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|75 records survival 784 ± 18 lifespan study|1003-29-10-61|10|1017|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-10|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|75 records survival 784 ± 18 lifespan study|1003-29-10-62|10|1018|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOVO/  ,MPATH: 242 - hemangiosarcoma|
1003-29-10|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|75 records survival 784 ± 18 lifespan study|1003-29-10-63|10|1019|Neoplasia unclassified|Ovary among reproductive system diseases|TOGC/   Metastases Lung|
1003-29-10|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|75 records survival 784 ± 18 lifespan study|1003-29-10-64|10|1021|n/a|n/a|n/a|
1003-29-10|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|75 records survival 784 ± 18 lifespan study|1003-29-10-65|10|1034|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-10|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|75 records survival 784 ± 18 lifespan study|1003-29-10-66|10|1040|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-10|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|75 records survival 784 ± 18 lifespan study|1003-29-10-67|10|1047|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  Head/neck missing,MPATH: 513 - Lymphoid neoplasms|
1003-29-10|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|75 records survival 784 ± 18 lifespan study|1003-29-10-68|10|1050|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  Head/neck missing Eye(s) missing,MPATH: 268 - adenocarcinoma|
1003-29-10|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|75 records survival 784 ± 18 lifespan study|1003-29-10-69|10|1064|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/  ,MPATH: 242 - hemangiosarcoma|
1003-29-10|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|75 records survival 784 ± 18 lifespan study|1003-29-10-70|10|1065|Inflammation and/or fibrotic diseases|Other local manifestations and miscellaneus,MA: 0000003 - organ system|MCIG/  ,MPATH: 213 - acute inflammation|
1003-29-10|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|75 records survival 784 ± 18 lifespan study|1003-29-10-71|10|1076|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  Head/neck missing,MPATH: 513 - Lymphoid neoplasms|
1003-29-10|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|75 records survival 784 ± 18 lifespan study|1003-29-10-72|10|1085|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/  ,MPATH: 242 - hemangiosarcoma|
1003-29-10|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|75 records survival 784 ± 18 lifespan study|1003-29-10-73|10|1104|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-10|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|75 records survival 784 ± 18 lifespan study|1003-29-10-74|10|1113|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOVO/  ,MPATH: 242 - hemangiosarcoma|
1003-29-10|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|75 records survival 784 ± 18 lifespan study|1003-29-10-75|10|1115|Other deterministic changes|Whole body|MCDU/|
1003-29-10|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|75 records survival 784 ± 18 lifespan study|1003-29-10-76|10|1115|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-10|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|75 records survival 784 ± 18 lifespan study|1003-29-10-77|10|1129|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-10|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|75 records survival 784 ± 18 lifespan study|1003-29-10-78|10|1143|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-10|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|75 records survival 784 ± 18 lifespan study|1003-29-10-79|10|1208|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/  ,MPATH: 242 - hemangiosarcoma|
1003-29-10|n/a,4X|1|100|gamma-rays Co-60|4.5|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|75 records survival 784 ± 18 lifespan study|1003-29-10-80|10|1343|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-1|11|113|n/a|n/a|n/a|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-2|11|145|n/a|n/a|n/a|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-3|11|145|n/a|n/a|n/a|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-4|11|145|n/a|n/a|n/a|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-5|11|173|n/a|n/a|n/a|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-6|11|173|n/a|n/a|n/a|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-7|11|173|n/a|n/a|n/a|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-8|11|173|n/a|n/a|n/a|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-9|11|173|n/a|n/a|n/a|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-10|11|173|n/a|n/a|n/a|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-11|11|173|n/a|n/a|n/a|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-12|11|180|n/a|n/a|n/a|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-13|11|180|n/a|n/a|n/a|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-14|11|180|n/a|n/a|n/a|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-15|11|180|n/a|n/a|n/a|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-16|11|180|n/a|n/a|n/a|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-17|11|180|n/a|n/a|n/a|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-18|11|180|n/a|n/a|n/a|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-19|11|180|n/a|n/a|n/a|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-20|11|180|n/a|n/a|n/a|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-21|11|180|n/a|n/a|n/a|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-22|11|180|n/a|n/a|n/a|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-23|11|183|n/a|n/a|n/a|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-24|11|183|n/a|n/a|n/a|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-25|11|216|n/a|n/a|n/a|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-26|11|222|n/a|n/a|n/a|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-27|11|222|n/a|n/a|n/a|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-28|11|222|n/a|n/a|n/a|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-29|11|223|n/a|n/a|n/a|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-30|11|223|n/a|n/a|n/a|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-31|11|223|n/a|n/a|n/a|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-32|11|223|n/a|n/a|n/a|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-33|11|263|n/a|n/a|n/a|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-34|11|264|n/a|n/a|n/a|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-35|11|264|n/a|n/a|n/a|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-36|11|264|n/a|n/a|n/a|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-37|11|278|n/a|n/a|n/a|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-38|11|278|n/a|n/a|n/a|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-39|11|278|n/a|n/a|n/a|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-40|11|278|n/a|n/a|n/a|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-41|11|278|n/a|n/a|n/a|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-42|11|278|n/a|n/a|n/a|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-43|11|278|n/a|n/a|n/a|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-44|11|278|n/a|n/a|n/a|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-45|11|284|n/a|n/a|n/a|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-46|11|284|n/a|n/a|n/a|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-47|11|285|n/a|n/a|n/a|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-48|11|285|n/a|n/a|n/a|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-49|11|285|n/a|n/a|n/a|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-50|11|285|n/a|n/a|n/a|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-51|11|285|n/a|n/a|n/a|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-52|11|285|n/a|n/a|n/a|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-53|11|285|n/a|n/a|n/a|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-54|11|285|n/a|n/a|n/a|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-55|11|285|n/a|n/a|n/a|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-56|11|285|n/a|n/a|n/a|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-57|11|285|n/a|n/a|n/a|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-58|11|285|n/a|n/a|n/a|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-59|11|360|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-60|11|380|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|TSBC/ nose.,MPATH: 446 - squamous cell carcinoma|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-61|11|381|n/a|n/a|n/a|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-62|11|381|n/a|n/a|n/a|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-63|11|381|n/a|n/a|n/a|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-64|11|383|n/a|n/a|n/a|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-65|11|383|n/a|n/a|n/a|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-66|11|383|n/a|n/a|n/a|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-67|11|383|n/a|n/a|n/a|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-68|11|383|n/a|n/a|n/a|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-69|11|383|n/a|n/a|n/a|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-70|11|383|n/a|n/a|n/a|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-71|11|388|n/a|n/a|n/a|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-72|11|390|n/a|n/a|n/a|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-73|11|390|n/a|n/a|n/a|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-74|11|390|n/a|n/a|n/a|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-75|11|390|n/a|n/a|n/a|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-76|11|390|n/a|n/a|n/a|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-77|11|390|n/a|n/a|n/a|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-78|11|390|n/a|n/a|n/a|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-79|11|390|n/a|n/a|n/a|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-80|11|390|n/a|n/a|n/a|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-81|11|390|n/a|n/a|n/a|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-82|11|417|n/a|n/a|n/a|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-83|11|417|n/a|n/a|n/a|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-84|11|417|n/a|n/a|n/a|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-85|11|417|n/a|n/a|n/a|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-86|11|423|Other deterministic changes|Whole body|MCDU/|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-87|11|424|n/a|n/a|n/a|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-88|11|424|n/a|n/a|n/a|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-89|11|424|n/a|n/a|n/a|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-90|11|424|n/a|n/a|n/a|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-91|11|424|n/a|n/a|n/a|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-92|11|424|n/a|n/a|n/a|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-93|11|424|n/a|n/a|n/a|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-94|11|424|n/a|n/a|n/a|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-95|11|424|n/a|n/a|n/a|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-96|11|424|n/a|n/a|n/a|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-97|11|424|n/a|n/a|n/a|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-98|11|424|n/a|n/a|n/a|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-99|11|424|n/a|n/a|n/a|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-100|11|424|n/a|n/a|n/a|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-101|11|424|n/a|n/a|n/a|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-102|11|424|n/a|n/a|n/a|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-103|11|424|n/a|n/a|n/a|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-104|11|424|n/a|n/a|n/a|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-105|11|453|n/a|n/a|n/a|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-106|11|453|n/a|n/a|n/a|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-107|11|457|n/a|n/a|n/a|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-108|11|457|n/a|n/a|n/a|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-109|11|460|n/a|n/a|n/a|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-110|11|460|n/a|n/a|n/a|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-111|11|471|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-112|11|523|n/a|n/a|n/a|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-113|11|523|n/a|n/a|n/a|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-114|11|523|n/a|n/a|n/a|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-115|11|523|n/a|n/a|n/a|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-116|11|523|n/a|n/a|n/a|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-117|11|523|n/a|n/a|n/a|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-118|11|523|n/a|n/a|n/a|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-119|11|530|n/a|n/a|n/a|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-120|11|530|n/a|n/a|n/a|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-121|11|530|n/a|n/a|n/a|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-122|11|530|n/a|n/a|n/a|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-123|11|530|n/a|n/a|n/a|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-124|11|530|n/a|n/a|n/a|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-125|11|530|n/a|n/a|n/a|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-126|11|530|n/a|n/a|n/a|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-127|11|530|n/a|n/a|n/a|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-128|11|530|n/a|n/a|n/a|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-129|11|530|n/a|n/a|n/a|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-130|11|530|n/a|n/a|n/a|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-131|11|530|n/a|n/a|n/a|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-132|11|530|n/a|n/a|n/a|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-133|11|548|n/a|n/a|n/a|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-134|11|548|n/a|n/a|n/a|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-135|11|548|n/a|n/a|n/a|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-136|11|548|n/a|n/a|n/a|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-137|11|548|n/a|n/a|n/a|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-138|11|548|n/a|n/a|n/a|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-139|11|548|n/a|n/a|n/a|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-140|11|548|n/a|n/a|n/a|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-141|11|548|n/a|n/a|n/a|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-142|11|548|n/a|n/a|n/a|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-143|11|548|n/a|n/a|n/a|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-144|11|548|n/a|n/a|n/a|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-145|11|548|n/a|n/a|n/a|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-146|11|548|n/a|n/a|n/a|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-147|11|548|n/a|n/a|n/a|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-148|11|550|Other deterministic changes|Whole body|MCDU/  Head/neck missing Lung missing Thorax missing|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-149|11|562|n/a|n/a|n/a|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-150|11|562|n/a|n/a|n/a|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-151|11|562|n/a|n/a|n/a|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-152|11|562|n/a|n/a|n/a|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-153|11|562|n/a|n/a|n/a|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-154|11|569|n/a|n/a|n/a|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-155|11|569|n/a|n/a|n/a|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-156|11|569|n/a|n/a|n/a|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-157|11|569|n/a|n/a|n/a|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-158|11|569|n/a|n/a|n/a|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-159|11|569|n/a|n/a|n/a|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-160|11|569|n/a|n/a|n/a|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-161|11|569|n/a|n/a|n/a|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-162|11|569|n/a|n/a|n/a|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-163|11|573|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-164|11|590|n/a|n/a|n/a|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-165|11|590|n/a|n/a|n/a|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-166|11|590|n/a|n/a|n/a|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-167|11|590|n/a|n/a|n/a|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-168|11|601|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-169|11|610|n/a|n/a|n/a|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-170|11|610|n/a|n/a|n/a|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-171|11|617|n/a|n/a|n/a|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-172|11|617|n/a|n/a|n/a|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-173|11|617|n/a|n/a|n/a|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-174|11|617|n/a|n/a|n/a|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-175|11|618|n/a|n/a|n/a|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-176|11|624|n/a|n/a|n/a|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-177|11|624|n/a|n/a|n/a|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-178|11|624|n/a|n/a|n/a|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-179|11|625|n/a|n/a|n/a|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-180|11|626|n/a|n/a|n/a|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-181|11|626|n/a|n/a|n/a|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-182|11|630|n/a|n/a|n/a|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-183|11|631|n/a|n/a|n/a|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-184|11|632|n/a|n/a|n/a|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-185|11|632|n/a|n/a|n/a|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-186|11|633|n/a|n/a|n/a|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-187|11|633|n/a|n/a|n/a|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-188|11|633|n/a|n/a|n/a|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-189|11|636|Neoplasia malignant|Bloodvessels among cardiovascular system|TCVS/ inguinal region.|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-190|11|647|n/a|n/a|n/a|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-191|11|655|n/a|n/a|n/a|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-192|11|655|n/a|n/a|n/a|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-193|11|655|n/a|n/a|n/a|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-194|11|661|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-195|11|663|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-196|11|666|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|TCFS/ surrounding penis. Metastases  tcfs invades peritoneum to grow on surface of spleen & pancreas. Metastases  Skin tcfs in skin of lower abd.,MPATH: 408 - soft tissue fibrosarcoma|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-197|11|688|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-198|11|690|n/a|n/a|n/a|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-199|11|695|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|TCFS/ surrounds femur. Metastases  Muscle tcfs invades skeletal muscle & muscle coats of lg. intestine.,MPATH: 408 - soft tissue fibrosarcoma|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-200|11|707|n/a|n/a|n/a|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-201|11|711|Neoplasia malignant|Bloodvessels among cardiovascular system|TYVS/  Heart|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-202|11|715|n/a|n/a|n/a|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-203|11|717|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-204|11|724|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-205|11|729|n/a|n/a|n/a|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-206|11|729|n/a|n/a|n/a|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-207|11|729|n/a|n/a|n/a|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-208|11|729|n/a|n/a|n/a|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-209|11|729|n/a|n/a|n/a|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-210|11|729|n/a|n/a|n/a|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-211|11|732|Neoplasia malignant|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|THVS/  ,MPATH: 242 - hemangiosarcoma|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-212|11|736|n/a|n/a|n/a|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-213|11|736|n/a|n/a|n/a|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-214|11|736|Other deterministic changes|Whole body|MCDU/|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-215|11|736|n/a|n/a|n/a|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-216|11|736|n/a|n/a|n/a|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-217|11|757|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/   Metastases  Muscle tcfs in skeletal muscle of lower abd.,MPATH: 513 - Lymphoid neoplasms|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-218|11|762|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-219|11|767|Other deterministic changes|Whole body|MCDU/|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-220|11|774|n/a|n/a|n/a|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-221|11|785|n/a|n/a|n/a|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-222|11|785|n/a|n/a|n/a|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-223|11|785|n/a|n/a|n/a|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-224|11|786|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-225|11|791|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  Thorax missing Eye(s) missing Head/neck missing,MPATH: 513 - Lymphoid neoplasms|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-226|11|799|n/a|n/a|n/a|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-227|11|799|n/a|n/a|n/a|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-228|11|799|n/a|n/a|n/a|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-229|11|799|n/a|n/a|n/a|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-230|11|799|n/a|n/a|n/a|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-231|11|799|n/a|n/a|n/a|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-232|11|815|n/a|n/a|n/a|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-233|11|841|Neoplasia unclassified|Other local manifestations and miscellaneus|THWG: TGAC TO LIVER.|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-234|11|845|n/a|n/a|n/a|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-235|11|853|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-236|11|853|Neoplasia unclassified|Other local manifestations and miscellaneus|THWR: TRAC TO THWR.|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-237|11|862|n/a|n/a|n/a|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-238|11|862|Other deterministic changes|Whole body|MCDU/|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-239|11|870|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-240|11|873|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-241|11|878|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  Head/neck missing Eye(s) missing Lung congestion ,MPATH: 513 - Lymphoid neoplasms|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-242|11|881|n/a|n/a|n/a|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-243|11|882|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-244|11|884|n/a|n/a|n/a|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-245|11|892|n/a|n/a|n/a|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-246|11|897|n/a|n/a|n/a|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-247|11|899|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/   Metastases  tcfs infiltr. of bulbourethral gland.,MPATH: 513 - Lymphoid neoplasms|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-248|11|903|Neoplasia unclassified|Other local manifestations and miscellaneus|THWR: TRAC TO THWR.|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-249|11|914|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|TSFS/ right pelvic region.,MPATH: 219 - adnexal and skin appendage tumor|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-250|11|918|Other deterministic changes|Whole body|MCDU/|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-251|11|918|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  Eye(s) missing Head/neck missing,MPATH: 513 - Lymphoid neoplasms|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-252|11|921|n/a|n/a|n/a|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-253|11|923|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-254|11|936|Neoplasia unclassified|Other local manifestations and miscellaneus|TMWC: TCFS IN SKELETAL MUSCLE OF LOWER ABD.|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-255|11|938|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-256|11|940|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/   Metastases Lung,MPATH: 513 - Lymphoid neoplasms|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-257|11|951|n/a|n/a|n/a|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-258|11|970|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-259|11|971|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  Eye(s) missing Head/neck missing,MPATH: 513 - Lymphoid neoplasms|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-260|11|971|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-261|11|975|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-262|11|977|n/a|n/a|n/a|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-263|11|978|n/a|n/a|n/a|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-264|11|979|Neoplasia malignant|Bloodvessels among cardiovascular system|TCVS/ rt ear region.|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-265|11|995|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases Liver Metastases Kidney Metastases Heart Metastases  Lymphoret.System trac to pt-- mediastinal.,MPATH: 268 - adenocarcinoma|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-266|11|1002|Neoplasia unclassified|Other local manifestations and miscellaneus|TMWC: TCVS INVADES MUSC OF HEAD IN RT EAR REGION.|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-267|11|1006|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-268|11|1007|Hyperplastic changes|Cardiovascular system|MPAN/  Polyarteritis nodosa|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-269|11|1010|n/a|n/a|n/a|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-270|11|1012|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-271|11|1015|n/a|n/a|n/a|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-272|11|1043|Neoplasia unclassified|Other local manifestations and miscellaneus|THWG: TGAC TO LIVER.|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-273|11|1044|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-274|11|1047|Neoplasia malignant|Endocrine system|TGAC/   Metastases Liver Metastases  Muscle tgac invades musc & skin of head.|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-275|11|1072|n/a|n/a|n/a|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-276|11|1076|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-277|11|1077|Neoplasia unclassified|Other local manifestations and miscellaneus|TRWG: NO PRIMARY FOUND. NO EYES- CANNIBALIZED.|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-278|11|1083|n/a|n/a|n/a|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-279|11|1092|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/   Metastases  Muscle tcvs invades musc of head in rt ear region.,MPATH: 513 - Lymphoid neoplasms|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-280|11|1112|Neoplasia unclassified|Other local manifestations and miscellaneus|TRWG: NO PRIMARY FOUND. NO EYES- CANNIBALIZED.|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-281|11|1124|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-282|11|1156|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-283|11|1168|n/a|n/a|n/a|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-284|11|1170|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-285|11|1176|Neoplasia unclassified|Other local manifestations and miscellaneus|TMWC: TCFS INVADES SKELETAL MUSCLE & MUSCLE COATS OF LG. INTESTINE.|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-286|11|1195|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/   Metastases  trac to pleura.,MPATH: 513 - Lymphoid neoplasms|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-287|11|1210|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-288|11|1226|Neoplasia unclassified|Other local manifestations and miscellaneus|TRWG: NO PRIMARY FOUND. NO EYES- CANNIBALIZED.|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-289|11|1232|n/a|n/a|n/a|
1003-29-11|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|290 (290 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|90 records survival 793 ± 20 lifespan study|1003-29-11-290|11|1280|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-29-12|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|79 records survival 745 ± 19 lifespan study|1003-29-12-1|12|151|n/a|n/a|n/a|
1003-29-12|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|79 records survival 745 ± 19 lifespan study|1003-29-12-2|12|424|Neoplasia malignant|Bloodvessels among cardiovascular system|TXVS/ pancreas|
1003-29-12|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|79 records survival 745 ± 19 lifespan study|1003-29-12-3|12|452|n/a|n/a|n/a|
1003-29-12|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|79 records survival 745 ± 19 lifespan study|1003-29-12-4|12|532|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-12|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|79 records survival 745 ± 19 lifespan study|1003-29-12-5|12|547|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-12|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|79 records survival 745 ± 19 lifespan study|1003-29-12-6|12|556|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-12|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|79 records survival 745 ± 19 lifespan study|1003-29-12-7|12|582|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-12|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|79 records survival 745 ± 19 lifespan study|1003-29-12-8|12|615|n/a|n/a|n/a|
1003-29-12|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|79 records survival 745 ± 19 lifespan study|1003-29-12-9|12|638|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-12|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|79 records survival 745 ± 19 lifespan study|1003-29-12-10|12|666|n/a|n/a|n/a|
1003-29-12|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|79 records survival 745 ± 19 lifespan study|1003-29-12-11|12|670|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-12|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|79 records survival 745 ± 19 lifespan study|1003-29-12-12|12|695|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  Head/neck missing,MPATH: 513 - Lymphoid neoplasms|
1003-29-12|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|79 records survival 745 ± 19 lifespan study|1003-29-12-13|12|696|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-12|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|79 records survival 745 ± 19 lifespan study|1003-29-12-14|12|713|Other deterministic changes|Whole body|MCDU/|
1003-29-12|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|79 records survival 745 ± 19 lifespan study|1003-29-12-15|12|715|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-12|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|79 records survival 745 ± 19 lifespan study|1003-29-12-16|12|718|n/a|n/a|n/a|
1003-29-12|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|79 records survival 745 ± 19 lifespan study|1003-29-12-17|12|722|n/a|n/a|n/a|
1003-29-12|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|79 records survival 745 ± 19 lifespan study|1003-29-12-18|12|726|n/a|n/a|n/a|
1003-29-12|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|79 records survival 745 ± 19 lifespan study|1003-29-12-19|12|729|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-12|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|79 records survival 745 ± 19 lifespan study|1003-29-12-20|12|729|n/a|n/a|n/a|
1003-29-12|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|79 records survival 745 ± 19 lifespan study|1003-29-12-21|12|733|Hyperplastic changes|Other local manifestations and miscellaneus,MA: 0000003 - organ system|MOCY/  Ovary or testis,MPATH: 62 - cyst|
1003-29-12|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|79 records survival 745 ± 19 lifespan study|1003-29-12-22|12|744|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/  ,MPATH: 242 - hemangiosarcoma|
1003-29-12|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|79 records survival 745 ± 19 lifespan study|1003-29-12-23|12|746|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-12|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|79 records survival 745 ± 19 lifespan study|1003-29-12-24|12|747|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-12|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|79 records survival 745 ± 19 lifespan study|1003-29-12-25|12|757|n/a|n/a|n/a|
1003-29-12|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|79 records survival 745 ± 19 lifespan study|1003-29-12-26|12|758|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-12|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|79 records survival 745 ± 19 lifespan study|1003-29-12-27|12|764|Hyperplastic changes|Other local manifestations and miscellaneus,MA: 0000003 - organ system|MOCY/  Ovary or testis,MPATH: 62 - cyst|
1003-29-12|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|79 records survival 745 ± 19 lifespan study|1003-29-12-28|12|766|Other deterministic changes|Whole body|MCDU/|
1003-29-12|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|79 records survival 745 ± 19 lifespan study|1003-29-12-29|12|768|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-12|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|79 records survival 745 ± 19 lifespan study|1003-29-12-30|12|779|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  Head/neck missing,MPATH: 513 - Lymphoid neoplasms|
1003-29-12|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|79 records survival 745 ± 19 lifespan study|1003-29-12-31|12|782|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  Eye(s) missing Head/neck missing Thorax missing,MPATH: 513 - Lymphoid neoplasms|
1003-29-12|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|79 records survival 745 ± 19 lifespan study|1003-29-12-32|12|820|n/a|n/a|n/a|
1003-29-12|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|79 records survival 745 ± 19 lifespan study|1003-29-12-33|12|828|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-12|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|79 records survival 745 ± 19 lifespan study|1003-29-12-34|12|831|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-12|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|79 records survival 745 ± 19 lifespan study|1003-29-12-35|12|841|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-12|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|79 records survival 745 ± 19 lifespan study|1003-29-12-36|12|844|n/a|n/a|n/a|
1003-29-12|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|79 records survival 745 ± 19 lifespan study|1003-29-12-37|12|850|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-12|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|79 records survival 745 ± 19 lifespan study|1003-29-12-38|12|851|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/  ,MPATH: 242 - hemangiosarcoma|
1003-29-12|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|79 records survival 745 ± 19 lifespan study|1003-29-12-39|12|853|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-12|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|79 records survival 745 ± 19 lifespan study|1003-29-12-40|12|856|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-12|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|79 records survival 745 ± 19 lifespan study|1003-29-12-41|12|862|n/a|n/a|n/a|
1003-29-12|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|79 records survival 745 ± 19 lifespan study|1003-29-12-42|12|864|Other deterministic changes|Whole body|MCDU/|
1003-29-12|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|79 records survival 745 ± 19 lifespan study|1003-29-12-43|12|874|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-12|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|79 records survival 745 ± 19 lifespan study|1003-29-12-44|12|882|n/a|n/a|n/a|
1003-29-12|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|79 records survival 745 ± 19 lifespan study|1003-29-12-45|12|884|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-12|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|79 records survival 745 ± 19 lifespan study|1003-29-12-46|12|887|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-12|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|79 records survival 745 ± 19 lifespan study|1003-29-12-47|12|898|n/a|n/a|n/a|
1003-29-12|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|79 records survival 745 ± 19 lifespan study|1003-29-12-48|12|905|n/a|n/a|n/a|
1003-29-12|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|79 records survival 745 ± 19 lifespan study|1003-29-12-49|12|915|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-12|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|79 records survival 745 ± 19 lifespan study|1003-29-12-50|12|917|n/a|n/a|n/a|
1003-29-12|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|79 records survival 745 ± 19 lifespan study|1003-29-12-51|12|919|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-29-12|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|79 records survival 745 ± 19 lifespan study|1003-29-12-52|12|921|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-12|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|79 records survival 745 ± 19 lifespan study|1003-29-12-53|12|926|n/a|n/a|n/a|
1003-29-12|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|79 records survival 745 ± 19 lifespan study|1003-29-12-54|12|932|Other deterministic changes|Whole body|MCDU/|
1003-29-12|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|79 records survival 745 ± 19 lifespan study|1003-29-12-55|12|945|n/a|n/a|n/a|
1003-29-12|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|79 records survival 745 ± 19 lifespan study|1003-29-12-56|12|948|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-12|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|79 records survival 745 ± 19 lifespan study|1003-29-12-57|12|951|n/a|n/a|n/a|
1003-29-12|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|79 records survival 745 ± 19 lifespan study|1003-29-12-58|12|955|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-12|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|79 records survival 745 ± 19 lifespan study|1003-29-12-59|12|961|n/a|n/a|n/a|
1003-29-12|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|79 records survival 745 ± 19 lifespan study|1003-29-12-60|12|975|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-12|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|79 records survival 745 ± 19 lifespan study|1003-29-12-61|12|977|Neoplasia malignant|Other local manifestations and miscellaneus|TMLS/ rt hind quarter. Metastases Lung tmls of rt hind quarter to lung.|
1003-29-12|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|79 records survival 745 ± 19 lifespan study|1003-29-12-62|12|993|n/a|n/a|n/a|
1003-29-12|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|79 records survival 745 ± 19 lifespan study|1003-29-12-63|12|997|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-12|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|79 records survival 745 ± 19 lifespan study|1003-29-12-64|12|999|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/  ,MPATH: 242 - hemangiosarcoma|
1003-29-12|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|79 records survival 745 ± 19 lifespan study|1003-29-12-65|12|1014|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/  Eye(s) missing Head/neck missing,MPATH: 242 - hemangiosarcoma|
1003-29-12|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|79 records survival 745 ± 19 lifespan study|1003-29-12-66|12|1015|Other deterministic changes|Whole body|MCDU/|
1003-29-12|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|79 records survival 745 ± 19 lifespan study|1003-29-12-67|12|1017|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-12|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|79 records survival 745 ± 19 lifespan study|1003-29-12-68|12|1018|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-12|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|79 records survival 745 ± 19 lifespan study|1003-29-12-69|12|1027|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-12|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|79 records survival 745 ± 19 lifespan study|1003-29-12-70|12|1030|Neoplasia malignant|Other local manifestations and miscellaneus|TXFS/ TXFS/ TXFS/ TXFS/ perirenal region.|
1003-29-12|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|79 records survival 745 ± 19 lifespan study|1003-29-12-71|12|1043|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOVO/  Thorax missing Head/neck missing,MPATH: 242 - hemangiosarcoma|
1003-29-12|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|79 records survival 745 ± 19 lifespan study|1003-29-12-72|12|1059|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-12|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|79 records survival 745 ± 19 lifespan study|1003-29-12-73|12|1060|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-12|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|79 records survival 745 ± 19 lifespan study|1003-29-12-74|12|1098|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/   Metastases  Lung txac of salivary gland to lung.Eye(s) missing Head/neck missing,MPATH: 513 - Lymphoid neoplasms|
1003-29-12|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|79 records survival 745 ± 19 lifespan study|1003-29-12-75|12|1106|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-12|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|79 records survival 745 ± 19 lifespan study|1003-29-12-76|12|1123|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-29-12|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|79 records survival 745 ± 19 lifespan study|1003-29-12-77|12|1136|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-12|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|79 records survival 745 ± 19 lifespan study|1003-29-12-78|12|1167|Inflammation and/or fibrotic diseases|Lower respiratory system,MA: 0000415 - lung|MRMP/  Murine,MPATH: 212 - inflammation|
1003-29-12|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|79 records survival 745 ± 19 lifespan study|1003-29-12-79|12|1196|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-12|n/a,5X|1|100|gamma-rays Co-60|6|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|79 records survival 745 ± 19 lifespan study|1003-29-12-80|12|1245|Neoplasia unclassified|Uterus among reproductive system diseases,MA: 0000389 - uterus|TUAC/   Metastases  tuac invas. of peritoneal surface of ovary.,MPATH: 218 - neoplasm|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-1|13|108|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-2|13|108|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-3|13|108|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-4|13|108|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-5|13|108|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-6|13|115|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-7|13|115|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-8|13|115|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-9|13|115|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-10|13|115|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-11|13|115|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-12|13|115|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-13|13|115|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-14|13|115|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-15|13|115|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-16|13|115|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-17|13|115|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-18|13|115|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-19|13|115|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-20|13|115|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-21|13|236|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-22|13|236|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-23|13|236|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-24|13|236|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-25|13|236|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-26|13|240|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-27|13|289|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-28|13|289|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-29|13|289|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-30|13|289|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-31|13|289|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-32|13|463|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-33|13|463|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-34|13|466|Other deterministic changes|Whole body|MCDU/|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-35|13|489|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-36|13|511|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-37|13|517|Hyperplastic changes|Cardiovascular system|MPAN/  Polyarteritis nodosa|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-38|13|527|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-39|13|568|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-40|13|573|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-41|13|575|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-42|13|575|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-43|13|597|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-44|13|600|Other deterministic changes|Whole body|MCDU/|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-45|13|600|Other deterministic changes|Whole body|MCDU/|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-46|13|604|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-47|13|613|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-48|13|615|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-49|13|616|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-50|13|618|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-51|13|623|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-52|13|624|Neoplasia malignant|Bloodvessels among cardiovascular system|TCVS/ ing. region. Metastases  Skin tcvs to dermis of ing. reg.|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-53|13|632|Other deterministic changes|Whole body|MCDU/|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-54|13|638|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-55|13|641|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-56|13|653|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-57|13|653|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-58|13|654|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-59|13|663|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-60|13|667|Other deterministic changes|Whole body|MCDU/|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-61|13|667|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-62|13|674|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-63|13|677|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-64|13|678|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-65|13|686|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-66|13|687|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-67|13|690|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-68|13|691|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-69|13|693|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-70|13|696|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-71|13|702|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-72|13|705|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases  Muscle trac to intercostal muscles.,MPATH: 268 - adenocarcinoma|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-73|13|706|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-74|13|708|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-75|13|710|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-76|13|711|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-77|13|715|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-78|13|716|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-79|13|722|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-80|13|724|Neoplasia malignant|Bloodvessels among cardiovascular system|TMVS/ hind leg - femur. Muscle|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-81|13|725|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-82|13|729|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-83|13|732|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-84|13|736|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-85|13|737|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-86|13|739|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-87|13|740|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-88|13|742|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-89|13|750|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-90|13|752|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-91|13|755|Neoplasia unclassified|Other local manifestations and miscellaneus|THWX: TXAC(PANCREATIC DUCTAL CELL) TO LIVER.|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-92|13|756|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-93|13|759|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-94|13|760|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-95|13|762|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-96|13|764|Other deterministic changes|Whole body|MCDU/|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-97|13|765|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-98|13|766|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-99|13|767|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-100|13|771|Other deterministic changes|Whole body|MCDU/|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-101|13|773|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-102|13|775|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-103|13|776|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-104|13|778|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-105|13|779|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-106|13|783|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-107|13|785|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-108|13|789|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-109|13|792|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-110|13|793|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-111|13|793|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-112|13|794|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-113|13|796|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-114|13|801|Other deterministic changes|Whole body|MCDU/|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-115|13|801|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-116|13|802|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-117|13|804|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-118|13|804|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-119|13|804|Neoplasia malignant|Liver among hepato-pancreatic system diseases|THAC/|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-120|13|811|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-121|13|812|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-122|13|812|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-123|13|812|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-124|13|814|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-125|13|814|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-126|13|816|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-127|13|819|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-128|13|820|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-129|13|821|Other deterministic changes|Whole body|MCDU/|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-130|13|821|Neoplasia malignant|Bloodvessels among cardiovascular system|TMVS/ thigh musc. Muscle|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-131|13|823|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-132|13|823|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/   Metastases  trac growth in mediastinum & heart base.,MPATH: 513 - Lymphoid neoplasms|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-133|13|823|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-134|13|831|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-135|13|835|Other deterministic changes|Whole body|MCDU/|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-136|13|837|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-137|13|837|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-138|13|838|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-139|13|839|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-140|13|841|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-141|13|843|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-142|13|845|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-143|13|846|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-144|13|847|Neoplasia malignant|Bone among musculo-skeletal system diseases|TBOS/ humerus. Metastases Lung|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-145|13|848|Neoplasia unclassified|Lower digestive tract,MA: 0000328 - intestine|TIAC/ pylorus.Head/neck missing Eye(s) missing,MPATH: 218 - neoplasm|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-146|13|849|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-147|13|850|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-148|13|851|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-149|13|852|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-150|13|852|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-151|13|853|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-152|13|855|Other deterministic changes|Whole body|MCDU/|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-153|13|856|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-154|13|858|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-155|13|858|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-156|13|858|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-157|13|858|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-158|13|860|Inflammation and/or fibrotic diseases|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|MHIA/  acute,MPATH: 212 - inflammation|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-159|13|862|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-160|13|862|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-161|13|862|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-162|13|863|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-163|13|864|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-164|13|864|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-165|13|867|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-166|13|867|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-167|13|869|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-168|13|870|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-169|13|871|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-170|13|872|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  Head/neck missing,MPATH: 513 - Lymphoid neoplasms|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-171|13|873|Neoplasia malignant|Liver among hepato-pancreatic system diseases|THAC/|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-172|13|874|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-173|13|876|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-174|13|877|Other deterministic changes|Whole body|MCDU/  Eye(s) missing|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-175|13|878|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-176|13|881|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-177|13|881|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-178|13|885|Neoplasia malignant|Bloodvessels among cardiovascular system|TSVS/ left groin region.Skin|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-179|13|887|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-180|13|888|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-181|13|888|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-182|13|889|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-183|13|890|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-184|13|891|Other deterministic changes|Whole body|MCDU/|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-185|13|893|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-186|13|897|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-187|13|897|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-188|13|897|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-189|13|898|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-190|13|899|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXL/  Mixed histiocyt.leukemia,MPATH: 513 - Lymphoid neoplasms|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-191|13|901|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-192|13|901|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-193|13|904|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-194|13|904|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-195|13|904|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-196|13|904|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-197|13|905|Other deterministic changes|Lower respiratory system|MPNC/  Lung congestionHead/neck missing|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-198|13|905|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-199|13|906|Neoplasia malignant|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|THVS/  ,MPATH: 242 - hemangiosarcoma|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-200|13|906|Other deterministic changes|Whole body|MCDU/|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-201|13|907|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-202|13|908|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-203|13|908|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-204|13|910|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-205|13|911|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-206|13|912|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-207|13|912|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-208|13|913|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-209|13|917|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-210|13|917|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-211|13|918|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-212|13|918|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-213|13|918|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-214|13|919|Other deterministic changes|Whole body|MCDU/|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-215|13|919|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-216|13|921|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-217|13|922|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-218|13|925|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-219|13|925|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-220|13|930|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-221|13|930|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-222|13|932|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-223|13|932|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLSL/  undifferentiated leukemia lymphoret.tissue,MPATH: 335 - hematopoietic/lymphoid malignancies/disorder|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-224|13|933|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  Head/neck missing Eye(s) missing,MPATH: 513 - Lymphoid neoplasms|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-225|13|933|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-226|13|933|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-227|13|936|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-228|13|936|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-229|13|937|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-230|13|937|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-231|13|937|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-232|13|938|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-233|13|938|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-234|13|939|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-235|13|943|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  Head/neck missing Eye(s) missing,MPATH: 513 - Lymphoid neoplasms|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-236|13|944|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-237|13|946|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-238|13|946|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-239|13|946|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-240|13|948|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-241|13|950|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-242|13|950|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-243|13|951|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-244|13|951|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-245|13|951|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-246|13|951|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-247|13|952|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  Head/neck missing,MPATH: 513 - Lymphoid neoplasms|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-248|13|953|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-249|13|953|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-250|13|954|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-251|13|954|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-252|13|954|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-253|13|954|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-254|13|954|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-255|13|956|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-256|13|956|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-257|13|956|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-258|13|959|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-259|13|959|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-260|13|960|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-261|13|961|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-262|13|962|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-263|13|965|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-264|13|967|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-265|13|967|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-266|13|967|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-267|13|968|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-268|13|970|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-269|13|973|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-270|13|974|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-271|13|975|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-272|13|976|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-273|13|977|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-274|13|977|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-275|13|977|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-276|13|980|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  Eye(s) missing Head/neck missing,MPATH: 513 - Lymphoid neoplasms|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-277|13|980|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-278|13|982|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-279|13|984|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-280|13|985|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-281|13|986|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-282|13|986|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-283|13|986|Neoplasia malignant|Liver among hepato-pancreatic system diseases|THAC/|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-284|13|987|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-285|13|989|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-286|13|990|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-287|13|990|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-288|13|991|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-289|13|991|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-290|13|991|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-291|13|991|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-292|13|992|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-293|13|992|Neoplasia unclassified|Other local manifestations and miscellaneus|THWX: TXEC OF UNKNOWN PRIMARY SITE TO LIVER & VISC PERIT.|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-294|13|995|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-295|13|996|Other deterministic changes|Whole body|MCDU/|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-296|13|996|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-297|13|996|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-298|13|997|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-299|13|997|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-300|13|997|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-301|13|998|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-302|13|998|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  Head/neck missing Eye(s) missing,MPATH: 513 - Lymphoid neoplasms|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-303|13|998|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-304|13|999|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-305|13|1000|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-306|13|1001|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-307|13|1003|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-308|13|1008|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-309|13|1009|Other deterministic changes|Whole body|MCDU/|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-310|13|1009|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-311|13|1009|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-312|13|1012|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-313|13|1012|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-314|13|1012|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-315|13|1013|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-316|13|1013|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-317|13|1013|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-318|13|1013|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-319|13|1013|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-320|13|1014|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-321|13|1014|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-322|13|1016|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-323|13|1017|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-324|13|1018|Neoplasia systemic|Haematolymphatic system|TLML/|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-325|13|1018|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-326|13|1018|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-327|13|1019|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-328|13|1019|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-329|13|1020|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-330|13|1021|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/  Head/neck missing Eye(s) missing,MPATH: 242 - hemangiosarcoma|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-331|13|1022|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-332|13|1023|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-333|13|1024|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-334|13|1025|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  Eye(s) missing,MPATH: 513 - Lymphoid neoplasms|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-335|13|1028|Other deterministic changes|Whole body|MCDU/|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-336|13|1030|Other deterministic changes|Whole body|MCDU/|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-337|13|1030|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-338|13|1030|Other deterministic changes|Whole body|MCDU/|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-339|13|1030|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-340|13|1032|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-341|13|1032|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-342|13|1033|Neoplasia systemic|Haematolymphatic system|TLML/|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-343|13|1034|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-344|13|1036|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-345|13|1037|Neoplasia malignant|Other local manifestations and miscellaneus|TXUS/ TXUS/ TXUS/ TXUS/ seminal ves. Metastases Liver|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-346|13|1037|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-347|13|1038|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-348|13|1039|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/  Eye(s) missing Head/neck missing,MPATH: 242 - hemangiosarcoma|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-349|13|1040|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-350|13|1041|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-351|13|1041|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-352|13|1042|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-353|13|1043|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-354|13|1043|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-355|13|1045|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-356|13|1047|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  Eye(s) missing Head/neck missing,MPATH: 513 - Lymphoid neoplasms|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-357|13|1048|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-358|13|1048|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-359|13|1048|Neoplasia unclassified|Other local manifestations and miscellaneus|TMWC: TCVS INVAS OF THIGH MUSC.|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-360|13|1049|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-361|13|1049|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-362|13|1050|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  Head/neck missing Eye(s) missing Thorax missing,MPATH: 513 - Lymphoid neoplasms|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-363|13|1050|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-364|13|1050|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-365|13|1050|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-366|13|1050|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-367|13|1051|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  Eye(s) missing,MPATH: 268 - adenocarcinoma|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-368|13|1051|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-369|13|1052|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-370|13|1052|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-371|13|1053|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-372|13|1055|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-373|13|1055|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-374|13|1056|Neoplasia unclassified|Other local manifestations and miscellaneus|THWX: TXEC OF UNKNOWN PRIMARY SITE TO LIVER & VISC PERIT.|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-375|13|1059|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-376|13|1063|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-377|13|1063|Neoplasia unclassified|Other local manifestations and miscellaneus|TSWC: TCVS TO DERMIS OF ING. REG.|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-378|13|1063|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-379|13|1064|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-380|13|1066|Hyperplastic changes|Cardiovascular system|MPAN/  Polyarteritis nodosa|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-381|13|1068|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-382|13|1072|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-383|13|1072|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-384|13|1073|Neoplasia systemic|Haematolymphatic system|TLML/|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-385|13|1073|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/   Metastases  Muscle tcvs invas of thigh musc.,MPATH: 242 - hemangiosarcoma|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-386|13|1075|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-387|13|1077|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-388|13|1077|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-389|13|1078|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-390|13|1079|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-391|13|1079|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-392|13|1080|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-393|13|1082|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-394|13|1083|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-395|13|1083|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-396|13|1084|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-397|13|1084|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-398|13|1086|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-399|13|1087|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-400|13|1088|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-401|13|1089|Neoplasia malignant|Bloodvessels among cardiovascular system|TXVS/ mediastinal tissues at base of heart & on serosa of trachea & invades major vein.Eye(s) missing Head/neck missing|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-402|13|1093|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-403|13|1095|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-404|13|1097|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  Eye(s) missing Head/neck missing,MPATH: 513 - Lymphoid neoplasms|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-405|13|1098|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-406|13|1100|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-407|13|1100|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-408|13|1101|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-409|13|1102|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-410|13|1104|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-411|13|1106|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-412|13|1106|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-413|13|1106|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-414|13|1107|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-415|13|1108|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-416|13|1108|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-417|13|1108|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-418|13|1109|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-419|13|1110|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-420|13|1111|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-421|13|1112|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-422|13|1114|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-423|13|1114|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-424|13|1114|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-425|13|1115|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-426|13|1115|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-427|13|1116|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-428|13|1117|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-429|13|1119|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  Eye(s) missing Head/neck missing,MPATH: 513 - Lymphoid neoplasms|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-430|13|1120|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-431|13|1122|Neoplasia unclassified|Other local manifestations and miscellaneus|TSWC: TCVS TO DERMIS OF ING. REG.|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-432|13|1122|Changes due to an abnormal circulation|Bloodvessels among cardiovascular system|MTHR/  auricular|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-433|13|1123|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-434|13|1123|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-435|13|1124|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-436|13|1126|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-437|13|1129|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-438|13|1129|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-439|13|1131|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-440|13|1132|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-441|13|1134|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/  ,MPATH: 242 - hemangiosarcoma|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-442|13|1135|Inflammation and/or fibrotic diseases|Lower digestive tract,MA: 0000328 - intestine|MIIA/ ileum.Enteritis acute,MPATH: 212 - inflammation|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-443|13|1135|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-444|13|1135|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-445|13|1135|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-446|13|1136|Other deterministic changes|Whole body|MCDU/|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-447|13|1136|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-448|13|1138|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  Head/neck missing Eye(s) missing,MPATH: 513 - Lymphoid neoplasms|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-449|13|1138|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-450|13|1141|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-451|13|1141|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-452|13|1142|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-453|13|1142|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-454|13|1142|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-455|13|1146|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-456|13|1146|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/  ,MPATH: 242 - hemangiosarcoma|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-457|13|1147|Neoplasia malignant|Liver among hepato-pancreatic system diseases|THAC/|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-458|13|1148|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-459|13|1148|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-460|13|1149|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-461|13|1149|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-462|13|1150|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-463|13|1151|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-464|13|1152|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-465|13|1152|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-466|13|1153|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  Head/neck missing Eye(s) missing,MPATH: 268 - adenocarcinoma|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-467|13|1155|Neoplasia unclassified|Other local manifestations and miscellaneus|TMWC: TCVS INVAS OF THIGH MUSC.|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-468|13|1155|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-469|13|1156|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-470|13|1157|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-471|13|1157|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-472|13|1157|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-473|13|1157|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-474|13|1158|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-475|13|1162|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-476|13|1163|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-477|13|1165|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-478|13|1166|Other deterministic changes|Whole body|MCDU/|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-479|13|1166|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-480|13|1167|Other deterministic changes|Whole body|MCDU/  Head/neck missing|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-481|13|1167|Neoplasia malignant|Other local manifestations and miscellaneus|TXUS/ TXUS/ TXUS/ TXUS/ prostate.|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-482|13|1169|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|TXAC/ pancreatic ductal cell. Metastases Liver,MPATH: 268 - adenocarcinoma|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-483|13|1170|Inflammation and/or fibrotic diseases|Cardiovascular system,MA: 0000164 - myocardium|MMCA/ MMCA/ MMCA/ MMCA/  acute,MPATH: 212 - inflammation|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-484|13|1171|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-485|13|1171|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-486|13|1171|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-487|13|1173|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-488|13|1173|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-489|13|1176|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-490|13|1176|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-491|13|1177|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-492|13|1177|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-493|13|1177|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-494|13|1179|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-495|13|1180|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-496|13|1183|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-497|13|1184|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-498|13|1185|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-499|13|1186|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-500|13|1186|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-501|13|1188|Neoplasia malignant|Bloodvessels among cardiovascular system|TIVS/ small intestine.|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-502|13|1188|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-503|13|1188|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-504|13|1188|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-505|13|1190|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-506|13|1191|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-507|13|1192|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-508|13|1198|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-509|13|1200|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-510|13|1202|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-511|13|1203|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-512|13|1205|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-513|13|1205|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-514|13|1205|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-515|13|1206|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-516|13|1206|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-517|13|1207|Neoplasia malignant|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|THVS/  ,MPATH: 242 - hemangiosarcoma|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-518|13|1207|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-519|13|1207|Neoplasia malignant|Urinary system,MA: 0002636 - lower urinary tract|TDTC/  Transitional cell,MPATH: 549 - carcinoma|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-520|13|1208|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-521|13|1208|Neoplasia malignant|Lower digestive tract,MA: 0000328 - intestine|TIAO/ pylorus.,MPATH: 549 - carcinoma|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-522|13|1208|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-523|13|1211|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-524|13|1212|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-525|13|1212|Other deterministic changes|Whole body|MCDU/|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-526|13|1213|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-527|13|1215|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-528|13|1216|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-529|13|1216|Neoplasia malignant|Adrenal gland  among endocrine systems|TAPS/|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-530|13|1217|Other deterministic changes|Whole body|MCDU/|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-531|13|1218|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-532|13|1218|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-533|13|1218|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-534|13|1225|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-535|13|1225|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-536|13|1226|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-537|13|1229|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-538|13|1231|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-539|13|1233|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/  ,MPATH: 242 - hemangiosarcoma|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-540|13|1234|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-541|13|1235|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-542|13|1235|Other deterministic changes|Whole body|MCDU/|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-543|13|1238|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-544|13|1240|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-545|13|1241|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-546|13|1243|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-547|13|1244|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-548|13|1244|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-549|13|1244|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-550|13|1248|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-551|13|1248|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-552|13|1248|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-553|13|1256|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-554|13|1256|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-555|13|1256|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-556|13|1257|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-557|13|1257|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-558|13|1260|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-559|13|1260|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-560|13|1261|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-561|13|1262|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-562|13|1262|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-563|13|1262|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-564|13|1266|Other deterministic changes|Whole body|MCDU/|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-565|13|1267|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-566|13|1267|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-567|13|1268|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-568|13|1270|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-569|13|1271|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-570|13|1276|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-571|13|1280|Neoplasia unclassified|Other local manifestations and miscellaneus|TRWB: TBOS OF HUMERUS TO LUNG.|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-572|13|1281|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-573|13|1294|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-574|13|1295|Other deterministic changes|Whole body|MCDU/|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-575|13|1297|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-576|13|1309|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-577|13|1309|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-578|13|1315|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-579|13|1315|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-580|13|1319|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-581|13|1321|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-582|13|1328|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-583|13|1328|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-584|13|1328|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-585|13|1332|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-586|13|1334|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-587|13|1334|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-588|13|1341|Other deterministic changes|Whole body|MCDU/|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-589|13|1347|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-590|13|1357|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-591|13|1359|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-592|13|1359|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-593|13|1359|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-594|13|1371|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-595|13|1371|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-596|13|1376|Neoplasia malignant|Adrenal gland  among endocrine systems|TAPS/|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-597|13|1382|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-598|13|1394|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-599|13|1448|n/a|n/a|n/a|
1003-29-13|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|566 records survival 893 ± 8 lifespan study|1003-29-13-600|13|1454|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-1|14|108|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-2|14|108|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-3|14|108|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-4|14|108|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-5|14|108|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-6|14|108|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-7|14|108|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-8|14|108|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-9|14|108|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-10|14|108|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-11|14|115|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-12|14|115|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-13|14|115|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-14|14|115|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-15|14|115|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-16|14|115|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-17|14|115|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-18|14|115|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-19|14|115|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-20|14|115|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-21|14|290|Other deterministic changes|Whole body|MCDU/|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-22|14|309|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-23|14|386|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-24|14|405|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-25|14|435|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases  trac to visceral pleura covering heart.,MPATH: 268 - adenocarcinoma|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-26|14|436|Hyperplastic changes|Cardiovascular system|MPAN/  Polyarteritis nodosa|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-27|14|466|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-28|14|466|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-29|14|466|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-30|14|466|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-31|14|466|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-32|14|477|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-33|14|508|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-34|14|509|Inflammation and/or fibrotic diseases|Kidney among urinary system diseases,MA: 0000368 - kidney|MPNE/  acute,MPATH: 212 - inflammation|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-35|14|527|Other deterministic changes|Whole body|MCDU/|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-36|14|546|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-37|14|547|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-38|14|547|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-39|14|547|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-40|14|547|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-41|14|547|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-42|14|549|Other deterministic changes|Whole body|MCDU/  Head/neck missing Eye(s) missing|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-43|14|551|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-44|14|554|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-45|14|555|Other deterministic changes|Whole body|MCDU/|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-46|14|559|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-47|14|565|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-48|14|574|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-49|14|582|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-50|14|605|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-51|14|615|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-52|14|618|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-53|14|638|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-54|14|639|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-55|14|643|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-56|14|646|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-57|14|660|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-58|14|666|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-59|14|667|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-60|14|670|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-61|14|670|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-62|14|673|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-63|14|677|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-64|14|681|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-65|14|687|Other deterministic changes|Whole body|MCDU/|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-66|14|690|Neoplasia malignant|Liver among hepato-pancreatic system diseases|THAC/|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-67|14|698|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-68|14|702|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-69|14|708|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-70|14|709|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-71|14|714|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-72|14|716|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-73|14|718|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-74|14|718|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-75|14|719|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-76|14|722|Other deterministic changes|Whole body|MCDU/|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-77|14|729|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-78|14|731|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/  ,MPATH: 242 - hemangiosarcoma|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-79|14|732|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-80|14|734|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-81|14|735|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-82|14|735|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-83|14|736|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-84|14|736|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-85|14|737|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-86|14|738|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-87|14|740|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-88|14|742|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-89|14|744|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-90|14|745|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-91|14|745|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-92|14|746|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-93|14|746|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-94|14|750|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-95|14|750|Other deterministic changes|Whole body|MCDU/|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-96|14|754|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-97|14|757|Neoplasia malignant|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|THVS/  ,MPATH: 242 - hemangiosarcoma|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-98|14|758|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-99|14|760|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-100|14|763|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-101|14|763|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-102|14|764|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-103|14|765|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|TCFS/ abdomen.,MPATH: 408 - soft tissue fibrosarcoma|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-104|14|769|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-105|14|771|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-106|14|771|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-107|14|772|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-108|14|773|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|TCFS/ back. Metastases  Muscle tcfs invas of musc & vertebra.,MPATH: 408 - soft tissue fibrosarcoma|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-109|14|773|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-110|14|774|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-111|14|775|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-112|14|776|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-113|14|776|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-114|14|777|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-115|14|778|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-116|14|780|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-117|14|782|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-118|14|785|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-119|14|786|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-120|14|792|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-121|14|793|Neoplasia malignant|Bloodvessels among cardiovascular system|TCVS/ inguinal region.|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-122|14|796|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-123|14|798|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-124|14|799|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-125|14|799|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-126|14|799|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-127|14|801|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/   Metastases  Muscle tgac invades musc of head.,MPATH: 513 - Lymphoid neoplasms|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-128|14|803|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-129|14|803|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-130|14|804|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-131|14|808|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-132|14|809|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-133|14|810|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-134|14|810|Hyperplastic changes|Other local manifestations and miscellaneus,MA: 0000003 - organ system|MOCY/  Ovary or testis Metastases  tcfs invas of spinal meninges.,MPATH: 62 - cyst|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-135|14|812|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|TUUS/   Metastases LungHead/neck missing Eye(s) missing,MPATH: 255 - adenoacanthoma|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-136|14|814|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-137|14|814|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-138|14|815|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-139|14|818|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-140|14|819|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-141|14|820|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|TCFS/ in axillary region.,MPATH: 408 - soft tissue fibrosarcoma|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-142|14|821|Other deterministic changes|Whole body|MCDU/|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-143|14|822|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-144|14|822|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-145|14|825|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-146|14|825|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-147|14|826|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/   Metastases  Muscle tcfs invades musc of abdomen.,MPATH: 513 - Lymphoid neoplasms|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-148|14|827|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-149|14|827|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-150|14|828|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-151|14|830|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-152|14|832|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-153|14|833|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-154|14|833|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-155|14|836|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-156|14|837|Other deterministic changes|Whole body|MCDU/|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-157|14|837|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-158|14|838|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-159|14|838|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-160|14|839|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-161|14|840|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-162|14|840|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-163|14|841|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-164|14|841|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-165|14|843|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-166|14|843|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-167|14|844|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-168|14|845|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-169|14|846|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-170|14|846|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-171|14|846|Other deterministic changes|Whole body|MCDU/  Head/neck missing Thorax missing Eye(s) missing|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-172|14|850|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-173|14|851|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-174|14|851|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-175|14|852|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-176|14|852|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-177|14|852|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-178|14|854|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-179|14|855|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-180|14|855|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-181|14|857|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-182|14|859|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-183|14|861|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-184|14|862|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-185|14|864|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-186|14|865|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-187|14|866|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-188|14|866|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-189|14|870|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-190|14|871|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-191|14|872|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-192|14|873|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-193|14|874|Other deterministic changes|Whole body|MCDU/|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-194|14|875|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-195|14|876|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-196|14|877|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-197|14|878|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-198|14|880|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-199|14|880|Neoplasia malignant|Endocrine system|TGAC/|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-200|14|881|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-201|14|883|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-202|14|883|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-203|14|884|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-204|14|884|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-205|14|885|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  Head/neck missing,MPATH: 513 - Lymphoid neoplasms|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-206|14|885|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-207|14|887|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-208|14|891|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-209|14|892|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-210|14|893|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-211|14|897|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-212|14|897|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-213|14|899|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-214|14|899|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-215|14|899|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-216|14|899|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-217|14|899|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-218|14|900|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  Head/neck missing Eye(s) missing,MPATH: 513 - Lymphoid neoplasms|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-219|14|901|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-220|14|905|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-221|14|905|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-222|14|906|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-223|14|906|Neoplasia malignant|Other local manifestations and miscellaneus|TMLS/ neck region of saliv gl. Metastases  tmls invades skin, conn tiss, & saliv gl.|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-224|14|908|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-225|14|909|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-226|14|911|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-227|14|911|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-228|14|912|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-229|14|913|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-230|14|914|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-231|14|916|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-232|14|918|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-233|14|919|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-234|14|921|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|TUUS/  Eye(s) missing Head/neck missing,MPATH: 255 - adenoacanthoma|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-235|14|922|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-236|14|923|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-237|14|923|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-238|14|925|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLSL/  undifferentiated leukemia lymphoret.tissue Metastases  Skin tcvs invades & ulcerates epidermis.,MPATH: 335 - hematopoietic/lymphoid malignancies/disorder|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-239|14|925|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-240|14|926|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-241|14|927|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-242|14|927|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-243|14|927|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-244|14|928|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-245|14|928|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-246|14|928|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-247|14|929|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-248|14|931|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-249|14|934|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-250|14|934|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-251|14|935|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-252|14|935|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-253|14|935|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-254|14|936|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-255|14|937|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-256|14|938|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-257|14|939|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-258|14|940|Other deterministic changes|Whole body|MCDU/|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-259|14|940|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-260|14|940|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-261|14|940|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-262|14|940|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-263|14|945|Inflammation and/or fibrotic diseases|Lower respiratory system,MA: 0000415 - lung|MRMP/  Murine,MPATH: 212 - inflammation|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-264|14|945|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-265|14|945|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-266|14|947|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  Eye(s) missing Head/neck missing,MPATH: 513 - Lymphoid neoplasms|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-267|14|947|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-268|14|947|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-269|14|947|Neoplasia malignant|Bone among musculo-skeletal system diseases|TBOS/ rt. leg-both upper & lower. Metastases Lung|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-270|14|947|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-271|14|949|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-272|14|950|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-273|14|950|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-274|14|951|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  Eye(s) missing Head/neck missing,MPATH: 513 - Lymphoid neoplasms|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-275|14|951|Neoplasia malignant|Other local manifestations and miscellaneus|TMLS/ retroperitoneum. Metastases Lung tmls invades lung.|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-276|14|952|Other deterministic changes|Whole body|MCDU/|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-277|14|953|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-278|14|953|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/  ,MPATH: 242 - hemangiosarcoma|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-279|14|953|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-280|14|953|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-281|14|953|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-282|14|954|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-283|14|954|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-284|14|954|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-285|14|956|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-286|14|958|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-287|14|958|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-288|14|959|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-289|14|959|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-290|14|960|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-291|14|960|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-292|14|960|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-293|14|962|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-294|14|962|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-295|14|962|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/  ,MPATH: 242 - hemangiosarcoma|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-296|14|964|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-297|14|965|Other deterministic changes|Whole body|MCDU/   Metastases Liver|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-298|14|966|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-299|14|967|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-300|14|971|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-301|14|971|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-302|14|971|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-303|14|973|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-304|14|973|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-305|14|973|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|TCFS/ thigh.,MPATH: 408 - soft tissue fibrosarcoma|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-306|14|974|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-307|14|974|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-308|14|976|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-309|14|978|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-310|14|984|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-311|14|984|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-312|14|984|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-313|14|985|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-314|14|985|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|TMAB/  Predominantly ductal Metastases  Muscle tmab (mamm) to diaphragm. Metastases  Kidney tmab (mamm) to kidneys. Metastases Liver Metastases Lung tmab (mamm) to lung. Metastases Heart Metastases  Lymphoret.System tmab (mamm) to pt ln.,MPATH: 218 - neoplasm|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-315|14|986|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-316|14|987|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-317|14|987|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-318|14|989|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-319|14|989|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-320|14|989|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-321|14|992|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-322|14|992|Other deterministic changes|Whole body|MCDU/  Head/neck missing Eye(s) missing|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-323|14|993|Other deterministic changes|Whole body|MCDU/|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-324|14|993|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-325|14|995|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-326|14|995|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-327|14|996|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-328|14|997|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-329|14|999|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-330|14|999|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-331|14|999|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-332|14|1002|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-333|14|1003|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-334|14|1004|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-335|14|1004|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-336|14|1004|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-337|14|1007|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-338|14|1008|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-339|14|1010|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-340|14|1011|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-341|14|1014|Inflammation and/or fibrotic diseases|Other local manifestations and miscellaneus,MA: 0000003 - organ system|MCIG/  Head/neck missing Eye(s) missing,MPATH: 213 - acute inflammation|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-342|14|1015|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-343|14|1015|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-344|14|1016|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-345|14|1016|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-346|14|1016|Neoplasia systemic|Haematolymphatic system|TLML/|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-347|14|1018|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-348|14|1018|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-349|14|1019|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-350|14|1020|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-351|14|1021|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-352|14|1022|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-353|14|1023|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-354|14|1024|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-355|14|1024|Neoplasia malignant|Other local manifestations and miscellaneus|TMLS/ thoracic region, dorsal.|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-356|14|1024|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-357|14|1024|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-358|14|1025|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-359|14|1025|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-360|14|1026|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-361|14|1027|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-362|14|1027|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-363|14|1027|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-364|14|1030|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-365|14|1031|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-366|14|1032|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-367|14|1035|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-368|14|1036|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-369|14|1036|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-370|14|1037|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-371|14|1037|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-372|14|1039|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/ with leukemia.,MPATH: 513 - Lymphoid neoplasms|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-373|14|1040|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-374|14|1041|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-375|14|1043|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-376|14|1043|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-377|14|1044|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-378|14|1044|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-379|14|1045|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-380|14|1046|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-381|14|1046|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-382|14|1049|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-383|14|1049|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-384|14|1050|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-385|14|1051|Neoplasia systemic|Haematolymphatic system|TLPS/|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-386|14|1051|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-387|14|1052|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-388|14|1052|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-389|14|1055|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-390|14|1055|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-391|14|1055|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-392|14|1056|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-393|14|1057|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-394|14|1058|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-395|14|1060|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOVO/   Metastases  Muscle tcvs invas of skel musc.,MPATH: 242 - hemangiosarcoma|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-396|14|1061|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|TCFS/ subcutis dorsal lumbar region. Metastases  tcfs perit over rib cage wall & diap. Metastases  Muscle tcfs invas of skel musc & ribs.,MPATH: 408 - soft tissue fibrosarcoma|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-397|14|1061|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-398|14|1065|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-399|14|1065|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-400|14|1067|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  Eye(s) missing Head/neck missing,MPATH: 513 - Lymphoid neoplasms|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-401|14|1068|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-402|14|1069|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-403|14|1069|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-404|14|1069|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-405|14|1070|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-406|14|1071|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-407|14|1071|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-408|14|1071|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-409|14|1071|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-410|14|1072|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-411|14|1072|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-412|14|1072|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-413|14|1073|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-414|14|1073|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-415|14|1075|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-416|14|1076|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-417|14|1076|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-418|14|1077|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-419|14|1078|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-420|14|1079|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-421|14|1079|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-422|14|1080|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-423|14|1081|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  Eye(s) missing Head/neck missing,MPATH: 513 - Lymphoid neoplasms|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-424|14|1081|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-425|14|1082|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-426|14|1082|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-427|14|1083|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-428|14|1083|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-429|14|1083|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-430|14|1084|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-431|14|1086|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-432|14|1086|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  Head/neck missing,MPATH: 513 - Lymphoid neoplasms|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-433|14|1087|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-434|14|1089|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-435|14|1089|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-436|14|1092|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-437|14|1093|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-438|14|1095|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-439|14|1095|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  Head/neck missing Thorax missing Eye(s) missing,MPATH: 513 - Lymphoid neoplasms|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-440|14|1096|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-441|14|1096|Neoplasia malignant|Bloodvessels among cardiovascular system|TCVS/ in lower abdom area.|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-442|14|1096|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-443|14|1099|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-444|14|1100|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-445|14|1100|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-446|14|1102|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-447|14|1103|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-448|14|1104|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-449|14|1104|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-450|14|1107|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-451|14|1108|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-452|14|1109|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-453|14|1110|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-454|14|1110|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-455|14|1110|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/  ,MPATH: 242 - hemangiosarcoma|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-456|14|1111|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-457|14|1112|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-458|14|1113|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-459|14|1113|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-460|14|1113|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-461|14|1113|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-462|14|1114|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-463|14|1115|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  Head/neck missing,MPATH: 513 - Lymphoid neoplasms|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-464|14|1117|Neoplasia malignant|Other local manifestations and miscellaneus|TCSS/ TCSS/ TCSS/ TCSS/ subcut. lower abd. area.|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-465|14|1122|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-466|14|1125|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-467|14|1126|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-468|14|1127|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-469|14|1128|Other deterministic changes|Whole body|MCDU/|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-470|14|1129|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-471|14|1132|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-472|14|1133|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-473|14|1133|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-474|14|1134|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-475|14|1136|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-476|14|1136|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-477|14|1137|Neoplasia unclassified|Ovary among reproductive system diseases|TOGC/|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-478|14|1137|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-479|14|1137|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-480|14|1138|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-481|14|1138|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-482|14|1138|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-483|14|1139|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-484|14|1139|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-485|14|1140|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-486|14|1141|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-487|14|1142|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-488|14|1142|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-489|14|1143|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-490|14|1143|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-491|14|1145|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-492|14|1145|Hyperplastic changes|Cardiovascular system|MPAN/  Polyarteritis nodosa|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-493|14|1145|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  Head/neck missing,MPATH: 513 - Lymphoid neoplasms|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-494|14|1146|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-495|14|1146|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-496|14|1146|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-497|14|1151|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-498|14|1152|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-499|14|1153|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-500|14|1157|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-501|14|1157|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-502|14|1158|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-503|14|1159|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-504|14|1160|Neoplasia malignant|Bloodvessels among cardiovascular system|TCVS/ fatty tiss of lower abdomen.|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-505|14|1161|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-506|14|1162|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-507|14|1163|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-508|14|1164|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-509|14|1164|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/   Metastases LungHead/neck missing Eye(s) missing,MPATH: 513 - Lymphoid neoplasms|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-510|14|1165|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-511|14|1165|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-512|14|1166|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  Head/neck missing,MPATH: 513 - Lymphoid neoplasms|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-513|14|1166|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|TCFS/ subcut. in ant reg. one dorsal & 2 lateral ventral. Metastases  Muscle tcfs infiltr. muscle of shoulder.,MPATH: 408 - soft tissue fibrosarcoma|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-514|14|1169|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-515|14|1170|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-516|14|1171|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-517|14|1171|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-518|14|1171|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-519|14|1174|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-520|14|1178|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-521|14|1178|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-522|14|1182|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-523|14|1182|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-524|14|1184|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-525|14|1184|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-526|14|1185|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-527|14|1185|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-528|14|1186|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-529|14|1186|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-530|14|1187|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-531|14|1187|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-532|14|1189|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-533|14|1190|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-534|14|1193|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-535|14|1194|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-536|14|1197|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-537|14|1200|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-538|14|1201|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-539|14|1201|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-540|14|1205|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-541|14|1205|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-542|14|1205|Other deterministic changes|Whole body|MCDU/|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-543|14|1209|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-544|14|1212|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-545|14|1212|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-546|14|1214|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-547|14|1219|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-548|14|1219|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-549|14|1220|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-550|14|1222|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-551|14|1223|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-552|14|1225|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-553|14|1226|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-554|14|1226|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-555|14|1227|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-556|14|1229|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-557|14|1234|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-558|14|1236|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-559|14|1237|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-560|14|1241|Neoplasia systemic|Haematolymphatic system|TLML/|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-561|14|1242|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-562|14|1252|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-563|14|1255|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-564|14|1257|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-565|14|1260|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-566|14|1263|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-567|14|1266|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-568|14|1270|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-569|14|1272|Other deterministic changes|Whole body|MCDU/|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-570|14|1274|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-571|14|1276|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-572|14|1276|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases  Lymphoret.System trac to pt ln. Metastases Heart,MPATH: 268 - adenocarcinoma|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-573|14|1277|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-574|14|1278|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-575|14|1282|Neoplasia unclassified|Lower digestive tract,MA: 0000328 - intestine|TIAC/ pylorus.,MPATH: 218 - neoplasm|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-576|14|1285|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-577|14|1287|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-578|14|1288|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-579|14|1289|Neoplasia malignant|Bone among musculo-skeletal system diseases|TBOS/ rt. femur.|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-580|14|1290|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-581|14|1291|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-582|14|1295|Neoplasia unclassified|Integumentary system,MA: 0000151 - skin|TSEC/ dorsal left flank. Metastases  tsec of left flank invas. of nerve sheaths.,MPATH: 218 - neoplasm|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-583|14|1300|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-584|14|1307|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-585|14|1310|Neoplasia malignant|Other local manifestations and miscellaneus|TMLS/ subcut. dorsal left hip.|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-586|14|1325|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-587|14|1335|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-588|14|1336|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-589|14|1373|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-590|14|1385|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-591|14|1387|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-592|14|1391|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-593|14|1408|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-594|14|1413|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-595|14|1415|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-596|14|1446|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-597|14|1453|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-598|14|1490|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-599|14|1498|n/a|n/a|n/a|
1003-29-14|n/a,1X|1|100|neutrons fission|0.02|grays|External exposure|code 1X (1A 1B 1C 1X combined) 60 fractions 20 m 1/w|600 (600 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|568 records survival 869 ± 8 lifespan study|1003-29-14-600|14|1505|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-1|15|115|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-2|15|115|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-3|15|115|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-4|15|115|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-5|15|115|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-6|15|143|Other deterministic changes|Whole body|MCDU/|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-7|15|150|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-8|15|172|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-9|15|172|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-10|15|172|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-11|15|172|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-12|15|172|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-13|15|172|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-14|15|179|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-15|15|179|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-16|15|179|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-17|15|179|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-18|15|179|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-19|15|179|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-20|15|179|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-21|15|179|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-22|15|179|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-23|15|179|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-24|15|179|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-25|15|214|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-26|15|215|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-27|15|215|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-28|15|221|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-29|15|222|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-30|15|222|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-31|15|222|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-32|15|247|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-33|15|277|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-34|15|277|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-35|15|277|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-36|15|277|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-37|15|277|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-38|15|277|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-39|15|277|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-40|15|284|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-41|15|284|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-42|15|284|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-43|15|284|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-44|15|284|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-45|15|284|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-46|15|284|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-47|15|284|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-48|15|284|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-49|15|284|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-50|15|284|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-51|15|284|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-52|15|358|Hyperplastic changes|Cardiovascular system|MPAN/  Polyarteritis nodosa|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-53|15|382|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-54|15|382|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-55|15|382|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-56|15|382|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-57|15|382|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-58|15|382|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-59|15|382|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-60|15|382|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-61|15|382|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-62|15|382|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-63|15|382|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-64|15|389|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-65|15|389|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-66|15|389|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-67|15|389|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-68|15|389|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-69|15|389|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-70|15|389|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-71|15|389|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-72|15|389|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-73|15|389|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-74|15|417|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-75|15|417|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-76|15|417|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-77|15|417|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-78|15|417|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-79|15|417|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-80|15|417|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-81|15|424|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-82|15|424|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-83|15|424|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-84|15|424|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-85|15|424|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-86|15|424|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-87|15|434|Other deterministic changes|Whole body|MCDU/|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-88|15|452|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-89|15|454|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-90|15|459|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-91|15|459|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-92|15|459|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-93|15|461|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-94|15|507|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-95|15|522|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-96|15|522|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-97|15|522|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-98|15|523|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-99|15|529|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-100|15|529|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-101|15|529|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-102|15|529|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-103|15|529|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-104|15|529|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-105|15|529|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-106|15|529|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-107|15|529|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-108|15|530|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-109|15|530|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-110|15|530|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-111|15|530|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-112|15|530|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-113|15|548|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-114|15|548|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-115|15|548|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-116|15|548|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-117|15|548|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-118|15|554|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-119|15|555|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-120|15|555|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-121|15|555|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-122|15|555|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-123|15|555|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-124|15|555|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-125|15|555|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-126|15|555|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-127|15|555|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-128|15|555|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-129|15|556|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-130|15|562|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-131|15|562|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-132|15|562|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-133|15|562|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-134|15|562|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-135|15|562|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-136|15|562|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-137|15|562|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-138|15|562|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-139|15|562|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-140|15|562|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-141|15|562|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-142|15|562|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-143|15|562|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-144|15|562|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-145|15|579|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-146|15|583|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-147|15|583|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-148|15|583|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-149|15|587|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-150|15|610|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-151|15|611|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-152|15|614|Neoplasia unclassified|Other local manifestations and miscellaneus|TMWG: TGAC INVADES MUSCLE & SKIN OF HEAD.|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-153|15|617|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-154|15|617|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-155|15|617|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-156|15|624|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-157|15|625|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-158|15|626|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases  Muscle trac to skeletal muscles of rib cage. Metastases  Lymphoret.System trac to to brachial & cervical nodes & parathymic.,MPATH: 268 - adenocarcinoma|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-159|15|626|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-160|15|631|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-161|15|631|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-162|15|631|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-163|15|631|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-164|15|631|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-165|15|632|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-166|15|632|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-167|15|632|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-168|15|633|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-169|15|634|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-170|15|634|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-171|15|634|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-172|15|634|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-173|15|638|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-174|15|655|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-175|15|655|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-176|15|655|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-177|15|656|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-178|15|660|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-179|15|662|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-180|15|662|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-181|15|662|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-182|15|662|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-183|15|669|Neoplasia unclassified|Other local manifestations and miscellaneus|TMWC: TCVS OF TAIL BASE INVAS OF TAIL MUSC.|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-184|15|674|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-185|15|686|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-186|15|690|Other deterministic changes|Whole body|MCDU/|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-187|15|690|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-188|15|695|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-189|15|705|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-190|15|710|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-191|15|711|Neoplasia unclassified|Other local manifestations and miscellaneus|TMWG: TGAC INVADES MUSCLE & SKIN OF HEAD.|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-192|15|722|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-193|15|729|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-194|15|729|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-195|15|734|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-196|15|736|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-197|15|736|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-198|15|736|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-199|15|736|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-200|15|736|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-201|15|736|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-202|15|736|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-203|15|736|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-204|15|736|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-205|15|736|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-206|15|736|Inflammation and/or fibrotic diseases|Other local manifestations and miscellaneus|MNIA/ cerebrum.|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-207|15|736|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-208|15|739|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-209|15|740|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-210|15|740|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-211|15|746|Neoplasia unclassified|Other local manifestations and miscellaneus|TMWC: TCVS OF TAIL BASE INVAS OF TAIL MUSC.|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-212|15|750|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-213|15|751|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-214|15|752|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-215|15|753|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-216|15|758|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-217|15|760|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-218|15|762|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-219|15|762|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-220|15|763|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-221|15|764|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-222|15|764|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-223|15|772|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-224|15|773|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-225|15|776|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-226|15|776|Neoplasia unclassified|Other local manifestations and miscellaneus|TRWK: TKAC TO LUNG.|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-227|15|781|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-228|15|784|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-229|15|785|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-230|15|785|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-231|15|785|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-232|15|785|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-233|15|791|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-234|15|792|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-235|15|792|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-236|15|793|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-237|15|794|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|TCFS/ dorsal lumbral-sacral region. Metastases  Muscle tcfs invas of skel musc & vertebral body of lumbar region.,MPATH: 408 - soft tissue fibrosarcoma|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-238|15|795|Other deterministic changes|Whole body|MCDU/|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-239|15|801|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-240|15|814|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-241|15|820|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-242|15|822|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-243|15|824|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-244|15|828|Other deterministic changes|Whole body|MCDU/  Eye(s) missing Head/neck missing|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-245|15|833|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-246|15|835|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-247|15|839|Neoplasia systemic|Haematolymphatic system|TLML/|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-248|15|840|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-249|15|842|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-250|15|843|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-251|15|844|Neoplasia unclassified|Other local manifestations and miscellaneus|TRWK: TKAC TO LUNG.|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-252|15|845|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-253|15|845|Neoplasia unclassified|Other local manifestations and miscellaneus|TMWG: TGAC INVADES MUSCLE & SKIN OF HEAD.|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-254|15|849|Neoplasia malignant|Endocrine system|TGAC/   Metastases  Muscle tgac invades muscle & skin of head.|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-255|15|852|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-256|15|858|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-257|15|861|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-258|15|864|Other deterministic changes|Whole body|MCDU/  Head/neck missing Eye(s) missing|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-259|15|866|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/  ,MPATH: 242 - hemangiosarcoma|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-260|15|866|Neoplasia unclassified|Integumentary system,MA: 0000151 - skin|TSEC/ head & neck. Metastases  tsec to base of heart & soft tissue. Metastases Lung,MPATH: 218 - neoplasm|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-261|15|873|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  Eye(s) missing Head/neck missing,MPATH: 513 - Lymphoid neoplasms|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-262|15|875|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-263|15|876|Neoplasia malignant|Bloodvessels among cardiovascular system|TCVS/ base of tail. Metastases  Muscle tcvs of tail base invas of tail musc.|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-264|15|876|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-265|15|879|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-266|15|879|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-267|15|883|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-268|15|885|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-269|15|885|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-270|15|889|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-271|15|890|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-272|15|890|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-273|15|896|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-274|15|897|Inflammation and/or fibrotic diseases|Kidney among urinary system diseases,MA: 0000368 - kidney|MPNE/  acute Metastases  tcfs invas of peritonium of ureter & intestine.,MPATH: 212 - inflammation|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-275|15|899|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-276|15|903|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-277|15|904|Neoplasia unclassified|Other local manifestations and miscellaneus|TMWC: TCFS INVAS. OF COSTAL MUSCLES.|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-278|15|910|Other deterministic changes|Whole body|MCDU/|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-279|15|911|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-280|15|913|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-281|15|919|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-282|15|921|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-283|15|922|Neoplasia unclassified|Other local manifestations and miscellaneus|TMWC: TCVS INVAS. OF SKELETAL MUSCLE.|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-284|15|923|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/ w/ leukemia.Eye(s) missing Head/neck missing,MPATH: 513 - Lymphoid neoplasms|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-285|15|924|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-286|15|924|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-287|15|925|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-288|15|927|Neoplasia systemic|Haematolymphatic system|TLML/ non-leukemic sarcoma.|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-289|15|927|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-290|15|928|Neoplasia unclassified|Other local manifestations and miscellaneus|TMWG: TGAC INVADES MUSCLE & SKIN OF HEAD.|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-291|15|930|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-292|15|931|Inflammation and/or fibrotic diseases|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|MHCN/  Coagulative focal hepatitis,MPATH: 212 - inflammation|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-293|15|931|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-294|15|933|Other deterministic changes|Whole body|MCDU/|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-295|15|933|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-296|15|934|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|TCFS/ rib cage. Metastases Lung Metastases  Muscle tcfs invas. of costal muscles. Metastases  tcfs invas. of parietal & visc. pleura.,MPATH: 408 - soft tissue fibrosarcoma|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-297|15|938|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-298|15|946|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-299|15|947|Neoplasia systemic|Haematolymphatic system|TLML/   Metastases  Lymphoret.System tsec of head & neck to cn ln.|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-300|15|956|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-301|15|958|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-302|15|959|Neoplasia unclassified|Other local manifestations and miscellaneus|TMWC: TCVS OF TAIL BASE INVAS OF TAIL MUSC.|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-303|15|959|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-304|15|961|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-305|15|961|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-306|15|962|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-307|15|963|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-308|15|964|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-309|15|967|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-310|15|968|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-311|15|969|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-312|15|969|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-313|15|969|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-314|15|973|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/  ,MPATH: 242 - hemangiosarcoma|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-315|15|974|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-316|15|974|Neoplasia systemic|Haematolymphatic system|TLML/|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-317|15|979|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-318|15|980|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-319|15|981|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-320|15|987|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-321|15|989|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-322|15|989|Other deterministic changes|Whole body|MCDU/|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-323|15|991|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-324|15|996|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-325|15|1000|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-326|15|1004|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-327|15|1005|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-328|15|1008|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-329|15|1008|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-330|15|1009|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|TPAO/  Adenoma,MPATH: 218 - neoplasm|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-331|15|1010|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-332|15|1013|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-333|15|1017|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-334|15|1018|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-335|15|1021|Neoplasia unclassified|Other local manifestations and miscellaneus|TLWR: TRAC INVAS. PT LN.|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-336|15|1022|Inflammation and/or fibrotic diseases|Lower respiratory system,MA: 0000415 - lung|MPNU/  Acute and subacute,MPATH: 212 - inflammation|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-337|15|1023|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-338|15|1023|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-339|15|1023|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-340|15|1023|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-341|15|1030|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-342|15|1031|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/   Metastases  Skin tcvs of tail base invas of tail skin.,MPATH: 513 - Lymphoid neoplasms|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-343|15|1034|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-344|15|1038|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-345|15|1040|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-346|15|1042|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-347|15|1042|Neoplasia unclassified|Other local manifestations and miscellaneus|TLWR: TRAC INVAS. PT LN.|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-348|15|1046|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-349|15|1046|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-350|15|1048|Other deterministic changes|Whole body|MCDU/|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-351|15|1048|Neoplasia unclassified|Other local manifestations and miscellaneus|TMWC: TCFS INVAS OF SKEL MUSC & VERTEBRAL BODY OF LUMBAR REGION.|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-352|15|1049|Neoplasia unclassified|Other local manifestations and miscellaneus|TLWR: TRAC INVAS. PT LN.|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-353|15|1050|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-354|15|1052|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-355|15|1053|Other deterministic changes|Whole body|MCDU/|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-356|15|1055|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  Eye(s) missing Head/neck missing,MPATH: 513 - Lymphoid neoplasms|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-357|15|1056|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-358|15|1056|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-359|15|1060|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-360|15|1060|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-361|15|1062|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-362|15|1064|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-363|15|1066|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-364|15|1067|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/  ,MPATH: 242 - hemangiosarcoma|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-365|15|1072|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-366|15|1072|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-367|15|1075|Neoplasia unclassified|Other local manifestations and miscellaneus|TLWS: TSEC OF HEAD & NECK TO CN LN.|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-368|15|1076|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/   Metastases Lung,MPATH: 242 - hemangiosarcoma|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-369|15|1078|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-370|15|1079|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-371|15|1086|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-372|15|1086|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-373|15|1087|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-374|15|1088|Neoplasia benign|Bloodvessels among cardiovascular system|TTVO/  Testis|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-375|15|1090|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-376|15|1093|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-377|15|1095|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-378|15|1097|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-379|15|1099|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-380|15|1102|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  Head/neck missing,MPATH: 513 - Lymphoid neoplasms|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-381|15|1103|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-382|15|1106|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-383|15|1110|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-384|15|1112|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-385|15|1116|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-386|15|1118|Neoplasia unclassified|Other local manifestations and miscellaneus|TRWK: TKAC TO LUNG.|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-387|15|1118|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-388|15|1122|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-389|15|1125|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-390|15|1127|Neoplasia unclassified|Other local manifestations and miscellaneus|TLWM: TMLS OF COLON WALL SPREAD TO MN LN.|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-391|15|1129|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  Head/neck missing Eye(s) missing,MPATH: 513 - Lymphoid neoplasms|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-392|15|1129|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-393|15|1130|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-394|15|1131|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases  Muscle trac invas. rib cage muscle. Metastases  Lymphoret.System trac invas. pt ln.Head/neck missing Eye(s) missing,MPATH: 268 - adenocarcinoma|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-395|15|1131|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-396|15|1135|Other deterministic changes|Whole body|MCDU/|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-397|15|1136|Neoplasia malignant|Bloodvessels among cardiovascular system|TCVS/ subcut.dorsal rt. shoulder & neck. Metastases Lung Metastases  Muscle tcvs invas. of skeletal muscle.|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-398|15|1146|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-399|15|1147|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-400|15|1148|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-401|15|1148|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-402|15|1149|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-403|15|1152|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|TKAC/  ,MPATH: 549 - carcinoma|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-404|15|1153|Neoplasia unclassified|Other local manifestations and miscellaneus|TMWC: TCFS INVAS OF SKEL MUSC & VERTEBRAL BODY OF LUMBAR REGION.|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-405|15|1153|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-406|15|1154|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-407|15|1158|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-408|15|1159|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-409|15|1166|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-410|15|1169|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-411|15|1171|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-412|15|1171|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-413|15|1174|Neoplasia malignant|Nervous system and special sense organs,MA: 0000016 - nervous system|TNMS/ thoracic spine.,MPATH: 551 - sarcoma|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-414|15|1177|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-415|15|1180|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-416|15|1181|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-417|15|1181|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-418|15|1183|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-419|15|1184|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-420|15|1185|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-421|15|1185|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-422|15|1188|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-423|15|1191|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-424|15|1193|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  Head/neck missing Eye(s) missing,MPATH: 513 - Lymphoid neoplasms|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-425|15|1194|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-426|15|1200|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-427|15|1203|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-428|15|1209|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/   Metastases  trac invasion of visc. & parietal pleura.,MPATH: 513 - Lymphoid neoplasms|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-429|15|1218|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-430|15|1219|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-431|15|1220|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-432|15|1226|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-433|15|1227|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-434|15|1232|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-435|15|1232|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-436|15|1237|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-437|15|1239|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-438|15|1255|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-439|15|1261|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-440|15|1261|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-441|15|1270|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-442|15|1277|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-443|15|1280|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-444|15|1280|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-445|15|1284|Neoplasia malignant|Other local manifestations and miscellaneus|TMLS/ intestinal wall-colon. Metastases  tmls of colon wall spread to visceral peritoneum. Metastases  Lymphoret.System tmls of colon wall spread to mn ln.|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-446|15|1291|Other deterministic changes|Whole body|MCDU/|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-447|15|1291|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-448|15|1292|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-449|15|1294|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-450|15|1296|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-451|15|1301|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-452|15|1308|Other deterministic changes|Whole body|MCDU/|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-453|15|1308|n/a|n/a|n/a|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-454|15|1351|Other deterministic changes|Whole body|MCDU/|
1003-29-15|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|455 (455 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|271 records survival 869 ± 11 lifespan study|1003-29-15-455|15|1393|n/a|n/a|n/a|
1003-29-16|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|247 records survival 837 ± 12 lifespan study|1003-29-16-1|16|143|n/a|n/a|n/a|
1003-29-16|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|247 records survival 837 ± 12 lifespan study|1003-29-16-2|16|144|n/a|n/a|n/a|
1003-29-16|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|247 records survival 837 ± 12 lifespan study|1003-29-16-3|16|324|Other deterministic changes|Whole body|MCDU/|
1003-29-16|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|247 records survival 837 ± 12 lifespan study|1003-29-16-4|16|386|n/a|n/a|n/a|
1003-29-16|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|247 records survival 837 ± 12 lifespan study|1003-29-16-5|16|406|Other deterministic changes|Whole body|MCDU/|
1003-29-16|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|247 records survival 837 ± 12 lifespan study|1003-29-16-6|16|433|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-16|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|247 records survival 837 ± 12 lifespan study|1003-29-16-7|16|438|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-16|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|247 records survival 837 ± 12 lifespan study|1003-29-16-8|16|439|n/a|n/a|n/a|
1003-29-16|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|247 records survival 837 ± 12 lifespan study|1003-29-16-9|16|468|n/a|n/a|n/a|
1003-29-16|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|247 records survival 837 ± 12 lifespan study|1003-29-16-10|16|488|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-16|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|247 records survival 837 ± 12 lifespan study|1003-29-16-11|16|494|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-16|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|247 records survival 837 ± 12 lifespan study|1003-29-16-12|16|496|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-16|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|247 records survival 837 ± 12 lifespan study|1003-29-16-13|16|512|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-16|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|247 records survival 837 ± 12 lifespan study|1003-29-16-14|16|528|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-16|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|247 records survival 837 ± 12 lifespan study|1003-29-16-15|16|535|Neoplasia malignant|Bone among musculo-skeletal system diseases|TBOS/ chest wall, possibly rib.|
1003-29-16|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|247 records survival 837 ± 12 lifespan study|1003-29-16-16|16|540|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOVO/  ,MPATH: 242 - hemangiosarcoma|
1003-29-16|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|247 records survival 837 ± 12 lifespan study|1003-29-16-17|16|646|n/a|n/a|n/a|
1003-29-16|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|247 records survival 837 ± 12 lifespan study|1003-29-16-18|16|646|n/a|n/a|n/a|
1003-29-16|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|247 records survival 837 ± 12 lifespan study|1003-29-16-19|16|659|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-16|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|247 records survival 837 ± 12 lifespan study|1003-29-16-20|16|661|n/a|n/a|n/a|
1003-29-16|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|247 records survival 837 ± 12 lifespan study|1003-29-16-21|16|673|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-16|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|247 records survival 837 ± 12 lifespan study|1003-29-16-22|16|683|n/a|n/a|n/a|
1003-29-16|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|247 records survival 837 ± 12 lifespan study|1003-29-16-23|16|692|n/a|n/a|n/a|
1003-29-16|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|247 records survival 837 ± 12 lifespan study|1003-29-16-24|16|698|n/a|n/a|n/a|
1003-29-16|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|247 records survival 837 ± 12 lifespan study|1003-29-16-25|16|698|n/a|n/a|n/a|
1003-29-16|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|247 records survival 837 ± 12 lifespan study|1003-29-16-26|16|701|n/a|n/a|n/a|
1003-29-16|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|247 records survival 837 ± 12 lifespan study|1003-29-16-27|16|702|n/a|n/a|n/a|
1003-29-16|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|247 records survival 837 ± 12 lifespan study|1003-29-16-28|16|707|n/a|n/a|n/a|
1003-29-16|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|247 records survival 837 ± 12 lifespan study|1003-29-16-29|16|712|n/a|n/a|n/a|
1003-29-16|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|247 records survival 837 ± 12 lifespan study|1003-29-16-30|16|718|n/a|n/a|n/a|
1003-29-16|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|247 records survival 837 ± 12 lifespan study|1003-29-16-31|16|726|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  Eye(s) missing Head/neck missing,MPATH: 513 - Lymphoid neoplasms|
1003-29-16|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|247 records survival 837 ± 12 lifespan study|1003-29-16-32|16|739|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-16|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|247 records survival 837 ± 12 lifespan study|1003-29-16-33|16|742|n/a|n/a|n/a|
1003-29-16|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|247 records survival 837 ± 12 lifespan study|1003-29-16-34|16|743|n/a|n/a|n/a|
1003-29-16|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|247 records survival 837 ± 12 lifespan study|1003-29-16-35|16|748|Hyperplastic changes|Other local manifestations and miscellaneus,MA: 0000003 - organ system|MOCY/  Ovary or testis,MPATH: 62 - cyst|
1003-29-16|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|247 records survival 837 ± 12 lifespan study|1003-29-16-36|16|748|Neoplasia malignant|Bone among musculo-skeletal system diseases|TBOS/ caudal vertebrae. Metastases  Muscle tbos of caudal vertebrae to muscle of tail. Metastases Lung|
1003-29-16|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|247 records survival 837 ± 12 lifespan study|1003-29-16-37|16|754|Other deterministic changes|Whole body|MCDU/|
1003-29-16|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|247 records survival 837 ± 12 lifespan study|1003-29-16-38|16|757|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/  ,MPATH: 242 - hemangiosarcoma|
1003-29-16|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|247 records survival 837 ± 12 lifespan study|1003-29-16-39|16|766|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-16|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|247 records survival 837 ± 12 lifespan study|1003-29-16-40|16|776|n/a|n/a|n/a|
1003-29-16|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|247 records survival 837 ± 12 lifespan study|1003-29-16-41|16|776|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-16|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|247 records survival 837 ± 12 lifespan study|1003-29-16-42|16|778|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-16|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|247 records survival 837 ± 12 lifespan study|1003-29-16-43|16|785|n/a|n/a|n/a|
1003-29-16|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|247 records survival 837 ± 12 lifespan study|1003-29-16-44|16|787|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/   Metastases Liver,MPATH: 513 - Lymphoid neoplasms|
1003-29-16|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|247 records survival 837 ± 12 lifespan study|1003-29-16-45|16|792|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-16|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|247 records survival 837 ± 12 lifespan study|1003-29-16-46|16|793|n/a|n/a|n/a|
1003-29-16|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|247 records survival 837 ± 12 lifespan study|1003-29-16-47|16|795|n/a|n/a|n/a|
1003-29-16|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|247 records survival 837 ± 12 lifespan study|1003-29-16-48|16|799|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-16|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|247 records survival 837 ± 12 lifespan study|1003-29-16-49|16|806|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  Head/neck missing Eye(s) missing,MPATH: 513 - Lymphoid neoplasms|
1003-29-16|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|247 records survival 837 ± 12 lifespan study|1003-29-16-50|16|815|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-16|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|247 records survival 837 ± 12 lifespan study|1003-29-16-51|16|817|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-16|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|247 records survival 837 ± 12 lifespan study|1003-29-16-52|16|819|n/a|n/a|n/a|
1003-29-16|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|247 records survival 837 ± 12 lifespan study|1003-29-16-53|16|821|n/a|n/a|n/a|
1003-29-16|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|247 records survival 837 ± 12 lifespan study|1003-29-16-54|16|827|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|TCFS/ in fat in right axilla. Metastases  Muscle tcfs invading muscle of forelimb.,MPATH: 408 - soft tissue fibrosarcoma|
1003-29-16|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|247 records survival 837 ± 12 lifespan study|1003-29-16-55|16|827|n/a|n/a|n/a|
1003-29-16|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|247 records survival 837 ± 12 lifespan study|1003-29-16-56|16|828|Other deterministic changes|Whole body|MCDU/  Head/neck missing Thorax missing Eye(s) missing|
1003-29-16|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|247 records survival 837 ± 12 lifespan study|1003-29-16-57|16|832|n/a|n/a|n/a|
1003-29-16|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|247 records survival 837 ± 12 lifespan study|1003-29-16-58|16|835|n/a|n/a|n/a|
1003-29-16|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|247 records survival 837 ± 12 lifespan study|1003-29-16-59|16|836|n/a|n/a|n/a|
1003-29-16|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|247 records survival 837 ± 12 lifespan study|1003-29-16-60|16|842|n/a|n/a|n/a|
1003-29-16|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|247 records survival 837 ± 12 lifespan study|1003-29-16-61|16|843|n/a|n/a|n/a|
1003-29-16|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|247 records survival 837 ± 12 lifespan study|1003-29-16-62|16|849|n/a|n/a|n/a|
1003-29-16|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|247 records survival 837 ± 12 lifespan study|1003-29-16-63|16|852|n/a|n/a|n/a|
1003-29-16|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|247 records survival 837 ± 12 lifespan study|1003-29-16-64|16|860|n/a|n/a|n/a|
1003-29-16|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|247 records survival 837 ± 12 lifespan study|1003-29-16-65|16|866|n/a|n/a|n/a|
1003-29-16|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|247 records survival 837 ± 12 lifespan study|1003-29-16-66|16|869|n/a|n/a|n/a|
1003-29-16|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|247 records survival 837 ± 12 lifespan study|1003-29-16-67|16|869|n/a|n/a|n/a|
1003-29-16|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|247 records survival 837 ± 12 lifespan study|1003-29-16-68|16|870|n/a|n/a|n/a|
1003-29-16|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|247 records survival 837 ± 12 lifespan study|1003-29-16-69|16|870|n/a|n/a|n/a|
1003-29-16|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|247 records survival 837 ± 12 lifespan study|1003-29-16-70|16|870|n/a|n/a|n/a|
1003-29-16|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|247 records survival 837 ± 12 lifespan study|1003-29-16-71|16|872|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-16|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|247 records survival 837 ± 12 lifespan study|1003-29-16-72|16|874|n/a|n/a|n/a|
1003-29-16|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|247 records survival 837 ± 12 lifespan study|1003-29-16-73|16|874|Neoplasia malignant|Other local manifestations and miscellaneus|TXUS/ TXUS/ TXUS/ TXUS/ chest & mediastinum.|
1003-29-16|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|247 records survival 837 ± 12 lifespan study|1003-29-16-74|16|882|n/a|n/a|n/a|
1003-29-16|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|247 records survival 837 ± 12 lifespan study|1003-29-16-75|16|883|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-16|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|247 records survival 837 ± 12 lifespan study|1003-29-16-76|16|884|n/a|n/a|n/a|
1003-29-16|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|247 records survival 837 ± 12 lifespan study|1003-29-16-77|16|885|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  Head/neck missing,MPATH: 513 - Lymphoid neoplasms|
1003-29-16|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|247 records survival 837 ± 12 lifespan study|1003-29-16-78|16|890|n/a|n/a|n/a|
1003-29-16|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|247 records survival 837 ± 12 lifespan study|1003-29-16-79|16|890|Other deterministic changes|Whole body|MCDU/|
1003-29-16|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|247 records survival 837 ± 12 lifespan study|1003-29-16-80|16|894|Neoplasia malignant|Musculo-skeletal system,MA: 0000015 - muscle organ|TMRS/ thoracic spinal region.,MPATH: 428 - rhabdomyosarcoma|
1003-29-16|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|247 records survival 837 ± 12 lifespan study|1003-29-16-81|16|895|n/a|n/a|n/a|
1003-29-16|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|247 records survival 837 ± 12 lifespan study|1003-29-16-82|16|895|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-16|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|247 records survival 837 ± 12 lifespan study|1003-29-16-83|16|897|n/a|n/a|n/a|
1003-29-16|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|247 records survival 837 ± 12 lifespan study|1003-29-16-84|16|897|Neoplasia malignant|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|THVS/  ,MPATH: 242 - hemangiosarcoma|
1003-29-16|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|247 records survival 837 ± 12 lifespan study|1003-29-16-85|16|899|n/a|n/a|n/a|
1003-29-16|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|247 records survival 837 ± 12 lifespan study|1003-29-16-86|16|899|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-16|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|247 records survival 837 ± 12 lifespan study|1003-29-16-87|16|899|n/a|n/a|n/a|
1003-29-16|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|247 records survival 837 ± 12 lifespan study|1003-29-16-88|16|901|n/a|n/a|n/a|
1003-29-16|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|247 records survival 837 ± 12 lifespan study|1003-29-16-89|16|903|n/a|n/a|n/a|
1003-29-16|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|247 records survival 837 ± 12 lifespan study|1003-29-16-90|16|903|n/a|n/a|n/a|
1003-29-16|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|247 records survival 837 ± 12 lifespan study|1003-29-16-91|16|908|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  Eye(s) missing Head/neck missing,MPATH: 513 - Lymphoid neoplasms|
1003-29-16|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|247 records survival 837 ± 12 lifespan study|1003-29-16-92|16|910|n/a|n/a|n/a|
1003-29-16|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|247 records survival 837 ± 12 lifespan study|1003-29-16-93|16|911|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-16|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|247 records survival 837 ± 12 lifespan study|1003-29-16-94|16|914|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-16|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|247 records survival 837 ± 12 lifespan study|1003-29-16-95|16|915|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-16|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|247 records survival 837 ± 12 lifespan study|1003-29-16-96|16|915|n/a|n/a|n/a|
1003-29-16|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|247 records survival 837 ± 12 lifespan study|1003-29-16-97|16|915|n/a|n/a|n/a|
1003-29-16|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|247 records survival 837 ± 12 lifespan study|1003-29-16-98|16|917|n/a|n/a|n/a|
1003-29-16|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|247 records survival 837 ± 12 lifespan study|1003-29-16-99|16|917|n/a|n/a|n/a|
1003-29-16|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|247 records survival 837 ± 12 lifespan study|1003-29-16-100|16|919|n/a|n/a|n/a|
1003-29-16|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|247 records survival 837 ± 12 lifespan study|1003-29-16-101|16|920|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-16|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|247 records survival 837 ± 12 lifespan study|1003-29-16-102|16|921|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-16|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|247 records survival 837 ± 12 lifespan study|1003-29-16-103|16|923|n/a|n/a|n/a|
1003-29-16|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|247 records survival 837 ± 12 lifespan study|1003-29-16-104|16|926|n/a|n/a|n/a|
1003-29-16|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|247 records survival 837 ± 12 lifespan study|1003-29-16-105|16|928|n/a|n/a|n/a|
1003-29-16|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|247 records survival 837 ± 12 lifespan study|1003-29-16-106|16|930|n/a|n/a|n/a|
1003-29-16|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|247 records survival 837 ± 12 lifespan study|1003-29-16-107|16|932|n/a|n/a|n/a|
1003-29-16|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|247 records survival 837 ± 12 lifespan study|1003-29-16-108|16|932|n/a|n/a|n/a|
1003-29-16|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|247 records survival 837 ± 12 lifespan study|1003-29-16-109|16|934|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-16|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|247 records survival 837 ± 12 lifespan study|1003-29-16-110|16|938|n/a|n/a|n/a|
1003-29-16|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|247 records survival 837 ± 12 lifespan study|1003-29-16-111|16|939|n/a|n/a|n/a|
1003-29-16|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|247 records survival 837 ± 12 lifespan study|1003-29-16-112|16|939|n/a|n/a|n/a|
1003-29-16|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|247 records survival 837 ± 12 lifespan study|1003-29-16-113|16|940|n/a|n/a|n/a|
1003-29-16|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|247 records survival 837 ± 12 lifespan study|1003-29-16-114|16|941|n/a|n/a|n/a|
1003-29-16|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|247 records survival 837 ± 12 lifespan study|1003-29-16-115|16|942|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-16|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|247 records survival 837 ± 12 lifespan study|1003-29-16-116|16|943|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-16|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|247 records survival 837 ± 12 lifespan study|1003-29-16-117|16|945|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-16|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|247 records survival 837 ± 12 lifespan study|1003-29-16-118|16|946|n/a|n/a|n/a|
1003-29-16|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|247 records survival 837 ± 12 lifespan study|1003-29-16-119|16|953|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  Thorax missing Head/neck missing Eye(s) missing,MPATH: 513 - Lymphoid neoplasms|
1003-29-16|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|247 records survival 837 ± 12 lifespan study|1003-29-16-120|16|956|n/a|n/a|n/a|
1003-29-16|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|247 records survival 837 ± 12 lifespan study|1003-29-16-121|16|962|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLSL/  undifferentiated leukemia lymphoret.tissue,MPATH: 335 - hematopoietic/lymphoid malignancies/disorder|
1003-29-16|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|247 records survival 837 ± 12 lifespan study|1003-29-16-122|16|963|n/a|n/a|n/a|
1003-29-16|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|247 records survival 837 ± 12 lifespan study|1003-29-16-123|16|964|n/a|n/a|n/a|
1003-29-16|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|247 records survival 837 ± 12 lifespan study|1003-29-16-124|16|966|n/a|n/a|n/a|
1003-29-16|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|247 records survival 837 ± 12 lifespan study|1003-29-16-125|16|966|n/a|n/a|n/a|
1003-29-16|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|247 records survival 837 ± 12 lifespan study|1003-29-16-126|16|968|Inflammation and/or fibrotic diseases|Kidney among urinary system diseases,MA: 0000368 - kidney|MINA/  acute,MPATH: 212 - inflammation|
1003-29-16|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|247 records survival 837 ± 12 lifespan study|1003-29-16-127|16|969|Other deterministic changes|Whole body|MCDU/|
1003-29-16|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|247 records survival 837 ± 12 lifespan study|1003-29-16-128|16|972|Neoplasia malignant|Other local manifestations and miscellaneus|TMLS/ chest musc.|
1003-29-16|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|247 records survival 837 ± 12 lifespan study|1003-29-16-129|16|974|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOVO/  Eye(s) missing Head/neck missing,MPATH: 242 - hemangiosarcoma|
1003-29-16|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|247 records survival 837 ± 12 lifespan study|1003-29-16-130|16|974|n/a|n/a|n/a|
1003-29-16|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|247 records survival 837 ± 12 lifespan study|1003-29-16-131|16|977|n/a|n/a|n/a|
1003-29-16|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|247 records survival 837 ± 12 lifespan study|1003-29-16-132|16|978|n/a|n/a|n/a|
1003-29-16|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|247 records survival 837 ± 12 lifespan study|1003-29-16-133|16|979|n/a|n/a|n/a|
1003-29-16|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|247 records survival 837 ± 12 lifespan study|1003-29-16-134|16|979|n/a|n/a|n/a|
1003-29-16|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|247 records survival 837 ± 12 lifespan study|1003-29-16-135|16|982|n/a|n/a|n/a|
1003-29-16|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|247 records survival 837 ± 12 lifespan study|1003-29-16-136|16|983|n/a|n/a|n/a|
1003-29-16|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|247 records survival 837 ± 12 lifespan study|1003-29-16-137|16|987|n/a|n/a|n/a|
1003-29-16|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|247 records survival 837 ± 12 lifespan study|1003-29-16-138|16|992|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-16|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|247 records survival 837 ± 12 lifespan study|1003-29-16-139|16|994|n/a|n/a|n/a|
1003-29-16|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|247 records survival 837 ± 12 lifespan study|1003-29-16-140|16|996|n/a|n/a|n/a|
1003-29-16|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|247 records survival 837 ± 12 lifespan study|1003-29-16-141|16|996|n/a|n/a|n/a|
1003-29-16|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|247 records survival 837 ± 12 lifespan study|1003-29-16-142|16|997|n/a|n/a|n/a|
1003-29-16|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|247 records survival 837 ± 12 lifespan study|1003-29-16-143|16|998|n/a|n/a|n/a|
1003-29-16|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|247 records survival 837 ± 12 lifespan study|1003-29-16-144|16|998|n/a|n/a|n/a|
1003-29-16|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|247 records survival 837 ± 12 lifespan study|1003-29-16-145|16|999|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-16|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|247 records survival 837 ± 12 lifespan study|1003-29-16-146|16|1001|n/a|n/a|n/a|
1003-29-16|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|247 records survival 837 ± 12 lifespan study|1003-29-16-147|16|1002|n/a|n/a|n/a|
1003-29-16|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|247 records survival 837 ± 12 lifespan study|1003-29-16-148|16|1002|n/a|n/a|n/a|
1003-29-16|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|247 records survival 837 ± 12 lifespan study|1003-29-16-149|16|1004|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  Eye(s) missing Head/neck missing,MPATH: 268 - adenocarcinoma|
1003-29-16|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|247 records survival 837 ± 12 lifespan study|1003-29-16-150|16|1006|Other deterministic changes|Whole body|MCDU/|
1003-29-16|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|247 records survival 837 ± 12 lifespan study|1003-29-16-151|16|1009|n/a|n/a|n/a|
1003-29-16|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|247 records survival 837 ± 12 lifespan study|1003-29-16-152|16|1011|n/a|n/a|n/a|
1003-29-16|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|247 records survival 837 ± 12 lifespan study|1003-29-16-153|16|1012|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-16|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|247 records survival 837 ± 12 lifespan study|1003-29-16-154|16|1015|n/a|n/a|n/a|
1003-29-16|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|247 records survival 837 ± 12 lifespan study|1003-29-16-155|16|1018|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  Head/neck missing,MPATH: 513 - Lymphoid neoplasms|
1003-29-16|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|247 records survival 837 ± 12 lifespan study|1003-29-16-156|16|1026|n/a|n/a|n/a|
1003-29-16|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|247 records survival 837 ± 12 lifespan study|1003-29-16-157|16|1026|n/a|n/a|n/a|
1003-29-16|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|247 records survival 837 ± 12 lifespan study|1003-29-16-158|16|1027|Neoplasia benign|Lower digestive tract,MA: 0000323 - gastrointestinal system|TIPO/ stomach.,MPATH: 491 - polyp|
1003-29-16|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|247 records survival 837 ± 12 lifespan study|1003-29-16-159|16|1031|n/a|n/a|n/a|
1003-29-16|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|247 records survival 837 ± 12 lifespan study|1003-29-16-160|16|1032|n/a|n/a|n/a|
1003-29-16|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|247 records survival 837 ± 12 lifespan study|1003-29-16-161|16|1033|n/a|n/a|n/a|
1003-29-16|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|247 records survival 837 ± 12 lifespan study|1003-29-16-162|16|1038|n/a|n/a|n/a|
1003-29-16|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|247 records survival 837 ± 12 lifespan study|1003-29-16-163|16|1039|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/  Head/neck missing Eye(s) missing,MPATH: 242 - hemangiosarcoma|
1003-29-16|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|247 records survival 837 ± 12 lifespan study|1003-29-16-164|16|1039|n/a|n/a|n/a|
1003-29-16|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|247 records survival 837 ± 12 lifespan study|1003-29-16-165|16|1042|Inflammation and/or fibrotic diseases|Lower respiratory system,MA: 0000415 - lung|MRMP/  Murine,MPATH: 212 - inflammation|
1003-29-16|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|247 records survival 837 ± 12 lifespan study|1003-29-16-166|16|1042|n/a|n/a|n/a|
1003-29-16|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|247 records survival 837 ± 12 lifespan study|1003-29-16-167|16|1044|n/a|n/a|n/a|
1003-29-16|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|247 records survival 837 ± 12 lifespan study|1003-29-16-168|16|1044|n/a|n/a|n/a|
1003-29-16|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|247 records survival 837 ± 12 lifespan study|1003-29-16-169|16|1045|Neoplasia malignant|Bloodvessels among cardiovascular system|TXVS/ no normal tiss; tumor from abdom area.|
1003-29-16|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|247 records survival 837 ± 12 lifespan study|1003-29-16-170|16|1046|n/a|n/a|n/a|
1003-29-16|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|247 records survival 837 ± 12 lifespan study|1003-29-16-171|16|1047|n/a|n/a|n/a|
1003-29-16|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|247 records survival 837 ± 12 lifespan study|1003-29-16-172|16|1047|n/a|n/a|n/a|
1003-29-16|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|247 records survival 837 ± 12 lifespan study|1003-29-16-173|16|1048|n/a|n/a|n/a|
1003-29-16|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|247 records survival 837 ± 12 lifespan study|1003-29-16-174|16|1048|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-16|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|247 records survival 837 ± 12 lifespan study|1003-29-16-175|16|1052|n/a|n/a|n/a|
1003-29-16|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|247 records survival 837 ± 12 lifespan study|1003-29-16-176|16|1052|Other deterministic changes|Whole body|MCDU/|
1003-29-16|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|247 records survival 837 ± 12 lifespan study|1003-29-16-177|16|1052|n/a|n/a|n/a|
1003-29-16|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|247 records survival 837 ± 12 lifespan study|1003-29-16-178|16|1053|n/a|n/a|n/a|
1003-29-16|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|247 records survival 837 ± 12 lifespan study|1003-29-16-179|16|1054|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  Head/neck missing Eye(s) missing,MPATH: 513 - Lymphoid neoplasms|
1003-29-16|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|247 records survival 837 ± 12 lifespan study|1003-29-16-180|16|1055|n/a|n/a|n/a|
1003-29-16|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|247 records survival 837 ± 12 lifespan study|1003-29-16-181|16|1059|Neoplasia systemic|Haematolymphatic system|TLML/|
1003-29-16|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|247 records survival 837 ± 12 lifespan study|1003-29-16-182|16|1065|n/a|n/a|n/a|
1003-29-16|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|247 records survival 837 ± 12 lifespan study|1003-29-16-183|16|1066|n/a|n/a|n/a|
1003-29-16|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|247 records survival 837 ± 12 lifespan study|1003-29-16-184|16|1067|n/a|n/a|n/a|
1003-29-16|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|247 records survival 837 ± 12 lifespan study|1003-29-16-185|16|1069|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-16|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|247 records survival 837 ± 12 lifespan study|1003-29-16-186|16|1073|n/a|n/a|n/a|
1003-29-16|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|247 records survival 837 ± 12 lifespan study|1003-29-16-187|16|1073|n/a|n/a|n/a|
1003-29-16|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|247 records survival 837 ± 12 lifespan study|1003-29-16-188|16|1076|n/a|n/a|n/a|
1003-29-16|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|247 records survival 837 ± 12 lifespan study|1003-29-16-189|16|1077|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-16|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|247 records survival 837 ± 12 lifespan study|1003-29-16-190|16|1078|n/a|n/a|n/a|
1003-29-16|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|247 records survival 837 ± 12 lifespan study|1003-29-16-191|16|1078|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOVO/  ,MPATH: 242 - hemangiosarcoma|
1003-29-16|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|247 records survival 837 ± 12 lifespan study|1003-29-16-192|16|1082|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-16|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|247 records survival 837 ± 12 lifespan study|1003-29-16-193|16|1086|n/a|n/a|n/a|
1003-29-16|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|247 records survival 837 ± 12 lifespan study|1003-29-16-194|16|1089|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-16|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|247 records survival 837 ± 12 lifespan study|1003-29-16-195|16|1090|n/a|n/a|n/a|
1003-29-16|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|247 records survival 837 ± 12 lifespan study|1003-29-16-196|16|1090|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-16|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|247 records survival 837 ± 12 lifespan study|1003-29-16-197|16|1091|n/a|n/a|n/a|
1003-29-16|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|247 records survival 837 ± 12 lifespan study|1003-29-16-198|16|1091|n/a|n/a|n/a|
1003-29-16|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|247 records survival 837 ± 12 lifespan study|1003-29-16-199|16|1092|n/a|n/a|n/a|
1003-29-16|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|247 records survival 837 ± 12 lifespan study|1003-29-16-200|16|1093|n/a|n/a|n/a|
1003-29-16|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|247 records survival 837 ± 12 lifespan study|1003-29-16-201|16|1094|n/a|n/a|n/a|
1003-29-16|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|247 records survival 837 ± 12 lifespan study|1003-29-16-202|16|1095|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  Head/neck missing Eye(s) missing,MPATH: 513 - Lymphoid neoplasms|
1003-29-16|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|247 records survival 837 ± 12 lifespan study|1003-29-16-203|16|1102|n/a|n/a|n/a|
1003-29-16|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|247 records survival 837 ± 12 lifespan study|1003-29-16-204|16|1117|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-16|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|247 records survival 837 ± 12 lifespan study|1003-29-16-205|16|1120|Other deterministic changes|Whole body|MCDU/|
1003-29-16|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|247 records survival 837 ± 12 lifespan study|1003-29-16-206|16|1123|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases  Muscle tbos of rib infiltr. of muscle.,MPATH: 268 - adenocarcinoma|
1003-29-16|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|247 records survival 837 ± 12 lifespan study|1003-29-16-207|16|1123|n/a|n/a|n/a|
1003-29-16|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|247 records survival 837 ± 12 lifespan study|1003-29-16-208|16|1123|n/a|n/a|n/a|
1003-29-16|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|247 records survival 837 ± 12 lifespan study|1003-29-16-209|16|1124|n/a|n/a|n/a|
1003-29-16|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|247 records survival 837 ± 12 lifespan study|1003-29-16-210|16|1124|n/a|n/a|n/a|
1003-29-16|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|247 records survival 837 ± 12 lifespan study|1003-29-16-211|16|1125|n/a|n/a|n/a|
1003-29-16|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|247 records survival 837 ± 12 lifespan study|1003-29-16-212|16|1125|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-16|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|247 records survival 837 ± 12 lifespan study|1003-29-16-213|16|1125|n/a|n/a|n/a|
1003-29-16|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|247 records survival 837 ± 12 lifespan study|1003-29-16-214|16|1127|n/a|n/a|n/a|
1003-29-16|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|247 records survival 837 ± 12 lifespan study|1003-29-16-215|16|1133|Other deterministic changes|Whole body|MCDU/|
1003-29-16|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|247 records survival 837 ± 12 lifespan study|1003-29-16-216|16|1135|n/a|n/a|n/a|
1003-29-16|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|247 records survival 837 ± 12 lifespan study|1003-29-16-217|16|1141|n/a|n/a|n/a|
1003-29-16|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|247 records survival 837 ± 12 lifespan study|1003-29-16-218|16|1143|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-16|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|247 records survival 837 ± 12 lifespan study|1003-29-16-219|16|1149|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-16|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|247 records survival 837 ± 12 lifespan study|1003-29-16-220|16|1150|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-16|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|247 records survival 837 ± 12 lifespan study|1003-29-16-221|16|1150|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-29-16|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|247 records survival 837 ± 12 lifespan study|1003-29-16-222|16|1152|n/a|n/a|n/a|
1003-29-16|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|247 records survival 837 ± 12 lifespan study|1003-29-16-223|16|1156|n/a|n/a|n/a|
1003-29-16|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|247 records survival 837 ± 12 lifespan study|1003-29-16-224|16|1157|n/a|n/a|n/a|
1003-29-16|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|247 records survival 837 ± 12 lifespan study|1003-29-16-225|16|1157|n/a|n/a|n/a|
1003-29-16|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|247 records survival 837 ± 12 lifespan study|1003-29-16-226|16|1158|n/a|n/a|n/a|
1003-29-16|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|247 records survival 837 ± 12 lifespan study|1003-29-16-227|16|1166|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-16|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|247 records survival 837 ± 12 lifespan study|1003-29-16-228|16|1167|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|TCFS/ subcut. left lower abd. region with invasion of skin & ulceration.,MPATH: 408 - soft tissue fibrosarcoma|
1003-29-16|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|247 records survival 837 ± 12 lifespan study|1003-29-16-229|16|1169|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-16|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|247 records survival 837 ± 12 lifespan study|1003-29-16-230|16|1170|n/a|n/a|n/a|
1003-29-16|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|247 records survival 837 ± 12 lifespan study|1003-29-16-231|16|1173|n/a|n/a|n/a|
1003-29-16|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|247 records survival 837 ± 12 lifespan study|1003-29-16-232|16|1175|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-16|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|247 records survival 837 ± 12 lifespan study|1003-29-16-233|16|1183|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/   Metastases  Muscle tcfs infiltr. skel. muscle of rib cage.,MPATH: 513 - Lymphoid neoplasms|
1003-29-16|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|247 records survival 837 ± 12 lifespan study|1003-29-16-234|16|1200|n/a|n/a|n/a|
1003-29-16|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|247 records survival 837 ± 12 lifespan study|1003-29-16-235|16|1209|n/a|n/a|n/a|
1003-29-16|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|247 records survival 837 ± 12 lifespan study|1003-29-16-236|16|1213|n/a|n/a|n/a|
1003-29-16|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|247 records survival 837 ± 12 lifespan study|1003-29-16-237|16|1219|n/a|n/a|n/a|
1003-29-16|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|247 records survival 837 ± 12 lifespan study|1003-29-16-238|16|1223|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-16|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|247 records survival 837 ± 12 lifespan study|1003-29-16-239|16|1234|n/a|n/a|n/a|
1003-29-16|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|247 records survival 837 ± 12 lifespan study|1003-29-16-240|16|1236|n/a|n/a|n/a|
1003-29-16|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|247 records survival 837 ± 12 lifespan study|1003-29-16-241|16|1246|n/a|n/a|n/a|
1003-29-16|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|247 records survival 837 ± 12 lifespan study|1003-29-16-242|16|1257|Neoplasia malignant|Other local manifestations and miscellaneus|TMLS/ caecum.|
1003-29-16|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|247 records survival 837 ± 12 lifespan study|1003-29-16-243|16|1261|n/a|n/a|n/a|
1003-29-16|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|247 records survival 837 ± 12 lifespan study|1003-29-16-244|16|1269|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-16|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|247 records survival 837 ± 12 lifespan study|1003-29-16-245|16|1273|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-29-16|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|247 records survival 837 ± 12 lifespan study|1003-29-16-246|16|1274|n/a|n/a|n/a|
1003-29-16|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|247 records survival 837 ± 12 lifespan study|1003-29-16-247|16|1277|n/a|n/a|n/a|
1003-29-16|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|247 records survival 837 ± 12 lifespan study|1003-29-16-248|16|1288|n/a|n/a|n/a|
1003-29-16|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|247 records survival 837 ± 12 lifespan study|1003-29-16-249|16|1331|n/a|n/a|n/a|
1003-29-16|n/a,2X|1|100|neutrons fission|0.075|grays|External exposure|code 2X (2A  2X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|247 records survival 837 ± 12 lifespan study|1003-29-16-250|16|1344|Other deterministic changes|Whole body|MCDU/|
1003-29-17|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|242 records survival 855 ± 11 lifespan study|1003-29-17-1|17|113|n/a|n/a|n/a|
1003-29-17|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|242 records survival 855 ± 11 lifespan study|1003-29-17-2|17|113|n/a|n/a|n/a|
1003-29-17|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|242 records survival 855 ± 11 lifespan study|1003-29-17-3|17|113|n/a|n/a|n/a|
1003-29-17|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|242 records survival 855 ± 11 lifespan study|1003-29-17-4|17|113|n/a|n/a|n/a|
1003-29-17|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|242 records survival 855 ± 11 lifespan study|1003-29-17-5|17|113|n/a|n/a|n/a|
1003-29-17|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|242 records survival 855 ± 11 lifespan study|1003-29-17-6|17|310|n/a|n/a|n/a|
1003-29-17|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|242 records survival 855 ± 11 lifespan study|1003-29-17-7|17|550|Neoplasia unclassified|Other local manifestations and miscellaneus|TMWG: TGAC INFILTRATION OF SKEL. MUSCLE.|
1003-29-17|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|242 records survival 855 ± 11 lifespan study|1003-29-17-8|17|577|n/a|n/a|n/a|
1003-29-17|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|242 records survival 855 ± 11 lifespan study|1003-29-17-9|17|583|Other deterministic changes|Whole body|MCDU/|
1003-29-17|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|242 records survival 855 ± 11 lifespan study|1003-29-17-10|17|584|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-17|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|242 records survival 855 ± 11 lifespan study|1003-29-17-11|17|585|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-17|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|242 records survival 855 ± 11 lifespan study|1003-29-17-12|17|587|n/a|n/a|n/a|
1003-29-17|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|242 records survival 855 ± 11 lifespan study|1003-29-17-13|17|595|n/a|n/a|n/a|
1003-29-17|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|242 records survival 855 ± 11 lifespan study|1003-29-17-14|17|599|n/a|n/a|n/a|
1003-29-17|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|242 records survival 855 ± 11 lifespan study|1003-29-17-15|17|611|n/a|n/a|n/a|
1003-29-17|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|242 records survival 855 ± 11 lifespan study|1003-29-17-16|17|612|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-17|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|242 records survival 855 ± 11 lifespan study|1003-29-17-17|17|614|n/a|n/a|n/a|
1003-29-17|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|242 records survival 855 ± 11 lifespan study|1003-29-17-18|17|616|n/a|n/a|n/a|
1003-29-17|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|242 records survival 855 ± 11 lifespan study|1003-29-17-19|17|640|n/a|n/a|n/a|
1003-29-17|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|242 records survival 855 ± 11 lifespan study|1003-29-17-20|17|656|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-17|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|242 records survival 855 ± 11 lifespan study|1003-29-17-21|17|659|n/a|n/a|n/a|
1003-29-17|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|242 records survival 855 ± 11 lifespan study|1003-29-17-22|17|663|n/a|n/a|n/a|
1003-29-17|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|242 records survival 855 ± 11 lifespan study|1003-29-17-23|17|699|n/a|n/a|n/a|
1003-29-17|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|242 records survival 855 ± 11 lifespan study|1003-29-17-24|17|700|n/a|n/a|n/a|
1003-29-17|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|242 records survival 855 ± 11 lifespan study|1003-29-17-25|17|712|n/a|n/a|n/a|
1003-29-17|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|242 records survival 855 ± 11 lifespan study|1003-29-17-26|17|718|Neoplasia malignant|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|THVS/  ,MPATH: 242 - hemangiosarcoma|
1003-29-17|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|242 records survival 855 ± 11 lifespan study|1003-29-17-27|17|724|Neoplasia unclassified|Integumentary system,MA: 0000151 - skin|TSEC/ jaw. Metastases  Muscle tsec invasion of jaw muscle. Metastases Lung,MPATH: 218 - neoplasm|
1003-29-17|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|242 records survival 855 ± 11 lifespan study|1003-29-17-28|17|726|n/a|n/a|n/a|
1003-29-17|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|242 records survival 855 ± 11 lifespan study|1003-29-17-29|17|727|n/a|n/a|n/a|
1003-29-17|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|242 records survival 855 ± 11 lifespan study|1003-29-17-30|17|727|n/a|n/a|n/a|
1003-29-17|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|242 records survival 855 ± 11 lifespan study|1003-29-17-31|17|730|n/a|n/a|n/a|
1003-29-17|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|242 records survival 855 ± 11 lifespan study|1003-29-17-32|17|731|n/a|n/a|n/a|
1003-29-17|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|242 records survival 855 ± 11 lifespan study|1003-29-17-33|17|737|n/a|n/a|n/a|
1003-29-17|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|242 records survival 855 ± 11 lifespan study|1003-29-17-34|17|737|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-17|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|242 records survival 855 ± 11 lifespan study|1003-29-17-35|17|738|n/a|n/a|n/a|
1003-29-17|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|242 records survival 855 ± 11 lifespan study|1003-29-17-36|17|743|n/a|n/a|n/a|
1003-29-17|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|242 records survival 855 ± 11 lifespan study|1003-29-17-37|17|754|n/a|n/a|n/a|
1003-29-17|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|242 records survival 855 ± 11 lifespan study|1003-29-17-38|17|757|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  Eye(s) missing Head/neck missing,MPATH: 513 - Lymphoid neoplasms|
1003-29-17|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|242 records survival 855 ± 11 lifespan study|1003-29-17-39|17|763|n/a|n/a|n/a|
1003-29-17|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|242 records survival 855 ± 11 lifespan study|1003-29-17-40|17|765|n/a|n/a|n/a|
1003-29-17|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|242 records survival 855 ± 11 lifespan study|1003-29-17-41|17|768|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases Heart Metastases  trac invades mediastinum.,MPATH: 268 - adenocarcinoma|
1003-29-17|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|242 records survival 855 ± 11 lifespan study|1003-29-17-42|17|782|n/a|n/a|n/a|
1003-29-17|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|242 records survival 855 ± 11 lifespan study|1003-29-17-43|17|788|n/a|n/a|n/a|
1003-29-17|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|242 records survival 855 ± 11 lifespan study|1003-29-17-44|17|792|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-17|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|242 records survival 855 ± 11 lifespan study|1003-29-17-45|17|799|n/a|n/a|n/a|
1003-29-17|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|242 records survival 855 ± 11 lifespan study|1003-29-17-46|17|801|n/a|n/a|n/a|
1003-29-17|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|242 records survival 855 ± 11 lifespan study|1003-29-17-47|17|802|Other deterministic changes|Whole body|MCDU/|
1003-29-17|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|242 records survival 855 ± 11 lifespan study|1003-29-17-48|17|805|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-17|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|242 records survival 855 ± 11 lifespan study|1003-29-17-49|17|816|n/a|n/a|n/a|
1003-29-17|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|242 records survival 855 ± 11 lifespan study|1003-29-17-50|17|817|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/   Metastases Lung,MPATH: 513 - Lymphoid neoplasms|
1003-29-17|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|242 records survival 855 ± 11 lifespan study|1003-29-17-51|17|817|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-17|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|242 records survival 855 ± 11 lifespan study|1003-29-17-52|17|820|n/a|n/a|n/a|
1003-29-17|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|242 records survival 855 ± 11 lifespan study|1003-29-17-53|17|822|n/a|n/a|n/a|
1003-29-17|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|242 records survival 855 ± 11 lifespan study|1003-29-17-54|17|822|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-17|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|242 records survival 855 ± 11 lifespan study|1003-29-17-55|17|827|n/a|n/a|n/a|
1003-29-17|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|242 records survival 855 ± 11 lifespan study|1003-29-17-56|17|830|Neoplasia unclassified|Other local manifestations and miscellaneus|TMWG: TGAC INVADES SKIN AND MUSCLE OF HEAD.|
1003-29-17|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|242 records survival 855 ± 11 lifespan study|1003-29-17-57|17|831|n/a|n/a|n/a|
1003-29-17|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|242 records survival 855 ± 11 lifespan study|1003-29-17-58|17|832|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-17|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|242 records survival 855 ± 11 lifespan study|1003-29-17-59|17|835|n/a|n/a|n/a|
1003-29-17|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|242 records survival 855 ± 11 lifespan study|1003-29-17-60|17|836|n/a|n/a|n/a|
1003-29-17|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|242 records survival 855 ± 11 lifespan study|1003-29-17-61|17|836|Neoplasia unclassified|Other local manifestations and miscellaneus|TXWR: TRAC TO PLEURA.|
1003-29-17|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|242 records survival 855 ± 11 lifespan study|1003-29-17-62|17|842|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/   Metastases  trac to pleura.,MPATH: 513 - Lymphoid neoplasms|
1003-29-17|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|242 records survival 855 ± 11 lifespan study|1003-29-17-63|17|844|Neoplasia unclassified|Other local manifestations and miscellaneus|TMWC: TCVS OF THIGH INVAS OF SKEL MUSC.|
1003-29-17|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|242 records survival 855 ± 11 lifespan study|1003-29-17-64|17|849|n/a|n/a|n/a|
1003-29-17|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|242 records survival 855 ± 11 lifespan study|1003-29-17-65|17|850|n/a|n/a|n/a|
1003-29-17|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|242 records survival 855 ± 11 lifespan study|1003-29-17-66|17|853|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-17|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|242 records survival 855 ± 11 lifespan study|1003-29-17-67|17|857|n/a|n/a|n/a|
1003-29-17|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|242 records survival 855 ± 11 lifespan study|1003-29-17-68|17|860|n/a|n/a|n/a|
1003-29-17|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|242 records survival 855 ± 11 lifespan study|1003-29-17-69|17|860|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-17|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|242 records survival 855 ± 11 lifespan study|1003-29-17-70|17|862|n/a|n/a|n/a|
1003-29-17|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|242 records survival 855 ± 11 lifespan study|1003-29-17-71|17|863|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/  Eye(s) missing,MPATH: 242 - hemangiosarcoma|
1003-29-17|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|242 records survival 855 ± 11 lifespan study|1003-29-17-72|17|864|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-17|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|242 records survival 855 ± 11 lifespan study|1003-29-17-73|17|868|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-29-17|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|242 records survival 855 ± 11 lifespan study|1003-29-17-74|17|868|Neoplasia malignant|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|THVS/  ,MPATH: 242 - hemangiosarcoma|
1003-29-17|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|242 records survival 855 ± 11 lifespan study|1003-29-17-75|17|870|Hyperplastic changes|Cardiovascular system|MPAN/  Polyarteritis nodosa|
1003-29-17|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|242 records survival 855 ± 11 lifespan study|1003-29-17-76|17|872|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-17|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|242 records survival 855 ± 11 lifespan study|1003-29-17-77|17|873|n/a|n/a|n/a|
1003-29-17|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|242 records survival 855 ± 11 lifespan study|1003-29-17-78|17|873|n/a|n/a|n/a|
1003-29-17|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|242 records survival 855 ± 11 lifespan study|1003-29-17-79|17|875|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-17|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|242 records survival 855 ± 11 lifespan study|1003-29-17-80|17|876|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-17|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|242 records survival 855 ± 11 lifespan study|1003-29-17-81|17|878|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/  ,MPATH: 242 - hemangiosarcoma|
1003-29-17|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|242 records survival 855 ± 11 lifespan study|1003-29-17-82|17|880|n/a|n/a|n/a|
1003-29-17|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|242 records survival 855 ± 11 lifespan study|1003-29-17-83|17|883|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/  ,MPATH: 242 - hemangiosarcoma|
1003-29-17|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|242 records survival 855 ± 11 lifespan study|1003-29-17-84|17|885|Neoplasia unclassified|Other local manifestations and miscellaneus|TMWC: TCFS INVAS OF SKEL MUSC.|
1003-29-17|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|242 records survival 855 ± 11 lifespan study|1003-29-17-85|17|888|n/a|n/a|n/a|
1003-29-17|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|242 records survival 855 ± 11 lifespan study|1003-29-17-86|17|892|n/a|n/a|n/a|
1003-29-17|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|242 records survival 855 ± 11 lifespan study|1003-29-17-87|17|892|n/a|n/a|n/a|
1003-29-17|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|242 records survival 855 ± 11 lifespan study|1003-29-17-88|17|894|n/a|n/a|n/a|
1003-29-17|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|242 records survival 855 ± 11 lifespan study|1003-29-17-89|17|895|n/a|n/a|n/a|
1003-29-17|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|242 records survival 855 ± 11 lifespan study|1003-29-17-90|17|898|n/a|n/a|n/a|
1003-29-17|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|242 records survival 855 ± 11 lifespan study|1003-29-17-91|17|899|n/a|n/a|n/a|
1003-29-17|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|242 records survival 855 ± 11 lifespan study|1003-29-17-92|17|901|n/a|n/a|n/a|
1003-29-17|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|242 records survival 855 ± 11 lifespan study|1003-29-17-93|17|904|Neoplasia unclassified|Other local manifestations and miscellaneus|TMWC: TCVS OF THIGH INVAS OF SKEL MUSC.|
1003-29-17|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|242 records survival 855 ± 11 lifespan study|1003-29-17-94|17|905|n/a|n/a|n/a|
1003-29-17|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|242 records survival 855 ± 11 lifespan study|1003-29-17-95|17|905|n/a|n/a|n/a|
1003-29-17|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|242 records survival 855 ± 11 lifespan study|1003-29-17-96|17|906|Neoplasia unclassified|Other local manifestations and miscellaneus|TMWC: TCFS INVAS OF SKEL MUSC.|
1003-29-17|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|242 records survival 855 ± 11 lifespan study|1003-29-17-97|17|908|n/a|n/a|n/a|
1003-29-17|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|242 records survival 855 ± 11 lifespan study|1003-29-17-98|17|910|n/a|n/a|n/a|
1003-29-17|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|242 records survival 855 ± 11 lifespan study|1003-29-17-99|17|913|n/a|n/a|n/a|
1003-29-17|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|242 records survival 855 ± 11 lifespan study|1003-29-17-100|17|917|n/a|n/a|n/a|
1003-29-17|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|242 records survival 855 ± 11 lifespan study|1003-29-17-101|17|917|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  Head/neck missing,MPATH: 513 - Lymphoid neoplasms|
1003-29-17|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|242 records survival 855 ± 11 lifespan study|1003-29-17-102|17|919|Neoplasia unclassified|Other local manifestations and miscellaneus|TMWS: TSEC INVASION OF JAW MUSCLE.|
1003-29-17|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|242 records survival 855 ± 11 lifespan study|1003-29-17-103|17|922|n/a|n/a|n/a|
1003-29-17|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|242 records survival 855 ± 11 lifespan study|1003-29-17-104|17|923|n/a|n/a|n/a|
1003-29-17|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|242 records survival 855 ± 11 lifespan study|1003-29-17-105|17|924|n/a|n/a|n/a|
1003-29-17|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|242 records survival 855 ± 11 lifespan study|1003-29-17-106|17|930|n/a|n/a|n/a|
1003-29-17|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|242 records survival 855 ± 11 lifespan study|1003-29-17-107|17|932|n/a|n/a|n/a|
1003-29-17|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|242 records survival 855 ± 11 lifespan study|1003-29-17-108|17|934|n/a|n/a|n/a|
1003-29-17|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|242 records survival 855 ± 11 lifespan study|1003-29-17-109|17|935|n/a|n/a|n/a|
1003-29-17|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|242 records survival 855 ± 11 lifespan study|1003-29-17-110|17|936|n/a|n/a|n/a|
1003-29-17|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|242 records survival 855 ± 11 lifespan study|1003-29-17-111|17|938|n/a|n/a|n/a|
1003-29-17|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|242 records survival 855 ± 11 lifespan study|1003-29-17-112|17|939|Neoplasia unclassified|Other local manifestations and miscellaneus|TLWG: TGAC INVAS PT LN.|
1003-29-17|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|242 records survival 855 ± 11 lifespan study|1003-29-17-113|17|940|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-17|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|242 records survival 855 ± 11 lifespan study|1003-29-17-114|17|940|Other deterministic changes|Whole body|MCDU/|
1003-29-17|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|242 records survival 855 ± 11 lifespan study|1003-29-17-115|17|941|n/a|n/a|n/a|
1003-29-17|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|242 records survival 855 ± 11 lifespan study|1003-29-17-116|17|944|n/a|n/a|n/a|
1003-29-17|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|242 records survival 855 ± 11 lifespan study|1003-29-17-117|17|946|n/a|n/a|n/a|
1003-29-17|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|242 records survival 855 ± 11 lifespan study|1003-29-17-118|17|948|n/a|n/a|n/a|
1003-29-17|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|242 records survival 855 ± 11 lifespan study|1003-29-17-119|17|949|Neoplasia unclassified|Other local manifestations and miscellaneus|TMWG: TGAC INFILTRATION OF SKEL. MUSCLE.|
1003-29-17|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|242 records survival 855 ± 11 lifespan study|1003-29-17-120|17|954|n/a|n/a|n/a|
1003-29-17|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|242 records survival 855 ± 11 lifespan study|1003-29-17-121|17|960|Neoplasia malignant|Endocrine system|TGAC/   Metastases  Muscle tgac infiltration of skel. muscle.|
1003-29-17|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|242 records survival 855 ± 11 lifespan study|1003-29-17-122|17|960|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-17|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|242 records survival 855 ± 11 lifespan study|1003-29-17-123|17|961|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-17|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|242 records survival 855 ± 11 lifespan study|1003-29-17-124|17|962|n/a|n/a|n/a|
1003-29-17|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|242 records survival 855 ± 11 lifespan study|1003-29-17-125|17|963|n/a|n/a|n/a|
1003-29-17|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|242 records survival 855 ± 11 lifespan study|1003-29-17-126|17|964|n/a|n/a|n/a|
1003-29-17|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|242 records survival 855 ± 11 lifespan study|1003-29-17-127|17|964|n/a|n/a|n/a|
1003-29-17|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|242 records survival 855 ± 11 lifespan study|1003-29-17-128|17|968|n/a|n/a|n/a|
1003-29-17|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|242 records survival 855 ± 11 lifespan study|1003-29-17-129|17|968|n/a|n/a|n/a|
1003-29-17|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|242 records survival 855 ± 11 lifespan study|1003-29-17-130|17|969|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-17|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|242 records survival 855 ± 11 lifespan study|1003-29-17-131|17|969|Neoplasia unclassified|Other local manifestations and miscellaneus|TMWG: TGAC INVADES SKIN AND MUSCLE OF HEAD.|
1003-29-17|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|242 records survival 855 ± 11 lifespan study|1003-29-17-132|17|971|n/a|n/a|n/a|
1003-29-17|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|242 records survival 855 ± 11 lifespan study|1003-29-17-133|17|975|n/a|n/a|n/a|
1003-29-17|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|242 records survival 855 ± 11 lifespan study|1003-29-17-134|17|978|n/a|n/a|n/a|
1003-29-17|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|242 records survival 855 ± 11 lifespan study|1003-29-17-135|17|978|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-17|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|242 records survival 855 ± 11 lifespan study|1003-29-17-136|17|978|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-29-17|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|242 records survival 855 ± 11 lifespan study|1003-29-17-137|17|980|n/a|n/a|n/a|
1003-29-17|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|242 records survival 855 ± 11 lifespan study|1003-29-17-138|17|980|n/a|n/a|n/a|
1003-29-17|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|242 records survival 855 ± 11 lifespan study|1003-29-17-139|17|982|n/a|n/a|n/a|
1003-29-17|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|242 records survival 855 ± 11 lifespan study|1003-29-17-140|17|982|Neoplasia systemic|Haematolymphatic system|TLML/|
1003-29-17|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|242 records survival 855 ± 11 lifespan study|1003-29-17-141|17|982|n/a|n/a|n/a|
1003-29-17|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|242 records survival 855 ± 11 lifespan study|1003-29-17-142|17|983|n/a|n/a|n/a|
1003-29-17|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|242 records survival 855 ± 11 lifespan study|1003-29-17-143|17|987|n/a|n/a|n/a|
1003-29-17|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|242 records survival 855 ± 11 lifespan study|1003-29-17-144|17|988|Neoplasia malignant|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|THVS/  ,MPATH: 242 - hemangiosarcoma|
1003-29-17|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|242 records survival 855 ± 11 lifespan study|1003-29-17-145|17|989|n/a|n/a|n/a|
1003-29-17|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|242 records survival 855 ± 11 lifespan study|1003-29-17-146|17|992|Neoplasia unclassified|Other local manifestations and miscellaneus|TXWR: TRAC TO PLEURA.|
1003-29-17|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|242 records survival 855 ± 11 lifespan study|1003-29-17-147|17|993|n/a|n/a|n/a|
1003-29-17|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|242 records survival 855 ± 11 lifespan study|1003-29-17-148|17|996|n/a|n/a|n/a|
1003-29-17|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|242 records survival 855 ± 11 lifespan study|1003-29-17-149|17|997|n/a|n/a|n/a|
1003-29-17|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|242 records survival 855 ± 11 lifespan study|1003-29-17-150|17|997|Other deterministic changes|Whole body|MCDU/|
1003-29-17|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|242 records survival 855 ± 11 lifespan study|1003-29-17-151|17|998|Neoplasia unclassified|Other local manifestations and miscellaneus|TMWG: TGAC INVADES SKIN AND MUSCLE OF HEAD.|
1003-29-17|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|242 records survival 855 ± 11 lifespan study|1003-29-17-152|17|998|n/a|n/a|n/a|
1003-29-17|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|242 records survival 855 ± 11 lifespan study|1003-29-17-153|17|1002|n/a|n/a|n/a|
1003-29-17|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|242 records survival 855 ± 11 lifespan study|1003-29-17-154|17|1002|Neoplasia malignant|Bloodvessels among cardiovascular system|TCVS/ rt thigh|
1003-29-17|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|242 records survival 855 ± 11 lifespan study|1003-29-17-155|17|1003|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases  trac to pleura & mediastinum.,MPATH: 268 - adenocarcinoma|
1003-29-17|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|242 records survival 855 ± 11 lifespan study|1003-29-17-156|17|1003|n/a|n/a|n/a|
1003-29-17|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|242 records survival 855 ± 11 lifespan study|1003-29-17-157|17|1007|n/a|n/a|n/a|
1003-29-17|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|242 records survival 855 ± 11 lifespan study|1003-29-17-158|17|1009|n/a|n/a|n/a|
1003-29-17|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|242 records survival 855 ± 11 lifespan study|1003-29-17-159|17|1009|n/a|n/a|n/a|
1003-29-17|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|242 records survival 855 ± 11 lifespan study|1003-29-17-160|17|1011|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  Head/neck missing,MPATH: 513 - Lymphoid neoplasms|
1003-29-17|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|242 records survival 855 ± 11 lifespan study|1003-29-17-161|17|1012|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-17|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|242 records survival 855 ± 11 lifespan study|1003-29-17-162|17|1013|Neoplasia unclassified|Other local manifestations and miscellaneus|TXWR: TRAC TO PLEURA.|
1003-29-17|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|242 records survival 855 ± 11 lifespan study|1003-29-17-163|17|1014|n/a|n/a|n/a|
1003-29-17|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|242 records survival 855 ± 11 lifespan study|1003-29-17-164|17|1015|n/a|n/a|n/a|
1003-29-17|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|242 records survival 855 ± 11 lifespan study|1003-29-17-165|17|1025|n/a|n/a|n/a|
1003-29-17|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|242 records survival 855 ± 11 lifespan study|1003-29-17-166|17|1026|n/a|n/a|n/a|
1003-29-17|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|242 records survival 855 ± 11 lifespan study|1003-29-17-167|17|1026|n/a|n/a|n/a|
1003-29-17|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|242 records survival 855 ± 11 lifespan study|1003-29-17-168|17|1028|n/a|n/a|n/a|
1003-29-17|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|242 records survival 855 ± 11 lifespan study|1003-29-17-169|17|1031|n/a|n/a|n/a|
1003-29-17|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|242 records survival 855 ± 11 lifespan study|1003-29-17-170|17|1032|Neoplasia malignant|Endocrine system|TGAC/   Metastases Lung Metastases  Lymphoret.System tgac invas pt ln. Metastases  tgac invas rib cage perit. Metastases  Muscle tgac invas of musc of head.|
1003-29-17|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|242 records survival 855 ± 11 lifespan study|1003-29-17-171|17|1037|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-17|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|242 records survival 855 ± 11 lifespan study|1003-29-17-172|17|1038|n/a|n/a|n/a|
1003-29-17|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|242 records survival 855 ± 11 lifespan study|1003-29-17-173|17|1041|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-17|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|242 records survival 855 ± 11 lifespan study|1003-29-17-174|17|1041|Other deterministic changes|Whole body|MCDU/  Eye(s) missing Head/neck missing|
1003-29-17|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|242 records survival 855 ± 11 lifespan study|1003-29-17-175|17|1044|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|TCFS/ lt axillary region. Metastases  Muscle tcfs invas of skel musc.,MPATH: 408 - soft tissue fibrosarcoma|
1003-29-17|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|242 records survival 855 ± 11 lifespan study|1003-29-17-176|17|1045|n/a|n/a|n/a|
1003-29-17|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|242 records survival 855 ± 11 lifespan study|1003-29-17-177|17|1046|n/a|n/a|n/a|
1003-29-17|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|242 records survival 855 ± 11 lifespan study|1003-29-17-178|17|1048|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-17|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|242 records survival 855 ± 11 lifespan study|1003-29-17-179|17|1054|n/a|n/a|n/a|
1003-29-17|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|242 records survival 855 ± 11 lifespan study|1003-29-17-180|17|1056|n/a|n/a|n/a|
1003-29-17|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|242 records survival 855 ± 11 lifespan study|1003-29-17-181|17|1057|n/a|n/a|n/a|
1003-29-17|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|242 records survival 855 ± 11 lifespan study|1003-29-17-182|17|1060|n/a|n/a|n/a|
1003-29-17|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|242 records survival 855 ± 11 lifespan study|1003-29-17-183|17|1068|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-17|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|242 records survival 855 ± 11 lifespan study|1003-29-17-184|17|1068|n/a|n/a|n/a|
1003-29-17|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|242 records survival 855 ± 11 lifespan study|1003-29-17-185|17|1071|n/a|n/a|n/a|
1003-29-17|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|242 records survival 855 ± 11 lifespan study|1003-29-17-186|17|1073|Neoplasia malignant|Endocrine system|MHCY/ TGAC/ MHCY/ TGAC/   Metastases  Muscle tgac invades skin and muscle of head.|
1003-29-17|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|242 records survival 855 ± 11 lifespan study|1003-29-17-187|17|1076|n/a|n/a|n/a|
1003-29-17|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|242 records survival 855 ± 11 lifespan study|1003-29-17-188|17|1076|n/a|n/a|n/a|
1003-29-17|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|242 records survival 855 ± 11 lifespan study|1003-29-17-189|17|1079|n/a|n/a|n/a|
1003-29-17|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|242 records survival 855 ± 11 lifespan study|1003-29-17-190|17|1081|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-17|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|242 records survival 855 ± 11 lifespan study|1003-29-17-191|17|1083|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRVS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-17|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|242 records survival 855 ± 11 lifespan study|1003-29-17-192|17|1084|n/a|n/a|n/a|
1003-29-17|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|242 records survival 855 ± 11 lifespan study|1003-29-17-193|17|1086|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-17|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|242 records survival 855 ± 11 lifespan study|1003-29-17-194|17|1086|Other deterministic changes|Whole body|MCDU/|
1003-29-17|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|242 records survival 855 ± 11 lifespan study|1003-29-17-195|17|1089|n/a|n/a|n/a|
1003-29-17|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|242 records survival 855 ± 11 lifespan study|1003-29-17-196|17|1096|n/a|n/a|n/a|
1003-29-17|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|242 records survival 855 ± 11 lifespan study|1003-29-17-197|17|1097|n/a|n/a|n/a|
1003-29-17|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|242 records survival 855 ± 11 lifespan study|1003-29-17-198|17|1099|Hyperplastic changes|Cardiovascular system|MPAN/  Polyarteritis nodosa Metastases  Muscle tcvs of thigh invas of skel musc.|
1003-29-17|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|242 records survival 855 ± 11 lifespan study|1003-29-17-199|17|1103|n/a|n/a|n/a|
1003-29-17|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|242 records survival 855 ± 11 lifespan study|1003-29-17-200|17|1107|n/a|n/a|n/a|
1003-29-17|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|242 records survival 855 ± 11 lifespan study|1003-29-17-201|17|1113|n/a|n/a|n/a|
1003-29-17|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|242 records survival 855 ± 11 lifespan study|1003-29-17-202|17|1115|Neoplasia benign|Liver among hepato-pancreatic system diseases|THAA/|
1003-29-17|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|242 records survival 855 ± 11 lifespan study|1003-29-17-203|17|1117|n/a|n/a|n/a|
1003-29-17|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|242 records survival 855 ± 11 lifespan study|1003-29-17-204|17|1118|n/a|n/a|n/a|
1003-29-17|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|242 records survival 855 ± 11 lifespan study|1003-29-17-205|17|1122|n/a|n/a|n/a|
1003-29-17|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|242 records survival 855 ± 11 lifespan study|1003-29-17-206|17|1125|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-17|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|242 records survival 855 ± 11 lifespan study|1003-29-17-207|17|1127|n/a|n/a|n/a|
1003-29-17|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|242 records survival 855 ± 11 lifespan study|1003-29-17-208|17|1131|n/a|n/a|n/a|
1003-29-17|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|242 records survival 855 ± 11 lifespan study|1003-29-17-209|17|1134|n/a|n/a|n/a|
1003-29-17|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|242 records survival 855 ± 11 lifespan study|1003-29-17-210|17|1134|Neoplasia unclassified|Other local manifestations and miscellaneus|TXWR: TRAC TO PLEURA & MEDIASTINUM.|
1003-29-17|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|242 records survival 855 ± 11 lifespan study|1003-29-17-211|17|1135|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-17|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|242 records survival 855 ± 11 lifespan study|1003-29-17-212|17|1135|n/a|n/a|n/a|
1003-29-17|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|242 records survival 855 ± 11 lifespan study|1003-29-17-213|17|1137|n/a|n/a|n/a|
1003-29-17|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|242 records survival 855 ± 11 lifespan study|1003-29-17-214|17|1137|n/a|n/a|n/a|
1003-29-17|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|242 records survival 855 ± 11 lifespan study|1003-29-17-215|17|1138|n/a|n/a|n/a|
1003-29-17|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|242 records survival 855 ± 11 lifespan study|1003-29-17-216|17|1143|n/a|n/a|n/a|
1003-29-17|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|242 records survival 855 ± 11 lifespan study|1003-29-17-217|17|1143|n/a|n/a|n/a|
1003-29-17|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|242 records survival 855 ± 11 lifespan study|1003-29-17-218|17|1145|n/a|n/a|n/a|
1003-29-17|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|242 records survival 855 ± 11 lifespan study|1003-29-17-219|17|1146|n/a|n/a|n/a|
1003-29-17|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|242 records survival 855 ± 11 lifespan study|1003-29-17-220|17|1148|n/a|n/a|n/a|
1003-29-17|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|242 records survival 855 ± 11 lifespan study|1003-29-17-221|17|1159|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-17|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|242 records survival 855 ± 11 lifespan study|1003-29-17-222|17|1162|n/a|n/a|n/a|
1003-29-17|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|242 records survival 855 ± 11 lifespan study|1003-29-17-223|17|1164|Neoplasia unclassified|Other local manifestations and miscellaneus|TXWR: TRAC TO VISC. PLEURA OF LUNG.|
1003-29-17|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|242 records survival 855 ± 11 lifespan study|1003-29-17-224|17|1165|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  Eye(s) missing Head/neck missing,MPATH: 513 - Lymphoid neoplasms|
1003-29-17|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|242 records survival 855 ± 11 lifespan study|1003-29-17-225|17|1165|n/a|n/a|n/a|
1003-29-17|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|242 records survival 855 ± 11 lifespan study|1003-29-17-226|17|1167|n/a|n/a|n/a|
1003-29-17|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|242 records survival 855 ± 11 lifespan study|1003-29-17-227|17|1182|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-17|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|242 records survival 855 ± 11 lifespan study|1003-29-17-228|17|1184|n/a|n/a|n/a|
1003-29-17|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|242 records survival 855 ± 11 lifespan study|1003-29-17-229|17|1192|Other deterministic changes|Whole body|MCDU/|
1003-29-17|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|242 records survival 855 ± 11 lifespan study|1003-29-17-230|17|1200|n/a|n/a|n/a|
1003-29-17|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|242 records survival 855 ± 11 lifespan study|1003-29-17-231|17|1208|n/a|n/a|n/a|
1003-29-17|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|242 records survival 855 ± 11 lifespan study|1003-29-17-232|17|1219|n/a|n/a|n/a|
1003-29-17|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|242 records survival 855 ± 11 lifespan study|1003-29-17-233|17|1233|Other deterministic changes|Whole body|MCDU/|
1003-29-17|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|242 records survival 855 ± 11 lifespan study|1003-29-17-234|17|1240|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-17|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|242 records survival 855 ± 11 lifespan study|1003-29-17-235|17|1247|n/a|n/a|n/a|
1003-29-17|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|242 records survival 855 ± 11 lifespan study|1003-29-17-236|17|1249|n/a|n/a|n/a|
1003-29-17|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|242 records survival 855 ± 11 lifespan study|1003-29-17-237|17|1257|n/a|n/a|n/a|
1003-29-17|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|242 records survival 855 ± 11 lifespan study|1003-29-17-238|17|1268|Other deterministic changes|Whole body|MCDU/|
1003-29-17|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|242 records survival 855 ± 11 lifespan study|1003-29-17-239|17|1271|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|TKAC/  ,MPATH: 549 - carcinoma|
1003-29-17|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|242 records survival 855 ± 11 lifespan study|1003-29-17-240|17|1280|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/  ,MPATH: 242 - hemangiosarcoma|
1003-29-17|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|242 records survival 855 ± 11 lifespan study|1003-29-17-241|17|1282|Neoplasia systemic|Haematolymphatic system|TLML/|
1003-29-17|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|242 records survival 855 ± 11 lifespan study|1003-29-17-242|17|1298|n/a|n/a|n/a|
1003-29-17|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|242 records survival 855 ± 11 lifespan study|1003-29-17-243|17|1301|n/a|n/a|n/a|
1003-29-17|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|242 records survival 855 ± 11 lifespan study|1003-29-17-244|17|1333|Neoplasia systemic|Haematolymphatic system|TLML/|
1003-29-17|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|242 records survival 855 ± 11 lifespan study|1003-29-17-245|17|1346|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases  trac to visc. pleura of lung.,MPATH: 268 - adenocarcinoma|
1003-29-17|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|242 records survival 855 ± 11 lifespan study|1003-29-17-246|17|1361|Neoplasia malignant|Liver among hepato-pancreatic system diseases|THAC/|
1003-29-17|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|242 records survival 855 ± 11 lifespan study|1003-29-17-247|17|1376|Neoplasia unclassified|Other local manifestations and miscellaneus|TMWS: TSEC INVASION OF JAW MUSCLE.|
1003-29-17|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|242 records survival 855 ± 11 lifespan study|1003-29-17-248|17|1378|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-17|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|242 records survival 855 ± 11 lifespan study|1003-29-17-249|17|1387|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-17|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|242 records survival 855 ± 11 lifespan study|1003-29-17-250|17|1395|Other deterministic changes|Whole body|MCDU/|
1003-29-18|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|237 records survival 809 ± 11 lifespan study|1003-29-18-1|18|106|n/a|n/a|n/a|
1003-29-18|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|237 records survival 809 ± 11 lifespan study|1003-29-18-2|18|106|n/a|n/a|n/a|
1003-29-18|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|237 records survival 809 ± 11 lifespan study|1003-29-18-3|18|106|n/a|n/a|n/a|
1003-29-18|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|237 records survival 809 ± 11 lifespan study|1003-29-18-4|18|106|n/a|n/a|n/a|
1003-29-18|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|237 records survival 809 ± 11 lifespan study|1003-29-18-5|18|106|n/a|n/a|n/a|
1003-29-18|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|237 records survival 809 ± 11 lifespan study|1003-29-18-6|18|112|n/a|n/a|n/a|
1003-29-18|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|237 records survival 809 ± 11 lifespan study|1003-29-18-7|18|112|n/a|n/a|n/a|
1003-29-18|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|237 records survival 809 ± 11 lifespan study|1003-29-18-8|18|114|n/a|n/a|n/a|
1003-29-18|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|237 records survival 809 ± 11 lifespan study|1003-29-18-9|18|114|n/a|n/a|n/a|
1003-29-18|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|237 records survival 809 ± 11 lifespan study|1003-29-18-10|18|114|n/a|n/a|n/a|
1003-29-18|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|237 records survival 809 ± 11 lifespan study|1003-29-18-11|18|114|n/a|n/a|n/a|
1003-29-18|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|237 records survival 809 ± 11 lifespan study|1003-29-18-12|18|114|n/a|n/a|n/a|
1003-29-18|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|237 records survival 809 ± 11 lifespan study|1003-29-18-13|18|306|Other deterministic changes|Whole body|MCDU/|
1003-29-18|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|237 records survival 809 ± 11 lifespan study|1003-29-18-14|18|526|Neoplasia malignant|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|THVS/  ,MPATH: 242 - hemangiosarcoma|
1003-29-18|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|237 records survival 809 ± 11 lifespan study|1003-29-18-15|18|527|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-18|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|237 records survival 809 ± 11 lifespan study|1003-29-18-16|18|533|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-29-18|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|237 records survival 809 ± 11 lifespan study|1003-29-18-17|18|534|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-18|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|237 records survival 809 ± 11 lifespan study|1003-29-18-18|18|564|Neoplasia malignant|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|THVS/  ,MPATH: 242 - hemangiosarcoma|
1003-29-18|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|237 records survival 809 ± 11 lifespan study|1003-29-18-19|18|568|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-18|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|237 records survival 809 ± 11 lifespan study|1003-29-18-20|18|591|Inflammation and/or fibrotic diseases|Other local manifestations and miscellaneus|MMTA/  Metritis|
1003-29-18|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|237 records survival 809 ± 11 lifespan study|1003-29-18-21|18|591|n/a|n/a|n/a|
1003-29-18|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|237 records survival 809 ± 11 lifespan study|1003-29-18-22|18|592|n/a|n/a|n/a|
1003-29-18|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|237 records survival 809 ± 11 lifespan study|1003-29-18-23|18|601|Other deterministic changes|Whole body|MCDU/|
1003-29-18|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|237 records survival 809 ± 11 lifespan study|1003-29-18-24|18|607|n/a|n/a|n/a|
1003-29-18|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|237 records survival 809 ± 11 lifespan study|1003-29-18-25|18|611|n/a|n/a|n/a|
1003-29-18|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|237 records survival 809 ± 11 lifespan study|1003-29-18-26|18|611|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-18|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|237 records survival 809 ± 11 lifespan study|1003-29-18-27|18|629|n/a|n/a|n/a|
1003-29-18|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|237 records survival 809 ± 11 lifespan study|1003-29-18-28|18|644|n/a|n/a|n/a|
1003-29-18|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|237 records survival 809 ± 11 lifespan study|1003-29-18-29|18|653|n/a|n/a|n/a|
1003-29-18|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|237 records survival 809 ± 11 lifespan study|1003-29-18-30|18|666|n/a|n/a|n/a|
1003-29-18|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|237 records survival 809 ± 11 lifespan study|1003-29-18-31|18|666|n/a|n/a|n/a|
1003-29-18|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|237 records survival 809 ± 11 lifespan study|1003-29-18-32|18|667|n/a|n/a|n/a|
1003-29-18|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|237 records survival 809 ± 11 lifespan study|1003-29-18-33|18|679|n/a|n/a|n/a|
1003-29-18|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|237 records survival 809 ± 11 lifespan study|1003-29-18-34|18|679|n/a|n/a|n/a|
1003-29-18|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|237 records survival 809 ± 11 lifespan study|1003-29-18-35|18|680|n/a|n/a|n/a|
1003-29-18|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|237 records survival 809 ± 11 lifespan study|1003-29-18-36|18|689|n/a|n/a|n/a|
1003-29-18|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|237 records survival 809 ± 11 lifespan study|1003-29-18-37|18|698|n/a|n/a|n/a|
1003-29-18|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|237 records survival 809 ± 11 lifespan study|1003-29-18-38|18|699|Other deterministic changes|Whole body|MCDU/|
1003-29-18|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|237 records survival 809 ± 11 lifespan study|1003-29-18-39|18|703|n/a|n/a|n/a|
1003-29-18|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|237 records survival 809 ± 11 lifespan study|1003-29-18-40|18|708|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-18|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|237 records survival 809 ± 11 lifespan study|1003-29-18-41|18|720|n/a|n/a|n/a|
1003-29-18|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|237 records survival 809 ± 11 lifespan study|1003-29-18-42|18|721|n/a|n/a|n/a|
1003-29-18|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|237 records survival 809 ± 11 lifespan study|1003-29-18-43|18|722|n/a|n/a|n/a|
1003-29-18|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|237 records survival 809 ± 11 lifespan study|1003-29-18-44|18|724|n/a|n/a|n/a|
1003-29-18|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|237 records survival 809 ± 11 lifespan study|1003-29-18-45|18|726|n/a|n/a|n/a|
1003-29-18|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|237 records survival 809 ± 11 lifespan study|1003-29-18-46|18|727|n/a|n/a|n/a|
1003-29-18|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|237 records survival 809 ± 11 lifespan study|1003-29-18-47|18|727|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-18|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|237 records survival 809 ± 11 lifespan study|1003-29-18-48|18|730|n/a|n/a|n/a|
1003-29-18|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|237 records survival 809 ± 11 lifespan study|1003-29-18-49|18|732|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-18|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|237 records survival 809 ± 11 lifespan study|1003-29-18-50|18|738|n/a|n/a|n/a|
1003-29-18|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|237 records survival 809 ± 11 lifespan study|1003-29-18-51|18|738|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|TCFS/ subcutis of right forelim. Metastases  tcfs in mediastinal tissues at base of heart.,MPATH: 408 - soft tissue fibrosarcoma|
1003-29-18|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|237 records survival 809 ± 11 lifespan study|1003-29-18-52|18|741|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-18|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|237 records survival 809 ± 11 lifespan study|1003-29-18-53|18|742|n/a|n/a|n/a|
1003-29-18|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|237 records survival 809 ± 11 lifespan study|1003-29-18-54|18|743|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/   Metastases  Muscle tcfs in intercostal muscles.,MPATH: 513 - Lymphoid neoplasms|
1003-29-18|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|237 records survival 809 ± 11 lifespan study|1003-29-18-55|18|744|n/a|n/a|n/a|
1003-29-18|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|237 records survival 809 ± 11 lifespan study|1003-29-18-56|18|746|n/a|n/a|n/a|
1003-29-18|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|237 records survival 809 ± 11 lifespan study|1003-29-18-57|18|747|n/a|n/a|n/a|
1003-29-18|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|237 records survival 809 ± 11 lifespan study|1003-29-18-58|18|749|n/a|n/a|n/a|
1003-29-18|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|237 records survival 809 ± 11 lifespan study|1003-29-18-59|18|749|n/a|n/a|n/a|
1003-29-18|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|237 records survival 809 ± 11 lifespan study|1003-29-18-60|18|754|n/a|n/a|n/a|
1003-29-18|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|237 records survival 809 ± 11 lifespan study|1003-29-18-61|18|767|n/a|n/a|n/a|
1003-29-18|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|237 records survival 809 ± 11 lifespan study|1003-29-18-62|18|772|n/a|n/a|n/a|
1003-29-18|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|237 records survival 809 ± 11 lifespan study|1003-29-18-63|18|778|n/a|n/a|n/a|
1003-29-18|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|237 records survival 809 ± 11 lifespan study|1003-29-18-64|18|780|n/a|n/a|n/a|
1003-29-18|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|237 records survival 809 ± 11 lifespan study|1003-29-18-65|18|780|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  Eye(s) missing Head/neck missing Thorax missing,MPATH: 513 - Lymphoid neoplasms|
1003-29-18|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|237 records survival 809 ± 11 lifespan study|1003-29-18-66|18|781|Other deterministic changes|Whole body|MCDU/|
1003-29-18|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|237 records survival 809 ± 11 lifespan study|1003-29-18-67|18|781|n/a|n/a|n/a|
1003-29-18|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|237 records survival 809 ± 11 lifespan study|1003-29-18-68|18|783|Other deterministic changes|Whole body|MCDU/|
1003-29-18|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|237 records survival 809 ± 11 lifespan study|1003-29-18-69|18|788|Neoplasia malignant|Lower digestive tract,MA: 0000328 - intestine|TIAO/ pylorus.,MPATH: 549 - carcinoma|
1003-29-18|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|237 records survival 809 ± 11 lifespan study|1003-29-18-70|18|789|n/a|n/a|n/a|
1003-29-18|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|237 records survival 809 ± 11 lifespan study|1003-29-18-71|18|790|n/a|n/a|n/a|
1003-29-18|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|237 records survival 809 ± 11 lifespan study|1003-29-18-72|18|798|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-18|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|237 records survival 809 ± 11 lifespan study|1003-29-18-73|18|798|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/  ,MPATH: 242 - hemangiosarcoma|
1003-29-18|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|237 records survival 809 ± 11 lifespan study|1003-29-18-74|18|805|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-18|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|237 records survival 809 ± 11 lifespan study|1003-29-18-75|18|806|n/a|n/a|n/a|
1003-29-18|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|237 records survival 809 ± 11 lifespan study|1003-29-18-76|18|807|n/a|n/a|n/a|
1003-29-18|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|237 records survival 809 ± 11 lifespan study|1003-29-18-77|18|810|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-18|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|237 records survival 809 ± 11 lifespan study|1003-29-18-78|18|813|n/a|n/a|n/a|
1003-29-18|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|237 records survival 809 ± 11 lifespan study|1003-29-18-79|18|817|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-18|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|237 records survival 809 ± 11 lifespan study|1003-29-18-80|18|820|n/a|n/a|n/a|
1003-29-18|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|237 records survival 809 ± 11 lifespan study|1003-29-18-81|18|826|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-18|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|237 records survival 809 ± 11 lifespan study|1003-29-18-82|18|827|n/a|n/a|n/a|
1003-29-18|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|237 records survival 809 ± 11 lifespan study|1003-29-18-83|18|832|n/a|n/a|n/a|
1003-29-18|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|237 records survival 809 ± 11 lifespan study|1003-29-18-84|18|833|n/a|n/a|n/a|
1003-29-18|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|237 records survival 809 ± 11 lifespan study|1003-29-18-85|18|836|n/a|n/a|n/a|
1003-29-18|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|237 records survival 809 ± 11 lifespan study|1003-29-18-86|18|837|n/a|n/a|n/a|
1003-29-18|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|237 records survival 809 ± 11 lifespan study|1003-29-18-87|18|841|Other deterministic changes|Whole body|MCDU/|
1003-29-18|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|237 records survival 809 ± 11 lifespan study|1003-29-18-88|18|847|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|TCFS/ subcut. in trunk. Metastases  tcfs invades visc. peritoneum of adrenal, adnexa of pancr. & kid. & pleura at hrt. base. Metastases  Skin tcfs invades dermis. Metastases  Muscle tcfs invades muscle of trunk.,MPATH: 408 - soft tissue fibrosarcoma|
1003-29-18|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|237 records survival 809 ± 11 lifespan study|1003-29-18-89|18|850|Hyperplastic changes|Other local manifestations and miscellaneus,MA: 0000003 - organ system|MOCY/  Ovary or testisEye(s) missing,MPATH: 62 - cyst|
1003-29-18|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|237 records survival 809 ± 11 lifespan study|1003-29-18-90|18|852|n/a|n/a|n/a|
1003-29-18|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|237 records survival 809 ± 11 lifespan study|1003-29-18-91|18|854|n/a|n/a|n/a|
1003-29-18|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|237 records survival 809 ± 11 lifespan study|1003-29-18-92|18|854|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  Head/neck missing Eye(s) missing,MPATH: 513 - Lymphoid neoplasms|
1003-29-18|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|237 records survival 809 ± 11 lifespan study|1003-29-18-93|18|858|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-18|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|237 records survival 809 ± 11 lifespan study|1003-29-18-94|18|860|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|TMAB/  Predominantly ductal,MPATH: 218 - neoplasm|
1003-29-18|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|237 records survival 809 ± 11 lifespan study|1003-29-18-95|18|861|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-18|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|237 records survival 809 ± 11 lifespan study|1003-29-18-96|18|861|n/a|n/a|n/a|
1003-29-18|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|237 records survival 809 ± 11 lifespan study|1003-29-18-97|18|864|n/a|n/a|n/a|
1003-29-18|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|237 records survival 809 ± 11 lifespan study|1003-29-18-98|18|865|Neoplasia malignant|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOVS/  ,MPATH: 242 - hemangiosarcoma|
1003-29-18|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|237 records survival 809 ± 11 lifespan study|1003-29-18-99|18|865|n/a|n/a|n/a|
1003-29-18|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|237 records survival 809 ± 11 lifespan study|1003-29-18-100|18|865|Neoplasia systemic|Haematolymphatic system|TLPS/|
1003-29-18|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|237 records survival 809 ± 11 lifespan study|1003-29-18-101|18|865|n/a|n/a|n/a|
1003-29-18|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|237 records survival 809 ± 11 lifespan study|1003-29-18-102|18|873|Other deterministic changes|Whole body|MCDU/|
1003-29-18|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|237 records survival 809 ± 11 lifespan study|1003-29-18-103|18|875|n/a|n/a|n/a|
1003-29-18|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|237 records survival 809 ± 11 lifespan study|1003-29-18-104|18|875|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-18|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|237 records survival 809 ± 11 lifespan study|1003-29-18-105|18|877|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  Eye(s) missing Head/neck missing,MPATH: 513 - Lymphoid neoplasms|
1003-29-18|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|237 records survival 809 ± 11 lifespan study|1003-29-18-106|18|877|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-18|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|237 records survival 809 ± 11 lifespan study|1003-29-18-107|18|878|n/a|n/a|n/a|
1003-29-18|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|237 records survival 809 ± 11 lifespan study|1003-29-18-108|18|878|n/a|n/a|n/a|
1003-29-18|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|237 records survival 809 ± 11 lifespan study|1003-29-18-109|18|878|n/a|n/a|n/a|
1003-29-18|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|237 records survival 809 ± 11 lifespan study|1003-29-18-110|18|879|n/a|n/a|n/a|
1003-29-18|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|237 records survival 809 ± 11 lifespan study|1003-29-18-111|18|886|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-18|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|237 records survival 809 ± 11 lifespan study|1003-29-18-112|18|886|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-18|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|237 records survival 809 ± 11 lifespan study|1003-29-18-113|18|888|n/a|n/a|n/a|
1003-29-18|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|237 records survival 809 ± 11 lifespan study|1003-29-18-114|18|889|n/a|n/a|n/a|
1003-29-18|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|237 records survival 809 ± 11 lifespan study|1003-29-18-115|18|890|Neoplasia malignant|Liver among hepato-pancreatic system diseases|THAC/   Metastases Lung|
1003-29-18|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|237 records survival 809 ± 11 lifespan study|1003-29-18-116|18|891|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  Eye(s) missing,MPATH: 513 - Lymphoid neoplasms|
1003-29-18|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|237 records survival 809 ± 11 lifespan study|1003-29-18-117|18|895|n/a|n/a|n/a|
1003-29-18|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|237 records survival 809 ± 11 lifespan study|1003-29-18-118|18|897|n/a|n/a|n/a|
1003-29-18|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|237 records survival 809 ± 11 lifespan study|1003-29-18-119|18|902|n/a|n/a|n/a|
1003-29-18|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|237 records survival 809 ± 11 lifespan study|1003-29-18-120|18|917|n/a|n/a|n/a|
1003-29-18|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|237 records survival 809 ± 11 lifespan study|1003-29-18-121|18|919|n/a|n/a|n/a|
1003-29-18|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|237 records survival 809 ± 11 lifespan study|1003-29-18-122|18|921|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-18|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|237 records survival 809 ± 11 lifespan study|1003-29-18-123|18|921|Neoplasia systemic|Haematolymphatic system|TLML/|
1003-29-18|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|237 records survival 809 ± 11 lifespan study|1003-29-18-124|18|926|n/a|n/a|n/a|
1003-29-18|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|237 records survival 809 ± 11 lifespan study|1003-29-18-125|18|927|n/a|n/a|n/a|
1003-29-18|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|237 records survival 809 ± 11 lifespan study|1003-29-18-126|18|929|n/a|n/a|n/a|
1003-29-18|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|237 records survival 809 ± 11 lifespan study|1003-29-18-127|18|930|n/a|n/a|n/a|
1003-29-18|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|237 records survival 809 ± 11 lifespan study|1003-29-18-128|18|933|n/a|n/a|n/a|
1003-29-18|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|237 records survival 809 ± 11 lifespan study|1003-29-18-129|18|934|n/a|n/a|n/a|
1003-29-18|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|237 records survival 809 ± 11 lifespan study|1003-29-18-130|18|934|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|TCFS/ subcut dorsal in reg of right hip.,MPATH: 408 - soft tissue fibrosarcoma|
1003-29-18|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|237 records survival 809 ± 11 lifespan study|1003-29-18-131|18|936|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-18|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|237 records survival 809 ± 11 lifespan study|1003-29-18-132|18|938|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-29-18|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|237 records survival 809 ± 11 lifespan study|1003-29-18-133|18|938|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-18|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|237 records survival 809 ± 11 lifespan study|1003-29-18-134|18|944|n/a|n/a|n/a|
1003-29-18|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|237 records survival 809 ± 11 lifespan study|1003-29-18-135|18|946|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-18|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|237 records survival 809 ± 11 lifespan study|1003-29-18-136|18|950|n/a|n/a|n/a|
1003-29-18|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|237 records survival 809 ± 11 lifespan study|1003-29-18-137|18|951|n/a|n/a|n/a|
1003-29-18|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|237 records survival 809 ± 11 lifespan study|1003-29-18-138|18|954|Neoplasia benign|Uterus among reproductive system diseases,MA: 0000389 - uterus|TUVO/  ,MPATH: 236 - angiofibroma|
1003-29-18|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|237 records survival 809 ± 11 lifespan study|1003-29-18-139|18|956|n/a|n/a|n/a|
1003-29-18|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|237 records survival 809 ± 11 lifespan study|1003-29-18-140|18|958|n/a|n/a|n/a|
1003-29-18|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|237 records survival 809 ± 11 lifespan study|1003-29-18-141|18|959|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  Eye(s) missing Head/neck missing,MPATH: 513 - Lymphoid neoplasms|
1003-29-18|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|237 records survival 809 ± 11 lifespan study|1003-29-18-142|18|959|Inflammation and/or fibrotic diseases|Lower respiratory system,MA: 0000415 - lung|MRMP/  Murine,MPATH: 212 - inflammation|
1003-29-18|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|237 records survival 809 ± 11 lifespan study|1003-29-18-143|18|961|n/a|n/a|n/a|
1003-29-18|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|237 records survival 809 ± 11 lifespan study|1003-29-18-144|18|964|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-18|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|237 records survival 809 ± 11 lifespan study|1003-29-18-145|18|964|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-18|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|237 records survival 809 ± 11 lifespan study|1003-29-18-146|18|964|n/a|n/a|n/a|
1003-29-18|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|237 records survival 809 ± 11 lifespan study|1003-29-18-147|18|964|Neoplasia malignant|Other local manifestations and miscellaneus|TMLS/ peritoneum.Eye(s) missing Head/neck missing|
1003-29-18|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|237 records survival 809 ± 11 lifespan study|1003-29-18-148|18|966|n/a|n/a|n/a|
1003-29-18|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|237 records survival 809 ± 11 lifespan study|1003-29-18-149|18|968|Neoplasia malignant|Other local manifestations and miscellaneus|TMLS/ soft tissue lt upper arm.|
1003-29-18|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|237 records survival 809 ± 11 lifespan study|1003-29-18-150|18|968|n/a|n/a|n/a|
1003-29-18|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|237 records survival 809 ± 11 lifespan study|1003-29-18-151|18|969|n/a|n/a|n/a|
1003-29-18|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|237 records survival 809 ± 11 lifespan study|1003-29-18-152|18|970|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-18|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|237 records survival 809 ± 11 lifespan study|1003-29-18-153|18|970|n/a|n/a|n/a|
1003-29-18|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|237 records survival 809 ± 11 lifespan study|1003-29-18-154|18|971|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-18|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|237 records survival 809 ± 11 lifespan study|1003-29-18-155|18|971|n/a|n/a|n/a|
1003-29-18|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|237 records survival 809 ± 11 lifespan study|1003-29-18-156|18|975|n/a|n/a|n/a|
1003-29-18|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|237 records survival 809 ± 11 lifespan study|1003-29-18-157|18|978|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-18|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|237 records survival 809 ± 11 lifespan study|1003-29-18-158|18|978|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  Head/neck missing Eye(s) missing,MPATH: 268 - adenocarcinoma|
1003-29-18|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|237 records survival 809 ± 11 lifespan study|1003-29-18-159|18|981|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/  ,MPATH: 242 - hemangiosarcoma|
1003-29-18|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|237 records survival 809 ± 11 lifespan study|1003-29-18-160|18|981|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-18|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|237 records survival 809 ± 11 lifespan study|1003-29-18-161|18|982|n/a|n/a|n/a|
1003-29-18|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|237 records survival 809 ± 11 lifespan study|1003-29-18-162|18|987|n/a|n/a|n/a|
1003-29-18|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|237 records survival 809 ± 11 lifespan study|1003-29-18-163|18|988|n/a|n/a|n/a|
1003-29-18|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|237 records survival 809 ± 11 lifespan study|1003-29-18-164|18|990|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOVO/  ,MPATH: 242 - hemangiosarcoma|
1003-29-18|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|237 records survival 809 ± 11 lifespan study|1003-29-18-165|18|991|Neoplasia systemic|Haematolymphatic system|TLML/|
1003-29-18|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|237 records survival 809 ± 11 lifespan study|1003-29-18-166|18|994|n/a|n/a|n/a|
1003-29-18|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|237 records survival 809 ± 11 lifespan study|1003-29-18-167|18|995|n/a|n/a|n/a|
1003-29-18|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|237 records survival 809 ± 11 lifespan study|1003-29-18-168|18|997|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-29-18|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|237 records survival 809 ± 11 lifespan study|1003-29-18-169|18|999|n/a|n/a|n/a|
1003-29-18|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|237 records survival 809 ± 11 lifespan study|1003-29-18-170|18|1000|n/a|n/a|n/a|
1003-29-18|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|237 records survival 809 ± 11 lifespan study|1003-29-18-171|18|1001|n/a|n/a|n/a|
1003-29-18|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|237 records survival 809 ± 11 lifespan study|1003-29-18-172|18|1001|Other deterministic changes|Whole body|MCDU/|
1003-29-18|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|237 records survival 809 ± 11 lifespan study|1003-29-18-173|18|1001|Neoplasia systemic|Haematolymphatic system|TLML/   Metastases  Lymphoret.System trac to lymphoid organ.|
1003-29-18|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|237 records survival 809 ± 11 lifespan study|1003-29-18-174|18|1002|n/a|n/a|n/a|
1003-29-18|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|237 records survival 809 ± 11 lifespan study|1003-29-18-175|18|1002|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|TCFS/ dorsal lumbar region. Metastases  Muscle tcfs of lumbar region invas. of musc. Metastases  tcfs invas of visc perit of kidn & adre & panc.,MPATH: 408 - soft tissue fibrosarcoma|
1003-29-18|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|237 records survival 809 ± 11 lifespan study|1003-29-18-176|18|1002|n/a|n/a|n/a|
1003-29-18|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|237 records survival 809 ± 11 lifespan study|1003-29-18-177|18|1003|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  Head/neck missing,MPATH: 513 - Lymphoid neoplasms|
1003-29-18|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|237 records survival 809 ± 11 lifespan study|1003-29-18-178|18|1005|n/a|n/a|n/a|
1003-29-18|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|237 records survival 809 ± 11 lifespan study|1003-29-18-179|18|1009|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-18|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|237 records survival 809 ± 11 lifespan study|1003-29-18-180|18|1009|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-18|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|237 records survival 809 ± 11 lifespan study|1003-29-18-181|18|1009|Neoplasia malignant|Bloodvessels among cardiovascular system|TCVS/ lower lt quadrant abdomen; subcut. Metastases  Skin tcvs invas of skin w/ ulceration & abcessation.Eye(s) missing Head/neck missing|
1003-29-18|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|237 records survival 809 ± 11 lifespan study|1003-29-18-182|18|1010|n/a|n/a|n/a|
1003-29-18|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|237 records survival 809 ± 11 lifespan study|1003-29-18-183|18|1012|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  Head/neck missing,MPATH: 513 - Lymphoid neoplasms|
1003-29-18|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|237 records survival 809 ± 11 lifespan study|1003-29-18-184|18|1019|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-18|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|237 records survival 809 ± 11 lifespan study|1003-29-18-185|18|1019|n/a|n/a|n/a|
1003-29-18|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|237 records survival 809 ± 11 lifespan study|1003-29-18-186|18|1021|n/a|n/a|n/a|
1003-29-18|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|237 records survival 809 ± 11 lifespan study|1003-29-18-187|18|1022|n/a|n/a|n/a|
1003-29-18|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|237 records survival 809 ± 11 lifespan study|1003-29-18-188|18|1025|n/a|n/a|n/a|
1003-29-18|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|237 records survival 809 ± 11 lifespan study|1003-29-18-189|18|1027|n/a|n/a|n/a|
1003-29-18|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|237 records survival 809 ± 11 lifespan study|1003-29-18-190|18|1030|n/a|n/a|n/a|
1003-29-18|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|237 records survival 809 ± 11 lifespan study|1003-29-18-191|18|1033|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-18|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|237 records survival 809 ± 11 lifespan study|1003-29-18-192|18|1035|Other deterministic changes|Whole body|MCDU/|
1003-29-18|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|237 records survival 809 ± 11 lifespan study|1003-29-18-193|18|1036|n/a|n/a|n/a|
1003-29-18|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|237 records survival 809 ± 11 lifespan study|1003-29-18-194|18|1037|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|TMAB/  Predominantly ductal Metastases Lung tmls from perit to lung.,MPATH: 218 - neoplasm|
1003-29-18|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|237 records survival 809 ± 11 lifespan study|1003-29-18-195|18|1041|n/a|n/a|n/a|
1003-29-18|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|237 records survival 809 ± 11 lifespan study|1003-29-18-196|18|1047|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-18|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|237 records survival 809 ± 11 lifespan study|1003-29-18-197|18|1051|n/a|n/a|n/a|
1003-29-18|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|237 records survival 809 ± 11 lifespan study|1003-29-18-198|18|1053|n/a|n/a|n/a|
1003-29-18|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|237 records survival 809 ± 11 lifespan study|1003-29-18-199|18|1056|n/a|n/a|n/a|
1003-29-18|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|237 records survival 809 ± 11 lifespan study|1003-29-18-200|18|1056|n/a|n/a|n/a|
1003-29-18|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|237 records survival 809 ± 11 lifespan study|1003-29-18-201|18|1057|n/a|n/a|n/a|
1003-29-18|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|237 records survival 809 ± 11 lifespan study|1003-29-18-202|18|1065|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-18|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|237 records survival 809 ± 11 lifespan study|1003-29-18-203|18|1078|n/a|n/a|n/a|
1003-29-18|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|237 records survival 809 ± 11 lifespan study|1003-29-18-204|18|1079|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-18|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|237 records survival 809 ± 11 lifespan study|1003-29-18-205|18|1080|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-18|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|237 records survival 809 ± 11 lifespan study|1003-29-18-206|18|1083|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-29-18|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|237 records survival 809 ± 11 lifespan study|1003-29-18-207|18|1089|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-18|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|237 records survival 809 ± 11 lifespan study|1003-29-18-208|18|1089|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/   Metastases Lung,MPATH: 513 - Lymphoid neoplasms|
1003-29-18|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|237 records survival 809 ± 11 lifespan study|1003-29-18-209|18|1090|n/a|n/a|n/a|
1003-29-18|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|237 records survival 809 ± 11 lifespan study|1003-29-18-210|18|1092|n/a|n/a|n/a|
1003-29-18|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|237 records survival 809 ± 11 lifespan study|1003-29-18-211|18|1094|Neoplasia malignant|Bone among musculo-skeletal system diseases|TBOS/ thoracic spine. Metastases  Muscle tbos of thoracic spine invades musc of spine. Metastases Lung|
1003-29-18|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|237 records survival 809 ± 11 lifespan study|1003-29-18-212|18|1097|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-18|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|237 records survival 809 ± 11 lifespan study|1003-29-18-213|18|1098|n/a|n/a|n/a|
1003-29-18|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|237 records survival 809 ± 11 lifespan study|1003-29-18-214|18|1098|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-18|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|237 records survival 809 ± 11 lifespan study|1003-29-18-215|18|1102|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-18|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|237 records survival 809 ± 11 lifespan study|1003-29-18-216|18|1108|n/a|n/a|n/a|
1003-29-18|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|237 records survival 809 ± 11 lifespan study|1003-29-18-217|18|1112|Inflammation and/or fibrotic diseases|Lower respiratory system,MA: 0000433 - pleura|MRPU/  local or generalized,MPATH: 212 - inflammation|
1003-29-18|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|237 records survival 809 ± 11 lifespan study|1003-29-18-218|18|1113|n/a|n/a|n/a|
1003-29-18|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|237 records survival 809 ± 11 lifespan study|1003-29-18-219|18|1115|n/a|n/a|n/a|
1003-29-18|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|237 records survival 809 ± 11 lifespan study|1003-29-18-220|18|1116|Neoplasia systemic|Haematolymphatic system|TLPS/|
1003-29-18|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|237 records survival 809 ± 11 lifespan study|1003-29-18-221|18|1119|n/a|n/a|n/a|
1003-29-18|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|237 records survival 809 ± 11 lifespan study|1003-29-18-222|18|1121|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-29-18|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|237 records survival 809 ± 11 lifespan study|1003-29-18-223|18|1123|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-18|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|237 records survival 809 ± 11 lifespan study|1003-29-18-224|18|1124|n/a|n/a|n/a|
1003-29-18|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|237 records survival 809 ± 11 lifespan study|1003-29-18-225|18|1124|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-18|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|237 records survival 809 ± 11 lifespan study|1003-29-18-226|18|1124|n/a|n/a|n/a|
1003-29-18|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|237 records survival 809 ± 11 lifespan study|1003-29-18-227|18|1125|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|TCFS/ left axillary region.,MPATH: 408 - soft tissue fibrosarcoma|
1003-29-18|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|237 records survival 809 ± 11 lifespan study|1003-29-18-228|18|1125|Hyperplastic changes|Cardiovascular system|MPAN/  Polyarteritis nodosa|
1003-29-18|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|237 records survival 809 ± 11 lifespan study|1003-29-18-229|18|1132|n/a|n/a|n/a|
1003-29-18|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|237 records survival 809 ± 11 lifespan study|1003-29-18-230|18|1146|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|TXEC/ salivary gl.,MPATH: 446 - squamous cell carcinoma|
1003-29-18|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|237 records survival 809 ± 11 lifespan study|1003-29-18-231|18|1151|n/a|n/a|n/a|
1003-29-18|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|237 records survival 809 ± 11 lifespan study|1003-29-18-232|18|1154|n/a|n/a|n/a|
1003-29-18|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|237 records survival 809 ± 11 lifespan study|1003-29-18-233|18|1155|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-18|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|237 records survival 809 ± 11 lifespan study|1003-29-18-234|18|1163|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-18|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|237 records survival 809 ± 11 lifespan study|1003-29-18-235|18|1163|n/a|n/a|n/a|
1003-29-18|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|237 records survival 809 ± 11 lifespan study|1003-29-18-236|18|1171|n/a|n/a|n/a|
1003-29-18|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|237 records survival 809 ± 11 lifespan study|1003-29-18-237|18|1177|n/a|n/a|n/a|
1003-29-18|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|237 records survival 809 ± 11 lifespan study|1003-29-18-238|18|1179|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-18|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|237 records survival 809 ± 11 lifespan study|1003-29-18-239|18|1186|Inflammation and/or fibrotic diseases|Kidney among urinary system diseases,MA: 0000368 - kidney|MINA/  acute,MPATH: 212 - inflammation|
1003-29-18|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|237 records survival 809 ± 11 lifespan study|1003-29-18-240|18|1188|n/a|n/a|n/a|
1003-29-18|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|237 records survival 809 ± 11 lifespan study|1003-29-18-241|18|1194|n/a|n/a|n/a|
1003-29-18|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|237 records survival 809 ± 11 lifespan study|1003-29-18-242|18|1197|n/a|n/a|n/a|
1003-29-18|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|237 records survival 809 ± 11 lifespan study|1003-29-18-243|18|1199|n/a|n/a|n/a|
1003-29-18|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|237 records survival 809 ± 11 lifespan study|1003-29-18-244|18|1205|Other deterministic changes|Whole body|MCDU/|
1003-29-18|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|237 records survival 809 ± 11 lifespan study|1003-29-18-245|18|1239|n/a|n/a|n/a|
1003-29-18|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|237 records survival 809 ± 11 lifespan study|1003-29-18-246|18|1245|Other deterministic changes|Whole body|MCDU/|
1003-29-18|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|237 records survival 809 ± 11 lifespan study|1003-29-18-247|18|1251|n/a|n/a|n/a|
1003-29-18|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|237 records survival 809 ± 11 lifespan study|1003-29-18-248|18|1269|n/a|n/a|n/a|
1003-29-18|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|237 records survival 809 ± 11 lifespan study|1003-29-18-249|18|1309|n/a|n/a|n/a|
1003-29-18|n/a,3X|1|100|neutrons fission|0.135|grays|External exposure|code 3X (3A  3X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|237 records survival 809 ± 11 lifespan study|1003-29-18-250|18|1351|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-1|19|113|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-2|19|113|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-3|19|113|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-4|19|113|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-5|19|113|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-6|19|135|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-7|19|135|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-8|19|135|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-9|19|148|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-10|19|170|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-11|19|170|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-12|19|170|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-13|19|170|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-14|19|170|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-15|19|170|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-16|19|170|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-17|19|170|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-18|19|177|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-19|19|177|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-20|19|177|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-21|19|177|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-22|19|177|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-23|19|177|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-24|19|177|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-25|19|177|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-26|19|177|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-27|19|177|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-28|19|177|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-29|19|213|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-30|19|219|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-31|19|219|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-32|19|220|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-33|19|220|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-34|19|220|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-35|19|220|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-36|19|275|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-37|19|275|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-38|19|275|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-39|19|275|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-40|19|275|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-41|19|275|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-42|19|275|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-43|19|275|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-44|19|282|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-45|19|282|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-46|19|282|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-47|19|282|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-48|19|282|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-49|19|282|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-50|19|282|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-51|19|282|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-52|19|282|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-53|19|282|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-54|19|282|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-55|19|282|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-56|19|282|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-57|19|380|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-58|19|380|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-59|19|380|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-60|19|380|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-61|19|380|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-62|19|380|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-63|19|380|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-64|19|380|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-65|19|380|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-66|19|380|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-67|19|380|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-68|19|380|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-69|19|380|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-70|19|380|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-71|19|380|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-72|19|380|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-73|19|383|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-74|19|387|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-75|19|387|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-76|19|387|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-77|19|387|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-78|19|408|Neoplasia malignant|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|THVS/  ,MPATH: 242 - hemangiosarcoma|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-79|19|417|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-80|19|417|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-81|19|417|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-82|19|417|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-83|19|421|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-84|19|424|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-85|19|424|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-86|19|424|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-87|19|424|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-88|19|424|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-89|19|424|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-90|19|424|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-91|19|424|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-92|19|424|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-93|19|450|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-94|19|450|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-95|19|450|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-96|19|452|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-97|19|457|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-98|19|459|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-99|19|488|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-100|19|488|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-101|19|488|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-102|19|488|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-103|19|488|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-104|19|520|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-105|19|520|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-106|19|520|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-107|19|520|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-108|19|520|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-109|19|521|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-110|19|521|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-111|19|521|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-112|19|521|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-113|19|521|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-114|19|521|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-115|19|523|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-116|19|527|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-117|19|527|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-118|19|527|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-119|19|527|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-120|19|527|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-121|19|527|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-122|19|527|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-123|19|528|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-124|19|528|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-125|19|534|Neoplasia malignant|Bloodvessels among cardiovascular system|TIVS/ stomach.|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-126|19|535|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-127|19|548|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-128|19|548|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-129|19|548|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-130|19|548|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-131|19|548|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-132|19|555|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-133|19|555|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-134|19|555|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-135|19|555|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-136|19|555|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-137|19|555|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-138|19|555|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-139|19|555|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-140|19|555|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-141|19|555|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-142|19|562|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-143|19|562|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-144|19|562|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-145|19|562|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-146|19|562|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-147|19|562|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-148|19|562|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-149|19|562|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-150|19|562|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-151|19|562|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-152|19|569|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-153|19|569|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-154|19|569|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-155|19|569|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-156|19|569|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-157|19|573|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-158|19|578|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-159|19|584|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-160|19|590|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-161|19|590|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-162|19|590|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-163|19|590|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-164|19|599|Neoplasia malignant|Bloodvessels among cardiovascular system|TMVS/ skeletal muscle of lumbar spine. Muscle|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-165|19|615|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-166|19|617|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-167|19|617|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-168|19|617|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-169|19|617|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-170|19|624|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-171|19|625|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-172|19|625|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-173|19|625|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-174|19|625|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-175|19|625|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-176|19|625|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-177|19|625|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-178|19|626|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-179|19|631|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-180|19|631|Neoplasia unclassified|Other local manifestations and miscellaneus|TLWR: TRAC TO BR. L.N.|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-181|19|632|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-182|19|632|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-183|19|632|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-184|19|632|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-185|19|633|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-186|19|633|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-187|19|633|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-188|19|634|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-189|19|635|Other deterministic changes|Whole body|MCDU/|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-190|19|641|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases  Muscle trac to intercostal muscles. Metastases  trac to peritoneum, mediastinum.,MPATH: 268 - adenocarcinoma|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-191|19|643|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-192|19|646|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-193|19|650|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-194|19|651|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-195|19|656|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-196|19|662|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-197|19|662|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-198|19|667|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-199|19|668|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases  trac in visc. peritoneum.,MPATH: 268 - adenocarcinoma|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-200|19|668|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-201|19|673|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-202|19|684|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-203|19|684|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-204|19|688|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-205|19|690|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-206|19|694|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-207|19|695|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-208|19|696|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-209|19|698|Neoplasia malignant|Bone among musculo-skeletal system diseases|TBOS/ pelvis. Metastases  Muscle tbos of pelvis to skeletal muscle of pelvis. Metastases Lung|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-210|19|701|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-211|19|706|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-212|19|712|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-213|19|724|Neoplasia unclassified|Other local manifestations and miscellaneus|TLWR: TRAC TO BR. L.N.|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-214|19|725|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-215|19|728|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-216|19|729|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-217|19|729|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-218|19|729|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-219|19|729|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-220|19|729|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-221|19|729|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-222|19|731|Other deterministic changes|Whole body|MCDU/|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-223|19|732|Neoplasia unclassified|Other local manifestations and miscellaneus|TMWB: TBOS OF PELVIS TO SKELETAL MUSCLE OF PELVIS.|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-224|19|736|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-225|19|736|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-226|19|736|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-227|19|736|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-228|19|736|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-229|19|736|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-230|19|740|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-231|19|742|Neoplasia malignant|Bloodvessels among cardiovascular system|TYVS/ extends to adnexal tissue.Heart|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-232|19|744|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-233|19|744|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/   Metastases  Muscle trac to intercostal & spinal muscles.,MPATH: 513 - Lymphoid neoplasms|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-234|19|750|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-235|19|752|Neoplasia unclassified|Other local manifestations and miscellaneus|TMWB: TBVS OF THIGH TO THIGH MUSC.|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-236|19|752|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-237|19|752|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases  trac to parietal pleura, rib cage, & visc. pleura. Metastases  Lymphoret.System trac to br. l.n.,MPATH: 268 - adenocarcinoma|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-238|19|753|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-239|19|759|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-240|19|770|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-241|19|771|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-242|19|773|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-243|19|777|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-244|19|781|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  Eye(s) missing Head/neck missing,MPATH: 513 - Lymphoid neoplasms|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-245|19|781|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-246|19|782|Neoplasia unclassified|Other local manifestations and miscellaneus|TMWB: TBVS OF THIGH TO THIGH MUSC.|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-247|19|782|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-248|19|783|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-249|19|785|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-250|19|785|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-251|19|786|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-252|19|787|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-253|19|791|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-254|19|792|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-255|19|792|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-256|19|792|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-257|19|794|Neoplasia unclassified|Other local manifestations and miscellaneus|TMWB: TBOS OF PELVIS TO SKELETAL MUSCLE OF PELVIS.|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-258|19|794|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-259|19|797|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-260|19|798|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-261|19|801|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|TCFS/ lateral chest wall.,MPATH: 408 - soft tissue fibrosarcoma|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-262|19|803|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-263|19|806|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-264|19|806|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-265|19|806|Neoplasia unclassified|Other local manifestations and miscellaneus|TMWR: TRAC TO INTERCOSTAL & SPINAL MUSCLES.|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-266|19|806|Neoplasia unclassified|Other local manifestations and miscellaneus|TMWR: TRAC TO INTERCOSTAL & SPINAL MUSCLES.|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-267|19|807|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-268|19|807|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  Head/neck missing Eye(s) missing,MPATH: 513 - Lymphoid neoplasms|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-269|19|812|Inflammation and/or fibrotic diseases|Other local manifestations and miscellaneus,MA: 0000003 - organ system|MCIG/  ,MPATH: 213 - acute inflammation|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-270|19|813|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-271|19|813|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-272|19|816|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-273|19|817|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-274|19|818|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-275|19|818|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-276|19|820|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-277|19|821|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/   Metastases  Skin invas of skin of chest by tcfs.,MPATH: 513 - Lymphoid neoplasms|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-278|19|825|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-279|19|826|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  Eye(s) missing,MPATH: 513 - Lymphoid neoplasms|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-280|19|830|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-281|19|834|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-282|19|836|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  Head/neck missing,MPATH: 513 - Lymphoid neoplasms|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-283|19|837|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-284|19|840|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-285|19|843|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-286|19|844|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-287|19|845|Neoplasia unclassified|Other local manifestations and miscellaneus|TRWH: TRAC TO LIVER.|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-288|19|847|Neoplasia malignant|Bloodvessels among cardiovascular system|TBVS/ femur. Metastases  Muscle tbvs of thigh to thigh musc.|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-289|19|852|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-290|19|855|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-291|19|856|Other deterministic changes|Whole body|MCDU/|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-292|19|856|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-293|19|860|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-294|19|861|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-295|19|863|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-296|19|864|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/  ,MPATH: 242 - hemangiosarcoma|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-297|19|864|Neoplasia systemic|Haematolymphatic system|TLML/|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-298|19|866|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-299|19|867|Neoplasia malignant|Liver among hepato-pancreatic system diseases|THAC/|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-300|19|875|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/  ,MPATH: 242 - hemangiosarcoma|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-301|19|876|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-302|19|887|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-303|19|888|Neoplasia unclassified|Other local manifestations and miscellaneus|TMWR: TRAC TO INTERCOSTAL MUSCLES.|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-304|19|889|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-305|19|889|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-306|19|890|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-307|19|891|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  Head/neck missing,MPATH: 268 - adenocarcinoma|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-308|19|893|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-309|19|898|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-310|19|899|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/  ,MPATH: 242 - hemangiosarcoma|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-311|19|901|Neoplasia malignant|Liver among hepato-pancreatic system diseases|THAC/   Metastases  Lymphoret.System thac metastasis to misc nodes. Metastases Lung Metastases Kidney|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-312|19|904|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-313|19|905|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-314|19|907|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-315|19|907|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-316|19|908|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-317|19|911|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-318|19|912|Neoplasia systemic|Haematolymphatic system|TLML/|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-319|19|915|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-320|19|918|Neoplasia unclassified|Other local manifestations and miscellaneus|TLWR: TRAC TO BR. L.N.|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-321|19|923|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-322|19|924|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-323|19|924|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-324|19|924|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-325|19|927|Other deterministic changes|Whole body|MCDU/|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-326|19|940|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-327|19|940|Neoplasia unclassified|Other local manifestations and miscellaneus|TMWB: TBOS OF PELVIS TO SKELETAL MUSCLE OF PELVIS.|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-328|19|942|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-329|19|943|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-330|19|945|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-331|19|953|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-332|19|953|Neoplasia unclassified|Other local manifestations and miscellaneus|TRWH: THAC TO LUNG.|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-333|19|953|Neoplasia unclassified|Other local manifestations and miscellaneus|TMWG: TGAC INFILTRATES MUSC.|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-334|19|958|Other deterministic changes|Whole body|MCDU/|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-335|19|960|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-336|19|962|Neoplasia unclassified|Other local manifestations and miscellaneus|TKWH: THAC TO KIDNEY.|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-337|19|963|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  Head/neck missing,MPATH: 513 - Lymphoid neoplasms|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-338|19|964|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-339|19|967|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-340|19|968|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-341|19|969|Neoplasia malignant|Liver among hepato-pancreatic system diseases|THAC/   Metastases Lung Metastases  trac to mediastinum.|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-342|19|969|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-343|19|969|Neoplasia unclassified|Other local manifestations and miscellaneus|TMWB: TBVS OF THIGH TO THIGH MUSC.|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-344|19|970|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-345|19|970|Neoplasia malignant|Bloodvessels among cardiovascular system|TXVS/ seminal vesicle.Eye(s) missing Head/neck missing|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-346|19|970|Neoplasia unclassified|Other local manifestations and miscellaneus|TMWR: TRAC TO INTERCOSTAL MUSCLES.|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-347|19|973|Other deterministic changes|Whole body|MCDU/|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-348|19|973|Neoplasia malignant|Liver among hepato-pancreatic system diseases|THAC/|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-349|19|975|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/   Metastases  Muscle tgac infiltrates musc.,MPATH: 513 - Lymphoid neoplasms|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-350|19|980|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-351|19|981|Neoplasia unclassified|Other local manifestations and miscellaneus|TKWH: THAC TO KIDNEY.|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-352|19|984|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-353|19|987|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-354|19|988|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-355|19|988|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-356|19|990|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-357|19|992|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-358|19|992|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-359|19|995|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  Eye(s) missing Head/neck missing,MPATH: 513 - Lymphoid neoplasms|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-360|19|997|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-361|19|998|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-362|19|998|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-363|19|1000|Other deterministic changes|Whole body|MCDU/|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-364|19|1001|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-365|19|1008|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-366|19|1009|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-367|19|1013|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-368|19|1013|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-369|19|1014|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-370|19|1015|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-371|19|1015|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-372|19|1019|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-373|19|1020|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-374|19|1020|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-375|19|1022|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-376|19|1024|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-377|19|1026|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-378|19|1026|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-379|19|1027|Other deterministic changes|Whole body|MCDU/|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-380|19|1027|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLSS/  undifferentiated lymphomaHead/neck missing Eye(s) missing,MPATH: 513 - Lymphoid neoplasms|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-381|19|1028|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-382|19|1030|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-383|19|1036|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-384|19|1038|Inflammation and/or fibrotic diseases|Kidney among urinary system diseases,MA: 0000368 - kidney|MINA/  acuteEye(s) missing Head/neck missing,MPATH: 212 - inflammation|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-385|19|1041|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-386|19|1043|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-387|19|1050|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-388|19|1055|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-389|19|1057|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-390|19|1064|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-391|19|1066|Neoplasia unclassified|Other local manifestations and miscellaneus|TKWH: THAC TO KIDNEY.|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-392|19|1067|Neoplasia unclassified|Other local manifestations and miscellaneus|TMWG: TGAC INFILTRATES MUSC.|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-393|19|1072|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-394|19|1072|Neoplasia malignant|Bloodvessels among cardiovascular system|TCVS/ subcut. on nose. Metastases  Muscle trac to intercostal muscles.|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-395|19|1072|Neoplasia malignant|Adrenal gland  among endocrine systems|TAPS/   Metastases Kidney Metastases Lung|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-396|19|1074|Neoplasia systemic|Haematolymphatic system|TLML/|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-397|19|1074|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-398|19|1077|Inflammation and/or fibrotic diseases|Lower respiratory system,MA: 0000415 - lung|MRMP/  MurineHead/neck missing,MPATH: 212 - inflammation|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-399|19|1083|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-400|19|1083|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-401|19|1084|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-402|19|1085|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-403|19|1087|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-404|19|1094|Neoplasia unclassified|Other local manifestations and miscellaneus|TMWG: TGAC INFILTRATES MUSC.|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-405|19|1096|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-406|19|1097|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-407|19|1098|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-408|19|1101|Other deterministic changes|Whole body|MCDU/|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-409|19|1101|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-410|19|1103|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-411|19|1106|Neoplasia malignant|Liver among hepato-pancreatic system diseases|THAC/   Metastases Lung|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-412|19|1113|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-413|19|1114|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-414|19|1121|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-415|19|1122|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-416|19|1123|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-417|19|1124|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-418|19|1126|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-419|19|1126|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-420|19|1142|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-421|19|1143|Neoplasia unclassified|Other local manifestations and miscellaneus|TRWH: TRAC TO LIVER.|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-422|19|1151|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-423|19|1152|Other deterministic changes|Whole body|MCDU/|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-424|19|1155|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-425|19|1156|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-426|19|1158|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-427|19|1160|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-428|19|1160|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-429|19|1162|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-430|19|1169|Neoplasia malignant|Bloodvessels among cardiovascular system|TMVS/ subcut. left inguinal region. Muscle|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-431|19|1177|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-432|19|1179|Neoplasia unclassified|Other local manifestations and miscellaneus|TMWB: TBVS OF THIGH TO THIGH MUSC.|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-433|19|1184|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-434|19|1189|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-435|19|1194|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-436|19|1198|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-437|19|1203|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-438|19|1209|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-439|19|1211|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-440|19|1227|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-441|19|1251|Other deterministic changes|Whole body|MCDU/|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-442|19|1255|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-443|19|1267|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-444|19|1278|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-445|19|1279|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-446|19|1294|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-447|19|1297|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-448|19|1338|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/  ,MPATH: 242 - hemangiosarcoma|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-449|19|1340|n/a|n/a|n/a|
1003-29-19|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|450 (450 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|254 records survival 817 ± 12 lifespan study|1003-29-19-450|19|1359|n/a|n/a|n/a|
1003-29-20|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 790 ± 12 lifespan study|1003-29-20-1|20|191|n/a|n/a|n/a|
1003-29-20|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 790 ± 12 lifespan study|1003-29-20-2|20|191|n/a|n/a|n/a|
1003-29-20|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 790 ± 12 lifespan study|1003-29-20-3|20|191|n/a|n/a|n/a|
1003-29-20|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 790 ± 12 lifespan study|1003-29-20-4|20|191|n/a|n/a|n/a|
1003-29-20|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 790 ± 12 lifespan study|1003-29-20-5|20|191|n/a|n/a|n/a|
1003-29-20|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 790 ± 12 lifespan study|1003-29-20-6|20|364|n/a|n/a|n/a|
1003-29-20|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 790 ± 12 lifespan study|1003-29-20-7|20|379|n/a|n/a|n/a|
1003-29-20|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 790 ± 12 lifespan study|1003-29-20-8|20|405|n/a|n/a|n/a|
1003-29-20|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 790 ± 12 lifespan study|1003-29-20-9|20|409|n/a|n/a|n/a|
1003-29-20|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 790 ± 12 lifespan study|1003-29-20-10|20|414|Neoplasia malignant|Other local manifestations and miscellaneus|TCSS/ TCSS/ TCSS/ TCSS/ musc. & skin of abd. wall. Metastases  Skin tcss infilt. of skin from abd. wall.|
1003-29-20|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 790 ± 12 lifespan study|1003-29-20-11|20|447|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-20|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 790 ± 12 lifespan study|1003-29-20-12|20|512|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-20|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 790 ± 12 lifespan study|1003-29-20-13|20|525|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-20|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 790 ± 12 lifespan study|1003-29-20-14|20|534|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-20|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 790 ± 12 lifespan study|1003-29-20-15|20|535|Inflammation and/or fibrotic diseases|Kidney among urinary system diseases,MA: 0000368 - kidney|MPNE/  acute,MPATH: 212 - inflammation|
1003-29-20|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 790 ± 12 lifespan study|1003-29-20-16|20|543|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-20|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 790 ± 12 lifespan study|1003-29-20-17|20|560|Inflammation and/or fibrotic diseases|Lower respiratory system,MA: 0000415 - lung|MRMP/  Murine,MPATH: 212 - inflammation|
1003-29-20|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 790 ± 12 lifespan study|1003-29-20-18|20|569|Neoplasia malignant|Bloodvessels among cardiovascular system|TIVS/ stomach wall.|
1003-29-20|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 790 ± 12 lifespan study|1003-29-20-19|20|573|Other deterministic changes|Whole body|MCDU/|
1003-29-20|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 790 ± 12 lifespan study|1003-29-20-20|20|600|Other deterministic changes|Whole body|MCDU/|
1003-29-20|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 790 ± 12 lifespan study|1003-29-20-21|20|603|n/a|n/a|n/a|
1003-29-20|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 790 ± 12 lifespan study|1003-29-20-22|20|618|Inflammation and/or fibrotic diseases|Other local manifestations and miscellaneus|MMTA/  Metritis|
1003-29-20|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 790 ± 12 lifespan study|1003-29-20-23|20|631|n/a|n/a|n/a|
1003-29-20|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 790 ± 12 lifespan study|1003-29-20-24|20|643|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-20|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 790 ± 12 lifespan study|1003-29-20-25|20|650|n/a|n/a|n/a|
1003-29-20|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 790 ± 12 lifespan study|1003-29-20-26|20|652|n/a|n/a|n/a|
1003-29-20|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 790 ± 12 lifespan study|1003-29-20-27|20|653|n/a|n/a|n/a|
1003-29-20|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 790 ± 12 lifespan study|1003-29-20-28|20|663|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-20|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 790 ± 12 lifespan study|1003-29-20-29|20|664|n/a|n/a|n/a|
1003-29-20|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 790 ± 12 lifespan study|1003-29-20-30|20|669|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-20|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 790 ± 12 lifespan study|1003-29-20-31|20|670|n/a|n/a|n/a|
1003-29-20|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 790 ± 12 lifespan study|1003-29-20-32|20|671|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-20|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 790 ± 12 lifespan study|1003-29-20-33|20|675|n/a|n/a|n/a|
1003-29-20|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 790 ± 12 lifespan study|1003-29-20-34|20|686|n/a|n/a|n/a|
1003-29-20|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 790 ± 12 lifespan study|1003-29-20-35|20|688|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-20|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 790 ± 12 lifespan study|1003-29-20-36|20|688|Hyperplastic changes|Other local manifestations and miscellaneus,MA: 0000003 - organ system|MOCY/  Ovary or testis,MPATH: 62 - cyst|
1003-29-20|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 790 ± 12 lifespan study|1003-29-20-37|20|688|n/a|n/a|n/a|
1003-29-20|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 790 ± 12 lifespan study|1003-29-20-38|20|696|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-20|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 790 ± 12 lifespan study|1003-29-20-39|20|698|n/a|n/a|n/a|
1003-29-20|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 790 ± 12 lifespan study|1003-29-20-40|20|701|n/a|n/a|n/a|
1003-29-20|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 790 ± 12 lifespan study|1003-29-20-41|20|701|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-20|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 790 ± 12 lifespan study|1003-29-20-42|20|705|n/a|n/a|n/a|
1003-29-20|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 790 ± 12 lifespan study|1003-29-20-43|20|710|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/  ,MPATH: 242 - hemangiosarcoma|
1003-29-20|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 790 ± 12 lifespan study|1003-29-20-44|20|723|n/a|n/a|n/a|
1003-29-20|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 790 ± 12 lifespan study|1003-29-20-45|20|726|n/a|n/a|n/a|
1003-29-20|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 790 ± 12 lifespan study|1003-29-20-46|20|727|Neoplasia malignant|Bloodvessels among cardiovascular system|TXVS/ mesenteric l.n.|
1003-29-20|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 790 ± 12 lifespan study|1003-29-20-47|20|735|n/a|n/a|n/a|
1003-29-20|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 790 ± 12 lifespan study|1003-29-20-48|20|737|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-20|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 790 ± 12 lifespan study|1003-29-20-49|20|741|n/a|n/a|n/a|
1003-29-20|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 790 ± 12 lifespan study|1003-29-20-50|20|744|n/a|n/a|n/a|
1003-29-20|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 790 ± 12 lifespan study|1003-29-20-51|20|744|n/a|n/a|n/a|
1003-29-20|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 790 ± 12 lifespan study|1003-29-20-52|20|746|Other deterministic changes|Whole body|MCDU/|
1003-29-20|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 790 ± 12 lifespan study|1003-29-20-53|20|748|n/a|n/a|n/a|
1003-29-20|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 790 ± 12 lifespan study|1003-29-20-54|20|749|n/a|n/a|n/a|
1003-29-20|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 790 ± 12 lifespan study|1003-29-20-55|20|752|n/a|n/a|n/a|
1003-29-20|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 790 ± 12 lifespan study|1003-29-20-56|20|759|n/a|n/a|n/a|
1003-29-20|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 790 ± 12 lifespan study|1003-29-20-57|20|761|n/a|n/a|n/a|
1003-29-20|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 790 ± 12 lifespan study|1003-29-20-58|20|765|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-20|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 790 ± 12 lifespan study|1003-29-20-59|20|767|n/a|n/a|n/a|
1003-29-20|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 790 ± 12 lifespan study|1003-29-20-60|20|771|n/a|n/a|n/a|
1003-29-20|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 790 ± 12 lifespan study|1003-29-20-61|20|771|n/a|n/a|n/a|
1003-29-20|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 790 ± 12 lifespan study|1003-29-20-62|20|777|n/a|n/a|n/a|
1003-29-20|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 790 ± 12 lifespan study|1003-29-20-63|20|781|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  Eye(s) missing Head/neck missing,MPATH: 513 - Lymphoid neoplasms|
1003-29-20|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 790 ± 12 lifespan study|1003-29-20-64|20|785|n/a|n/a|n/a|
1003-29-20|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 790 ± 12 lifespan study|1003-29-20-65|20|791|n/a|n/a|n/a|
1003-29-20|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 790 ± 12 lifespan study|1003-29-20-66|20|791|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-20|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 790 ± 12 lifespan study|1003-29-20-67|20|794|n/a|n/a|n/a|
1003-29-20|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 790 ± 12 lifespan study|1003-29-20-68|20|798|Other deterministic changes|Whole body|MCDU/|
1003-29-20|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 790 ± 12 lifespan study|1003-29-20-69|20|800|Neoplasia malignant|Bloodvessels among cardiovascular system|TMVS/ thigh muscle. Muscle|
1003-29-20|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 790 ± 12 lifespan study|1003-29-20-70|20|801|n/a|n/a|n/a|
1003-29-20|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 790 ± 12 lifespan study|1003-29-20-71|20|801|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-20|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 790 ± 12 lifespan study|1003-29-20-72|20|804|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-20|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 790 ± 12 lifespan study|1003-29-20-73|20|804|n/a|n/a|n/a|
1003-29-20|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 790 ± 12 lifespan study|1003-29-20-74|20|805|n/a|n/a|n/a|
1003-29-20|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 790 ± 12 lifespan study|1003-29-20-75|20|805|Hyperplastic changes|Other local manifestations and miscellaneus,MA: 0000003 - organ system|MOCY/  Ovary or testis,MPATH: 62 - cyst|
1003-29-20|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 790 ± 12 lifespan study|1003-29-20-76|20|809|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-20|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 790 ± 12 lifespan study|1003-29-20-77|20|810|n/a|n/a|n/a|
1003-29-20|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 790 ± 12 lifespan study|1003-29-20-78|20|813|n/a|n/a|n/a|
1003-29-20|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 790 ± 12 lifespan study|1003-29-20-79|20|816|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-20|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 790 ± 12 lifespan study|1003-29-20-80|20|817|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-20|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 790 ± 12 lifespan study|1003-29-20-81|20|817|n/a|n/a|n/a|
1003-29-20|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 790 ± 12 lifespan study|1003-29-20-82|20|817|n/a|n/a|n/a|
1003-29-20|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 790 ± 12 lifespan study|1003-29-20-83|20|820|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-20|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 790 ± 12 lifespan study|1003-29-20-84|20|824|n/a|n/a|n/a|
1003-29-20|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 790 ± 12 lifespan study|1003-29-20-85|20|826|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-20|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 790 ± 12 lifespan study|1003-29-20-86|20|828|n/a|n/a|n/a|
1003-29-20|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 790 ± 12 lifespan study|1003-29-20-87|20|829|Other deterministic changes|Whole body|MCDU/|
1003-29-20|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 790 ± 12 lifespan study|1003-29-20-88|20|829|n/a|n/a|n/a|
1003-29-20|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 790 ± 12 lifespan study|1003-29-20-89|20|834|n/a|n/a|n/a|
1003-29-20|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 790 ± 12 lifespan study|1003-29-20-90|20|838|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-20|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 790 ± 12 lifespan study|1003-29-20-91|20|844|n/a|n/a|n/a|
1003-29-20|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 790 ± 12 lifespan study|1003-29-20-92|20|845|n/a|n/a|n/a|
1003-29-20|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 790 ± 12 lifespan study|1003-29-20-93|20|845|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/  ,MPATH: 242 - hemangiosarcoma|
1003-29-20|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 790 ± 12 lifespan study|1003-29-20-94|20|846|n/a|n/a|n/a|
1003-29-20|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 790 ± 12 lifespan study|1003-29-20-95|20|848|n/a|n/a|n/a|
1003-29-20|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 790 ± 12 lifespan study|1003-29-20-96|20|848|n/a|n/a|n/a|
1003-29-20|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 790 ± 12 lifespan study|1003-29-20-97|20|850|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-20|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 790 ± 12 lifespan study|1003-29-20-98|20|850|Other deterministic changes|Whole body|MCDU/  Eye(s) missing Head/neck missing|
1003-29-20|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 790 ± 12 lifespan study|1003-29-20-99|20|851|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-20|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 790 ± 12 lifespan study|1003-29-20-100|20|852|Other deterministic changes|Whole body|MCDU/   Metastases  tivs of stomach wall invades pancreas & mesenteric fat.|
1003-29-20|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 790 ± 12 lifespan study|1003-29-20-101|20|852|Other deterministic changes|Whole body|MCDU/|
1003-29-20|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 790 ± 12 lifespan study|1003-29-20-102|20|854|n/a|n/a|n/a|
1003-29-20|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 790 ± 12 lifespan study|1003-29-20-103|20|854|n/a|n/a|n/a|
1003-29-20|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 790 ± 12 lifespan study|1003-29-20-104|20|855|n/a|n/a|n/a|
1003-29-20|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 790 ± 12 lifespan study|1003-29-20-105|20|862|n/a|n/a|n/a|
1003-29-20|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 790 ± 12 lifespan study|1003-29-20-106|20|864|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLSL/  undifferentiated leukemia lymphoret.tissue,MPATH: 335 - hematopoietic/lymphoid malignancies/disorder|
1003-29-20|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 790 ± 12 lifespan study|1003-29-20-107|20|866|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-20|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 790 ± 12 lifespan study|1003-29-20-108|20|868|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-20|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 790 ± 12 lifespan study|1003-29-20-109|20|869|n/a|n/a|n/a|
1003-29-20|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 790 ± 12 lifespan study|1003-29-20-110|20|875|n/a|n/a|n/a|
1003-29-20|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 790 ± 12 lifespan study|1003-29-20-111|20|877|n/a|n/a|n/a|
1003-29-20|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 790 ± 12 lifespan study|1003-29-20-112|20|877|n/a|n/a|n/a|
1003-29-20|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 790 ± 12 lifespan study|1003-29-20-113|20|879|n/a|n/a|n/a|
1003-29-20|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 790 ± 12 lifespan study|1003-29-20-114|20|879|Degenerative changes|Kidney among urinary system diseases,MA: 0000368 - kidney|MCRD/  Head/neck missing,MPATH: 1 - cell and tissue damage|
1003-29-20|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 790 ± 12 lifespan study|1003-29-20-115|20|879|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  Thorax missing Eye(s) missing Head/neck missing,MPATH: 513 - Lymphoid neoplasms|
1003-29-20|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 790 ± 12 lifespan study|1003-29-20-116|20|883|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-20|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 790 ± 12 lifespan study|1003-29-20-117|20|887|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-20|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 790 ± 12 lifespan study|1003-29-20-118|20|887|n/a|n/a|n/a|
1003-29-20|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 790 ± 12 lifespan study|1003-29-20-119|20|887|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-20|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 790 ± 12 lifespan study|1003-29-20-120|20|894|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-20|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 790 ± 12 lifespan study|1003-29-20-121|20|895|Other deterministic changes|Whole body|MCDU/|
1003-29-20|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 790 ± 12 lifespan study|1003-29-20-122|20|898|n/a|n/a|n/a|
1003-29-20|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 790 ± 12 lifespan study|1003-29-20-123|20|899|n/a|n/a|n/a|
1003-29-20|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 790 ± 12 lifespan study|1003-29-20-124|20|900|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-20|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 790 ± 12 lifespan study|1003-29-20-125|20|901|n/a|n/a|n/a|
1003-29-20|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 790 ± 12 lifespan study|1003-29-20-126|20|903|n/a|n/a|n/a|
1003-29-20|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 790 ± 12 lifespan study|1003-29-20-127|20|904|Inflammation and/or fibrotic diseases|Lower respiratory system,MA: 0000415 - lung|MRMP/  Murine Metastases  Muscle tcss infilt. of musc. from abd. wall.,MPATH: 212 - inflammation|
1003-29-20|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 790 ± 12 lifespan study|1003-29-20-128|20|904|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOVO/  ,MPATH: 242 - hemangiosarcoma|
1003-29-20|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 790 ± 12 lifespan study|1003-29-20-129|20|906|n/a|n/a|n/a|
1003-29-20|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 790 ± 12 lifespan study|1003-29-20-130|20|906|n/a|n/a|n/a|
1003-29-20|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 790 ± 12 lifespan study|1003-29-20-131|20|907|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-20|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 790 ± 12 lifespan study|1003-29-20-132|20|907|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-20|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 790 ± 12 lifespan study|1003-29-20-133|20|908|Hyperplastic changes|Other local manifestations and miscellaneus,MA: 0000003 - organ system|MOCY/  Ovary or testis,MPATH: 62 - cyst|
1003-29-20|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 790 ± 12 lifespan study|1003-29-20-134|20|910|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-20|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 790 ± 12 lifespan study|1003-29-20-135|20|912|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-20|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 790 ± 12 lifespan study|1003-29-20-136|20|912|n/a|n/a|n/a|
1003-29-20|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 790 ± 12 lifespan study|1003-29-20-137|20|915|n/a|n/a|n/a|
1003-29-20|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 790 ± 12 lifespan study|1003-29-20-138|20|916|Neoplasia malignant|Other local manifestations and miscellaneus|TMLS/ back of neck.|
1003-29-20|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 790 ± 12 lifespan study|1003-29-20-139|20|918|n/a|n/a|n/a|
1003-29-20|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 790 ± 12 lifespan study|1003-29-20-140|20|920|n/a|n/a|n/a|
1003-29-20|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 790 ± 12 lifespan study|1003-29-20-141|20|920|n/a|n/a|n/a|
1003-29-20|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 790 ± 12 lifespan study|1003-29-20-142|20|921|n/a|n/a|n/a|
1003-29-20|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 790 ± 12 lifespan study|1003-29-20-143|20|933|n/a|n/a|n/a|
1003-29-20|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 790 ± 12 lifespan study|1003-29-20-144|20|933|n/a|n/a|n/a|
1003-29-20|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 790 ± 12 lifespan study|1003-29-20-145|20|936|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/  ,MPATH: 242 - hemangiosarcoma|
1003-29-20|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 790 ± 12 lifespan study|1003-29-20-146|20|937|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-20|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 790 ± 12 lifespan study|1003-29-20-147|20|938|n/a|n/a|n/a|
1003-29-20|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 790 ± 12 lifespan study|1003-29-20-148|20|938|n/a|n/a|n/a|
1003-29-20|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 790 ± 12 lifespan study|1003-29-20-149|20|940|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-20|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 790 ± 12 lifespan study|1003-29-20-150|20|942|n/a|n/a|n/a|
1003-29-20|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 790 ± 12 lifespan study|1003-29-20-151|20|943|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/   Metastases Lung,MPATH: 513 - Lymphoid neoplasms|
1003-29-20|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 790 ± 12 lifespan study|1003-29-20-152|20|943|n/a|n/a|n/a|
1003-29-20|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 790 ± 12 lifespan study|1003-29-20-153|20|947|n/a|n/a|n/a|
1003-29-20|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 790 ± 12 lifespan study|1003-29-20-154|20|947|n/a|n/a|n/a|
1003-29-20|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 790 ± 12 lifespan study|1003-29-20-155|20|947|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-20|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 790 ± 12 lifespan study|1003-29-20-156|20|947|n/a|n/a|n/a|
1003-29-20|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 790 ± 12 lifespan study|1003-29-20-157|20|953|n/a|n/a|n/a|
1003-29-20|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 790 ± 12 lifespan study|1003-29-20-158|20|956|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-20|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 790 ± 12 lifespan study|1003-29-20-159|20|958|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-20|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 790 ± 12 lifespan study|1003-29-20-160|20|966|n/a|n/a|n/a|
1003-29-20|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 790 ± 12 lifespan study|1003-29-20-161|20|966|n/a|n/a|n/a|
1003-29-20|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 790 ± 12 lifespan study|1003-29-20-162|20|967|n/a|n/a|n/a|
1003-29-20|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 790 ± 12 lifespan study|1003-29-20-163|20|969|n/a|n/a|n/a|
1003-29-20|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 790 ± 12 lifespan study|1003-29-20-164|20|969|n/a|n/a|n/a|
1003-29-20|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 790 ± 12 lifespan study|1003-29-20-165|20|977|Neoplasia malignant|Bloodvessels among cardiovascular system|TCVS/ paravertebral soft tiss.|
1003-29-20|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 790 ± 12 lifespan study|1003-29-20-166|20|979|n/a|n/a|n/a|
1003-29-20|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 790 ± 12 lifespan study|1003-29-20-167|20|983|n/a|n/a|n/a|
1003-29-20|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 790 ± 12 lifespan study|1003-29-20-168|20|984|n/a|n/a|n/a|
1003-29-20|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 790 ± 12 lifespan study|1003-29-20-169|20|986|n/a|n/a|n/a|
1003-29-20|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 790 ± 12 lifespan study|1003-29-20-170|20|986|n/a|n/a|n/a|
1003-29-20|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 790 ± 12 lifespan study|1003-29-20-171|20|987|n/a|n/a|n/a|
1003-29-20|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 790 ± 12 lifespan study|1003-29-20-172|20|987|n/a|n/a|n/a|
1003-29-20|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 790 ± 12 lifespan study|1003-29-20-173|20|988|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-20|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 790 ± 12 lifespan study|1003-29-20-174|20|989|n/a|n/a|n/a|
1003-29-20|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 790 ± 12 lifespan study|1003-29-20-175|20|989|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-20|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 790 ± 12 lifespan study|1003-29-20-176|20|997|n/a|n/a|n/a|
1003-29-20|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 790 ± 12 lifespan study|1003-29-20-177|20|999|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-20|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 790 ± 12 lifespan study|1003-29-20-178|20|999|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-20|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 790 ± 12 lifespan study|1003-29-20-179|20|1005|Neoplasia malignant|Liver among hepato-pancreatic system diseases|THAC/|
1003-29-20|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 790 ± 12 lifespan study|1003-29-20-180|20|1009|n/a|n/a|n/a|
1003-29-20|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 790 ± 12 lifespan study|1003-29-20-181|20|1010|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-20|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 790 ± 12 lifespan study|1003-29-20-182|20|1011|Inflammation and/or fibrotic diseases|Lower respiratory system,MA: 0000415 - lung|MRMP/  MurineHead/neck missing Eye(s) missing,MPATH: 212 - inflammation|
1003-29-20|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 790 ± 12 lifespan study|1003-29-20-183|20|1016|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-20|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 790 ± 12 lifespan study|1003-29-20-184|20|1022|n/a|n/a|n/a|
1003-29-20|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 790 ± 12 lifespan study|1003-29-20-185|20|1028|n/a|n/a|n/a|
1003-29-20|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 790 ± 12 lifespan study|1003-29-20-186|20|1029|Other deterministic changes|Whole body|MCDU/|
1003-29-20|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 790 ± 12 lifespan study|1003-29-20-187|20|1029|n/a|n/a|n/a|
1003-29-20|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 790 ± 12 lifespan study|1003-29-20-188|20|1031|n/a|n/a|n/a|
1003-29-20|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 790 ± 12 lifespan study|1003-29-20-189|20|1032|n/a|n/a|n/a|
1003-29-20|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 790 ± 12 lifespan study|1003-29-20-190|20|1034|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-20|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 790 ± 12 lifespan study|1003-29-20-191|20|1037|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-20|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 790 ± 12 lifespan study|1003-29-20-192|20|1037|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-20|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 790 ± 12 lifespan study|1003-29-20-193|20|1039|n/a|n/a|n/a|
1003-29-20|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 790 ± 12 lifespan study|1003-29-20-194|20|1045|n/a|n/a|n/a|
1003-29-20|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 790 ± 12 lifespan study|1003-29-20-195|20|1046|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLSS/  undifferentiated lymphoma,MPATH: 513 - Lymphoid neoplasms|
1003-29-20|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 790 ± 12 lifespan study|1003-29-20-196|20|1046|n/a|n/a|n/a|
1003-29-20|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 790 ± 12 lifespan study|1003-29-20-197|20|1048|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-20|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 790 ± 12 lifespan study|1003-29-20-198|20|1052|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-20|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 790 ± 12 lifespan study|1003-29-20-199|20|1052|n/a|n/a|n/a|
1003-29-20|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 790 ± 12 lifespan study|1003-29-20-200|20|1053|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-20|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 790 ± 12 lifespan study|1003-29-20-201|20|1054|n/a|n/a|n/a|
1003-29-20|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 790 ± 12 lifespan study|1003-29-20-202|20|1054|n/a|n/a|n/a|
1003-29-20|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 790 ± 12 lifespan study|1003-29-20-203|20|1055|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-20|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 790 ± 12 lifespan study|1003-29-20-204|20|1058|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLSL/  undifferentiated leukemia lymphoret.tissue,MPATH: 335 - hematopoietic/lymphoid malignancies/disorder|
1003-29-20|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 790 ± 12 lifespan study|1003-29-20-205|20|1058|Neoplasia malignant|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOVS/   Metastases Uterus,MPATH: 242 - hemangiosarcoma|
1003-29-20|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 790 ± 12 lifespan study|1003-29-20-206|20|1066|Neoplasia malignant|Lower digestive tract,MA: 0000328 - intestine|TIEC/ stomach.Head/neck missing,MPATH: 549 - carcinoma|
1003-29-20|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 790 ± 12 lifespan study|1003-29-20-207|20|1068|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|TKAC/   Metastases Lung,MPATH: 549 - carcinoma|
1003-29-20|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 790 ± 12 lifespan study|1003-29-20-208|20|1069|n/a|n/a|n/a|
1003-29-20|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 790 ± 12 lifespan study|1003-29-20-209|20|1073|n/a|n/a|n/a|
1003-29-20|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 790 ± 12 lifespan study|1003-29-20-210|20|1074|n/a|n/a|n/a|
1003-29-20|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 790 ± 12 lifespan study|1003-29-20-211|20|1080|n/a|n/a|n/a|
1003-29-20|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 790 ± 12 lifespan study|1003-29-20-212|20|1082|Inflammation and/or fibrotic diseases|Other local manifestations and miscellaneus|MUCC/  Cystitis|
1003-29-20|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 790 ± 12 lifespan study|1003-29-20-213|20|1083|n/a|n/a|n/a|
1003-29-20|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 790 ± 12 lifespan study|1003-29-20-214|20|1086|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-20|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 790 ± 12 lifespan study|1003-29-20-215|20|1090|n/a|n/a|n/a|
1003-29-20|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 790 ± 12 lifespan study|1003-29-20-216|20|1091|n/a|n/a|n/a|
1003-29-20|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 790 ± 12 lifespan study|1003-29-20-217|20|1093|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-20|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 790 ± 12 lifespan study|1003-29-20-218|20|1094|n/a|n/a|n/a|
1003-29-20|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 790 ± 12 lifespan study|1003-29-20-219|20|1095|n/a|n/a|n/a|
1003-29-20|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 790 ± 12 lifespan study|1003-29-20-220|20|1098|n/a|n/a|n/a|
1003-29-20|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 790 ± 12 lifespan study|1003-29-20-221|20|1100|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-20|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 790 ± 12 lifespan study|1003-29-20-222|20|1109|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-29-20|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 790 ± 12 lifespan study|1003-29-20-223|20|1111|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-20|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 790 ± 12 lifespan study|1003-29-20-224|20|1113|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-29-20|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 790 ± 12 lifespan study|1003-29-20-225|20|1115|n/a|n/a|n/a|
1003-29-20|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 790 ± 12 lifespan study|1003-29-20-226|20|1116|n/a|n/a|n/a|
1003-29-20|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 790 ± 12 lifespan study|1003-29-20-227|20|1118|n/a|n/a|n/a|
1003-29-20|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 790 ± 12 lifespan study|1003-29-20-228|20|1119|n/a|n/a|n/a|
1003-29-20|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 790 ± 12 lifespan study|1003-29-20-229|20|1119|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|TCFS/ upper portion of lt forelimb. Metastases  tcfs invas of salivary gl. Metastases  Muscle tcfs invas of skel musc.,MPATH: 408 - soft tissue fibrosarcoma|
1003-29-20|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 790 ± 12 lifespan study|1003-29-20-230|20|1121|n/a|n/a|n/a|
1003-29-20|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 790 ± 12 lifespan study|1003-29-20-231|20|1130|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-20|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 790 ± 12 lifespan study|1003-29-20-232|20|1146|n/a|n/a|n/a|
1003-29-20|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 790 ± 12 lifespan study|1003-29-20-233|20|1152|n/a|n/a|n/a|
1003-29-20|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 790 ± 12 lifespan study|1003-29-20-234|20|1160|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-20|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 790 ± 12 lifespan study|1003-29-20-235|20|1163|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-20|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 790 ± 12 lifespan study|1003-29-20-236|20|1183|n/a|n/a|n/a|
1003-29-20|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 790 ± 12 lifespan study|1003-29-20-237|20|1184|n/a|n/a|n/a|
1003-29-20|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 790 ± 12 lifespan study|1003-29-20-238|20|1191|n/a|n/a|n/a|
1003-29-20|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 790 ± 12 lifespan study|1003-29-20-239|20|1205|n/a|n/a|n/a|
1003-29-20|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 790 ± 12 lifespan study|1003-29-20-240|20|1212|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases Liver,MPATH: 268 - adenocarcinoma|
1003-29-20|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 790 ± 12 lifespan study|1003-29-20-241|20|1214|n/a|n/a|n/a|
1003-29-20|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 790 ± 12 lifespan study|1003-29-20-242|20|1220|n/a|n/a|n/a|
1003-29-20|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 790 ± 12 lifespan study|1003-29-20-243|20|1222|n/a|n/a|n/a|
1003-29-20|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 790 ± 12 lifespan study|1003-29-20-244|20|1224|Inflammation and/or fibrotic diseases|Kidney among urinary system diseases,MA: 0000368 - kidney|MINA/  acute,MPATH: 212 - inflammation|
1003-29-20|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 790 ± 12 lifespan study|1003-29-20-245|20|1257|n/a|n/a|n/a|
1003-29-20|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 790 ± 12 lifespan study|1003-29-20-246|20|1258|Inflammation and/or fibrotic diseases|Other local manifestations and miscellaneus|MUCA/  Cystitis|
1003-29-20|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 790 ± 12 lifespan study|1003-29-20-247|20|1289|Neoplasia malignant|Adrenal gland  among endocrine systems,MA: 0000116 - adrenal gland|TACC/   Metastases Lung,MPATH: 549 - carcinoma|
1003-29-20|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 790 ± 12 lifespan study|1003-29-20-248|20|1303|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-20|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 790 ± 12 lifespan study|1003-29-20-249|20|1322|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-20|n/a,4X|1|100|neutrons fission|0.21|grays|External exposure|code 4X (4A  4X combined) 60 fractions 20 m 1/w|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 790 ± 12 lifespan study|1003-29-20-250|20|1329|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-21|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 779 ± 16 lifespan study|1003-29-21-1|21|160|Neoplasia unclassified|Other local manifestations and miscellaneus|TMWG: TGAC INVAS OF MUSC AROUND HARDERIAN GL.|
1003-29-21|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 779 ± 16 lifespan study|1003-29-21-2|21|294|Hyperplastic changes|Cardiovascular system|MPAN/  Polyarteritis nodosa|
1003-29-21|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 779 ± 16 lifespan study|1003-29-21-3|21|296|n/a|n/a|n/a|
1003-29-21|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 779 ± 16 lifespan study|1003-29-21-4|21|431|Hyperplastic changes|Cardiovascular system|MPAN/  Polyarteritis nodosa|
1003-29-21|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 779 ± 16 lifespan study|1003-29-21-5|21|450|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-21|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 779 ± 16 lifespan study|1003-29-21-6|21|477|Neoplasia malignant|Bloodvessels among cardiovascular system|TCVS/ subcut. invas. of muscle.|
1003-29-21|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 779 ± 16 lifespan study|1003-29-21-7|21|532|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-21|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 779 ± 16 lifespan study|1003-29-21-8|21|557|Changes due to an abnormal circulation|Bloodvessels among cardiovascular system|MTHR/  auricular|
1003-29-21|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 779 ± 16 lifespan study|1003-29-21-9|21|585|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-21|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 779 ± 16 lifespan study|1003-29-21-10|21|590|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-21|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 779 ± 16 lifespan study|1003-29-21-11|21|616|Neoplasia unclassified|Other local manifestations and miscellaneus|TLWR: TRAC TO BRACHIAL LYMPH NODE.|
1003-29-21|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 779 ± 16 lifespan study|1003-29-21-12|21|618|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/  Eye(s) missing,MPATH: 242 - hemangiosarcoma|
1003-29-21|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 779 ± 16 lifespan study|1003-29-21-13|21|628|n/a|n/a|n/a|
1003-29-21|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 779 ± 16 lifespan study|1003-29-21-14|21|640|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-21|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 779 ± 16 lifespan study|1003-29-21-15|21|644|Other deterministic changes|Whole body|MCDU/|
1003-29-21|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 779 ± 16 lifespan study|1003-29-21-16|21|648|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases  Muscle trac to skeletal muscle of thorax. Metastases  Lymphoret.System trac to brachial lymph node. Metastases  trac to visc. & parietal pleura.,MPATH: 268 - adenocarcinoma|
1003-29-21|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 779 ± 16 lifespan study|1003-29-21-17|21|659|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  Head/neck missing Eye(s) missing Thorax missing,MPATH: 513 - Lymphoid neoplasms|
1003-29-21|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 779 ± 16 lifespan study|1003-29-21-18|21|660|n/a|n/a|n/a|
1003-29-21|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 779 ± 16 lifespan study|1003-29-21-19|21|667|Other deterministic changes|Whole body|MCDU/|
1003-29-21|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 779 ± 16 lifespan study|1003-29-21-20|21|668|Other deterministic changes|Whole body|MCDU/|
1003-29-21|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 779 ± 16 lifespan study|1003-29-21-21|21|683|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-21|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 779 ± 16 lifespan study|1003-29-21-22|21|687|n/a|n/a|n/a|
1003-29-21|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 779 ± 16 lifespan study|1003-29-21-23|21|689|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  Eye(s) missing Head/neck missing,MPATH: 513 - Lymphoid neoplasms|
1003-29-21|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 779 ± 16 lifespan study|1003-29-21-24|21|692|Neoplasia unclassified|Other local manifestations and miscellaneus|TLWR: TRAC TO BRACHIAL LYMPH NODE.|
1003-29-21|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 779 ± 16 lifespan study|1003-29-21-25|21|695|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-21|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 779 ± 16 lifespan study|1003-29-21-26|21|701|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-29-21|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 779 ± 16 lifespan study|1003-29-21-27|21|702|Neoplasia unclassified|Other local manifestations and miscellaneus|TRWS: TSBC OF SKIN OF NECK/THROAT TO LUNG.|
1003-29-21|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 779 ± 16 lifespan study|1003-29-21-28|21|712|n/a|n/a|n/a|
1003-29-21|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 779 ± 16 lifespan study|1003-29-21-29|21|715|n/a|n/a|n/a|
1003-29-21|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 779 ± 16 lifespan study|1003-29-21-30|21|716|n/a|n/a|n/a|
1003-29-21|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 779 ± 16 lifespan study|1003-29-21-31|21|717|Hyperplastic changes|Cardiovascular system|MPAN/  Polyarteritis nodosa|
1003-29-21|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 779 ± 16 lifespan study|1003-29-21-32|21|717|Neoplasia malignant|Bloodvessels among cardiovascular system|TMVS/ thigh. Muscle Metastases Lung tmvs of thigh to lung.|
1003-29-21|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 779 ± 16 lifespan study|1003-29-21-33|21|729|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-21|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 779 ± 16 lifespan study|1003-29-21-34|21|732|n/a|n/a|n/a|
1003-29-21|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 779 ± 16 lifespan study|1003-29-21-35|21|739|n/a|n/a|n/a|
1003-29-21|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 779 ± 16 lifespan study|1003-29-21-36|21|743|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-21|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 779 ± 16 lifespan study|1003-29-21-37|21|750|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|TSBC/ skin of the neck/throat. Metastases Lung Metastases  tsbc of neck/throat invades salivary gland.,MPATH: 446 - squamous cell carcinoma|
1003-29-21|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 779 ± 16 lifespan study|1003-29-21-38|21|755|Neoplasia unclassified|Other local manifestations and miscellaneus|TRWS: TSBC OF SKIN OF NECK/THROAT TO LUNG.|
1003-29-21|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 779 ± 16 lifespan study|1003-29-21-39|21|762|Neoplasia unclassified|Other local manifestations and miscellaneus|TMWC: TCVS INVASION OF SKEL. MUSCLE OF FORELIMB.|
1003-29-21|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 779 ± 16 lifespan study|1003-29-21-40|21|773|n/a|n/a|n/a|
1003-29-21|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 779 ± 16 lifespan study|1003-29-21-41|21|774|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/  ,MPATH: 242 - hemangiosarcoma|
1003-29-21|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 779 ± 16 lifespan study|1003-29-21-42|21|775|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-21|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 779 ± 16 lifespan study|1003-29-21-43|21|776|n/a|n/a|n/a|
1003-29-21|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 779 ± 16 lifespan study|1003-29-21-44|21|786|n/a|n/a|n/a|
1003-29-21|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 779 ± 16 lifespan study|1003-29-21-45|21|787|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-21|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 779 ± 16 lifespan study|1003-29-21-46|21|788|Neoplasia unclassified|Other local manifestations and miscellaneus|TMWC: TCVS INVASION OF SKEL. MUSCLE OF FORELIMB.|
1003-29-21|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 779 ± 16 lifespan study|1003-29-21-47|21|792|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-21|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 779 ± 16 lifespan study|1003-29-21-48|21|792|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-21|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 779 ± 16 lifespan study|1003-29-21-49|21|793|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-21|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 779 ± 16 lifespan study|1003-29-21-50|21|799|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-21|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 779 ± 16 lifespan study|1003-29-21-51|21|799|n/a|n/a|n/a|
1003-29-21|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 779 ± 16 lifespan study|1003-29-21-52|21|800|n/a|n/a|n/a|
1003-29-21|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 779 ± 16 lifespan study|1003-29-21-53|21|807|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/  ,MPATH: 242 - hemangiosarcoma|
1003-29-21|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 779 ± 16 lifespan study|1003-29-21-54|21|817|Neoplasia unclassified|Other local manifestations and miscellaneus|TLWR: TRAC TO PTLN.|
1003-29-21|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 779 ± 16 lifespan study|1003-29-21-55|21|829|n/a|n/a|n/a|
1003-29-21|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 779 ± 16 lifespan study|1003-29-21-56|21|833|Neoplasia unclassified|Other local manifestations and miscellaneus|TMWR: TRAC TO THORACIC SPINAL MUSCLE, ESOPHAGUS & TRACHEA.|
1003-29-21|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 779 ± 16 lifespan study|1003-29-21-57|21|833|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-21|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 779 ± 16 lifespan study|1003-29-21-58|21|837|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  Head/neck missing,MPATH: 513 - Lymphoid neoplasms|
1003-29-21|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 779 ± 16 lifespan study|1003-29-21-59|21|844|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  Head/neck missing,MPATH: 513 - Lymphoid neoplasms|
1003-29-21|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 779 ± 16 lifespan study|1003-29-21-60|21|845|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases  Muscle tcvs invasion of skel. muscle of forelimb.,MPATH: 268 - adenocarcinoma|
1003-29-21|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 779 ± 16 lifespan study|1003-29-21-61|21|848|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  Head/neck missing,MPATH: 513 - Lymphoid neoplasms|
1003-29-21|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 779 ± 16 lifespan study|1003-29-21-62|21|852|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-21|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 779 ± 16 lifespan study|1003-29-21-63|21|859|Other deterministic changes|Whole body|MCDU/|
1003-29-21|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 779 ± 16 lifespan study|1003-29-21-64|21|861|Other deterministic changes|Whole body|MCDU/|
1003-29-21|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 779 ± 16 lifespan study|1003-29-21-65|21|863|Neoplasia unclassified|Other local manifestations and miscellaneus|TLWR: TRAC TO MEDIASTINAL NODE.|
1003-29-21|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 779 ± 16 lifespan study|1003-29-21-66|21|872|Neoplasia unclassified|Other local manifestations and miscellaneus|TLWR: TRAC TO MEDIASTINAL NODE.|
1003-29-21|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 779 ± 16 lifespan study|1003-29-21-67|21|881|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-21|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 779 ± 16 lifespan study|1003-29-21-68|21|883|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases  Lymphoret.System trac to mediastinal node.,MPATH: 268 - adenocarcinoma|
1003-29-21|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 779 ± 16 lifespan study|1003-29-21-69|21|884|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-21|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 779 ± 16 lifespan study|1003-29-21-70|21|886|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-21|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 779 ± 16 lifespan study|1003-29-21-71|21|890|n/a|n/a|n/a|
1003-29-21|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 779 ± 16 lifespan study|1003-29-21-72|21|890|n/a|n/a|n/a|
1003-29-21|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 779 ± 16 lifespan study|1003-29-21-73|21|891|Neoplasia malignant|Bloodvessels among cardiovascular system|TCVS/ between shoulders.|
1003-29-21|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 779 ± 16 lifespan study|1003-29-21-74|21|893|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  Eye(s) missing,MPATH: 513 - Lymphoid neoplasms|
1003-29-21|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 779 ± 16 lifespan study|1003-29-21-75|21|894|Other deterministic changes|Whole body|MCDU/|
1003-29-21|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 779 ± 16 lifespan study|1003-29-21-76|21|894|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-21|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 779 ± 16 lifespan study|1003-29-21-77|21|895|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases  trac to pleura. Metastases  Lymphoret.System trac to ptln.,MPATH: 268 - adenocarcinoma|
1003-29-21|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 779 ± 16 lifespan study|1003-29-21-78|21|902|Neoplasia unclassified|Other local manifestations and miscellaneus|TRWM: TMVS OF THIGH TO LUNG.|
1003-29-21|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 779 ± 16 lifespan study|1003-29-21-79|21|904|Neoplasia malignant|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|THVS/  ,MPATH: 242 - hemangiosarcoma|
1003-29-21|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 779 ± 16 lifespan study|1003-29-21-80|21|904|n/a|n/a|n/a|
1003-29-21|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 779 ± 16 lifespan study|1003-29-21-81|21|909|n/a|n/a|n/a|
1003-29-21|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 779 ± 16 lifespan study|1003-29-21-82|21|911|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  Head/neck missing,MPATH: 513 - Lymphoid neoplasms|
1003-29-21|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 779 ± 16 lifespan study|1003-29-21-83|21|915|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/  ,MPATH: 242 - hemangiosarcoma|
1003-29-21|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 779 ± 16 lifespan study|1003-29-21-84|21|920|n/a|n/a|n/a|
1003-29-21|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 779 ± 16 lifespan study|1003-29-21-85|21|921|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-21|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 779 ± 16 lifespan study|1003-29-21-86|21|921|Neoplasia benign|Lower digestive tract,MA: 0000323 - gastrointestinal system|TIPL/  Plaque pylorique region,MPATH: 491 - polyp|
1003-29-21|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 779 ± 16 lifespan study|1003-29-21-87|21|928|n/a|n/a|n/a|
1003-29-21|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 779 ± 16 lifespan study|1003-29-21-88|21|929|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/   Metastases  trac to pleura.,MPATH: 513 - Lymphoid neoplasms|
1003-29-21|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 779 ± 16 lifespan study|1003-29-21-89|21|930|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-21|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 779 ± 16 lifespan study|1003-29-21-90|21|931|n/a|n/a|n/a|
1003-29-21|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 779 ± 16 lifespan study|1003-29-21-91|21|934|Neoplasia malignant|Liver among hepato-pancreatic system diseases|THAC/|
1003-29-21|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 779 ± 16 lifespan study|1003-29-21-92|21|936|Degenerative changes|Kidney among urinary system diseases,MA: 0000368 - kidney|MCRD/  ,MPATH: 1 - cell and tissue damage|
1003-29-21|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 779 ± 16 lifespan study|1003-29-21-93|21|937|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/  ,MPATH: 242 - hemangiosarcoma|
1003-29-21|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 779 ± 16 lifespan study|1003-29-21-94|21|939|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  Head/neck missing Eye(s) missing,MPATH: 513 - Lymphoid neoplasms|
1003-29-21|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 779 ± 16 lifespan study|1003-29-21-95|21|956|Neoplasia malignant|Liver among hepato-pancreatic system diseases|THAC/|
1003-29-21|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 779 ± 16 lifespan study|1003-29-21-96|21|964|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-29-21|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 779 ± 16 lifespan study|1003-29-21-97|21|968|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-21|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 779 ± 16 lifespan study|1003-29-21-98|21|972|Other deterministic changes|Whole body|MCDU/|
1003-29-21|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 779 ± 16 lifespan study|1003-29-21-99|21|973|n/a|n/a|n/a|
1003-29-21|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 779 ± 16 lifespan study|1003-29-21-100|21|979|n/a|n/a|n/a|
1003-29-21|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 779 ± 16 lifespan study|1003-29-21-101|21|983|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  Head/neck missing,MPATH: 513 - Lymphoid neoplasms|
1003-29-21|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 779 ± 16 lifespan study|1003-29-21-102|21|990|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-21|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 779 ± 16 lifespan study|1003-29-21-103|21|992|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-21|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 779 ± 16 lifespan study|1003-29-21-104|21|996|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-21|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 779 ± 16 lifespan study|1003-29-21-105|21|999|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|TKAC/  ,MPATH: 549 - carcinoma|
1003-29-21|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 779 ± 16 lifespan study|1003-29-21-106|21|1003|Neoplasia unclassified|Other local manifestations and miscellaneus|TRWH: THAC TO LUNG.|
1003-29-21|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 779 ± 16 lifespan study|1003-29-21-107|21|1008|Neoplasia unclassified|Other local manifestations and miscellaneus|TMWG: TGAC INVAS OF MUSC AROUND HARDERIAN GL.|
1003-29-21|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 779 ± 16 lifespan study|1003-29-21-108|21|1008|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-21|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 779 ± 16 lifespan study|1003-29-21-109|21|1008|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/  ,MPATH: 242 - hemangiosarcoma|
1003-29-21|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 779 ± 16 lifespan study|1003-29-21-110|21|1013|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-21|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 779 ± 16 lifespan study|1003-29-21-111|21|1028|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-29-21|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 779 ± 16 lifespan study|1003-29-21-112|21|1028|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-21|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 779 ± 16 lifespan study|1003-29-21-113|21|1029|n/a|n/a|n/a|
1003-29-21|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 779 ± 16 lifespan study|1003-29-21-114|21|1035|Neoplasia malignant|Liver among hepato-pancreatic system diseases|THAC/|
1003-29-21|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 779 ± 16 lifespan study|1003-29-21-115|21|1036|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-21|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 779 ± 16 lifespan study|1003-29-21-116|21|1037|n/a|n/a|n/a|
1003-29-21|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 779 ± 16 lifespan study|1003-29-21-117|21|1044|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-21|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 779 ± 16 lifespan study|1003-29-21-118|21|1048|n/a|n/a|n/a|
1003-29-21|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 779 ± 16 lifespan study|1003-29-21-119|21|1053|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  Head/neck missing Eye(s) missing,MPATH: 513 - Lymphoid neoplasms|
1003-29-21|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 779 ± 16 lifespan study|1003-29-21-120|21|1055|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-21|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 779 ± 16 lifespan study|1003-29-21-121|21|1056|Neoplasia malignant|Liver among hepato-pancreatic system diseases|THAC/   Metastases Lung|
1003-29-21|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 779 ± 16 lifespan study|1003-29-21-122|21|1065|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-21|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 779 ± 16 lifespan study|1003-29-21-123|21|1066|n/a|n/a|n/a|
1003-29-21|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 779 ± 16 lifespan study|1003-29-21-124|21|1067|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-21|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 779 ± 16 lifespan study|1003-29-21-125|21|1070|n/a|n/a|n/a|
1003-29-21|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 779 ± 16 lifespan study|1003-29-21-126|21|1079|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-21|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 779 ± 16 lifespan study|1003-29-21-127|21|1081|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/   Metastases  Muscle trac to thoracic spinal muscle, esophagus & trachea.,MPATH: 513 - Lymphoid neoplasms|
1003-29-21|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 779 ± 16 lifespan study|1003-29-21-128|21|1082|Inflammation and/or fibrotic diseases|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|MHCN/  Coagulative focal hepatitis,MPATH: 212 - inflammation|
1003-29-21|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 779 ± 16 lifespan study|1003-29-21-129|21|1091|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  Eye(s) missing,MPATH: 513 - Lymphoid neoplasms|
1003-29-21|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 779 ± 16 lifespan study|1003-29-21-130|21|1093|Neoplasia malignant|Adrenal gland  among endocrine systems|TAPS/|
1003-29-21|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 779 ± 16 lifespan study|1003-29-21-131|21|1103|Neoplasia systemic|Haematolymphatic system|TLML/|
1003-29-21|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 779 ± 16 lifespan study|1003-29-21-132|21|1124|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/   Metastases  Muscle tgac invas of musc around harderian gl.,MPATH: 513 - Lymphoid neoplasms|
1003-29-21|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 779 ± 16 lifespan study|1003-29-21-133|21|1132|Neoplasia unclassified|Other local manifestations and miscellaneus|TMWC: TCVS INVASION OF SKEL. MUSCLE OF FORELIMB.|
1003-29-21|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 779 ± 16 lifespan study|1003-29-21-134|21|1134|n/a|n/a|n/a|
1003-29-21|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 779 ± 16 lifespan study|1003-29-21-135|21|1135|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-21|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 779 ± 16 lifespan study|1003-29-21-136|21|1151|n/a|n/a|n/a|
1003-29-21|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 779 ± 16 lifespan study|1003-29-21-137|21|1154|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-21|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 779 ± 16 lifespan study|1003-29-21-138|21|1162|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-29-21|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 779 ± 16 lifespan study|1003-29-21-139|21|1162|n/a|n/a|n/a|
1003-29-21|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 779 ± 16 lifespan study|1003-29-21-140|21|1180|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|TKAC/  Head/neck missing Eye(s) missing,MPATH: 549 - carcinoma|
1003-29-21|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 779 ± 16 lifespan study|1003-29-21-141|21|1183|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-21|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 779 ± 16 lifespan study|1003-29-21-142|21|1184|Neoplasia unclassified|Other local manifestations and miscellaneus|TLWR: TRAC TO PTLN.|
1003-29-21|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 779 ± 16 lifespan study|1003-29-21-143|21|1195|Other deterministic changes|Whole body|MCDU/|
1003-29-21|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 779 ± 16 lifespan study|1003-29-21-144|21|1205|Neoplasia malignant|Bloodvessels among cardiovascular system|TCVS/ ventral abd.; urogenital reg. Metastases  tcvs spread to peritoneum. Metastases  Muscle tcvs invades muscle.|
1003-29-21|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 779 ± 16 lifespan study|1003-29-21-145|21|1215|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-29-21|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 779 ± 16 lifespan study|1003-29-21-146|21|1216|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-21|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 779 ± 16 lifespan study|1003-29-21-147|21|1237|Neoplasia malignant|Bloodvessels among cardiovascular system|TCVS/ in the peritoneal cavity- lower rt. quadrant.|
1003-29-21|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 779 ± 16 lifespan study|1003-29-21-148|21|1243|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-29-21|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 779 ± 16 lifespan study|1003-29-21-149|21|1254|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-21|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 779 ± 16 lifespan study|1003-29-21-150|21|1377|Other deterministic changes|Whole body|MCDU/|
1003-29-22|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|150 records survival 771 ± 15 lifespan study|1003-29-22-1|22|404|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-22|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|150 records survival 771 ± 15 lifespan study|1003-29-22-2|22|404|n/a|n/a|n/a|
1003-29-22|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|150 records survival 771 ± 15 lifespan study|1003-29-22-3|22|407|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|TMAB/  Predominantly ductalHead/neck missing Thorax missing Eye(s) missing,MPATH: 218 - neoplasm|
1003-29-22|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|150 records survival 771 ± 15 lifespan study|1003-29-22-4|22|451|Neoplasia malignant|Other local manifestations and miscellaneus|TXUS/ TXUS/ TXUS/ TXUS/ salivary gland.|
1003-29-22|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|150 records survival 771 ± 15 lifespan study|1003-29-22-5|22|463|n/a|n/a|n/a|
1003-29-22|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|150 records survival 771 ± 15 lifespan study|1003-29-22-6|22|483|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/   Metastases  txus of salivary gland invading neck muscle.,MPATH: 513 - Lymphoid neoplasms|
1003-29-22|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|150 records survival 771 ± 15 lifespan study|1003-29-22-7|22|502|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases  Lymphoret.System trac to pt. l.n. Metastases Heart,MPATH: 268 - adenocarcinoma|
1003-29-22|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|150 records survival 771 ± 15 lifespan study|1003-29-22-8|22|505|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/   Metastases  trac to visc. periton.,MPATH: 513 - Lymphoid neoplasms|
1003-29-22|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|150 records survival 771 ± 15 lifespan study|1003-29-22-9|22|533|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-22|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|150 records survival 771 ± 15 lifespan study|1003-29-22-10|22|600|Hyperplastic changes|Cardiovascular system|MPAN/  Polyarteritis nodosaHead/neck missing|
1003-29-22|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|150 records survival 771 ± 15 lifespan study|1003-29-22-11|22|621|Hyperplastic changes|Other local manifestations and miscellaneus,MA: 0000003 - organ system|MOCY/  Ovary or testis,MPATH: 62 - cyst|
1003-29-22|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|150 records survival 771 ± 15 lifespan study|1003-29-22-12|22|641|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-22|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|150 records survival 771 ± 15 lifespan study|1003-29-22-13|22|642|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-22|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|150 records survival 771 ± 15 lifespan study|1003-29-22-14|22|646|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|TMAB/  Predominantly ductal,MPATH: 218 - neoplasm|
1003-29-22|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|150 records survival 771 ± 15 lifespan study|1003-29-22-15|22|661|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-22|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|150 records survival 771 ± 15 lifespan study|1003-29-22-16|22|666|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|TUVS/  ,MPATH: 242 - hemangiosarcoma|
1003-29-22|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|150 records survival 771 ± 15 lifespan study|1003-29-22-17|22|670|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-22|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|150 records survival 771 ± 15 lifespan study|1003-29-22-18|22|682|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-22|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|150 records survival 771 ± 15 lifespan study|1003-29-22-19|22|682|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-29-22|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|150 records survival 771 ± 15 lifespan study|1003-29-22-20|22|686|n/a|n/a|n/a|
1003-29-22|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|150 records survival 771 ± 15 lifespan study|1003-29-22-21|22|689|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-22|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|150 records survival 771 ± 15 lifespan study|1003-29-22-22|22|695|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-22|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|150 records survival 771 ± 15 lifespan study|1003-29-22-23|22|701|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-22|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|150 records survival 771 ± 15 lifespan study|1003-29-22-24|22|703|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/  ,MPATH: 242 - hemangiosarcoma|
1003-29-22|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|150 records survival 771 ± 15 lifespan study|1003-29-22-25|22|707|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/   Metastases  Muscle tmab to skeletal muscle.,MPATH: 513 - Lymphoid neoplasms|
1003-29-22|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|150 records survival 771 ± 15 lifespan study|1003-29-22-26|22|717|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|TCFS/ jaw. Metastases  Muscle tcfs infiltration of jaw muscle & bone.,MPATH: 408 - soft tissue fibrosarcoma|
1003-29-22|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|150 records survival 771 ± 15 lifespan study|1003-29-22-27|22|718|n/a|n/a|n/a|
1003-29-22|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|150 records survival 771 ± 15 lifespan study|1003-29-22-28|22|719|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-22|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|150 records survival 771 ± 15 lifespan study|1003-29-22-29|22|723|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-22|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|150 records survival 771 ± 15 lifespan study|1003-29-22-30|22|724|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|TPAC/  Carcinoma Metastases  tpac invades brain.,MPATH: 218 - neoplasm|
1003-29-22|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|150 records survival 771 ± 15 lifespan study|1003-29-22-31|22|726|n/a|n/a|n/a|
1003-29-22|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|150 records survival 771 ± 15 lifespan study|1003-29-22-32|22|740|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  Eye(s) missing Head/neck missing,MPATH: 513 - Lymphoid neoplasms|
1003-29-22|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|150 records survival 771 ± 15 lifespan study|1003-29-22-33|22|743|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-22|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|150 records survival 771 ± 15 lifespan study|1003-29-22-34|22|745|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-22|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|150 records survival 771 ± 15 lifespan study|1003-29-22-35|22|749|Other deterministic changes|Whole body|MCDU/|
1003-29-22|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|150 records survival 771 ± 15 lifespan study|1003-29-22-36|22|751|Other deterministic changes|Whole body|MCDU/|
1003-29-22|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|150 records survival 771 ± 15 lifespan study|1003-29-22-37|22|752|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-22|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|150 records survival 771 ± 15 lifespan study|1003-29-22-38|22|759|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-22|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|150 records survival 771 ± 15 lifespan study|1003-29-22-39|22|763|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-22|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|150 records survival 771 ± 15 lifespan study|1003-29-22-40|22|767|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-22|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|150 records survival 771 ± 15 lifespan study|1003-29-22-41|22|771|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  Head/neck missing,MPATH: 513 - Lymphoid neoplasms|
1003-29-22|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|150 records survival 771 ± 15 lifespan study|1003-29-22-42|22|779|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-22|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|150 records survival 771 ± 15 lifespan study|1003-29-22-43|22|779|n/a|n/a|n/a|
1003-29-22|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|150 records survival 771 ± 15 lifespan study|1003-29-22-44|22|786|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|TPAC/  Carcinoma,MPATH: 218 - neoplasm|
1003-29-22|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|150 records survival 771 ± 15 lifespan study|1003-29-22-45|22|786|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-22|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|150 records survival 771 ± 15 lifespan study|1003-29-22-46|22|793|n/a|n/a|n/a|
1003-29-22|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|150 records survival 771 ± 15 lifespan study|1003-29-22-47|22|795|Neoplasia malignant|Adrenal gland  among endocrine systems|TAPS/|
1003-29-22|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|150 records survival 771 ± 15 lifespan study|1003-29-22-48|22|797|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-22|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|150 records survival 771 ± 15 lifespan study|1003-29-22-49|22|801|Hyperplastic changes|Cardiovascular system|MPAN/  Polyarteritis nodosa|
1003-29-22|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|150 records survival 771 ± 15 lifespan study|1003-29-22-50|22|812|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-22|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|150 records survival 771 ± 15 lifespan study|1003-29-22-51|22|813|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-22|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|150 records survival 771 ± 15 lifespan study|1003-29-22-52|22|816|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-22|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|150 records survival 771 ± 15 lifespan study|1003-29-22-53|22|820|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLSL/  undifferentiated leukemia lymphoret.tissue,MPATH: 335 - hematopoietic/lymphoid malignancies/disorder|
1003-29-22|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|150 records survival 771 ± 15 lifespan study|1003-29-22-54|22|821|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/   Metastases  invasion of abd. cavity & growth on visceral perit. of spleen & kidney by tmab.,MPATH: 513 - Lymphoid neoplasms|
1003-29-22|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|150 records survival 771 ± 15 lifespan study|1003-29-22-55|22|825|n/a|n/a|n/a|
1003-29-22|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|150 records survival 771 ± 15 lifespan study|1003-29-22-56|22|828|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-22|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|150 records survival 771 ± 15 lifespan study|1003-29-22-57|22|834|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|TUVS/  ,MPATH: 242 - hemangiosarcoma|
1003-29-22|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|150 records survival 771 ± 15 lifespan study|1003-29-22-58|22|838|Other deterministic changes|Whole body|MCDU/|
1003-29-22|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|150 records survival 771 ± 15 lifespan study|1003-29-22-59|22|842|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-22|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|150 records survival 771 ± 15 lifespan study|1003-29-22-60|22|845|Inflammation and/or fibrotic diseases|Lower respiratory system,MA: 0000415 - lung|MPNU/  Acute and subacute,MPATH: 212 - inflammation|
1003-29-22|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|150 records survival 771 ± 15 lifespan study|1003-29-22-61|22|848|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-22|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|150 records survival 771 ± 15 lifespan study|1003-29-22-62|22|849|n/a|n/a|n/a|
1003-29-22|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|150 records survival 771 ± 15 lifespan study|1003-29-22-63|22|850|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-22|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|150 records survival 771 ± 15 lifespan study|1003-29-22-64|22|850|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLSL/  undifferentiated leukemia lymphoret.tissue,MPATH: 335 - hematopoietic/lymphoid malignancies/disorder|
1003-29-22|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|150 records survival 771 ± 15 lifespan study|1003-29-22-65|22|851|Neoplasia systemic|Haematolymphatic system|TLPS/|
1003-29-22|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|150 records survival 771 ± 15 lifespan study|1003-29-22-66|22|853|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-22|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|150 records survival 771 ± 15 lifespan study|1003-29-22-67|22|869|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-29-22|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|150 records survival 771 ± 15 lifespan study|1003-29-22-68|22|869|Inflammation and/or fibrotic diseases|Lower respiratory system,MA: 0000415 - lung|MRMP/  Murine,MPATH: 212 - inflammation|
1003-29-22|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|150 records survival 771 ± 15 lifespan study|1003-29-22-69|22|871|n/a|n/a|n/a|
1003-29-22|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|150 records survival 771 ± 15 lifespan study|1003-29-22-70|22|878|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-22|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|150 records survival 771 ± 15 lifespan study|1003-29-22-71|22|883|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-22|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|150 records survival 771 ± 15 lifespan study|1003-29-22-72|22|883|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-22|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|150 records survival 771 ± 15 lifespan study|1003-29-22-73|22|884|n/a|n/a|n/a|
1003-29-22|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|150 records survival 771 ± 15 lifespan study|1003-29-22-74|22|891|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-22|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|150 records survival 771 ± 15 lifespan study|1003-29-22-75|22|892|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-22|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|150 records survival 771 ± 15 lifespan study|1003-29-22-76|22|892|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|TCFS/ on back-- subcutaneous.,MPATH: 408 - soft tissue fibrosarcoma|
1003-29-22|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|150 records survival 771 ± 15 lifespan study|1003-29-22-77|22|894|Inflammation and/or fibrotic diseases|Other local manifestations and miscellaneus|MMTA/  Metritis|
1003-29-22|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|150 records survival 771 ± 15 lifespan study|1003-29-22-78|22|895|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  Head/neck missing Eye(s) missing,MPATH: 268 - adenocarcinoma|
1003-29-22|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|150 records survival 771 ± 15 lifespan study|1003-29-22-79|22|898|Hyperplastic changes|Other local manifestations and miscellaneus,MA: 0000003 - organ system|MOCY/  Ovary or testis,MPATH: 62 - cyst|
1003-29-22|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|150 records survival 771 ± 15 lifespan study|1003-29-22-80|22|899|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-22|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|150 records survival 771 ± 15 lifespan study|1003-29-22-81|22|899|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-22|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|150 records survival 771 ± 15 lifespan study|1003-29-22-82|22|900|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-22|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|150 records survival 771 ± 15 lifespan study|1003-29-22-83|22|905|n/a|n/a|n/a|
1003-29-22|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|150 records survival 771 ± 15 lifespan study|1003-29-22-84|22|905|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  Eye(s) missing Head/neck missing,MPATH: 513 - Lymphoid neoplasms|
1003-29-22|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|150 records survival 771 ± 15 lifespan study|1003-29-22-85|22|910|Neoplasia malignant|Other local manifestations and miscellaneus|TXUS/ TXUS/ TXUS/ TXUS/ in soft tiss of abdom cavity.|
1003-29-22|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|150 records survival 771 ± 15 lifespan study|1003-29-22-86|22|911|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/ with leukemia.,MPATH: 513 - Lymphoid neoplasms|
1003-29-22|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|150 records survival 771 ± 15 lifespan study|1003-29-22-87|22|917|n/a|n/a|n/a|
1003-29-22|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|150 records survival 771 ± 15 lifespan study|1003-29-22-88|22|927|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-29-22|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|150 records survival 771 ± 15 lifespan study|1003-29-22-89|22|929|n/a|n/a|n/a|
1003-29-22|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|150 records survival 771 ± 15 lifespan study|1003-29-22-90|22|931|n/a|n/a|n/a|
1003-29-22|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|150 records survival 771 ± 15 lifespan study|1003-29-22-91|22|932|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-22|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|150 records survival 771 ± 15 lifespan study|1003-29-22-92|22|935|Neoplasia malignant|Other local manifestations and miscellaneus|TXUS/ TXUS/ TXUS/ TXUS/ sclera of eye. Metastases  txus of sclera of the eye metastatis to eye adnexal muscles.|
1003-29-22|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|150 records survival 771 ± 15 lifespan study|1003-29-22-93|22|940|n/a|n/a|n/a|
1003-29-22|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|150 records survival 771 ± 15 lifespan study|1003-29-22-94|22|942|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-22|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|150 records survival 771 ± 15 lifespan study|1003-29-22-95|22|942|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-22|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|150 records survival 771 ± 15 lifespan study|1003-29-22-96|22|952|n/a|n/a|n/a|
1003-29-22|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|150 records survival 771 ± 15 lifespan study|1003-29-22-97|22|957|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-29-22|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|150 records survival 771 ± 15 lifespan study|1003-29-22-98|22|961|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  Head/neck missing,MPATH: 513 - Lymphoid neoplasms|
1003-29-22|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|150 records survival 771 ± 15 lifespan study|1003-29-22-99|22|964|n/a|n/a|n/a|
1003-29-22|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|150 records survival 771 ± 15 lifespan study|1003-29-22-100|22|967|n/a|n/a|n/a|
1003-29-22|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|150 records survival 771 ± 15 lifespan study|1003-29-22-101|22|971|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-22|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|150 records survival 771 ± 15 lifespan study|1003-29-22-102|22|973|n/a|n/a|n/a|
1003-29-22|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|150 records survival 771 ± 15 lifespan study|1003-29-22-103|22|974|n/a|n/a|n/a|
1003-29-22|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|150 records survival 771 ± 15 lifespan study|1003-29-22-104|22|976|Neoplasia malignant|Lower digestive tract,MA: 0000328 - intestine|TIAO/ pylorus.,MPATH: 549 - carcinoma|
1003-29-22|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|150 records survival 771 ± 15 lifespan study|1003-29-22-105|22|976|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-22|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|150 records survival 771 ± 15 lifespan study|1003-29-22-106|22|979|Neoplasia malignant|Bone among musculo-skeletal system diseases|TBOS/ sacral spine.|
1003-29-22|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|150 records survival 771 ± 15 lifespan study|1003-29-22-107|22|979|Inflammation and/or fibrotic diseases|Lower respiratory system,MA: 0000415 - lung|MRMP/  MurineHead/neck missing,MPATH: 212 - inflammation|
1003-29-22|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|150 records survival 771 ± 15 lifespan study|1003-29-22-108|22|980|n/a|n/a|n/a|
1003-29-22|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|150 records survival 771 ± 15 lifespan study|1003-29-22-109|22|981|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-22|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|150 records survival 771 ± 15 lifespan study|1003-29-22-110|22|983|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-22|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|150 records survival 771 ± 15 lifespan study|1003-29-22-111|22|996|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  Head/neck missing,MPATH: 513 - Lymphoid neoplasms|
1003-29-22|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|150 records survival 771 ± 15 lifespan study|1003-29-22-112|22|997|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-22|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|150 records survival 771 ± 15 lifespan study|1003-29-22-113|22|1004|Neoplasia systemic|Haematolymphatic system|TLML/   Metastases  Muscle trac to diaphragmatic musc.|
1003-29-22|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|150 records survival 771 ± 15 lifespan study|1003-29-22-114|22|1005|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-22|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|150 records survival 771 ± 15 lifespan study|1003-29-22-115|22|1017|Neoplasia malignant|Liver among hepato-pancreatic system diseases|THAC/   Metastases LungHead/neck missing Eye(s) missing|
1003-29-22|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|150 records survival 771 ± 15 lifespan study|1003-29-22-116|22|1017|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-22|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|150 records survival 771 ± 15 lifespan study|1003-29-22-117|22|1018|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|TMAB/  Predominantly ductal,MPATH: 218 - neoplasm|
1003-29-22|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|150 records survival 771 ± 15 lifespan study|1003-29-22-118|22|1020|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-22|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|150 records survival 771 ± 15 lifespan study|1003-29-22-119|22|1020|Neoplasia malignant|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|THVS/  ,MPATH: 242 - hemangiosarcoma|
1003-29-22|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|150 records survival 771 ± 15 lifespan study|1003-29-22-120|22|1028|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-22|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|150 records survival 771 ± 15 lifespan study|1003-29-22-121|22|1041|n/a|n/a|n/a|
1003-29-22|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|150 records survival 771 ± 15 lifespan study|1003-29-22-122|22|1050|Hyperplastic changes|Cardiovascular system|MPAN/  Polyarteritis nodosa|
1003-29-22|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|150 records survival 771 ± 15 lifespan study|1003-29-22-123|22|1053|n/a|n/a|n/a|
1003-29-22|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|150 records survival 771 ± 15 lifespan study|1003-29-22-124|22|1065|n/a|n/a|n/a|
1003-29-22|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|150 records survival 771 ± 15 lifespan study|1003-29-22-125|22|1071|n/a|n/a|n/a|
1003-29-22|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|150 records survival 771 ± 15 lifespan study|1003-29-22-126|22|1072|n/a|n/a|n/a|
1003-29-22|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|150 records survival 771 ± 15 lifespan study|1003-29-22-127|22|1093|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-22|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|150 records survival 771 ± 15 lifespan study|1003-29-22-128|22|1094|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-22|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|150 records survival 771 ± 15 lifespan study|1003-29-22-129|22|1096|Inflammation and/or fibrotic diseases|Lower respiratory system,MA: 0000415 - lung|MRMP/  Murine,MPATH: 212 - inflammation|
1003-29-22|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|150 records survival 771 ± 15 lifespan study|1003-29-22-130|22|1104|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-29-22|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|150 records survival 771 ± 15 lifespan study|1003-29-22-131|22|1105|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  Eye(s) missing,MPATH: 513 - Lymphoid neoplasms|
1003-29-22|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|150 records survival 771 ± 15 lifespan study|1003-29-22-132|22|1111|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases  Lymphoret.System trac to pt ln.,MPATH: 268 - adenocarcinoma|
1003-29-22|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|150 records survival 771 ± 15 lifespan study|1003-29-22-133|22|1114|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|TCFS/ ventral lower abdominal region with infiltration of outer musc. wall & to a lesser extent of mucosa of the gut.,MPATH: 408 - soft tissue fibrosarcoma|
1003-29-22|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|150 records survival 771 ± 15 lifespan study|1003-29-22-134|22|1114|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-22|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|150 records survival 771 ± 15 lifespan study|1003-29-22-135|22|1121|Degenerative changes|Kidney among urinary system diseases,MA: 0000368 - kidney|MCRD/  ,MPATH: 1 - cell and tissue damage|
1003-29-22|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|150 records survival 771 ± 15 lifespan study|1003-29-22-136|22|1122|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-22|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|150 records survival 771 ± 15 lifespan study|1003-29-22-137|22|1128|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-22|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|150 records survival 771 ± 15 lifespan study|1003-29-22-138|22|1140|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-22|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|150 records survival 771 ± 15 lifespan study|1003-29-22-139|22|1144|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-22|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|150 records survival 771 ± 15 lifespan study|1003-29-22-140|22|1148|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-22|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|150 records survival 771 ± 15 lifespan study|1003-29-22-141|22|1150|Neoplasia unclassified|Ovary among reproductive system diseases|TOGC/|
1003-29-22|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|150 records survival 771 ± 15 lifespan study|1003-29-22-142|22|1184|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOVO/  ,MPATH: 242 - hemangiosarcoma|
1003-29-22|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|150 records survival 771 ± 15 lifespan study|1003-29-22-143|22|1196|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-22|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|150 records survival 771 ± 15 lifespan study|1003-29-22-144|22|1197|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-22|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|150 records survival 771 ± 15 lifespan study|1003-29-22-145|22|1201|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-22|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|150 records survival 771 ± 15 lifespan study|1003-29-22-146|22|1215|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-22|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|150 records survival 771 ± 15 lifespan study|1003-29-22-147|22|1235|n/a|n/a|n/a|
1003-29-22|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|150 records survival 771 ± 15 lifespan study|1003-29-22-148|22|1247|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-29-22|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|150 records survival 771 ± 15 lifespan study|1003-29-22-149|22|1258|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-22|n/a,5X|1|100|neutrons fission|0.3|grays|External exposure|code 5X (5A  5X combined) 60 fractions 20 m 1/w|150 (150 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|150 records survival 771 ± 15 lifespan study|1003-29-22-150|22|1258|n/a|n/a|n/a|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-1|23|135|n/a|n/a|n/a|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-2|23|135|n/a|n/a|n/a|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-3|23|135|n/a|n/a|n/a|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-4|23|170|n/a|n/a|n/a|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-5|23|170|n/a|n/a|n/a|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-6|23|170|n/a|n/a|n/a|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-7|23|170|n/a|n/a|n/a|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-8|23|170|n/a|n/a|n/a|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-9|23|170|n/a|n/a|n/a|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-10|23|170|n/a|n/a|n/a|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-11|23|170|n/a|n/a|n/a|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-12|23|170|n/a|n/a|n/a|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-13|23|170|n/a|n/a|n/a|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-14|23|170|n/a|n/a|n/a|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-15|23|170|n/a|n/a|n/a|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-16|23|170|n/a|n/a|n/a|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-17|23|170|n/a|n/a|n/a|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-18|23|170|n/a|n/a|n/a|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-19|23|170|n/a|n/a|n/a|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-20|23|170|n/a|n/a|n/a|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-21|23|177|n/a|n/a|n/a|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-22|23|177|n/a|n/a|n/a|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-23|23|177|n/a|n/a|n/a|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-24|23|212|n/a|n/a|n/a|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-25|23|212|n/a|n/a|n/a|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-26|23|213|n/a|n/a|n/a|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-27|23|213|n/a|n/a|n/a|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-28|23|213|n/a|n/a|n/a|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-29|23|213|n/a|n/a|n/a|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-30|23|220|n/a|n/a|n/a|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-31|23|253|n/a|n/a|n/a|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-32|23|269|Hyperplastic changes|Cardiovascular system|MPAN/  Polyarteritis nodosa|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-33|23|275|n/a|n/a|n/a|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-34|23|275|n/a|n/a|n/a|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-35|23|275|n/a|n/a|n/a|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-36|23|275|n/a|n/a|n/a|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-37|23|275|n/a|n/a|n/a|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-38|23|275|n/a|n/a|n/a|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-39|23|275|n/a|n/a|n/a|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-40|23|275|n/a|n/a|n/a|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-41|23|275|n/a|n/a|n/a|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-42|23|275|n/a|n/a|n/a|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-43|23|275|n/a|n/a|n/a|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-44|23|275|n/a|n/a|n/a|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-45|23|275|n/a|n/a|n/a|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-46|23|275|n/a|n/a|n/a|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-47|23|275|n/a|n/a|n/a|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-48|23|275|n/a|n/a|n/a|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-49|23|275|n/a|n/a|n/a|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-50|23|275|n/a|n/a|n/a|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-51|23|282|n/a|n/a|n/a|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-52|23|282|Neoplasia unclassified|Other local manifestations and miscellaneus|TMWG: TGAC INVADES ADJACENT MUSC.|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-53|23|282|n/a|n/a|n/a|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-54|23|282|n/a|n/a|n/a|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-55|23|282|Neoplasia unclassified|Other local manifestations and miscellaneus|TMWG: TGAC INVADES ADJACENT MUSC.|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-56|23|380|n/a|n/a|n/a|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-57|23|380|n/a|n/a|n/a|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-58|23|380|n/a|n/a|n/a|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-59|23|380|n/a|n/a|n/a|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-60|23|380|n/a|n/a|n/a|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-61|23|380|n/a|n/a|n/a|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-62|23|380|n/a|n/a|n/a|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-63|23|380|n/a|n/a|n/a|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-64|23|380|n/a|n/a|n/a|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-65|23|384|n/a|n/a|n/a|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-66|23|387|n/a|n/a|n/a|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-67|23|387|n/a|n/a|n/a|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-68|23|387|n/a|n/a|n/a|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-69|23|387|n/a|n/a|n/a|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-70|23|387|n/a|n/a|n/a|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-71|23|387|n/a|n/a|n/a|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-72|23|387|n/a|n/a|n/a|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-73|23|391|Neoplasia unclassified|Other local manifestations and miscellaneus|TMWG: TGAC INVADES ADJACENT MUSC.|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-74|23|391|n/a|n/a|n/a|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-75|23|391|Neoplasia unclassified|Other local manifestations and miscellaneus|TMWG: TGAC INVADES ADJACENT MUSC.|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-76|23|417|n/a|n/a|n/a|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-77|23|417|n/a|n/a|n/a|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-78|23|417|n/a|n/a|n/a|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-79|23|417|n/a|n/a|n/a|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-80|23|417|n/a|n/a|n/a|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-81|23|417|n/a|n/a|n/a|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-82|23|417|n/a|n/a|n/a|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-83|23|417|n/a|n/a|n/a|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-84|23|417|n/a|n/a|n/a|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-85|23|424|n/a|n/a|n/a|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-86|23|424|n/a|n/a|n/a|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-87|23|424|n/a|n/a|n/a|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-88|23|424|n/a|n/a|n/a|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-89|23|450|n/a|n/a|n/a|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-90|23|450|n/a|n/a|n/a|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-91|23|450|n/a|n/a|n/a|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-92|23|450|n/a|n/a|n/a|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-93|23|450|n/a|n/a|n/a|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-94|23|457|n/a|n/a|n/a|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-95|23|471|n/a|n/a|n/a|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-96|23|498|Neoplasia benign|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVO/  Head/neck missing Eye(s) missing,MPATH: 240 - hemangioma|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-97|23|520|n/a|n/a|n/a|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-98|23|520|n/a|n/a|n/a|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-99|23|520|n/a|n/a|n/a|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-100|23|520|n/a|n/a|n/a|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-101|23|520|n/a|n/a|n/a|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-102|23|521|n/a|n/a|n/a|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-103|23|521|n/a|n/a|n/a|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-104|23|521|n/a|n/a|n/a|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-105|23|521|n/a|n/a|n/a|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-106|23|521|n/a|n/a|n/a|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-107|23|527|n/a|n/a|n/a|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-108|23|527|n/a|n/a|n/a|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-109|23|527|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-110|23|527|n/a|n/a|n/a|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-111|23|527|n/a|n/a|n/a|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-112|23|527|n/a|n/a|n/a|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-113|23|528|n/a|n/a|n/a|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-114|23|528|n/a|n/a|n/a|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-115|23|528|n/a|n/a|n/a|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-116|23|543|n/a|n/a|n/a|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-117|23|543|n/a|n/a|n/a|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-118|23|548|n/a|n/a|n/a|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-119|23|548|n/a|n/a|n/a|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-120|23|548|n/a|n/a|n/a|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-121|23|548|n/a|n/a|n/a|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-122|23|548|n/a|n/a|n/a|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-123|23|548|n/a|n/a|n/a|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-124|23|548|n/a|n/a|n/a|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-125|23|548|n/a|n/a|n/a|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-126|23|548|n/a|n/a|n/a|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-127|23|548|n/a|n/a|n/a|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-128|23|555|n/a|n/a|n/a|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-129|23|555|n/a|n/a|n/a|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-130|23|555|n/a|n/a|n/a|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-131|23|555|n/a|n/a|n/a|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-132|23|555|n/a|n/a|n/a|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-133|23|562|n/a|n/a|n/a|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-134|23|562|n/a|n/a|n/a|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-135|23|562|n/a|n/a|n/a|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-136|23|562|n/a|n/a|n/a|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-137|23|569|n/a|n/a|n/a|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-138|23|569|n/a|n/a|n/a|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-139|23|569|n/a|n/a|n/a|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-140|23|569|n/a|n/a|n/a|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-141|23|569|n/a|n/a|n/a|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-142|23|569|n/a|n/a|n/a|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-143|23|569|n/a|n/a|n/a|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-144|23|569|n/a|n/a|n/a|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-145|23|569|n/a|n/a|n/a|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-146|23|569|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-147|23|569|n/a|n/a|n/a|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-148|23|583|n/a|n/a|n/a|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-149|23|583|n/a|n/a|n/a|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-150|23|583|n/a|n/a|n/a|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-151|23|583|n/a|n/a|n/a|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-152|23|583|n/a|n/a|n/a|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-153|23|590|Neoplasia malignant|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|THVS/  ,MPATH: 242 - hemangiosarcoma|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-154|23|598|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases  trac to mediastinum & pleura of thorax. Metastases  Lymphoret.System trac to parathymus & brachial l.n.'s.,MPATH: 268 - adenocarcinoma|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-155|23|600|n/a|n/a|n/a|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-156|23|603|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-157|23|610|n/a|n/a|n/a|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-158|23|624|n/a|n/a|n/a|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-159|23|625|n/a|n/a|n/a|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-160|23|625|n/a|n/a|n/a|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-161|23|625|n/a|n/a|n/a|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-162|23|625|n/a|n/a|n/a|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-163|23|625|n/a|n/a|n/a|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-164|23|625|n/a|n/a|n/a|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-165|23|625|n/a|n/a|n/a|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-166|23|625|n/a|n/a|n/a|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-167|23|625|n/a|n/a|n/a|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-168|23|625|n/a|n/a|n/a|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-169|23|625|n/a|n/a|n/a|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-170|23|625|n/a|n/a|n/a|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-171|23|626|n/a|n/a|n/a|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-172|23|626|n/a|n/a|n/a|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-173|23|626|n/a|n/a|n/a|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-174|23|631|n/a|n/a|n/a|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-175|23|632|n/a|n/a|n/a|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-176|23|632|Neoplasia malignant|Bloodvessels among cardiovascular system|TTVS/  Testis|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-177|23|632|n/a|n/a|n/a|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-178|23|633|n/a|n/a|n/a|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-179|23|638|n/a|n/a|n/a|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-180|23|655|n/a|n/a|n/a|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-181|23|657|Neoplasia malignant|Bloodvessels among cardiovascular system|TCVS/ rt. hip. Metastases  Skin tcvs to skin of rt. hip. Metastases  Muscle tcvs to muscle of rt. hip.|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-182|23|658|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/  ,MPATH: 242 - hemangiosarcoma|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-183|23|669|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-184|23|676|Neoplasia malignant|Bloodvessels among cardiovascular system|TXVS/ in mesenteries & invasion of pancreas.|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-185|23|678|Neoplasia systemic|Haematolymphatic system|TLML/|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-186|23|718|n/a|n/a|n/a|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-187|23|722|Other deterministic changes|Whole body|MCDU/|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-188|23|725|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases Kidney Metastases  trac invasion of mediastinum, visc. pleura, heart, lung. Metastases Liver,MPATH: 268 - adenocarcinoma|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-189|23|726|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|TCFS/ lumbar region - surrounds kidneys.,MPATH: 408 - soft tissue fibrosarcoma|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-190|23|729|n/a|n/a|n/a|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-191|23|729|n/a|n/a|n/a|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-192|23|729|n/a|n/a|n/a|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-193|23|736|Neoplasia unclassified|Other local manifestations and miscellaneus|THWR: TRAC TO LIVER.|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-194|23|736|n/a|n/a|n/a|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-195|23|736|n/a|n/a|n/a|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-196|23|736|n/a|n/a|n/a|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-197|23|736|Neoplasia unclassified|Other local manifestations and miscellaneus|THWR: TRAC TO LIVER.|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-198|23|736|n/a|n/a|n/a|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-199|23|736|Neoplasia unclassified|Other local manifestations and miscellaneus|THWR: TRAC TO LIVER.|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-200|23|739|n/a|n/a|n/a|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-201|23|739|Neoplasia malignant|Bloodvessels among cardiovascular system|TNVS/ brain. Metastases Heart|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-202|23|739|Neoplasia unclassified|Other local manifestations and miscellaneus|TMWC: TCFS IN BONE & MUSCLE OF SPINE.|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-203|23|745|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-204|23|745|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-205|23|763|Other deterministic changes|Whole body|MCDU/  Eye(s) missing Head/neck missing Thorax missing|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-206|23|766|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-207|23|773|Neoplasia malignant|Bloodvessels among cardiovascular system|TTVS/  Testis|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-208|23|782|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-209|23|785|n/a|n/a|n/a|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-210|23|785|n/a|n/a|n/a|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-211|23|792|n/a|n/a|n/a|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-212|23|799|n/a|n/a|n/a|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-213|23|799|n/a|n/a|n/a|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-214|23|799|n/a|n/a|n/a|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-215|23|804|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-216|23|806|n/a|n/a|n/a|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-217|23|806|Neoplasia unclassified|Other local manifestations and miscellaneus|THWR: TRAC TO LIVER.|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-218|23|806|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-219|23|806|n/a|n/a|n/a|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-220|23|815|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  Head/neck missing,MPATH: 513 - Lymphoid neoplasms|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-221|23|824|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-222|23|832|Neoplasia malignant|Nervous system and special sense organs,MA: 0000016 - nervous system|TNMS/ brain.,MPATH: 551 - sarcoma|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-223|23|834|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-224|23|843|Neoplasia malignant|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|THVS/  ,MPATH: 242 - hemangiosarcoma|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-225|23|844|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-226|23|849|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  Head/neck missing Eye(s) missing,MPATH: 513 - Lymphoid neoplasms|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-227|23|860|n/a|n/a|n/a|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-228|23|869|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases  trac to parietal pleura, rib cage. Metastases  Muscle trac to rib cage musc.,MPATH: 268 - adenocarcinoma|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-229|23|869|Neoplasia unclassified|Other local manifestations and miscellaneus|TMWC: TCVS TO MUSCLE OF RT. HIP.|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-230|23|876|Neoplasia malignant|Liver among hepato-pancreatic system diseases|THAC/  Head/neck missing Eye(s) missing|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-231|23|883|n/a|n/a|n/a|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-232|23|887|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-233|23|898|n/a|n/a|n/a|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-234|23|907|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-235|23|924|n/a|n/a|n/a|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-236|23|926|n/a|n/a|n/a|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-237|23|934|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  Eye(s) missing Head/neck missing,MPATH: 513 - Lymphoid neoplasms|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-238|23|938|n/a|n/a|n/a|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-239|23|939|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-240|23|941|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  Eye(s) missing Thorax missing Head/neck missing,MPATH: 513 - Lymphoid neoplasms|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-241|23|954|Neoplasia unclassified|Other local manifestations and miscellaneus|TMWR: TRAC TO RIB CAGE MUSC.|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-242|23|960|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/  ,MPATH: 242 - hemangiosarcoma|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-243|23|960|Neoplasia unclassified|Other local manifestations and miscellaneus|TRWH: THAC TO LUNG.|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-244|23|965|n/a|n/a|n/a|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-245|23|968|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-246|23|976|Inflammation and/or fibrotic diseases|Lower respiratory system,MA: 0000415 - lung|MRMP/  MurineEye(s) missing,MPATH: 212 - inflammation|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-247|23|983|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-248|23|988|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-249|23|989|n/a|n/a|n/a|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-250|23|995|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  Head/neck missing,MPATH: 513 - Lymphoid neoplasms|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-251|23|996|Hyperplastic changes|Cardiovascular system|MPAN/  Polyarteritis nodosa|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-252|23|1001|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-253|23|1009|n/a|n/a|n/a|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-254|23|1011|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-255|23|1012|n/a|n/a|n/a|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-256|23|1015|Neoplasia benign|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|THVO/  ,MPATH: 235 - blood vessel tumor|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-257|23|1020|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-258|23|1025|n/a|n/a|n/a|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-259|23|1027|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-260|23|1032|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-261|23|1033|n/a|n/a|n/a|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-262|23|1033|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  Head/neck missing Eye(s) missing,MPATH: 513 - Lymphoid neoplasms|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-263|23|1039|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-264|23|1041|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-265|23|1045|Neoplasia unclassified|Other local manifestations and miscellaneus|TMWC: TCFS IN BONE & MUSCLE OF SPINE.|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-266|23|1052|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-267|23|1059|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  Head/neck missing,MPATH: 268 - adenocarcinoma|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-268|23|1060|n/a|n/a|n/a|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-269|23|1065|n/a|n/a|n/a|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-270|23|1074|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/   Metastases Lung,MPATH: 513 - Lymphoid neoplasms|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-271|23|1075|n/a|n/a|n/a|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-272|23|1081|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases  Muscle tgac invades adjacent musc.,MPATH: 268 - adenocarcinoma|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-273|23|1085|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases Lung,MPATH: 268 - adenocarcinoma|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-274|23|1099|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-275|23|1104|Neoplasia unclassified|Other local manifestations and miscellaneus|TMWC: TCFS IN BONE & MUSCLE OF SPINE.|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-276|23|1108|n/a|n/a|n/a|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-277|23|1114|n/a|n/a|n/a|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-278|23|1115|Other deterministic changes|Whole body|MCDU/|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-279|23|1119|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases  Muscle tcfs in bone & muscle of spine.,MPATH: 268 - adenocarcinoma|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-280|23|1158|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-281|23|1191|n/a|n/a|n/a|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-282|23|1199|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-283|23|1204|n/a|n/a|n/a|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-284|23|1243|Other deterministic changes|Whole body|MCDU/|
1003-29-23|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|285 (285 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|98 records survival 805 ± 18 lifespan study|1003-29-23-285|23|1259|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-24|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|79 records survival 717 ± 19 lifespan study|1003-29-24-1|24|427|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-24|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|79 records survival 717 ± 19 lifespan study|1003-29-24-2|24|457|n/a|n/a|n/a|
1003-29-24|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|79 records survival 717 ± 19 lifespan study|1003-29-24-3|24|475|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-24|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|79 records survival 717 ± 19 lifespan study|1003-29-24-4|24|539|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|TCFS/ axilla and left thorax. Metastases Liver,MPATH: 408 - soft tissue fibrosarcoma|
1003-29-24|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|79 records survival 717 ± 19 lifespan study|1003-29-24-5|24|541|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-24|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|79 records survival 717 ± 19 lifespan study|1003-29-24-6|24|567|Other deterministic changes|Whole body|MCDU/|
1003-29-24|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|79 records survival 717 ± 19 lifespan study|1003-29-24-7|24|588|Neoplasia malignant|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|THVS/  ,MPATH: 242 - hemangiosarcoma|
1003-29-24|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|79 records survival 717 ± 19 lifespan study|1003-29-24-8|24|590|n/a|n/a|n/a|
1003-29-24|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|79 records survival 717 ± 19 lifespan study|1003-29-24-9|24|591|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases  trac to mediast. pleura. Metastases  Muscle trac to skel. muscle of thorax.,MPATH: 268 - adenocarcinoma|
1003-29-24|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|79 records survival 717 ± 19 lifespan study|1003-29-24-10|24|597|n/a|n/a|n/a|
1003-29-24|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|79 records survival 717 ± 19 lifespan study|1003-29-24-11|24|600|Neoplasia malignant|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|THVS/  ,MPATH: 242 - hemangiosarcoma|
1003-29-24|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|79 records survival 717 ± 19 lifespan study|1003-29-24-12|24|600|Neoplasia malignant|Nervous system and special sense organs,MA: 0000016 - nervous system|TNMS/  ,MPATH: 551 - sarcoma|
1003-29-24|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|79 records survival 717 ± 19 lifespan study|1003-29-24-13|24|619|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-24|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|79 records survival 717 ± 19 lifespan study|1003-29-24-14|24|623|Other deterministic changes|Whole body|MCDU/|
1003-29-24|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|79 records survival 717 ± 19 lifespan study|1003-29-24-15|24|642|Other deterministic changes|Whole body|MCDU/  Trunk missing Head/neck missing|
1003-29-24|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|79 records survival 717 ± 19 lifespan study|1003-29-24-16|24|653|Neoplasia malignant|Liver among hepato-pancreatic system diseases|THAC/   Metastases  Muscle tcvs of left femur to skeletal muscle of femur.|
1003-29-24|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|79 records survival 717 ± 19 lifespan study|1003-29-24-17|24|690|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  Eye(s) missing Head/neck missing,MPATH: 513 - Lymphoid neoplasms|
1003-29-24|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|79 records survival 717 ± 19 lifespan study|1003-29-24-18|24|695|n/a|n/a|n/a|
1003-29-24|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|79 records survival 717 ± 19 lifespan study|1003-29-24-19|24|705|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-24|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|79 records survival 717 ± 19 lifespan study|1003-29-24-20|24|706|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|TXEC/ salivary gland. Metastases  txec of salivary gland invas. of head/neck muscle.,MPATH: 446 - squamous cell carcinoma|
1003-29-24|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|79 records survival 717 ± 19 lifespan study|1003-29-24-21|24|710|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|TKAC/  ,MPATH: 549 - carcinoma|
1003-29-24|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|79 records survival 717 ± 19 lifespan study|1003-29-24-22|24|715|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-24|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|79 records survival 717 ± 19 lifespan study|1003-29-24-23|24|719|Neoplasia malignant|Endocrine system|TGAC/   Metastases Lung tmab (mammary) invades lung. Metastases  Muscle tgac to orbital muscle & skin.|
1003-29-24|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|79 records survival 717 ± 19 lifespan study|1003-29-24-24|24|726|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-24|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|79 records survival 717 ± 19 lifespan study|1003-29-24-25|24|728|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/   Metastases  tkac in visc. peritoneum.,MPATH: 513 - Lymphoid neoplasms|
1003-29-24|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|79 records survival 717 ± 19 lifespan study|1003-29-24-26|24|743|Neoplasia malignant|Bone among musculo-skeletal system diseases|TBOS/ orbit. Metastases  Muscle tbos of orbit infilt. muscles of head.|
1003-29-24|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|79 records survival 717 ± 19 lifespan study|1003-29-24-27|24|749|Neoplasia malignant|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|THVS/  ,MPATH: 242 - hemangiosarcoma|
1003-29-24|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|79 records survival 717 ± 19 lifespan study|1003-29-24-28|24|757|Neoplasia malignant|Liver among hepato-pancreatic system diseases|THAC/   Metastases  tbos of orbit infilt. squamous lined cavity & maxillary tissue.|
1003-29-24|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|79 records survival 717 ± 19 lifespan study|1003-29-24-29|24|779|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  Eye(s) missing Head/neck missing,MPATH: 513 - Lymphoid neoplasms|
1003-29-24|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|79 records survival 717 ± 19 lifespan study|1003-29-24-30|24|785|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/   Metastases Lung,MPATH: 513 - Lymphoid neoplasms|
1003-29-24|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|79 records survival 717 ± 19 lifespan study|1003-29-24-31|24|787|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-24|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|79 records survival 717 ± 19 lifespan study|1003-29-24-32|24|788|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/   Metastases Lung,MPATH: 513 - Lymphoid neoplasms|
1003-29-24|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|79 records survival 717 ± 19 lifespan study|1003-29-24-33|24|790|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-29-24|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|79 records survival 717 ± 19 lifespan study|1003-29-24-34|24|793|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-24|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|79 records survival 717 ± 19 lifespan study|1003-29-24-35|24|798|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-29-24|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|79 records survival 717 ± 19 lifespan study|1003-29-24-36|24|816|n/a|n/a|n/a|
1003-29-24|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|79 records survival 717 ± 19 lifespan study|1003-29-24-37|24|831|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-24|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|79 records survival 717 ± 19 lifespan study|1003-29-24-38|24|839|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  Head/neck missing,MPATH: 513 - Lymphoid neoplasms|
1003-29-24|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|79 records survival 717 ± 19 lifespan study|1003-29-24-39|24|842|n/a|n/a|n/a|
1003-29-24|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|79 records survival 717 ± 19 lifespan study|1003-29-24-40|24|843|Other deterministic changes|Whole body|MCDU/|
1003-29-24|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|79 records survival 717 ± 19 lifespan study|1003-29-24-41|24|845|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-24|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|79 records survival 717 ± 19 lifespan study|1003-29-24-42|24|850|n/a|n/a|n/a|
1003-29-24|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|79 records survival 717 ± 19 lifespan study|1003-29-24-43|24|857|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-24|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|79 records survival 717 ± 19 lifespan study|1003-29-24-44|24|861|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-24|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|79 records survival 717 ± 19 lifespan study|1003-29-24-45|24|862|n/a|n/a|n/a|
1003-29-24|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|79 records survival 717 ± 19 lifespan study|1003-29-24-46|24|868|Hyperplastic changes|Other local manifestations and miscellaneus,MA: 0000003 - organ system|MOCY/  Ovary or testis,MPATH: 62 - cyst|
1003-29-24|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|79 records survival 717 ± 19 lifespan study|1003-29-24-47|24|869|Other deterministic changes|Whole body|MCDU/|
1003-29-24|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|79 records survival 717 ± 19 lifespan study|1003-29-24-48|24|872|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|TCFS/ rt flank-- subcut dorsal. Metastases Lung,MPATH: 408 - soft tissue fibrosarcoma|
1003-29-24|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|79 records survival 717 ± 19 lifespan study|1003-29-24-49|24|885|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|TMAB/  Predominantly ductal,MPATH: 218 - neoplasm|
1003-29-24|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|79 records survival 717 ± 19 lifespan study|1003-29-24-50|24|888|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-24|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|79 records survival 717 ± 19 lifespan study|1003-29-24-51|24|891|Other deterministic changes|Whole body|MCDU/|
1003-29-24|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|79 records survival 717 ± 19 lifespan study|1003-29-24-52|24|900|Neoplasia systemic|Haematolymphatic system|TLML/|
1003-29-24|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|79 records survival 717 ± 19 lifespan study|1003-29-24-53|24|900|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-24|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|79 records survival 717 ± 19 lifespan study|1003-29-24-54|24|903|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-24|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|79 records survival 717 ± 19 lifespan study|1003-29-24-55|24|911|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-24|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|79 records survival 717 ± 19 lifespan study|1003-29-24-56|24|912|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-24|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|79 records survival 717 ± 19 lifespan study|1003-29-24-57|24|919|n/a|n/a|n/a|
1003-29-24|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|79 records survival 717 ± 19 lifespan study|1003-29-24-58|24|930|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|TMAA/  Head/neck missing,MPATH: 218 - neoplasm|
1003-29-24|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|79 records survival 717 ± 19 lifespan study|1003-29-24-59|24|933|n/a|n/a|n/a|
1003-29-24|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|79 records survival 717 ± 19 lifespan study|1003-29-24-60|24|933|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-24|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|79 records survival 717 ± 19 lifespan study|1003-29-24-61|24|948|n/a|n/a|n/a|
1003-29-24|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|79 records survival 717 ± 19 lifespan study|1003-29-24-62|24|950|n/a|n/a|n/a|
1003-29-24|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|79 records survival 717 ± 19 lifespan study|1003-29-24-63|24|950|Other deterministic changes|Whole body|MCDU/|
1003-29-24|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|79 records survival 717 ± 19 lifespan study|1003-29-24-64|24|954|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  Head/neck missing Eye(s) missing,MPATH: 513 - Lymphoid neoplasms|
1003-29-24|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|79 records survival 717 ± 19 lifespan study|1003-29-24-65|24|961|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-24|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|79 records survival 717 ± 19 lifespan study|1003-29-24-66|24|961|n/a|n/a|n/a|
1003-29-24|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|79 records survival 717 ± 19 lifespan study|1003-29-24-67|24|961|n/a|n/a|n/a|
1003-29-24|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|79 records survival 717 ± 19 lifespan study|1003-29-24-68|24|970|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLSL/  undifferentiated leukemia lymphoret.tissue,MPATH: 335 - hematopoietic/lymphoid malignancies/disorder|
1003-29-24|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|79 records survival 717 ± 19 lifespan study|1003-29-24-69|24|986|n/a|n/a|n/a|
1003-29-24|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|79 records survival 717 ± 19 lifespan study|1003-29-24-70|24|1008|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-24|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|79 records survival 717 ± 19 lifespan study|1003-29-24-71|24|1013|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-24|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|79 records survival 717 ± 19 lifespan study|1003-29-24-72|24|1014|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-24|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|79 records survival 717 ± 19 lifespan study|1003-29-24-73|24|1026|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-24|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|79 records survival 717 ± 19 lifespan study|1003-29-24-74|24|1047|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/  ,MPATH: 242 - hemangiosarcoma|
1003-29-24|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|79 records survival 717 ± 19 lifespan study|1003-29-24-75|24|1057|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-24|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|79 records survival 717 ± 19 lifespan study|1003-29-24-76|24|1084|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-24|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|79 records survival 717 ± 19 lifespan study|1003-29-24-77|24|1100|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-24|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|79 records survival 717 ± 19 lifespan study|1003-29-24-78|24|1142|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-29-24|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|79 records survival 717 ± 19 lifespan study|1003-29-24-79|24|1150|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-29-24|n/a,6X|1|100|neutrons fission|0.4|grays|External exposure|code 6X (6A  6X combined) 60 fractions 20 m 1/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|79 records survival 717 ± 19 lifespan study|1003-29-24-80|24|1279|Other deterministic changes|Whole body|MCDU/|
